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Over half of all human proteins have one or more complex sugar chains, known as glycans, 
attached to their surface. The arrangement of glycans is important for determining how 
individual proteins function within the body and genetic changes which dramatically affect 
these glycans are associated with serious diseases. Glycan profiles are also known to vary 
with age and in many medical conditions. This has attracted interest in their use for diagnosis 
and as targets for new treatments. Until recently, it has not been possible to measure glycans 
in a high-throughput manner, so investigations into the genetics underlying glycan 
manufacture and composition could not be done. In collaboration with groups at various 
European centres, this project aimed to investigate the genes influencing glycan structure and 
abundance through the use of genome-wide association studies (GWAS). These association 
studies are a method for determining if a particular region of the genome is associated with 
variation in a measured outcome. This outcome may be disease cases versus unaffected 
controls, or a continuous variable such as blood pressure, glucose levels, or here, plasma 
concentrations of a particular glycan. However, the results of these association studies do not 
inform about causality and generally require laboratory follow-up before conclusions about 
biology can be drawn. 
Glycans were removed from all proteins within an individual plasma sample and 46 glycan 
structures measured. This was done for plasma samples collected from over 3,500 
individuals from four European populations which also had genetic information available. 
GWAS was done for each of these 46 glycan structures. Statistically significant results were 
found in genes coding for proteins with known roles in glycosylation (such as enzymes that 
add a specific sugar at a particular location on a glycan chain). One unexpected and 
important result was the association of a gene whose protein product (HNF1A) is responsible 
for regulating the concentrations of many proteins produced in the liver. Laboratory work by 
collaborators found HNF1A to be a “master regulator” of several enzymes involved in 
addition of the sugar fucose to plasma glycans. Genetic changes in HNF1A are known to 
cause a form of diabetes (MODY3) which requires a different treatment than type-2 or type-
1 diabetes. An important finding was that glycans could act as “biomarkers” to separate 
people with MODY3 from T2D and T1D.  
After the success of the total plasma protein glycan GWAS, it was thought that more 
biologically interpretable associations may be found from the investigation of glycans 
isolated from a single protein. The addition of glycans to immunoglobulin G (IgG) 
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influences which immune response is activated in the body when exposed to foreign 
molecules. To identify genetic networks that govern glycosylation of IgG, IgG glycans were 
measured in over 2000 individuals from the same populations as before. GWAS of the 77 
glycan structures identified 16 statistically significant gene regions. Four of these contained 
genes with known functions in glycan synthesis, while the remainder were completely new 
findings.  
Finally, several different methods for high-throughput analysis of glycans have been 
developed in the past few years but have not been thoroughly compared. To this end, 
comparison of IgG glycan structures generated by all four methods in the same dataset of 
1,201 individuals was done by correlation of the raw trait values and by comparison of the 
results of GWAS studies. All methods performed well but have different advantages and 
disadvantages.  
This work shows that new genetic regions that control glycan structure of plasma proteins 
can be identified using GWAS and shows the potential of glycans for disease diagnostics. It 




The majority of human proteins are post-translationally modified by covalent addition of one 
or more complex oligosaccharides (glycans). Alterations in glycosylation processing are 
associated with numerous diseases and glycans are attracting increasing attention both as 
disease biomarkers and as targets for novel therapeutic approaches.  
Using a recently developed high performance liquid chromatography (HPLC) method for 
high-throughput glycan analysis, genome-wide association studies (GWAS) of 33 directly 
measured and 13 derived N-glycan features were performed in 3533 individuals from four 
European isolated populations. Polymorphisms at six loci were found to show genome-wide 
significant association with plasma concentrations of N-glycans. Several of these gene 
products have well characterised roles in glycosylation, however, SLC9A9 and HNF1A were 
two of the novel findings. Subsequent work performed by collaborators found HNF1A to be 
a “master regulator” of genes involved in the fucosylation of plasma N-glycans. 
Additionally, this work led to the discovery that N-glycans could act as biomarkers to 
discriminate HNF1A-MODY from type 1 and type 2 diabetes mellitus (T1D, T2D) patients.  
After the success of the total plasma N-glycan GWAS, it was thought that stronger and more 
biologically interpretable associations may be found from the investigation of N-glycans 
isolated from a single protein. Glycosylation of immunoglobulin G (IgG) influences IgG 
effector function by modulating binding to Fc receptors. To identify genetic networks that 
govern IgG glycosylation, N-linked IgG glycans were quantitated using ultra performance 
liquid chromatography (UPLC) in 2247 individuals from the same four European 
populations from the previous study. GWAS of the 77 N-glycan measures identified 15 loci 
with a p-value<5x10
-08
. Four loci contained genes encoding glycosyltransferases, while the 
remaining loci contained genes that have not previously been implicated in protein 
glycosylation. However, most have been associated with autoimmune and inflammatory 
conditions and/or hematological cancers.  
Several high-throughput methods for the analysis of N-glycans have been developed in the 
past few years but thorough validation and standardization of these methods is required 
before significant resources are invested in large-scale studies. To this end, four of these 
methods were compared, UPLC, multiplexed capillary gel electrophoresis (xCGE), and two 
mass spectrometric (MS) methods, for quantitative profiling of N-glycosylation of plasma 
IgG in a subset of 1201 individuals recruited from two of the cohorts used in the previous 
GWAS studies. A “minimal” dataset was compiled of N-glycan structures able to be 
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measured by all four methods. To evaluate their accuracy, correlations were calculated for 
each structure in the minimal dataset. Additionally, GWAS was performed to test if the same 
associations would be observed across methodologies. Chromatographic methods with either 
fluorescent or MS-detection yielded slightly stronger associations than MS-only and xCGE, 
but at the expense of lower levels of throughput. Advantages and disadvantages of each 
method were identified, which should aid in the selection of the most appropriate method for 
future studies. 
This work shows that it is possible to identify new loci that control glycosylation of plasma 
proteins using GWAS and the potential of N-glycans for biomarker development. It also 
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Chapter 1 - Introduction 
1.1 Success of Genome-wide Association Studies for Mapping 
Quantitative Trait Loci 
Genome-wide association studies (GWAS) have come to the forefront in human genetics in 
the past 6-8 years. Linkage studies had great success identifying genes for Mendelian 
disorders but were not proving as fruitful for common diseases. This is due to the fact that 
linkage relied upon causal mutations of large effect which could be traced down a pedigree, 
and usually involved the analysis of relatively few markers per chromosome due to low 
recombination between generations within a family [1]. It is a low resolution technique, 
often pinpointing to regions of several megabases, and for common diseases, the effect sizes 
were too small to track [2]. In addition, linkage required families which limited the sample 
sizes available for those studies. In order to perform linkage, it is necessary to follow 
segments which are shared identity-by-descent (IBD). The probability of a segment being 
shared by descent is estimated using various algorithms that rely on assumptions that may 
not be accurate, especially for large extended pedigrees. These problems also apply for 
linkage analysis of quantitative traits using variance components. 
GWAS is a simple regression technique of phenotypic value on genotype, which does not 
require evaluation of identity by descent status and works best under the common disease-
common variant (CDCV) hypothesis. The latter holds that genetic variants contributing to 
the majority of the population risk for common diseases must themselves be common [3,4], 
rather than rare with high allelic heterogeneity. With the GWAS technique, the mapping 
resolution across the genome is increased, as many recombination events separate two 
random individuals who share a common susceptibility variant. By exploiting linkage 
disequilibrium (LD), the concept that alleles located close together on a chromosome tend to 
be inherited together, researchers were able to investigate much smaller blocks of the haploid 
genome or “haplotypes” simply by looking at an individual “tagging” single nucleotide 
polymorphism (SNP) [5]. This means that by analysing approximately 1 SNP per 5-10kb (or 
approximately 300,000 -500,000 SNPs across the genome) in non-African populations, the 
majority of common variants across the genome could be interrogated [6]. Additionally, this 
method no longer required families but could be used on a population scale which allowed 
increased sample sizes and therefore increased power to detect true associations. Another 
contribution to increased sample size was the rapidly decreasing cost of genotyping which, 
combined with increased throughput, allowed existing larger cohorts to acquire the genetic 
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data required for analysis. These in turn have driven the development of better analytical and 
computational tools to handle data on this scale. 
Like linkage, GWAS has the advantage of being “hypothesis free” in that it is an unbiased 
scan of the entire genome rather than using prior biological knowledge which may be flawed 
or incomplete. This allows for the discovery of genes not previously associated with a 
particular trait or disease and new avenues for further laboratory or clinically-based studies. 
However, one has to keep in mind that association with a trait does not imply causation and 
further studies into the function of loci in the association region will be required for a clear 
biological understanding. Also, due to the number of tests, multiple testing is an issue but 
increased sample sizes or clever study design can help to overcome this barrier. Finally, 
single marker GWAS is unlikely to identify rare variant associations unless very large 
samples and different genotype data are used (i.e. imputed dosages where a broad allele 
frequency spectrum is present or specially designed arrays for rare variants are used) but 
even then there are different analytical techniques that are better suited to this task.   
To date, approximately 2000 GWAS papers have been published which report associations 
with P-values < 1x10
-05
 for over 13,000 common SNPs, covering a variety of quantitative 
traits and diseases illustrating the undeniable success of this technique [7]. Genetic 
architecture of the traits assessed varied from height, a polygenic trait with hundreds of 
associated loci of small effect, to von Willibrand factor (vWF), with one locus, ABO, able to 
alter vWF levels by 25 – 30% [8,9]. In general, quantitative traits seem to be highly 
polygenic and the traits that are outputs of a simple process, such as some biochemical 
measures or transcript levels, often have loci with large effects. Despite the majority of 
associated loci being found to be intronic or intergenic, it seems that intergenic associations 
are actually underrepresented when compared to a random set of SNPs. In addition, there 
appears to be an overrepresentation of associated loci in regulatory regions and non-
synonymous sites [10]. 
1.2 Rare Variant Analysis 
Despite the success of GWAS performed so far, the common variants associated with 
quantitative traits still do not explain all of the trait heritability. For example, in the vWF 
paper mentioned above, despite this massive phenotypic change caused by ABO blood 
group, the 8 loci reported in this paper only explain 12.8% of the trait variance [9]. It has 
been hypothesized that this may be due to additional loci of small effect that have not been 
measured, rare variants of possibly large effect that are not present in the data available to 
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date, structural variants which are not well captured by current genotyping technology, gene-
gene interactions, or inflated heritability estimates due to unaccounted for shared 
environment in the populations used to calculate these estimates [11].  
In order to tackle one of these postulated causes, the “Exome Chip” was designed. This is a 
genotyping chip that is focussed on low-frequency and rare variants, identified through 
exome sequencing projects, that are predicted to be functional. In order to limit false 
candidates on the chip, only variants observed at least 3 times across two or more sequencing 
efforts were included on the chip (http://genome.sph.umich.edu/wiki/Exome_Chip_Design).  
Due to the fact that these variants are rare, traditional analysis methods do not have much 
power to detect association with quantitative traits. For this reason, methods have been 
developed to aggregate the effect of multiple rare variants across a region then to test for 
association with this “burden” of rare variation. This results in a p-value for the region rather 
than for a variant. These are called burden tests and generally the region is defined as a gene, 
but in theory the genome can be partitioned in any way the analyst would like [12,13].  
1.3 Studied Populations 
The CROATIA study was initiated to investigate the use of isolated rather than urban 
populations for the identification of genes associated with medically-relevant quantitative 
traits. These include traits that are used to measure or predict a disease outcome such as 
blood pressure, body mass index (BMI) or cholesterol levels. The decision to use isolated 
populations was based on the prediction that the genetic make-up of a population, the more 
homogeneous environment, and the use of quantitative traits rather than disease end points 
would increase the ability to detect associated genetic loci [14]. Three cohorts have been 
recruited as part of the CROATIA study: CROATIA-Vis, CROATIA-Korcula and 
CROATIA-Split. Only CROATIA-Vis and CROATIA-Korcula were used in this study.  
CROATIA-Vis was the first to be collected when 1008 Croatians aged 18-93 were recruited 
from the villages of Komiza and Vis on the Dalmatian island of Vis. Recruitment occurred 
from 2003 to 2004 with participants donating blood for DNA extraction and biochemical 
measurements as well as undergoing some anthropometric measurements and physiological 
tests to measure traits such as height, weight and blood pressure, and finally completing 
several questionnaires relating to general health, medical history, diet and lifestyle. 
CROATIA-Korcula was recruited from 2007 to 2008 from several towns and villages on the 
island of Korcula, Croatia with 969 adults aged 18-98 agreeing to participate. This study 
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followed the same recruitment procedures as CROATIA-Vis and the same samples and tests 
were collected. 
The Orkney Complex Disease Study (ORCADES) was performed in the Scottish archipelago 
of Orkney. Genetic diversity is decreased, just as on the Croatian islands, compared to the 
Scottish mainland, consistent with high levels of historical endogamy [15]. Participants were 
recruited between 2005 and 2011 following similar procedures and collecting similar data as 
the CROATIA studies in order to have complementary phenotypes for analysis. Close to 
2000 people were recruited into this study, aged 16-98. 
The Northern Swedish Population Health Study (NSPHS) is a family-based population study 
including a comprehensive health investigation and collection of data on family structure, 
lifestyle, diet, medical history and samples for laboratory analyses from peoples living in the 
north of Sweden. Data from this population isolates was available from 700 participants aged 
14–91 years [16]. 
The Leiden Longevity Study was designed to investigate genetic factors contributing to long 
life. Siblings aged 89 years and over for men and 91 years and over for women, were 
recruited along with their offspring and offspring spouses. Both parents of the nonagenarians 
had to be Dutch and Caucasian [17].  
Geographic locations of all studied cohorts are presented in Figure 1. 
1.4 Role of Glycosylation 
Glycosylation is a common post-translational protein modification that modulates the 
structure and function of polypeptide components of glycoproteins [18,19]. It is estimated 
that the glycome (defined as the complete set of all glycans) of a eukaryotic cell is composed 
of more than a million different glycosylated structures [20], which contain up to 10,000 
structural glycan epitopes for interaction with antibodies, lectins, receptors, toxins, microbial 
adhesins, or enzymes [21]. Over half of all known proteins are modified by covalently bound 
glycans, which are important for various physiological processes, including protein folding, 
degradation and secretion, cell signalling, immune function and transcription [22-25]. The 
configuration and composition of attached glycans significantly change the structure and 
activity of polypeptide portions of glycoproteins [19] and since this process is not template 
driven, the complexity of the glycoproteome is estimated to be several orders of magnitude 
greater than for the proteome itself [26]. Terminal variability in glycans is common (e.g. 




Figure 1: Location of Population Cohorts. 
NSPHS: Northern Swedish Population Health Study; ORCADES: Orkeny Complex Disease 
Study; CROATIA: the CROATIA study; LLS: Leiden Longevity Study. 
 
pathogens and adapt to changing environments [27]. Dysregulation of glycosylation 
isassociated with a wide range of diseases, including cancer, diabetes, cardiovascular, 
congenital, immunological and infectious disorders [22,23,28]. Enzymes that are involved in 
glycosylation may therefore be promising targets for therapy [29]. A recent report endorsed 
by the US National Academies concluded that “glycans are directly involved in the 
pathophysiology of every major disease and that additional knowledge from glycoscience 
will be needed to realize the goals of personalized medicine” [40]. 
There are two major classes of glycans, “O-” and “N-” linked based on the linkage of the 
glycan to the attached lipid or protein. This project concerned the analysis of N-linked 
glycans only. Preformed glycans are transferred onto proteins as they appear out of the 
ribosomes in the endoplasmic reticulum (ER). The N-linked glycans are then remade in the 
Golgi depending on the protein they have been attached to, the cell they are found within and 
enzyme concentrations. Figure 2 shows an overview of this process. All N-glycans contain 
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two core N-acetylglucosamine (GlcNAc) residues, to which a ‘‘core’’ fucose can be α1,6-
linked to the inner GlcNAc, which is directly linked to an asparagine residue on the protein. 
This asparagine must be followed by any amino acid other than proline, then by either a 
serine or threonine. Additional fucose residues can be transferred to different positions on 
antennas that have been added to the core glycan structure. A generic structure for an N-
glycan is found in  
 
Figure 3. N-glycans are essential for multicellular life, with complete absence being lethal 
[30], however a group of rare diseases named congenital disorders of glycosylation [31] have 
been identified where different mutations in the biosynthesis pathway of N-glycans cause 
significant mortality and extensive motor, immunological, digestive and neurological 
symptoms [32,33]. These can affect any point in the glycosylation pathway shown in Figure 
2. Due to experimental limitations in quantifying glycans in complex biological samples, the 
current understanding of their role in biological processes lags significantly behind 
knowledge about proteins or DNA [38,39]. However, recent technological advances have 
allowed reliable, high-throughput quantitation of N-glycans [34], which now permits 
investigation of the genetic regulation and biological roles of glycan structures and brings 
glycomics into line with genomics, proteomics and metabolomics [35]. Recent population- 
based studies indicated that the composition of the human plasma N-glycome varies 
significantly between individuals [36,37]. Since glycans have important structural and 
regulatory functions on numerous glycoproteins [38] , the observed variability suggests that 
differences in glycosylation might contribute to human phenotypic variability.  
1.5 IgG N-Glycosylation 
Variation in protein glycosylation also has physiological significance, with immunoglobulin 
G (IgG) being a well-documented example. Each heavy chain of IgG carries a single 
covalently attached bi-antennary N-glycan at the highly conserved asparagine 297 residue in 
each of the CH2 domains of the Fc region of the molecule (Figure 4). The attached 
oligosaccharides are structurally important for the stability of the antibody and its effector 
functions [39]. Thirty-six different glycans can be attached to the conserved Asn297 of the 
IgG heavy chain [40,41], leading to hundreds of different IgG isomers that can be generated 
from this single glycosylation site. In addition, some 15–20% of normal IgG molecules have 
complex bi-antennary oligosaccharides in the variable regions of light or heavy chain 
[42,43]. Figure 4 shows N-glycosylation sites on IgG molecules. 
26 
 
Glycosylation of IgG has important regulatory functions. The absence of galactose residues 
in association with rheumatoid arthritis was reported nearly 30 years ago [44]. The addition  
 
Figure 2: N-glycan biosynthetic pathway 
(Modified figure from Freeze et al., 2006 [33]) The 
steps in the biosynthetic pathway for N-glycan 
synthesis are presented along with the cellular location. 
Preformed N-glycans are attached to the nascent 
protein as it is formed by the ribosome. Remodelling of 
the N-linked glycan starts in the endoplasmic reticulum 
(ER) but mainly occurs in the Golgi. The structures 
depicted here contain sialic acid (purple diamond), 
galactose (red circle), mannose (green circle), glucose 




























Figure 3: Generic N-glycan structure. 
(Adapted from Ma et al., 2006 [45].) A generic N-glycan containing a tri-mannosyl core 
(“CORE”) and an antenna (“ANTENNA”). An N-glycan can have up to four antennae with two 
attached to each of the mannoses indicated and can be lengthened as indicated by the box 
with “n”. An N-glycan is attached to an asparagine (Asn) residue on the protein which must 
be followed by any amino acid other than proline (*), then by either a serine (Ser) or 
threonine (Thr). The structures depicted here contain Sialic acid (purple diamond), Galactose 







Figure 4: N-glycan attachment sites on Immunoglobulin G (IgG). 
(Adapted from Zauner et al. (2013) [46].) The main N-glycosylation site at Asn297 is marked 
by 297. Stars represent N-glycosylation sites; Fab= fragment antigen binding region; Fc= 
fragment crystallisable region; VH= variable heavy chain; VL= variable light chain; CH1 = 
constant heavy chain 1; CH2 = constant heavy chain 2; CH3 = constant heavy chain 3. 
 
of sialic acid dramatically changes the physiological role of IgGs, converting them from pro-
inflammatory to anti-inflammatory agents [47,48]. Addition of fucose to the glycan 
coreinterferes with the binding of IgG to FcγRIIIa receptors and greatly diminishes its 
capacity for antibody dependent cell-mediated cytotoxicity (ADCC) [49,50]. ADCC is a 
process whereby effector cells of the immune system (natural killer cells, macrophages, 
neutrophils and eosinophils) bind to and kill target cells which have been bound by 
antibodies. This is one of the major pathways by which the immune system prevents 
infection but requires prior knowledge that the target cell is dangerous in order to have 
antibodies directed against it [51]. Structural analysis of the IgG-Fc/FcγRIIIa complex has 
demonstrated that specific glycans on FcγRIIIa are also essential for this effect of core-
fucose [52] and that removal of core fucose from IgG glycans increases clinical efficacy of 
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monoclonal antibodies, enhancing their therapeutic effect through ADCC mediated killing 
[53-55]. 
1.6 Methodology for the Analysis of Glycans 
A number of studies have investigated the role of glycans in human disease, including 
autoimmune diseases and cancer [56,57]. However, most human glycan studies have been 
conducted with very small sample sizes. Given the complex causal pathways involved in the 
pathophysiology of common complex disease, and thus the likely modest effect sizes 
associated with individual factors, the majority of these studies are very likely to be 
substantially underpowered. In the case of inflammatory bowel disease (IBD), only 20% of 
reported IBD glycan associations were replicated in subsequent studies, suggesting that most 
are false positive findings and that there is publication bias favouring the publication of 
positive findings [58]. This situation is similar to that which occurred in the field of genetic 
epidemiology in the past when many underpowered candidate gene studies were published 
and later found to consist of mainly false positive findings [59,60]. It is essential, therefore, 
that robust and affordable methods for high-throughput analysis are developed so that 
adequately powered studies can be conducted and the publication of large numbers of small 
studies reporting false positive results (which could threaten the credibility of glycoscience) 
be avoided. 
Several methodologies have the capacity for high throughput glycan analysis including high 
performance liquid chromatography (HPLC), ultra performance liquid chromatography 
(UPLC), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS), nano liquid chromatography electrospray ionisation mass spectrometry 
(LC-ESI-MS) and multiplex capillary gel electrophoresis with laser induced fluorescence 
detection (xCGE-LIF), but there is currently no “gold standard” [34,61-66]. 
UPLC and xCGE-LIF separate glycans based on structure whereas the MS-based methods 
separate glycans based on mass. Another important difference between UPLC and xCGE-
LIF versus MS-based methods is that UPLC and xCGE-LIF analyse glycosylation at the 
level of released glycan while the MS-based methods presented here analyse glycopeptides. 
Although in-depth analysis of released glycans may provide a detailed picture of the glycan 
structure, no information on the original glycan attachment site is provided from UPLC or 
xCGE-LIF analyses. Such site-specific information can be obtained by the direct analysis of 
glycopeptides. This means that by analysing glycans at the glycopeptide level MS-based 
methods are able to give information about the protein from which the glycan was released. 
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However, unlike the MS-based methods used in this study, UPLC and xCGE-LIF provide 
branch-specific information. 
1.7 Thesis Aims 
The aim of this thesis was to investigate the genetic contributions to natural variation in 
concentrations of N-glycans in the above mentioned population cohorts. This was done 
through the use of GWAS to look at the contributions of common variants and burden tests 
to look at rare genetic variation. The initial investigation centred on the analysis of N-glycans 
isolated from total plasma proteins, then specifically of those attached to IgG. Finally, a 
comparison of the quantitative abilities of the different methodologies for N-glycan 
measurement was undertaken using correlation analysis and GWAS. 
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Chapter 2 - Materials & Methods 
2.1 Studied Cohorts 
All cohort recruitment, phenotyping and SNP genotyping was done by colleagues at the 
University of Edinburgh, the University of Zagreb, the University of Split Medical School, 
Uppsala University and Leiden University Medical Center.  
2.1.1 The CROATIA Study 
There are fifteen islands in the Adriatic Sea along the Croatian Dalmatian coast that have 
populations greater than 1000 which have been isolated from other villages and the mainland 
for many centuries.  All have their own unique history and founder population and the 
anthropology of these population have been studied for many decades by colleagues at the 
Institute for Anthropological Research in Zagreb, Croatia [67].  
A pilot study was initiated in 2002 in ten Dalmatian island villages selected for their 
differing population genetic history including founding times, admixture, bottleneck events 
and ethnic history. One hundred individuals from each isolate were collected to determine 
their suitability for recruitment into a larger population cohort to be used for further genetic 
studies of complex trait genetics. High levels of differentiation and structure were observed 
between most of the villages which was most likely due their geographic isolation as well as 
endogamy [68]. 
 The island of Vis was selected for further recruitment with volunteers collected from the 
villages of Komiza and Vis between 2003 and 2004 (Figure 5). 1008 unselected adult 
participants aged 18-93 were recruited with almost even participation between villages. 
Blood was collected along with medical histories and various anthropometric and physical 
measures. Several questionnaires were completed covering the participant’s medical history, 
general heath, lifestyle and diet. Both plasma and serum was collected and stored for use in 
various biochemical measurements and DNA was isolated for genotyping. For the rest of this 
thesis this population will be referred to as CROATIA-Vis. 
The second population to be collected was from the town of Korcula and villages of 
Lumbarda, Zrnovo and Racisce on the island of Korcula (Figure 5).  Recruitment occurred 
from 2007 to 2008 with 969 adults aged 18-98 agreeing to participate. This study followed 
the same recruitment procedures as Vis and the same samples and tests were collected. Some 
additional samples and tests were added to reflect the academic expertise in Edinburgh, 
32 
 
including the collection of urine samples and an expanded battery of cognitive tests. In 2012 
it was decided to continue recruitment on this island with the hope of eventually expanding 
the size of the cohort to 4000.  
In order to have an “urban” population for comparison, volunteers were recruited from the 
Dalmatian mainland city of Split in 2009-2010 (Figure 5).  This is the main ferry port to the 
islands and is the second largest city in Croatia and the largest along the Dalmatian coast. 
1012 adults aged 18-85 were recruited using the same methodology and with the same 
samples collected as in Korcula. Samples from CROATIA-Split were not used for this work.  
Ethical approval was given for recruitment of all CROATIA study populations by ethics 
committees in both Scotland and Croatia. All volunteers gave informed consent prior to 
participation. 
 
Figure 5: Recruitment Sites for CROATIA cohort participants 
2.1.2 The Orkney Complex Disease Study (ORCADES) 
The Orkney Complex Disease study (ORCADES) is an ongoing family-based, cross-
sectional study with adult participants recruited from the Scottish Orkney islands and was 
designed as a sister study to CROATIA-Vis.  The Orkney islands are an archipelago found 
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north of mainland Scotland (Figure 6). The Northern Isles of Orkney are comprised of a 
group of 10 inhabited islands with populations ranging from approximately 30-600 people. 
Despite recent improvements in transportation links between the Northern Isles and the rest 
of Orkney, they are still isolated and would have been more so in the past. Genetic diversity 
is decreased, just as on the Croatian islands, compared to the Scottish mainland consistent 
with high levels of historical endogamy[15]. All participants recruited into the study were 
residing in Orkney at the time of study recruitment (2005 - 2011) and had at least one 
grandparent who was born in the Northern Isles of Orkney. The final study sample size is 
just over 2000 people, however only data from the first two waves of genotyping were used 
for this study. This included 889 participants aged 16–98 years. 
Ethical approval was given for recruitment of ORCADES participants by ethics committees 
in Scotland in 2004 and all volunteers gave informed consent prior to participation. 
 
 
Figure 6: Location of Orkney Islands 
2.1.3 The Northern Swedish Population Health Study (NSPHS) 
The Northern Swedish Population Health Study (NSPHS) was designed to investigate the 
differences between individuals living a modern, sedentary lifestyle versus individuals 
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following a traditional, semi-nomadic way of life based on reindeer herding. Participants 
recruited into this family-based population study completed a comprehensive health 
investigation and provided data on family structure, lifestyle, diet, medical history and 
samples for laboratory analyses. Individuals were recruited from the northern part of the 
Swedish mountain region (County of Norrbotten, Parish of Karesuando) in 2006 [16,69]. 
Approximately half of the eligible inhabitants of the parish agreed to participate in the study 
for a final sample size of 658 aged 14-91. Historic records indicated that there has been little 
immigration or other drastic population changes in this area in the last 200 years [70]. An 
additional 350 participants were recruited from Soppero and Vittangi, which are located just 
south of the initial collection area in the same County, in 2009. A map of the recruitment site 
locations is found in Figure 7. 
The NSPHS study was approved by the local ethics committee at the University of Uppsala 
(Regionala Etikprövningsnämnden, Uppsala, Dnr 2005:325) in compliance with the 
Declaration of Helsinki. All participants gave their written informed consent and if the 
participant was not of legal age, a legal guardian also signed. In this study only participants 
from the first recruitment and aged over 18 were included. 
2.1.4 The Leiden Longevity Study (LLS) 
The Leiden Longevity Study was designed to investigate genetic factors contributing to long 
life. Siblings aged 89 years and over for men and 91 years and over for women, were 
recruited along with their offspring and offspring spouses. Both parents of the nonagenarians 
had to be Dutch and Caucasian. Siblings were recruited in order to decrease environmental 
cofounders and the offspring spouses provided population controls. In total, 3,359 
individuals were included: 944 long-lived proband siblings with a mean age of 94 years 
(range 89–104 years), 1,671 offspring with a mean age of 60 years (range 39–81 years), and 
744 controls with a mean age of 60 years (range 36–79 years) at baseline. Recruitment 
occurred between July 2002 and May 2006 and no additional selection based on health or 
demographic categories was performed. Non-fasting blood samples were taken at baseline 
for extraction of DNA and RNA and measurement of other serum and plasma parameters. 
Blood cell counts were performed using standard procedures. Additional information and 
biological samples were collected from the offspring and their spouses from November 2006 
to May 2008. The LLS was approved by the Medical Ethical Committee of Leiden 




Figure 7: Location of Recruitment Sites for NSPHS. 
 
2.1.5 Diabetes Cohorts 
All type 2 diabetes (T2D) and half of the Maturity Onset Diabetes of the Young 3 (MODY3) 
patients were obtained from the South of England. The first set of MODY3 patients were all 
found to harbour a mutation (confirmed by sequencing in a certified UK diagnostic centre) in 
HNF1A (n=19). T2D subjects were selected from the Young Diabetes in Oxford (YDX) 
study (n=41), comprising subjects diagnosed with diabetes ≤ 45 years of age. Criteria for 
diagnosis were: C-peptide positive, no requirement for permanent insulin within 3 months of 
diagnosis and negative glutamic acid decarboxylase (GAD) antibodies. Subjects with a 
clinical label of T2D did not meet clinical criteria for MODY diagnostic testing or had been 
tested and were negative for mutations in genes that are known to cause the most common 
types of MODY (HNF1A, HNF4A or GCK). The study was approved by the Oxfordshire 
Local Research Ethics Committee and all subjects gave informed consent. 
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The rest of the MODY3 samples comprise subjects who were collected in Edinburgh and 
had a mutation (confirmed by sequencing in a certified UK diagnostic centre) in HNF1A 
(n=14). All Edinburgh participants contributed plasma samples and were used in both the 
initial pilot and the expanded study. The study was approved by the Lothian Research Ethics 
Committee and all subjects gave written informed consent.  
2.2 Genetic Data 
All SNP genotyping and quality control was performed by colleagues at the University of 
Edinburgh, the University of Zagreb, the University of Split Medical School, Uppsala 
University and Leiden Univeristy Medical Center. HapMap2 imputation of all datasets was 
completed by Yurii Aulchenko (CROATIA-Vis & NSPHS), Christian Fuchsberger 
(CROATIA-Korcula) and Mirna Kirin (ORCADES). I performed genotype quality control of 
the CROATIA-Korcula data prior to starting my PhD. An overall descriptive chart of all 
participating population cohorts and genotying information is found in Table 1. 
2.2.1 SNP Genotyping and Quality Control 
SNP genotyping for CROATIA-Vis was performed by the Wellcome Trust Clinical 
Research Facility (WTCRF) at the Western General Hospital, Edinburgh, UK, using the 
Illumina Infinium HumanHap300 BeadChip. NSPHS and the majority of ORCADES 
samples were also genotyped using this chip (at Helmholz Zentrum München, GmbH, 
Neuherberg, Germany) with the remainder of ORCADES genotyped using the Illumina 
HumanHap370CNV duo chip (Integragen, Paris, France). CROATIA-Korcula was 
genotyped on the Illumina HumanHap370CNV duo chip as well by Helmholz Zentrum 
München.  
SNP genotypes were clustered using BeadStudio. Verification that the correct individual had 
been genotyped was carried out by checking for sex discrepancies and verifying expected 
relationships, where known, using PLINK [72]. Individuals were removed if there was not 
an obvious solution (e.g. samples flipped on the genotyping chip). Final SNP quality control 
was undertaken using the GenABEL package for R (from the *ABEL suite of programs, 
www.genabel.org) [73].  Individuals with a call rate less than 97% were removed as well as 
SNPs with a call rate less than 98% (95% for CROATIA-Vis), minor allele frequency less 
than 0.02 or Hardy-Weinberg equilibrium p-value (pHWE) less than 1x10
-06
. 924 individuals 
passed all genotype quality control thresholds from CROATIA-Vis, 898 from CROATIA-
Korcula, 889 from ORCADES, and 656 from NSPHS. After quality control was complete, 
an identity-by-state (IBS) matrix was computed for each cohort using the “ibs” function of 
 
 
Table 1: Participating population cohort, genotyping, and imputation descriptions. 
 CROATIA-Vis CROATIA-Korcula NSPHS ORCADES LLS 
Study Type Population-based Population-based Population-based Population-based Population-based 
Population Type Isolate Isolate Isolate Isolate General 
Year of 
Recruitment 






















ind call rate > 97% 
SNP call rate > 95% 
MAF > 0.02 
HWE > 1E-06 
ind call rate > 97% 
SNP call rate > 98% 
MAF > 0.02 
HWE > 1E-06 
ind call rate > 97% 
SNP call rate > 98% 
MAF > 0.02 
HWE > 1E-06 
ind call rate > 97% 
SNP call rate > 98% 
MAF > 0.02 
HWE > 1E-06 
ind call rate > 95% 
SNP call rate > 95% 
MAF > 0.01 
HWE > 1E-04 
N SNPs after QC 308,996 316,751 289,203 293,687 296,619 
N ind after QC 924 898 656 889 1,848 
% female 58.0% 63.8% 52.9% 54.6% NA 
mean age in 
years (sd) 




MACH version 1.15 MACH version 1.15 MACH version 1.15 MACH version 1.15 IMPUTE2 
Pre-Imputation 
Filters  
ind call rate > 97% 
SNP call rate > 98% 
MAF > 0.01 
HWE > 1E-06 
ind call rate > 97% 
SNP call rate > 98% 
MAF > 0.01 
HWE > 1E-06 
ind call rate > 97% 
SNP call rate > 98% 
MAF > 0.01 
HWE > 1E-06 
ind call rate > 97% 
SNP call rate > 98% 
MAF > 0.01 
HWE > 1E-06 
ind call rate > 95% 
SNP call rate > 95% 
MAF > 0.01 
HWE > 1E-04 
GWAS Analysis 
Software 
GenABEL/ProbABEL GenABEL/ProbABEL GenABEL/ProbABEL GenABEL/ProbABEL QTassoc 
N=number, ind = individuals, SNP= single nucleotide polymorphism, MAF= minor allele frequency, HWE = Hardy-Weinberg equilibrium, sd= standard 
deviation, QC= quality control, GWAS= genome-wide association study
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GenABEL (using weight= “freq” option), which uses genomic data to estimate the realized 
pair-wise kinship coefficient. This was used to verify pedigree information reported at 
recruitment. It is also the matrix which was used to account for relatedness in the genome-
wide association analyses reported later. 
The Leiden Longevity Study had 1345 individuals genotyped using Illumina660 W 
(Rotterdam, Netherlands) and 503 individuals genotyped using Illumina OmniExpress 
(Estonian Biocentre, Genotyping Core Facility, Estonia). LLS analysts performed all 
genotyping quality control, imputation and statistical analysis for their cohort data. The 
GenomeStudio algorithm was used for genotype calling. Sample call rates were >95%, and 
SNP exclusions criteria were Hardy-Weinberg equilibrium p-value < 1x10
-04
, SNP call rate < 
95%, and minor allele frequency < 1%. The number of overlapping SNPs that passed quality 
controls in both samples was 296,619.  
2.2.2 HapMap 2 Imputation 
Imputation of approximately 2.5 million SNPs was completed for CROATIA-Vis, 
CROATIA-Korcula, ORCADES and NSPHS using the release 22 HapMap CEU population 
as the reference. MACH version 1.15 (http://www.sph.umich.edu/csg/abecasis/MACH) [74] 
was used, after filtering out SNPs with MAF < 0.01, call rate < 98%, and pHWE < 10
-6
. LLS 
used IMPUTE2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) [75] with the same 
reference panel for their imputation. Family structure was not accounted for during the 
imputation process as software had not been developed at the time to do so. Inclusion of 
population-specific phased sequence data has been shown to improve imputation, especially 
in isolated populations, but this was not available at the time the HapMap2 imputation was 
performed [76-78]. 
2.2.3 Rare variants 
CROATIA-Korcula only was genotyped using the Illumina HumanExome BeadChip v1.0 
(“Exome Chip”). The Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) Consortium [79] organised joint genotyping and SNP calling using this chip in 
62,000 individuals of European, African, Asian and Hispanic ancestry. This allowed for 
reliable calling of variants where only one copy of the minor allele may have been present in 
a single cohort and these files were made available to all collaborating cohorts [80]. Since 
CROATIA-Korcula was not part of this joint calling, SNPs were clustered using 
GenomeStudio (Illumina) and cluster files provided from the CHARGE consortium. Further 
quality control was performed following procedures set out by the CHARGE consortium 
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(detailed in [80,81]) to remove variants and people with low call rates (97% cutoff for both 
SNP and individual) and SNPs grossly out of Hardy-Weinberg equilibrium. Y-chromosome 
SNPs which were called in female participants were removed. Y and mitochondrial SNPs 
were also checked to ensure no heterozygous genotypes were present. Finally, X 
chromosome SNPs were checked for heterozygous male genotypes, if > 2 were present, the 
SNP was removed, if <2, the genotype was set to missing. Genotype data for 855 individuals 
and 236, 308 SNPs successfully passed all quality control procedures of which 67,417 SNPs 
were polymorphic. 
2.3 Quantitation of N-Glycosylation 
All methods presented here were performed by external collaborators. Isolation of plasma 
proteins and HPLC glycan measurement was performed at Genos, Zagreb, Croatia and 
NIBRT, Dublin, Ireland. I visited NIBRT for 3 months during the course of my PhD to learn 
how HPLC & UPLC analysis of N-glycans is performed, under the supervision of Barbara 
Adamczyk. 
2.3.1 Glycan release and labelling 
The N-glycans from plasma sample (5 µl) proteins were released and labelled with 2-
aminobenzamide (LudgerTag 2-AB labelling kit Ludger Ltd., Abingdon, UK) as described 
previously [34]. Labelled glycans were dried in a vacuum centrifuge and redissolved in a 
known volume of water for further analysis. 
2.3.2 Sialidase digestion 
After initial HPLC quantification of N-glycans, sialidase digestion was performed to 
improve measurement precision. This removes sialic acid from glycan structures. Aliquots of 
the 2-AB-labelled glycan pool were dried down in 200-µl microcentrifuge tubes. To these, 
the following was added: 1 µl of 500 mM sodium acetate incubation buffer (pH 5.5), 1 µl 
(0.005 units) of ABS, Arthrobacter ureafaciens sialidase (releases a2–3, 6, 8 sialic acid, 
Prozyme, Leandro, CA, USA) and water to make up to 10 µl. This was incubated overnight 
(16–18 h) at 37ºC and then passed through a Micropure-EZ enzyme remover (Millipore, 
Billerica, MA, USA) before applying it to the HPLC column. 
2.3.3 Hydrophilic interaction high-performance liquid chromatography 
(HILIC-HPLC) 
Released glycans were subjected to hydrophilic interaction high performance liquid 
chromatography (HILIC-HPLC) on a 4.6 mm i.d. 5 µm particle packed TSKgel Amide 80 
column (Tosoh Bioscience, Stuttgart, Germany) at 30ºC with 50 mM formic acid adjusted to 
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pH 4.4 with ammonia solution as solvent A and acetonitrile as solvent B. 60 min runs were 
carried out on a 2795 Alliance separation module (Waters, Milford, MA). HPLCs were 
equipped with a Waters temperature control module and a Waters 2475 fluorescence detector 
set with excitation and emission wavelengths of 330 and 420 nm, respectively. The system 
was calibrated using an external standard of hydrolyzed and 2-AB-labelled glucose 
oligomerase from which the retention times for the individual glycans were converted to 
glucose units (GU) [62]. Glycans were analysed on the basis of their elution positions and 
measured in GUs, then compared to reference values in the National Institute for 
Biotechnology and Training’s (NIBRT) ‘‘GlycoBase v3.0 ’’ database 
(http://glycobase.nibrt.ie) for structure assignment [82]. HPLC analysis was performed partly 
at NIBRT in Dublin, Ireland, and partly at the Glycobiology laboratory of Genos Ltd in 
Zagreb, Croatia. Both laboratories used the same columns and separation conditions. 
Duplicate analysis of a number of samples was performed and confirmed full reproducibility 
of the analytical results both within and between laboratories. 
Chromatography yielded a total of 33 directly measured traits. From the HPLC analysis, 
undigested N-glycans were separated into 16 structurally related groups of glycans, referred 
to as glycan peak (GP)1–16. Desialylated 2AB-labelled N-glycans were also separated into 
13 structurally related groups of glycans, referred to as desialylated glycan (DG)1–13. Weak 
anion exchange (WAX) chromatography resulted in four peaks defining the amount of 
sialylation of structures: mono (MonoS), di (DiS), tri (TriS) or tetra (TetraS). The amount of 
N-glycans measured in each of these groups was quantified relatively, as a proportion of the 
total plasma N-glycome. An additional 13 parameters were gained by calculating some 
structural determinants from measured traits. A description of each glycan trait is presented 
in Appendix Table 15 along with equations for the additional 13 derived traits. 
2.4 Quantitation of Immunoglobulin G N-Glycosylation 
All methods presented here were performed by external collaborators. Isolation of IgG and 
UPLC glycan measurement was performed at Genos, Zagreb, Croatia. All mass spectrometry 
methods were performed by colleagues in Manfred Wuhrer’s laboratory at LUMC, Leiden, 
Netherlands. xCGE-LIF methods were performed by colleagues in Erdmann Rapp’s 
laboratory at MPI, Magdaburg, Germany and their associated company, glyXera, 
Magdaburg, Germany. Brief methods are presented here with full methods in the Appendix 
Section 9.1 and in Huffman et al., 2014 [83]. 
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2.4.1 Isolation of IgG 
Immunoglobulin G was isolated from plasma (50 μl) by affinity chromatography using 96-
well protein G monolithic plates (BIA Separations, Ajdovščina, Slovenia). Aliquots were 
sent to each laboratory for IgG N-glycan analysis by the following four methods. 
 
2.4.2 IgG N-Glycosylation by Hydrophilic Interaction Chromatography  
2.4.2.1 Glycan release and labelling  
The N-glycans from the protein G eluates (200 µl dried down and reconstituted to 5 µl) were 
released and labelled with 2-aminobenzamide (LudgerTag 2-AB labelling kit Ludger Ltd., 
Abingdon, UK) as described previously [34]. Labelled glycans were dried in a vacuum 
centrifuge and redissolved in a known volume of water for further analysis. 
2.4.2.2 Hydrophilic interaction chromatography 
2-AB labelled IgG N-glycans were separated by hydrophilic interaction chromatography on a 
Waters Acquity UPLC instrument consisting of a quaternary solvent manager, sample 
manager and a FLR fluorescence detector set with excitation and emission wavelengths of 
330 and 420 nm, respectively. The instrument was under the control of Empower 2 software, 
build 2145 (Waters). Labelled N-glycans were separated on a Waters BEH Glycan 
chromatography column, 100 x 2.1 mm i.d., 1.7 µm BEH particles, with 100 mM 
ammonium formate, pH 4.4, as solvent A and ACN as solvent B. A linear gradient of 75-
62% ACN was used at flow rate of 0.4 ml/min in a 20 min analytical run. Samples were 
maintained at 5°C prior to injection, and the separation temperature was 60°C. The system 
was calibrated using an external standard of hydrolyzed and 2-AB labelled glucose 
oligomers from which the retention times for the individual glycans were converted to 
glucose units (GU). Data processing was performed using an automatic processing method 
with a traditional integration algorithm after which each chromatogram was manually 
corrected to maintain the same intervals of integration for all the samples. The 
chromatograms obtained were all separated in the same manner into 24 peaks and the 
amount of glycans in each peak was expressed as % of total integrated area. Additional 
structures could be derived from these 24 peaks to give a total of 77 structures. All structures 
and formulas are described in Appendix Table 16 . 
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2.4.3 IgG N-Glycosylation by Mass Spectrometry 
2.4.3.1 Trypsin digestion and reverse-phase solid-phase extraction (RP-SPE)  
Aliquots (50 μl) of the protein G eluates were applied to 96-well polypropylene V-bottom 
microtitre plates. Trypsin digestion was performed overnight followed by reverse-phase 
desalting and purification of glycopeptides. 
2.4.3.2 MALDI-TOF-MS  
Purified and desalted tryptic IgG glycopeptides (3 μl) were spotted onto MTP 384 polished 
steel target plates (Bruker Daltonics, Bremen, Germany) and allowed to dry at room 
temperature. Subsequently 1 μl of 5 mg/ml 4-chloro-α-cyanocinnamic acid (Cl-CCA; 95 % 
purity; Bionet Research, Camelford, Cornwall, UK) in 50 % ACN was applied on top of 
each sample and allowed to dry. Glycopeptides were analyzed on an UltrafleX II MALDI-
TOF/TOF mass spectrometer (Bruker Daltonics) operated in the negative-ion reflectron 
mode, since negative-ion mode has been found well-suited for the analysis of IgG 
glycopeptides and specifically for sialylated glycopeptides [84], while reflectron mode 
greatly improves the resolution and sensitivity of the analysis. Ions between m/z 1000 and 
3800 were recorded. To allow homogeneous spot sampling a random walk laser movement 
with 50 laser shots per raster spot was applied and each IgG glycopeptide sum mass 
spectrum was generated by accumulation of 2000 laser shots. Mass spectra were internally 
calibrated using a list of known glycopeptides. Data processing and evaluation were 
performed with FlexAnalysis Software (Bruker Daltonics) and Microsoft Excel, respectively. 
Structural assignment of the detected glycoforms was performed on the basis of literature 
knowledge of IgG N-glycosylation [44,85-89]. The data were baseline subtracted and the 
intensities of a defined set of 27 glycopeptides (16 glycoforms for IgG1 and 11 for IgG2&3) 
were automatically defined for each spectrum as described before [90].  
In Caucasian populations, IgG2 and IgG3 have identical peptide moieties 
(E293EQFNSTFR301) of their tryptic Fc glycopeptides and were, therefore, not distinguished 
by the profiling method [91]. Relative intensities of IgG Fc glycopeptides were obtained by 
integrating and summing four isotopic peaks followed by normalization to the total subclass 
specific glycopeptide intensities, as described previously [90]. Additional structures could be 
derived from these directly measured values to give a total of 103 structures. All structures 
and formulas are described in Appendix Table 17. The list of the assigned IgG1, IgG2&3 
and IgG4 glycopeptides as well as the charge states corresponding m/z values is given in 
Appendix Table 18.  
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2.4.3.3 Reverse phase nano-LC-sheath-flow-ESI-MS (LC-ESI-MS) 
Purified and desalted tryptic IgG glycopeptides were also analysed on an Ultimate 3000 
HPLC system (Dionex Corporation, Sunnyvale, CA, USA), consisting of a degasser unit, 
binary loading pump, dual binary gradient pump, autosampler maintained at 5°C and fitted 
with a 10μl PEEK sample loop, and two column oven compartments set at 30°C. Samples 
(250-5000 nl) were applied to a Dionex Acclaim PepMap100 C18 (5 mm x 300 μm i.d.) SPE 
trap column conditioned with 0.1 % TFA (mobile phase A) for 1 min at 25 μl/min. After 
sample loading the trap column was switched in-line with the gradient and Ascentis Express 
C18 nano-LC column (50 mm x 75 μm i.d., 2.7 μm HALO fused core particles; Supelco, 
Bellefonte, USA) for 8 min while sample elution took place. The separation was coupled to a 
quadrupole-TOF-MS (micrOTOF-Q; Bruker Daltonics, Bremen, Germany) equipped with a 
standard ESI source (Bruker Daltonics) and a sheath-flow ESI sprayer (capillary 
electrophoresis ESI-MS sprayer; Agilent Technologies, Santa Clara, USA). The software 
used to operate the Ultimate 3000 HPLC system and the Bruker micrOTOF-Q were 
Chromeleon Client version 6.8 and micrOTOF control version 2.3, respectively. 
Each LC-MS dataset was calibrated internally using a list of known glycopeptides, exported 
to the open mzXML format by Bruker DataAnalysis 4.0 in batch mode [92] and aligned to a 
master dataset of a typical sample (containing many of the (glyco)peptide species shared 
between multiple samples) using msalign2 [93] and a simple warping script in AWK [94]. 
From each dataset a list of 402 pre-defined features defined as peak maximum within a  mass 
window of + m/z 0.04 and a retention time window of +10 [95] , were extracted using the in-
house developed “Xtractor2D” software and merged to a complete data matrix as described 
previously [65]. The software and ancillary scripts are freely available at www.ms-
utils.org/Xtractor2D. The complete sample-data matrix was finally evaluated using 
Microsoft Excel.  
Structural assignment of the detected glycoforms was performed on the basis of literature 
knowledge of IgG N-glycosylation [44,85-89]. Relative intensities of 20 IgG1, 20 IgG2/3 
and 10 IgG4 glycopeptide species were obtained by integrating and summing the first three 
isotopic peaks of both doubly and triply charged glycopeptide species followed by 
background correction and normalization to the total IgG subclass specific glycopeptide 
intensities. The list of the assigned IgG1, IgG2&3 and IgG4 glycopeptides as well as the 
charge states corresponding m/z values is given in Appendix Table 19 as well as in [65]. 
Additional structures could be derived from these directly measured species to give a total of 
205 structures. All structures and formulas are described in Appendix Table 20. 
44 
 
2.4.4 IgG N-Glycosylation by Multiplex Capillary Gel Electrophoresis 
with Laser-Induced Fluorescence (xCGE-LIF) 
2.4.4.1 Glycan release and labeling 
Approximately 10 μg of the protein G monolithic plate IgG eluates were redissolved in 3 μl 
1× PBS (Sigma-Aldrich) and dispensed into a 96-well microtitre plate (Greiner Bio-One, 
Solingen, Germany). IgG samples were denatured and N-glycans were released using 
PNGase F (BioReagent ≥ 95 %, Sigma-Aldrich). After N-glycan release samples were dried 
in a vacuum centrifuge and stored until labeling at -80°C. N-glycans were labelled with 2-
picoline-borane (2-PB; Sigma-Aldrich). Post derivatization sample clean-up was performed 
by HILIC-solid phase extraction (SPE). Samples were further cleaned to remove free APTS, 
reducing agent and other impurities. The cleaned and labelled N-glycans were either 
analysed immediately by xCGE-LIF or stored at -20°C until required. 
2.4.4.2 xCGE-LIF 
For xCGE-LIF measurement, 1 μl of N-glycan eluate was mixed with 1 μl GeneScan 500 
LIZ Size Standard (Life Technologies, Darmstadt, Germany; 1:50 dilution in Hi-Di 
Formamide) and 9 μl Hi-Di Formamide (Life Technologies). The xCGE-LIF measurement 
was performed in a 3130xl Genetic Analyzer, equipped with a 50 cm 16-capillary array filled 
with POP-7 polymer (all from Life Technologies). After electrokinetic sample injection, 
samples were analysed with a running voltage of 15 kV. Data were collected for 45 min. 
Raw data files were converted to .xml file format using DataFileConverter (Life 
Technologies) and subsequently analysed using the MATLAB (The Mathworks, Inc., 
Natick, MA, USA) based glycan analysis tools glyXtool and glyXalign. GlyXtool was used 
for structural identification by patented migration time normalization to  an internal standard 
and N-glycan database driven peak annotation [96]. The data comparison was performed by 
glyXalign [97]. Additional structures could be derived from to give a total of 92 structures. 
All structures and formulas are described in Appendix Table 21. 
2.4.5 Comparison of Methods for IgG N-Glycosylation Analysis 
UPLC and xCGE-LIF separate glycans based on structure whereas the MS-based methods 
separate glycans based on mass. Another important difference between UPLC and xCGE-
LIF versus MS-based methods is that UPLC and xCGE-LIF analyse glycosylation at the 
level of released glycan while the MS-based methods presented here analyse glycopeptides. 
Although in-depth analysis of released glycans may provide a detailed picture of the glycan 
structure, no information on the original glycan attachment site is provided from UPLC or 
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xCGE-LIF analyses. Such site-specific information can be obtained by the direct analysis of 
glycopeptides. This means that by analysing glycans at the glycopeptide level MS-based 
methods are able to give information about the protein from which the glycan was released. 
However, unlike the MS-based methods used in this study, UPLC and xCGE-LIF provide 
branch-specific information. Figure 8 shows an example IgG spectrum from each of the four 
methods discussed above. This figure was prepared by colleagues at Genos, LUMC and MPI 
and is taken from Huffman et al., 2014 [83]. 
2.5 Statistical Analysis 
2.5.1 GWAS using GenABEL & ProbABEL 
GenABEL and ProbABEL are from the GenABEL suite of programs for association analysis 
(www.genabel.org) [73,98]. GenABEL is a package for R designed for use with directly 
genotyped SNP data whereas ProbABEL is a stand-alone program for use with imputed 
dosages or probabilities. One of the main benefits is their ability to account for relatedness 
among individuals using a kinship matrix rather than requiring a defined pedigree. This is 
especially suited for our populations since, due to their isolated nature, there tends to be 
more complex relatedness then traditional pedigree-based programs allow. It also allows us 
to account for distant, unknown or unreported relatedness that would not exist in a pedigree. 
Association analysis, while accounting for relatedness, is achieved using the “polygenic” and 
“mmscore” functions. The “polygenic” function estimates the parameters of the fitted linear 
mixed model using a maximum likelihood method. This function uses the genomic identity-
by-state kinship matrix generated using the “ibs” function of GenABEL, (described in 
Section 2.2.1).  The output produced can be directly used in GenABEL for association 
analysis, or the residuals (“residualY”) and the inverse of the variance-covariance matrix 
(“InvSigma”) can be extracted for use with ProbABEL, using the “mmscore” function. This 
is a score test for family-based association which takes into account relationship structure 
and allows unbiased estimations of SNP allelic effects when relatedness is present between 
examinees. If association analysis is not the next step, residuals with the polygenic effects 
removed can be extracted as well (“pgresidualY”). 
2.5.2 Meta-Analysis with MetABEL 
MetABEL is a meta-analysis program from the GenABEL suite of programs for association 
analysis (www.genabel.org) [73]. Inverse-variance weighted meta-analysis was carried out 
for all analyses using this program. SNPs with poor imputation quality (R
2
 < 0.3) were 
excluded prior to meta-analysis. 
 
 
Figure 8: Spectrum from 
four methods for analysis 
of IgG glycosylation in the 
same individual. 
(Taken from Huffman et al., 
2014 [83]). Data from IgG N-
glycosylation analysis of the 
same individual by (A) UPLC 
(continuous lines - total IgG N-
glycans), (B) MALDI-TOF-MS 
(dotted lines - IgG1, striated 
lines - IgG2&3, (C) xCGE-LIF 
(continuous lines - total IgG N-
glycans), and (D) LC-ESI-MS 
(dotted lines - IgG1). Structures 
include: pep (peptide moiety), 
blue square (N-
acetylglucosamine), red triangle 
(fucose), green circle 
(mannose), yellow circle 
(galactose), and purple 
diamond (N-acetylneuraminic 
acid). Linkage information is 
given to indicate separation of 
linkage isomers by UPLC and 
xCGE-LIF. Glycan structures 




2.5.2.1 Transformations and Correction for Population Stratification 
Extensive testing was performed on the total N-glycan traits to find best trait-specific models 
with normally-distributed residuals, an essential assumption of the test statistics used for 
GWAS but these often were involving different transformations and adjusted covariates 
depending on the cohort investigated (results not included). In the end it was found that 
quantile normalization was the only transformation that worked consistently across cohorts. 
It allowed a “high-throughput analysis pipeline” to be developed that could be used for all 
traits. Additionally, the properties of the quantile normalisation allowed for comparison of 
effect sizes across traits, and across methods in the case of Chapter 7, since the units are the 
same for all traits after transformation. Quantile-normalisation was performed after 
adjustment for covariates because they may change the shape of the distribution of the 
residuals so would have required a second transformation to ensure normality of the 
residuals for analysis. We have tested the results of performing the adjustments for 
covariates before or after quantile normalisation when the residuals of a model after 
adjustments for covariates are not normally distributed and found very little impact on the 
GWAS results. 
Principal components (PCs) derived from the IBS kinship matrix (described in Section 2.2.1) 
were included as fixed effects to account for population stratification. We have found that it 
is often not necessary but that for some traits some of the first PCs are still significantly 
associated with the phenotype in the mixed model used for analysis i.e. despite inclusion of a 
random polygenic effect derived from the same IBS matrix the PCs are calculated from. It is 
known that very first PCs usually capture geographic locations so may be accounting for 
some unknown environmental confounder. This being said, correlation between the PCs and 
the glycan traits was not tested systematically for all traits and cohorts. I therefore 
acknowledge that this may be an over-correction but is likely to result in a slight loss of 
signal rather than false positives. The choice to include 3 PCs (rather than 2 or 4) is common 
practice in GWAS where it has been shown that 3 PCs generally account for most of the 
population stratification in European populations [99].  
2.5.2.2 Multiple Testing Correction for Total Plasma N-glycans 
To account for the number of traits analysed, a multiple testing correction was applied based 
on the number of directly measured structures (n=33) since the rest were derived, therefore 
are not entirely independent. An association was considered statistically significant at the 
genome-wide level if the P-value for an individual SNP was less than 1.52x10
-09
 and 




. The effect of the 
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most significant SNP in each gene region expressed as a percentage of the variance 
explained was calculated for each glycan trait after adjustment for sex, age and the first three 
PCs in each cohort individually, using the ‘polygenic’ function of the GenABEL package for 
R [73]. 
2.5.2.3 Multiple Testing Correction for IgG N-glycans 
Principal component analysis was performed using R to determine the number of 
independent traits used for these analyses. 21 principal components explained 99% of the 
variance so an association was considered statistically significant at the genome-wide level if 
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2.5.3 IgG N-glycan Replication by Leiden Longevity Study 
All genotyping, quality control, imputation, statistical analysis and IgG N-glycan 
measurement was performed by colleagues in Leiden, the Netherlands. 
The Leiden Longevity Study (LLS) cohort and genotyping methods are described in Section 
2.1.4 and 2.2.1. 1848 individuals with available genotypic and IgG measurements data were 
included in the replication sample. HapMap2 imputed dosages were used for analysis of all 
SNPs from the discovery analysis listed in Table 3. The only exception was rs11621121, 
which had low imputation accuracy and did not pass quality control criteria. For this SNP, a 
set of 11 proxy SNPs from HapMap r. 22 (all with R
2 
> 0.85) were studied. All studied SNPs 
had imputation qualities of 0.3 or greater. In LLS, all IgG measurements were log-
transformed. The score statistic for testing for an additive effect of a diallelic locus on 
quantitative phenotype was used. To account for relatedness in offspring data the kinship 
coefficients matrix was used when computing the variance of the score statistic. Imputation 
was dealt with by accounting for loss of information due to genotype uncertainty [101]. For 
the association analysis of the GWAS data, a score test was applied for the quantitative trait 
correcting for sex and age using an executable C++ program QTassoc 
(http://www.lumc.nl/uh, under GWAS Software).   
IgG was isolated from plasma samples of 1848 participants. Glycosylation patterns of IgG1 
and IgG2 were investigated by analysis of tryptic glycopeptides using MALDI-TOF MS. Six 
glycoforms per IgG subclass were determined by MALDI-TOF-MS. Since the intensities of 
all glycoforms were related to the monogalactosylated, core-fucosylated biantennary species 
(glycoform B), five relative intensities were registered per IgG subclass [102]. Detailed 




2.5.4 Results Interpretation 
Regions of association were visualized using the web-based software LocusZoom [103] to 
display the LD relationship between SNPs in the region. The effect of the most significant 
SNP in each gene region expressed as a percentage of the variance explained was calculated 
for each glycan trait after adjustment for sex, age and the first 3 principal components in 
each cohort individually, using the ‘‘polygenic’’ function of the GenABEL package for R. 
Conditional analysis was undertaken for all significant and suggestive regions. GWAS was 
performed as described above but with the dosage of the top SNP in the region included as 
an additional covariate. This was run only for the chromosome containing the association 
locus. Subsequent meta-analysis was performed as described previously and the results 
visualised using LocusZoom to ensure that the association peak had been removed. 
A preliminary literature search for each associated gene was performed using the NHGRI 
GWAS Catalog [7] for associations reaching genome-wide significance within a study or 
reasonably suggestive, if the sample size was large (≥10 000). Additional associations were 
reported if they were suggestive in a study with a smaller sample size but replicated by 
another population either within the original publication or in another study. SNAP [104] 
was used to look at LD between SNP associations from the literature and this study. 1000 
Genomes Pilot 1 data from the CEU population was used to calculate LD, and SNPs were 
accepted to be tagging the same region if D’ = 1 and r
2
 > 0.8. 
2.5.5 Rare Variant Burden Analysis with seqMeta 
All statistical analyses were performed using the seqMeta package for R version 1.3 (no 
paper published but discussed in [81] and uses methodology from [12,13,105,106]) and 
Exome Chip genotypes. The same phenotypic models were run as for the common variant 
GWAS. This package is able to account for relationship between individuals using an IBS 
kinship matrix. This matrix was generated using only Exome Chip SNPs with a MAF > 5% 
(n~30,000). SNP-to-gene allocations and variant consequences were taken from the SNP 
Information file compiled within the CHARGE consortium [80,81]. 
The unidirectional burden tests [107] assume that all variants collaped into an indicator 
variable are causal and have the same magnitude and direction of effects. Variants 
considered are often restricted to those with low minor allele frequency (cut-off set at 1% or 
5%) presumed likely to be more deleterious and/or those having a “functional” annotation 
(ie. missense, stop-gain, stop-loss or splice site) also indicating a deleterious effect. 
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Therefore these tests are more powerful when these assumptions hold and their power 
declines if they do not. Bidirectional [13] tests are more robust when the variants may have 
effects on a phenotype in opposite directions and thus are more powerful when this is true. 
As the traits’ underlying genetic architecture is unknown and functional effect somewhat of a 
guess, both unidirectional and bidirectional tests were performed to capture both situations. 
Bidirectional (SKAT) and unidirectional (T5) burden tests were performed using only 
variants with a minor allele frequency (MAF) < 5%. Unidirectional burden tests were also 
performed using a 1% MAF threshold (T1). The unidirectional tests were unweighted, so 
were simply based on the number of rare-variants present within an individual in the defined 
“gene”.  All genes needed to contain more than one SNP to be included in the analysis and 
have a cumulative minor allele frequency (cmaf) greater than the frequency calculated for 5 
minor alleles within the meta-analysis sample size. A Bonferroni corrected gene-based p-
value threshold of 1.85x10
-06
 was used for burden tests (0.05/26,965 genes). 
Single variant tests were also run on all SNPs, but only used to further elucidate regions 
which attained significance in the burden tests. 
2.5.6 MODY3 Biomarker Analysis 
Standardised residuals were obtained from the linear regression of each N-glycan trait 
adjusting for age, sex and HbA1c.  HbA1c was included as a covariate in order to remove 
any differences between the groups potentially caused by elevated glucose in the blood due 
to diabetes in T2D and MODY3 patients.  Non-diabetic controls were selected from the 
ORCADES study and were age and sex-matched to the MODY3 cases to have 
approximately 2 non-diabetic controls for each MODY3 case. One-way ANOVA was 
performed on each trait to compare the means of different treatment groups (Controls; T2D; 
MODY3).  This analysis was done including all groups (3 stratum test) as well as for all 
pairwise comparisons in order to determine exactly which groups were statistically different.  
All glycan groups reaching statistical significance were included together in a backwards 
linear regression to determine which glycan groups were required to build the best disease 
prediction model.  All analysis was performed in SPSS 17.0. 
2.5.7 Correlation Analysis of IgG N-glycan Analytical Methods 
All glycan traits from the IgG minimal dataset were adjusted for sex, age and relatedness 
using the “polygenic” function of the GenABEL package for R. The “pgresiduals”, which 
have the polygenic effect removed, were used to calculate Pearson's product-moment 
correlation coefficients and corresponding p-values using the "cor.test" function in the stats 
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package for R [108]. Correlation coefficients were computed using the same individuals used 
for GWAS as the genetic data was required to account for relatedness within the population. 
The correlations were then compared for the same structure from the minimal dataset 




Chapter 3 - Genetic analysis of total plasma protein N-
glycosylation 
3.1 Introduction 
Recent technological advances have allowed N-glycan structures to be measured in a high-
throughput manner. Methods, such as high/ultra performance liquid chromatography 
(HPLC/UPLC), MALDI-TOF mass spectrometry (MS) and capillary electrophoresis (CE), 
allow us to quantitate N-linked glycans from an individual or a pool of proteins in various 
biological samples. Colleagues from the Rudd laboratory at NIBRT in Dublin, Ireland and 
the Lauc laboratory in Zagreb, Croatia, pioneered these high-throughput methods for HPLC 
& UPLC and have found that the variability of glycans far exceeds the variability of proteins 
and DNA [36]. However, within a single individual the composition of the plasma N-
glycome is rather stable over a short period of time [109]. The majority of these N-glycans 
can be influenced to a moderate extent by environmental factors such as smoking, alcohol 
consumption and diet [110]. Heritabilities ranging from <0.010 to 0.581 were reported [36] 
suggesting that the discovery of genes regulating variation in the amount of specific N-
glycan features may be possible.  In this Chapter I will present the first GWAS of plasma N-
glycans in four population isolates [111,112]. 
3.2 Methods 
The CROATIA-Vis, CROATIA-Korcula, ORCADES and NSPHS cohort data used for this 
study are described in the Methods Chapter (Section 2.1). SNP genotyping and quality 
control methods are described in Section 2.2.1. 
In all four populations plasma protein N-glycans were isolated then analysed by HPLC in 
3367 individuals. Detailed methods are contained in Section 2.3. Chromatography yielded a 
total of 33 measured traits: glycan peak (GP)1–16, desialylate glycan (DG)1–13 and four 
traits based on the number of sialic acids (MonoS, DiS, TriS and TetraS). An additional 13 
parameters were gained by calculating some structural determinants from measured traits. A 
description of each glycan trait is presented in Appendix Table 15 along with equations for 
the additional 13 derived traits.  
Data were checked for any extreme values which would indicate gross measurement error. 
After phenotype quality control the number of individuals with complete phenotype, 
covariate and genotype information for the meta-analysis was 3104 for GP, 3093 for DG and 
3148 for WAX. For the maximum sample size (WAX) this consisted of 894 from 
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CROATIA-Vis, 896 from CROATIA-Korcula, 886 from ORCADES and 652 from NSPHS, 
with slightly more women than men (approximately 60:40 split across all cohorts). 
In the discovery populations, genome-wide association analysis was firstly performed for 
each population and then combined using an inverse-variance weighted meta-analysis for all 
traits. Each trait was adjusted for sex, age and the first 3 principal components. The residuals 
were transformed to ensure their normal distribution using quantile normalisation. Initially 
GWAS was performed on directly genotyped data then later rerun using HapMap2 imputed 
genotype dosages. Analysis results for this association only are presented in the results 
section. Results from the initial analysis of directly genotyped data were published in Lauc et 
al. (2010) [112] and Huffman et al. (2011) [111]. Inverse-variance weighted meta-analysis 
was performed using the MetABEL package [73] for R. All methods used for statistical 
analysis are described in more detail in the Methods Chapter (Section 2.5.1). 
Rare variant analysis was undertaken for only the N-glycan traits which achieved a p-value < 
5x10
-08
 in the common variant GWAS using Exome Chip genotypes. This data was available 
in CROATIA-Korcula only (n=855). Analysis was performed using the seqMeta package 
(v1.3) for R. A bidirectional burden test (SKAT) at a 5% MAF threshold and unidirectional 
burden tests using a 5% (T5) or 1% (T1) MAF threshold were performed. A Bonferroni 
corrected gene-based p-value threshold of 1.85x10
-06
 was used for burden tests (0.05/26,965 
genes). See Sections 2.2.3 and 2.5.5 for more detailed information on the genotyping chip 
and statistical methods. 
A table describing which samples contributed to which analysis is found in Appendix Table 
22. 
3.3 Results 
3.3.1 Genome-wide Association Study 
A meta-analysis of genome-wide association results was conducted for 46 plasma N-glycan 
traits (Table 15) measured in four population-based samples, CROATIA-Vis, CROATIA-
Korcula, ORCADES and NSPHS. Initial results from genotype (rather than imputed data) 
suggested that there were no sex-specific differences that could reliably be attributed to sex, 
rather than the sample size difference so sex-specific analyses were not undertaken for the 
imputed dataset (Appendix Table 23). Descriptive statistics and heritabilities for all traits are 
presented in Table 2. Heritability estimates were variable between populations, as might be 
expected given the isolated nature of the populations. However, all traits had at least one 
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population displaying a heritability > 0.2, with most having at least one population in which 
heritability was > 0.4. DG10 showed a fairly consistent heritability across populations (h
2 
= 
0.37–0.46), whereas GP10 was much more variable (h
2
 = 0.23–0.70).  
Meta-analysis summary data for each significantly associated gene region are presented in 
Table 3. Summary data for all SNPs achieving a P-value<1x10
-07
 are presented in Appendix 
Table 24. Quantile–quantile plots for each association were consistent with an excess of true 
genetic associations, with low genomic control inflation for each population (inflation factor 
< 1.05 for all traits in each population (range=0.97-1.04, mean=1.00) as well as the meta-
analysis (range=0.98-1.02, mean=1.00)), suggesting that the observed results were not due to 
population stratification. 
The most statistically significant association was found with several SNPs located on 
chromosome 19. GP13, GP14, DG7, DG8, DG9, DG11, DG12 and A-FUC were all 
significantly associated with SNPs in this region. The most significant association was found 
with DG9 for SNP rs3760775 (P = 2.92x10
-45
), located 1.6 kb 5′ of fucosyltranferase 6 
(FUT6, Entrez GeneID: 2528). The effect size of the T allele of rs3760775 was the largest of 
all traits, -0.74 (SE 0.05) for DG9 [z-score units, after adjustment for sex, age and principal 
components (PC)]. Figure 9 shows the cohort level beta values along with their contribution 
to the meta-analysis effect size. The association region for this SNP contains the NRTN, 
FUT6 and FUT3 genes between two recombination hotspots (Figure 9). FUT6 encodes the 
enzyme fucosyltransferase VI, which was reported to be the key enzyme responsible for the 
antennary fucosylation of plasma proteins [113], thus the causal variant(s) probably affect 
this gene. SNP rs3760775 explained 2.3, 8.8, 8.2 and 8.5% of the variance of DG9 (adjusted 
for sex, age and PC) in CROATIA-Vis, CROATIA-Korcula, ORCADES and NSPHS, 
respectively. After conditioning on this top SNP for DG9, another SNP (rs10406157) in the 
same region was still significant (PCOND=9.05x10
-13
) (Figure 10a). It explained an additional 
0.3, 2.1, 1.1 and 9.0% of the variance of DG9 (adjusted for sex, age, PC) on top of 
rs3760775 in CROATIA-Vis, CROATIA-Korcula, ORCADES and NSPHS, respectively. 
This SNP was not well imputed (mean RSq across cohorts = 0.40) therefore these estimates 
should be treated with caution. After adjusting for rs3760775 and rs10406157, a second peak 
remained with the top SNPs covering FUT5 and NDUFA11 which lie adjacent to the 
FUT6/FUT3 region (Figure 10b). The top SNP (rs10421538) does not achieve significance 
but there is an obvious peak which did not appear in the discovery analysis. It explained an 
additional 1.5, 0.9, 1.2 and 0.1% of the variance of DG9 (adjusted for sex, age, PC) on top of 
rs3760775 and rs10406157 in CROATIA-Vis, CROATIA-Korcula, ORCADES and NSPHS,   
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Table 2: Mean, standard deviation and heritabilities for total N-glycan traits. 









Vis 918 56.36 15.54 NA NA NA 
Korcula 898 56.27 13.94 NA NA NA 
ORCADES 889 53.49 15.73 NA NA NA 
NSPHS 656 46.98 20.70 NA NA NA 
GP1 
 
Vis 872 0.18 0.09 0.4227 0.0989 1.90E-05 
Korcula 893 0.16 0.13 0.5919 0.1124 1.39E-07 
ORCADES 878 0.22 0.30 0.3804 0.0743 3.03E-07 
NSPHS 646 0.12 0.07 0.5295 0.0659 9.15E-16 
GP2 
Vis 872 4.15 1.58 0.2304 0.0963 1.68E-02 
Korcula 893 3.41 1.21 0.3031 0.1043 3.65E-03 
ORCADES 878 4.01 1.92 0.2237 0.0640 4.75E-04 
NSPHS 646 4.08 1.62 0.5503 0.0580 2.19E-21 
GP3 
Vis 872 2.12 0.45 0.1251 0.0803 1.19E-01 
Korcula 893 2.03 0.45 0.3671 0.1223 2.69E-03 
ORCADES 878 2.50 0.86 0.3046 0.0707 1.63E-05 
NSPHS 646 2.03 0.43 0.5761 0.0826 3.06E-12 
GP4 
Vis 872 5.94 1.16 0.1941 0.0826 1.88E-02 
Korcula 893 5.06 1.13 0.4594 0.1015 6.06E-06 
ORCADES 878 6.46 2.03 0.3134 0.0650 1.44E-06 
NSPHS 646 5.91 1.33 0.4467 0.0499 3.42E-19 
GP5 
Vis 872 2.28 0.41 0.3896 0.0992 8.57E-05 
Korcula 893 2.48 0.45 0.4247 0.0990 1.78E-05 
ORCADES 878 3.87 1.00 0.1417 0.0496 4.30E-03 
NSPHS 646 2.16 0.41 0.5511 0.0673 2.66E-16 
GP6 
Vis 872 4.10 0.86 0.2163 0.0835 9.61E-03 
Korcula 893 3.61 0.82 0.4900 0.0940 1.86E-07 
ORCADES 878 5.11 1.18 0.2821 0.0691 4.47E-05 
NSPHS 646 4.24 0.88 0.4275 0.0609 2.28E-12 
GP7 
Vis 872 10.58 2.30 0.1215 0.0706 8.53E-02 
Korcula 893 11.11 3.05 0.1659 0.0714 2.02E-02 
ORCADES 878 15.18 2.48 0.2162 0.0497 1.39E-05 
NSPHS 646 9.32 1.44 0.4154 0.0684 1.23E-09 
GP8 
Vis 872 9.97 1.54 0.2067 0.0869 1.74E-02 
Korcula 893 9.10 1.45 0.3823 0.0816 2.82E-06 
ORCADES 878 10.18 1.70 0.5071 0.0736 5.43E-12 
NSPHS 646 9.64 1.44 0.3986 0.0680 4.51E-09 
GP9 
Vis 872 36.92 3.01 0.2766 0.1002 5.79E-03 
Korcula 893 38.02 3.05 0.5443 0.1043 1.80E-07 
ORCADES 878 33.95 4.70 0.0480 0.0405 2.36E-01 
NSPHS 646 37.71 2.95 0.4769 0.0598 1.47E-15 
GP10 
Vis 872 7.55 1.77 0.2298 0.0977 1.87E-02 
Korcula 893 7.52 1.47 0.4901 0.0830 3.46E-09 
ORCADES 878 5.87 2.53 0.3664 0.0774 2.19E-06 
NSPHS 646 7.96 1.49 0.6962 0.0838 9.80E-17 
GP11 
Vis 872 2.35 0.67 0.2916 0.0996 3.42E-03 
Korcula 893 1.67 0.44 0.3362 0.0757 8.83E-06 
ORCADES 878 2.59 0.61 0.2297 0.0580 7.46E-05 
NSPHS 646 1.50 0.20 0.1230 0.0553 2.63E-02 
GP12 
Vis 872 1.48 0.29 0.4744 0.1021 3.38E-06 
Korcula 893 1.91 0.52 0.5393 0.0885 1.09E-09 
ORCADES 878 2.56 0.99 0.1916 0.0617 1.90E-03 
NSPHS 646 1.78 0.32 0.4650 0.0743 3.90E-10 
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Vis 872 4.92 1.41 0.5732 0.1047 4.38E-08 
Korcula 893 5.55 1.52 0.4723 0.0949 6.41E-07 
ORCADES 878 3.03 1.41 0.2583 0.0607 2.11E-05 
NSPHS 646 5.64 1.57 0.6405 0.0757 2.55E-17 
GP14 
Vis 872 6.33 1.42 0.4792 0.0953 4.90E-07 
Korcula 893 6.66 1.56 0.4247 0.1009 2.54E-05 
ORCADES 878 3.77 1.85 0.3338 0.0692 1.41E-06 
NSPHS 646 6.19 1.54 0.4446 0.0728 1.01E-09 
GP15 
Vis 872 0.45 0.17 0.3487 0.0962 2.89E-04 
Korcula 893 0.61 0.19 0.4933 0.0878 1.95E-08 
ORCADES 877 0.33 0.48 0.2501 0.0624 6.18E-05 
NSPHS 646 0.62 0.20 0.5401 0.0809 2.44E-11 
GP16 
Vis 872 0.67 0.23 0.2330 0.0836 5.33E-03 
Korcula 893 1.09 0.27 0.3510 0.1041 7.49E-04 
ORCADES 874 0.38 0.28 0.2677 0.0644 3.19E-05 
NSPHS 646 1.11 0.25 0.2952 0.0679 1.39E-05 
DG1 
Vis 893 0.19 0.09 0.5359 0.1172 4.82E-06 
Korcula 884 0.20 0.12 0.5244 0.1132 3.64E-06 
ORCADES 850 0.22 0.24 0.3824 0.0694 3.61E-08 
NSPHS 646 0.15 0.07 0.5491 0.0673 3.55E-16 
DG2 
Vis 893 4.21 1.53 0.2809 0.0981 4.19E-03 
Korcula 884 3.59 1.15 0.2675 0.1013 8.26E-03 
ORCADES 850 3.77 1.38 0.1896 0.0564 7.71E-04 
NSPHS 646 4.29 1.58 0.5477 0.0578 2.68E-21 
DG3 
Vis 893 2.71 0.51 0.1621 0.0842 5.42E-02 
Korcula 884 2.72 0.50 0.4032 0.1225 9.97E-04 
ORCADES 850 3.18 0.70 0.2752 0.0605 5.46E-06 
NSPHS 646 2.65 0.51 0.4444 0.0796 2.41E-08 
DG4 
Vis 893 7.00 1.27 0.1569 0.0756 3.80E-02 
Korcula 884 6.27 1.18 0.3812 0.1007 1.54E-04 
ORCADES 850 6.58 1.36 0.3287 0.0529 5.36E-10 
NSPHS 646 7.12 1.48 0.4774 0.0535 4.70E-19 
DG5 
Vis 893 49.19 3.58 0.0062 0.0085 4.67E-01 
Korcula 884 50.51 3.97 0.2749 0.0902 2.32E-03 
ORCADES 850 51.26 2.86 0.3157 0.0755 2.92E-05 
NSPHS 646 48.89 3.43 0.4168 0.0553 4.93E-14 
DG6 
Vis 893 16.00 2.94 0.1693 0.0738 2.18E-02 
Korcula 884 14.22 2.61 0.4431 0.0930 1.90E-06 
ORCADES 850 13.87 2.33 0.3715 0.0815 5.14E-06 
NSPHS 646 15.26 2.55 0.5114 0.0780 5.54E-11 
DG7 
Vis 893 1.55 0.41 0.4590 0.0993 3.78E-06 
Korcula 884 1.62 0.50 0.2456 0.0775 1.54E-03 
ORCADES 850 1.49 0.40 0.5588 0.0804 3.65E-12 
NSPHS 646 1.61 0.73 0.4618 0.0595 8.13E-15 
DG8 
Vis 893 10.92 2.07 0.5337 0.0951 1.99E-08 
Korcula 884 11.90 2.25 0.4307 0.1000 1.66E-05 
ORCADES 850 11.70 2.61 0.3506 0.0641 4.57E-08 
NSPHS 646 11.96 2.29 0.6243 0.0732 1.49E-17 
DG9 
Vis 893 3.67 1.31 0.4860 0.0941 2.44E-07 
Korcula 884 3.80 1.41 0.4484 0.0956 2.71E-06 
ORCADES 850 3.43 1.46 0.4401 0.0727 1.40E-09 
NSPHS 646 3.37 1.46 0.5928 0.0676 1.92E-18 
DG10 
Vis 893 1.08 0.18 0.3876 0.0995 9.83E-05 
Korcula 884 1.16 0.19 0.4571 0.0998 4.64E-06 
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ORCADES 850 1.02 0.40 0.3884 0.0667 5.73E-09 
NSPHS 646 1.01 0.17 0.3692 0.0685 7.09E-08 
DG11 
Vis 893 2.18 0.54 0.4542 0.0878 2.34E-07 
Korcula 884 2.45 0.55 0.4045 0.0985 4.04E-05 
ORCADES 850 2.23 0.77 0.1779 0.0612 3.62E-03 
NSPHS 646 2.41 0.58 0.4712 0.0671 2.13E-12 
DG12 
Vis 893 0.71 0.31 0.3446 0.0831 3.36E-05 
Korcula 884 0.79 0.31 0.3633 0.0908 6.32E-05 
ORCADES 849 0.67 0.35 0.3486 0.0712 9.65E-07 
NSPHS 646 0.67 0.32 0.5331 0.0651 2.55E-16 
DG13 
Vis 893 0.58 0.30 0.1128 0.0697 1.06E-01 
Korcula 884 0.78 0.25 0.3057 0.0915 8.31E-04 
ORCADES 843 0.61 0.32 0.1667 0.0661 1.17E-02 
NSPHS 646 0.61 0.20 0.2943 0.0655 6.91E-06 
MonoS 
Vis 900 24.60 3.26 0.3824 0.0994 1.19E-04 
Korcula 896 23.65 3.90 0.3657 0.1037 4.21E-04 
ORCADES 886 27.48 3.99 0.3163 0.0753 2.66E-05 
NSPHS 652 22.59 2.57 0.4633 0.0769 1.68E-09 
DiS 
Vis 900 58.43 2.32 0.5289 0.0983 7.48E-08 
Korcula 896 57.30 2.47 0.3808 0.1174 1.18E-03 
ORCADES 886 57.35 2.76 0.4434 0.0686 1.02E-10 
NSPHS 652 60.00 1.97 0.3395 0.0599 1.44E-08 
TriS 
Vis 900 14.86 2.07 0.3880 0.0954 4.78E-05 
Korcula 896 15.06 2.34 0.4334 0.0997 1.38E-05 
ORCADES 886 13.34 2.65 0.1575 0.0639 1.37E-02 
NSPHS 652 15.15 2.00 0.4191 0.0710 3.56E-09 
TetraS 
Vis 900 2.11 0.69 0.3962 0.1025 1.11E-04 
Korcula 896 3.99 1.29 0.4152 0.0896 3.55E-06 
ORCADES 886 1.71 0.67 0.0438 0.0398 2.71E-01 
NSPHS 652 2.26 0.54 0.4352 0.0753 7.65E-09 
BAMS 
Vis 863 30.77 3.11 0.3662 0.0961 1.39E-04 
Korcula 879 30.40 3.59 0.2429 0.0954 1.09E-02 
ORCADES 840 38.10 4.19 0.1593 0.0491 1.17E-03 
NSPHS 646 28.46 3.96 0.3269 0.0629 2.01E-07 
BADS 
Vis 863 70.25 3.86 0.3057 0.0990 2.01E-03 
Korcula 879 71.29 4.33 0.3453 0.0989 4.82E-04 
ORCADES 840 63.71 6.87 0.0000 0.0000 4.92E-01 
NSPHS 646 70.92 8.64 0.3833 0.0725 1.22E-07 
BA 
Vis 893 80.85 2.39 0.3095 0.0861 3.26E-04 
Korcula 884 79.12 2.76 0.4419 0.1100 5.91E-05 
ORCADES 850 80.36 3.64 0.1924 0.0542 3.88E-04 
NSPHS 646 79.96 2.54 0.3887 0.0750 2.21E-07 
TRIA 
Vis 893 15.67 1.88 0.3525 0.0915 1.17E-04 
Korcula 884 16.85 2.20 0.4536 0.1108 4.23E-05 
ORCADES 850 16.15 2.75 0.1968 0.0529 2.00E-04 
NSPHS 646 16.35 2.00 0.4347 0.0777 2.22E-08 
TA 
Vis 893 3.48 0.85 0.2741 0.0758 2.97E-04 
Korcula 884 4.03 0.78 0.3721 0.0970 1.25E-04 
ORCADES 850 3.49 1.16 0.1700 0.0606 5.06E-03 
NSPHS 646 3.69 0.73 0.3241 0.0678 1.73E-06 
C-FUC 
Vis 893 24.54 4.35 0.1061 0.0629 9.14E-02 
Korcula 884 22.00 4.10 0.3835 0.0933 3.95E-05 
ORCADES 850 21.27 3.37 0.3915 0.0832 2.51E-06 
NSPHS 646 23.80 3.87 0.4972 0.0732 1.11E-11 
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Vis 893 3.06 0.82 0.4338 0.1043 3.18E-05 
Korcula 884 3.12 0.99 0.2855 0.0794 3.23E-04 
ORCADES 850 2.84 0.77 0.5015 0.0781 1.34E-10 
NSPHS 646 3.18 1.41 0.4539 0.0658 5.42E-12 
A2 
Vis 863 0.19 0.09 0.5117 0.1159 1.00E-05 
Korcula 879 0.18 0.12 0.5671 0.1131 5.33E-07 
ORCADES 840 0.22 0.27 0.3791 0.0742 3.23E-07 
NSPHS 647 0.14 0.07 0.5387 0.0654 1.75E-16 
G0 
Vis 893 4.40 1.57 0.2747 0.0990 5.53E-03 
Korcula 884 3.79 1.19 0.2624 0.1046 1.21E-02 
ORCADES 850 3.99 1.44 0.2043 0.0573 3.64E-04 
NSPHS 647 4.43 1.62 0.5331 0.0575 1.74E-20 
G1 
Vis 893 9.71 1.48 0.1576 0.0825 5.62E-02 
Korcula 884 8.99 1.37 0.3513 0.1044 7.66E-04 
ORCADES 850 9.75 1.75 0.3089 0.0538 9.68E-09 
NSPHS 647 9.75 1.66 0.5015 0.0575 2.71E-18 
G2 
Vis 893 66.74 2.81 0.1504 0.0719 3.64E-02 
Korcula 884 66.34 3.03 0.2573 0.0893 3.96E-03 
ORCADES 850 66.62 2.63 0.2217 0.0681 1.14E-03 
NSPHS 647 65.65 3.88 0.3982 0.0499 1.49E-15 
G3 
Vis 872 12.73 1.92 0.3933 0.1023 1.22E-04 
Korcula 893 14.13 2.31 0.4157 0.1107 1.74E-04 
ORCADES 878 9.37 3.58 0.2646 0.0648 4.44E-05 
NSPHS 654 13.45 2.50 0.3638 0.0679 8.41E-08 
G4 
Vis 872 1.12 0.36 0.2457 0.0854 4.00E-03 
Korcula 893 1.70 0.43 0.4267 0.1005 2.16E-05 
ORCADES 878 0.72 0.66 0.2436 0.0625 9.57E-05 
NSPHS 654 1.71 0.45 0.3406 0.0675 4.55E-07 
N: number of samples with both genotype and trait data available; Mean: trait mean, SD: trait 
standard deviation; h
2
: heritability estimate; se(h
2
): standarad error of the heritability 
estimate; p(h
2
): p-value for heritability estimate  




Table 3: Genome-wide significant (P<1.52x10-09) or strongly suggestive (P<5x10-08) SNP associations with total plasma N-
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 -0.237 (0.043) 0.228 0.483 1 1 FCGR2C GP4  
2 rs2681019 3.73x10
-08
 -0.144 (0.026) 0.448 0.991 4 1 no genes +/- 400kb DG3  
2 rs13030345 2.66x10
-09
 -0.210 (0.035) 0.186 0.868 7 1 MRPL33; RBKS DG3  
4 rs13107325 4.73x10
-09
 0.284 (0.048) 0.076 0.903 1 1 BANK1; SLC39A8 GP5  
6 rs3094093 1.69x10
-08
 0.247 (0.044) 0.101 0.755 1 1 MDC1 GP1  
11 rs7948031 3.93x10
-08
 -0.233 (0.042) 0.116 0.930 2 1 B3GAT1 DG13  
nHits:number of SNPs with GW-significant or strongly suggestive association; nTraits:number of N-glycan traits associated with the region at GW-
significant level; MAF: minor allele frequency; Mean RSq: average imputation quality (RSq) across meta-analysis populations 
*
 effect size is for the minor allele in standard deviation units after adjustment for sex, age and first 3 principle components; 
+
 description of the traits 
provided in Table 15; 
$









Figure 9: Significance (a) and Forest (b) plots for chromosome 19 region of 
the DG9 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 








Figure 10: Significance plot for chromosome 19 region of the DG9 meta-
analysis after conditioning on (a) rs3760775 and (b) rs3760775 + rs10406157. 
 -Log
10
 of the p-values are plotted against chromosome position. The most significant SNP is 
labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown based 




respectively. A final analysis of DG9 conditioning on all three SNPs removed all signal from 
the region. This was the only association which had a secondary association peak after 
conditional analysis. 
An association peak containing 248 SNPs was located in the region encompassing the 
fucosyltranferase 8 (FUT8, Entrez GeneID: 2530) gene on chromosome 14 (Figure 11). 
SNPs in this region were associated with DG1, DG6, DG10, GP1, GP10, C-FUC and A2. 
The FUT8 gene product, fucosytransferase VIII, is responsible for the core fucosylation of 
N-glycans and all SNP association effects were in a manner consistent with the biological 
role of the FUT8 enzyme [45]. The most significant signal for DG1 was located 102kb 5′ of 
the gene (rs11847263, P = 7.57x10
-31
). It explained 2.8, 9.3, 3.0 and 3.0% of the variance of 
DG1 (adjusted for sex, age and PC) in CROATIA-Vis, CROATIA-Korcula, ORCADES and 
NSPHS, respectively. All SNPs significantly associated with DG1 levels were in high LD (r
2
 
>0.5) and located between two recombination hotspots, while no associations were found 
with SNPs located outside these boundaries nor with other genes located within this 
association interval.  
Five SNPs on chromosome 12, the most significant being rs7310409, showed genome-wide 
significant associations with DG7 (P = 2.63x10
-13
). SNPs within this region were also 
associated with GP13 (P = 3.47x10
-09
), GP15 (P = 3.96x10
-08





) and FUC-A (P=1.31x10
-11
). All SNPs are located within or 5′ of the HNF1 
homeobox A (HNF1A, Entrez GeneID: 6927) gene region, with rs7310409 located 
intronically. Four other genes are located between the recombination hotspots that comprise 
the boundaries of the association interval, C12orf27, HNF1A-AS1, C12orf43 and OASL 
(Figure 12); however, none of the most significantly associated SNPs are located in these 
genes. An antisense transcript (HNF1A-ASI) is present in this region so even though the top 
SNP is in HNF1A, it is possible that it is affecting the regulation of the antisense transcript. 
Further functional work would need to be undertaken to investigate this fully. SNP 
rs7310409 explained 3.5, 1.2, 1.0 and 2.5% of the variance of sex-, age- and PC-adjusted 
DG7 in CROATIA-Vis, CROATIA-Korcula, ORCADES and NSPHS, respectively. 
An association peak on chromosome 2 was associated with DG11 and TA, a derived trait 
quantifying tetra-antennary glycans. The top SNP, rs2442046, (P = 6.09x10
-10
, P = 1.79x10
-
10
) is intronic within the gene encoding mannosyl (alpha-1,6)-glycoprotein (beta-1,6)-N-
acetylglucosaminyltransferase (MGAT5, Entrez GeneID: 4249). There is an area of high 
recombination in the middle of the MGAT5, indicating that the causal variant is most likely 









Figure 11: Significance (a) and Forest (b) plots for chromosome 14 region of 
the DG1 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 









Figure 12: Significance (a) and Forest (b) plots for chromosome 12 region of 
the DG7 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 








Figure 13: Significance (a) and Forest (b) plots for chromosome 2 region of 
the TA meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 




0.184 (SE 0.030) for DG11 and 0.187 (SE 0.029) for TA (z-score units, after adjustment for 
sex, age and PC). SNP rs2442046 explained 1.2, 1.6, 0.8 and 1.7% of the variance of sex-, 
age- and PC-adjusted TA in CROATIA-Vis, CROATIA-Korcula, ORCADES and 
NSPHS,respectively. 
A group of SNPs on chromosome 3 were significantly associated with tetrasialylated glycans 
(TetraS) with top SNP rs9829667 (P = 2.12 x10
-12
).  All associated SNPs are found 3′ of 
solute carrier family 9, member 9 (SLC9A9 Entrez GeneID: 285195). The effect size for the 
minor allele rs9829667 is 0.217 (SE 0.031) (z-score units, after adjustment for sex, age and 
PC). All significant SNPs fall between the 3′ end of the SLC9A9 gene and just before the 3′ 
end of CHST2 but not within CHST2, which is oriented tail-to-tail with SLC9A9 (Figure 14). 
There is a large spike in the recombination rate separating the region of association from the 
3′ end of CHST2 so the causal variant most likely falls in the region closer to SLC9A9. SNP 
rs9829667 explained 3.1, 1.4, 0.9 and 2.4% of the variance of tetrasialylated glycans 
(adjusted for sex, age and PC) in CROATIA-Vis, CROATIA-Korcula, ORCADES and 
NSPHS, respectively. 
Finally, a region on chromosome 16 was associated with levels of GP7, TriS, BAMS, BA 
and G3. The top SNP in the region was rs217181 and was most significantly associated with 
G3 (P= 8.58x10
-13
), explaining 2.9, 2.0, 0.7 and 3.1% of the variance (adjusted for age, sex 
and PCs) in CROATIA-Vis, CROATIA-Korcula, ORCADES and NSPHS. This SNP is 
located just 3’ of haptoglobin-related protein (HPR, Entrez GeneID: 3250) (Figure 15). 
Other genes in the region include hatoglobin (HP, Entrez GeneID: 3240) and dihydroorotate 
dehydrogenase (DHODH, Entrez GeneID: 1723). There are many genes in this region 
without a recombination spike, but none have any obvious relation to N-glycosylation, 
therefore it is not certain what functional unit (gene, miRNA, regulatory region, etc.) is 
causing this association. 
A peak on chromosome 1 achieved strongly suggestive p-values with the association of GP4 
(Figure 16). This region contains many genes, several of which belong to thelow-affinity 
immunoglobulin gamma Fc receptor family. LD information was not available within the 
EUR 1000G dataset used for plotting. The top SNP was rs1984769 (P=2.54 x10
-08
) which is 
located within Fc fragment of IgG, low affinity IIc (FCGR2C, EntrezGeneID: 9103) which is 
a receptor for CD32. 
Two additional peaks on chromosome 2 were strongly suggestively associated with DG3. 
The first had no genes located +/- 400kb of the top SNP (rs2681019, P=3.73 x10
-08








Figure 14: Significance (a) and Forest (b) plots for chromosome 3 region of 
the TetraS meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 








Figure 15: Significance (a) and Forest (b) plots for chromosome 16 region of 
the G3 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 









Figure 16: Significance (a) and Forest (b) plots for chromosome 1 region of 
the GP4 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 









Figure 17: Significance (a) and Forest (b) plots for the first chromosome 2 
region of the DG3 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 









Figure 18: Significance (a) and Forest (b) plots for the second chromosome 2 
region of the DG3 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 




depicted in Figure 17. The second peak was located in another region containing many genes 
with widespread LD so the true associated gene cannot be determined from these analyses 
alone (Figure 18). The top SNP, rs13030345 (P=2.66 x10
-09
), is located between the 3’ ends 
of mitochondrial ribosomal protein L33 (MRPL33, Entrez GeneID: 9553) and ribokinase 
(RBKS, EntrezGeneID: 64080). 
A single missense mutation in solute carrier family 39 (zinc transporter), member 8 
(SLC39A8 Entrez GeneID: 64116) on chromosome 4 was strongly suggestively associated 
with levels of GP5 (rs13107325, P=4.73 x10
-09
) (Figure 19). The minor allele (T) encodes an 
Ala to Thr change at amino acid 391. It explained 1.9, 2.3, 0.1 and 0.7% of the variance of 
GP5 (adjusted for sex, age and PC) in CROATIA-Vis, CROATIA-Korcula, ORCADES and 
NSPHS.  
A single region on chromosome 6 was strongly suggestively associated with levels of GP1. 
A single intronic SNP rs3094093 in mediator of DNA-damage checkpoint 1 gene (MDC1, 
Entrez GeneID: 9656 achieved suggestive significance with GP1 (P=1.69x10
-08
). There are 
many genes in this region with widespread LD which makes it difficult to pinpoint the locus 
causing the association (Figure 20).  
A single SNP located on chromosome 11, rs7948031, was strongly suggestively associated 
with DG13 (P = 3.93x10
-08
). This SNP is located in the final intron of the b-1,3-
glucuronyltransferase1 (B3GAT1, Entrez GeneID: 27087) gene. There is a spike in the 
recombination rate towards the end of B3GAT1; therefore, the variant causing the 
association is most likely located 5′ of this spot (Figure 21).  Some functional follow-up was 
undertaken based on the intial GWAS results from genotyped rather than imputed data and 
this gene was selected due to the known biological role of B3GAT1. 
3.3.2 Rare Variant Analysis 
Rare variant burden tests were successfully run for all 10 N-glycan traits which gave 
genome-wide significant or strongly suggestive p-values in the common variant GWAS. 
There were approximately 791 people with both genotype and phenotype information 
(depending on the phenotype) which is approximately 90 people less than with HapMap2 
imputed data.  
No genes achieved the Bonferroni-corrected threshold for any trait or analysis. When 
looking only at the genes that achieved a p-value < 5x10
-08
 in the common variant GWAS, 
only FUT8 achieved a p-value < 0.05, however, only one SNP in this gene region had a 
MAF < 5% (rs2229678, MAF= 0.030, P= 2.13x10
-03








Figure 19: Significance (a) and Forest (b) plots for chromosome 4 region of 
the GP5 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 








Figure 20: Significance (a) and Forest (b) plots for chromosome 6 region of 
the GP1 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 








Figure 21: Significance (a) and Forest (b) plots for chromosome 11 region of 
the DG13 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 




but a single (low-frequency) SNP association. The P-value presented is for the single SNP 
analysis, but is equivalent to the SKAT and T5 gene-based P-values for FUT8 since this was 
the only SNP tested. After conditioning on the most significant common variant in the region 
(rs7159888, MAF=0.464, P=1.45x10
-11
), the effect for this SNP is still nominally significant 
(Pcond=1.6313x10
-02
). Conditioning on the rare SNP has little effect on the common variant 
(Pcond=8.87x10
-11
). This low-frequency variant is not present in the HapMap2 imputed data 
and codes for a lysine to glutamine change at amino acid 101 of FUT8. This finding is 
interesting by potentially highlighting a second contributing signal independent of the 
common signal but needs to be taken with caution until replicated due to the extremely small 
sample size. 
3.4 Discussion 
This study represents the first analysis of N-glycans in a population sample of this size. For 
some traits, there appears to be some differences in both the sample mean and variance, and 
heritability estimates between populations. Since all populations were isolates this could be 
down to population-specific differences (environmental or genetic) as well as differences in 
cohort plasma sample collection, processing and storage. It is also possible that this is due to 
the measurements themselves caused by uncorrected batch effects 
(operator/machine/laboratory) or subtle differences in the laboratory procedure between 
cohorts. Recent work within the glycobiology laboratory group has identified batch effects 
and several collaborating groups have been investigating the best practices for correcting 
these in glycan data. These had not been established at the time these data were analysed so 
it is acknowledged that there are batch effects within this dataset which have not been 
accounted for. Due to collection procedures in the Croatian cohorts, individuals tended to 
come to the recruitment centre with their family members, so in the process of accounting 
for relatedness, the batch effects are likely to have been also partially removed. This is not 
the case for ORCADES where sample order does not correlate with relatedness. Preliminary 
reports that batch correction methods show more of an effect on GWAS p-values in 
ORCADES than in the CROATIA cohorts support this. Presence of batch effects also has 
implications for the heritability estimates which may potentially be inflated in the CROATIA 
cohorts. Regardless, initial reports of results after correction for the batch effects indicate 
that GWAS is quite robust to these batch effects since GWAS meta-analysis p-values 
changed, in general, by one order of magnitude so will primarily only affect the detection of 





This first genome-wide association meta-analysis of the human plasma N-glycome, 
represented by 46 N-glycosylation traits analysed from the plasma of 3148 individuals from 
four European populations , yielded several genome-wide significant loci associated with 
quantitation of N-glycans subtypes despite the modest sample size. 
FUT8 encodes the fucosyltransferase responsible for the alpha-(1,6)-fucosylation of the core 
N-acetylglucosamine (GlcNAc) structure of N-glycans [114]. N-glycan groups associated by 
GWAS with the gene region surrounding FUT8 contain fucose attached to their glycan core, 
or were associated with effects in the opposite direction for structures without core fucose, so 
the results are consistent with the known biological role of FUT8. In contrast, groups DG7, 
DG9 and DG12 include glycans containing antennary fucose, and A-FUC was derived as an 
overall measure of antennary fucosylation on biantennary glycans. FUT6 encodes the 
enzyme fucosyltransferase VI, which was reported to be the key enzyme responsible for the 
alpha-(1,3)-fucosylation of plasma N-glycans [113] and is involved in the creation of sialyl-
Lewis X, an E-selectin ligand. FUT3 encodes the enzyme fucosyltransferase III, which has 
both alpha-(1,3)-fucosyltransferase and alpha-(1,4)-fucosyltransferase activities reported 
[115] and has a role in the synthesis of Lewis blood group antigens. Both FUT6 and FUT3 
add fucose to the antenna of an N-glycan structure, therefore the association of FUT8, FUT6 
and FUT3 with N-glycan structures containing core and antennary fucosylation is supported 
by their known biological functions [45]. Recently, the same top SNP in the FUT6 region 
has been associated with tumour biomarkers cancer antigen 19-9 and carcinoembryonic 
antigen in Chinese individuals [116]. In addition, another SNP in this region, rs3760776, has 
been associated with vitamin B12 levels in Chinese men [117]. Although not in high LD 
with our top SNP (CEU: r
2
=0.358, D’=0.711; CHB/JPT: r
2
=0.038, D’=0.288), this was the 
same top SNP that was associated in our initial GWAS using genotyped rather than imputed 
data. Both reported associations are consistant with the reported roles of FUT6 and FUT3 in 
the synthesis of these tumour biomarkers and postulated mechanisms influencing absorption 
of vitamin B12 through the gut. A figure showing where these fucosyltransferases act on the 
generic N-glycan structure from  
 
Figure 3 is found in Figure 22. 
SNPs within HNF1A were associated with several glycan traits but the mechanism for this 
association was not obvious. Functional studies performed by Dr. Abdelkader Essafi, 




regulate the expression of most fucosyltransferase genes (FUT3–11) in liver-derived HepG2 
cells, as well as gene expression levels of key enzymes needed for synthesis of GDP-fucose, 
the substrate for fucosyltransferases. Through this mechanism HNF1A is able to regulate 
both core and antennary fucosylation [112]. Common polymorphisms in HNF1A have been 
associated with many traits now, including variation of the plasma concentrations of C-
reactive protein (CRP) [118-126], low-density lipoprotein [127-129] and total cholesterol 
[128,129], homocysteine [130], urate [131], and gamma-glutamyl transferase (GGT) [132-
134], and have been found to be susceptibility loci for type 2 diabetes [135,136], coronary 
heart disease [137] and pancreatic cancer [138]. Although only one of the GGT studies and 
two of the CRP studies reported the same top SNP as our study, none could be discounted 
from tagging the same region. There is support for the lipid (rs1169288) and coronary heart 
disease loci (rs1169310) to be tagging the same regions as was associated with N-glycan 
concentrations because the reported SNPs are in moderate linkage disequilibrium (LD) with 
our top SNP (rs1169288: r
2
 = 0.532, D′ = 0.945; rs1169288: r
2
 = 0.583, D′ = 0.834). The top 
SNPs in the type 2 diabetes studies (rs7957197: r
2
 = 0.122, D′ = 1; rs7305618: r
2
=0.138, 
D’=0.871) are most likely not tagging the same pleiotropic signal but due to the very high D′ 
value this cannot be completely ruled out without further investigation. 
The MGAT5 gene codes for the enzyme mannosyl (alpha-1,6-)-glycoprotein (beta-1,6)-N-
acetyl-glucosaminyltransferase V (GnT-V), which adds GlcNAc residues to mannose in a 
beta-1,6 orientation on the antennary structure of N-glycans. This is an essential step in the 
generation of tetra-antennary glycans. The majority of structures contained within the DG11 
peak are tetra-antennary glycans [36]; therefore, the associations with DG11 and TA (a 
derived trait quantifying total tetra-antennary glycans) are biologically plausible. Tetra-
antennary glycans are important regulators of membrane function [24] since they affect the 
half-life of numerous receptors on the cell membrane [139]. This has important implications 
for many dynamic processes, from immunity to cancer progression and metastasis. The 
MGAT5 gene product synthesizes cell-surface ligands for galectins—proteins involved in the 
proliferation of T-cells and apoptosis. Loss of MGAT5 expression lowers the threshold 
needed for T-cell activation, and as Mgat5-deficient mice displayed several autoimmune 
phenotypes, it was hypothesized that MGAT5 expression might be implicated in autoimmune 
disorders in humans [140]. Recently, polymorphisms within MGAT5 have been tentatively 
associated with the severity of multiple sclerosis [141,142] in two small studies which may 
support this theory; however, the SNPs reported in these studies do not appear to be tagging 
the same LD blocks as our glycan associated SNPs (r
2
=0.097, D’=0.487). Expression of 




the cell surface allows the tumour cell to retain growth factors such as epidermal growth 
factor and transforming growth factor-beta [143]. 
 
Figure 22: Sites of human N-glycan fucosylation. 
Adapted from Ma et al., 2006 [45]. A generic N-glycan showing sites of fucosylation along 
with the fucosyltransferases responsible. The structures depicted here contain Sialic acid 
(purple diamond), Galactose (red circle), Mannose (green circle) and N-acetylglucosamine 
(GlcNAc, blue square). 
 
SLC9A9, solute carrier family 9 (sodium/hydrogen exchanger), is a proton pump which 
affects pH in the endosomal compartment [144]. This gene was not previously linked to 
glycosylation, but it was recently reported that changes in Golgi pH can impair protein 
sialylation [145], thus the association between SLC9A9 and tetrasialylated glycans makes 
biological sense. Sialic acids are found in cell secretions and are usually the terminal 
component of glycoproteins and glycolipids on the outer cell surface and therefore are 
involved in cell communication and defence. They act to shield recognition sites that may be 




such as hormones, inorganic cations and antibodies [146]. Microorganisms are able to 
exploit the prominent role of sialic acids within the human body by either coating themselves 
with or binding to sialic acid in order to penetrate and infect the cell. A better understanding 
of processes and pathways underlying sialylation could lead to new avenues for the treatment 
of infection and disease [147]. Polymorphisms in SLC9A9 have recently been suggestively 
associated with attention-deficit hyperactivity disorder (ADHD (MIM:143465)) [148,149]. 
The first study reported only a gene-based P-value so it cannot be determined if the variant 
underlying the reported signal could be the same as for the glycosylation signal, whereas in 
the latter study, the reported SNP tagging the disease signal is not in strong LD with our top 
SNP (rs9810857, r
2
= 0.106, D′ = 0.727). Plasma N-glycosylation analysis in ADHD patients 
has also revealed a difference in tetrasialylated glycans between children with ADHD and 
matching controls [150]. Although disease causality cannot be ascertained by this data, the 
associations still provide a novel set of molecules which could act as clinical markers of 
disease. 
SLC39A8 (also know as ZIP8) is located in the plasma membrane and mitochondria and is 
one of the transporters responsible for the cellular import of zinc at the onset of 
inflammation. It is reported to act as a transcriptional target of NF-κB and is involved in a 
negative feedback loop to downregulate proinflammatory responses via IκB kinase activity 
[151]. The same SNP associated here with GP5, has been associated by GWAS with HDL 
cholesterol [128,129], diastolic blood pressure, systolic blood pressure, hypertension [152], 
mean arterial pressure [153] and BMI [154]. The gene itself has been implicated as a 
pleiotropic gene involved in adiposity/obesity related phenotypes, lipids and inflammation 
[155].  
B3GAT1 is a member of the glucuronyltransferase gene family. This gene product functions 
as the key enzyme in a glucuronyl transfer reaction during the biosynthesis of the 
carbohydrate epitope HNK-1. It acts to add a glucuronic acid (GlcA) to the terminal N-
acetyl-lactosamine (Lac) disaccharide to form the HNK-1 epitope precursor [156,157]. The 
HNK-1 epitope is expressed on a subset of human lymphocytes, including natural killer 
cells, but it was not previously reported to exist on plasma proteins. Colleagues from Dr. 
Manfred Wuhrer’s laboratory in Leiden were able to show through mass spectrometry (MS) 
analysis that glucuronic acid is present on some glycans which make up the DG13 plasma 
glycan pool, explaining this association [111]. 
Rare variant analysis yielded little results but was very under-powered due to the small 




rare variants were not present in the cohort therefore many genes only contained one or two 
rare SNPs that were polymorphic. Further studies with larger samples sizes are warranted 
before any conclusions can be drawn. Despite the decision to include only SNPs predicted to 
alter the final protein product, it is possible that not all of these SNPs had an effect on the 
phenotype therefore reduced the power to detect an association. The inclusion of reliable 
information about tissue specific expression and differential transcription may help to 
determine which variants to include in these tests. Both of these issues need to be addressed 
before coming to any strong conclusions with regards to the effect of rare variants on the 
genomic regulation of N-glycans. 
3.5 Conclusion 
Recent advances in high-throughput methods of analysing N-glycans have now made it 
possible to measure these traits in large cohorts. GWAS analyses revealed several 
associations of large effect illuminating the genetic control of distinct biological pathways, 
including fucosylation, sialylation and glucuronyl transfer. Some of these biological 
processes are known to be altered in several disease states. For example, fucosylation of 
acute phase proteins is modified in many diseases, such as acute inflammation [158,159], 
rheumatoid arthritis [160] and diabetes [161], and changes in the levels of fucosylated 
glycans have been shown to be associated with several important pathological processes, 
including cancer and inflammation [162].  Although not the same variant, the finding that 
loci associated with disease (e.g. SLC9A9 in ADHD or HNF1A in MODY3) are modulating 
various glycan species offers novel insight into disease mechanisms and pathways and offers 
new avenues for biomarker discovery. Variation in the glycosylation of plasma proteins 
caused by the polymorphisms identified here could be a predisposing or prognostic factor in 
numerous diseases and warrants further examination of these effects in plasma samples from 





Chapter 4 - Maturity Onset Diabetes of the Young 3 (MODY3) 
N-glycan Biomarker Analysis 
4.1 Introduction 
Since SNPs in HNF1A were shown to be associated with plasma concentrations of various 
N-glycan species, it was hypothesized that N-glycans might provide biomarkers for Maturity 
Onset Diabetes of the Young 3 (MODY3, (MIM: 600496)) which is caused by mutations in 
HNF1A.   
MODY3 is the most common form of monogenic diabetes and is caused by mutations in 
HNF1A [163]. Often MODY3 patients are misdiagnosed as having T2D or type 1 diabetes 
(T1D) [164] and the optimal treatment differs from these other more common disorders with 
MODY3 patients optimally treated with low dose sulfonylurea drugs [165]. The only way to 
reliably diagnose MODY3 is by sequencing the HNF1A gene to look for causal mutations 
[166]. Therefore, N-glycans were tested to determine if they could act as biomarkers to 
prioritise potential MODY3 patients for definitive diagnostic gene sequencing and reduce the 
rate of mis-diagnosis. The results presented here are for the pilot dataset only. 
4.2 Methods 
Plasma N-glycans were analysed by HPLC (by Jayesh Kattla from NIBRT, Dublin, Ireland) 
in 33 MODY3 patients (22 female, 11 males) and 41 T2D patients (22 females, 19 males) 
from the United Kingdom. Age and sex-matched non-diabetic controls were taken from the 
ORCADES dataset (n=59, 40 females, 19 males) to have approximately two non-diabetic 
controls for each MODY patient. The controls were checked to ensure that there were no 
relationships within this group.  Analyses were undertaken to determine which N-glycan 
species was able to distinguish either just the MODY3 patients from the other two groups, or 
classify all three groupings. Only the directly measured traits were tested. Detailed methods 
are described in Sections 2.1.5, 2.3 and 2.5.6 and a table describing which samples 
contributed to this analysis is found in Appendix Table 22. 
4.3 Results 
Results of the ANOVA analysis are reported in Table 4. All structures with a P-value<0.05 
and MODY3 as the category that was different were taken forward for backwards linear 
regression to try to build the best predictive model to discriminate MODY3 from T2D 
patients. The best full model included GP13, DG8, DG9 and DG11. These glycans, as well 




operator characteristic (ROC) curve statistics. The full model gave a correct classification of 
85.9% compared to the null model 57.7% and gave a C-statistic of 0.961. These results are 
shown in Table 5 and Figure 23. 
 




P-Value from ANOVA CATEGORY 
DIFFERENT* C, T, M C, T C, M T, M 
GP1 NO 0.08 0.058 0.455 0.033  
GP2 NO 0.15 0.104 0.699 0.041  
GP3 NO 0.16 0.056 0.533 0.237  
GP4 NO 0.12 0.056 0.345 0.343  
GP5 NO 0.19 0.511 0.113 0.104  
GP6 NO 0.18 0.084 0.303 0.575  
GP7 NO 0.25 0.777 0.195 0.039  
GP8 NO 0.09 0.04 0.087 0.975  
















































DG1 NO 0.25 0.166 0.587 0.161  
DG2 NO 0.21 0.372 0.293 0.070  
DG3 NO 0.23 0.152 0.712 0.112  
DG4 NO 0.28 0.141 0.941 0.205  
DG5 NO 0.25 0.193 0.694 0.132  






















































MonoS NO 0.91 0.737 0.747 0.964  
DiS NO 0.52 0.408 0.362 0.768  
TriS NO 0.18 0.226 0.102 0.513  
TetraS NO 0.17 0.997 0.098 0.062  
SIG GWAS= were SNPs in HNF1A region significantly associated with this N-glycan 
structure; C=Control, T= T2D, M= MODY3 
* DIABETICS (opp) = both T2D and MODY different from controls but in different directions 






Table 5: Percentage of correct classification and receiver operator 
characteristic (ROC) statistics to discriminiate MODY3 from T2D patients 
using plasma N-glycans. 
Trait 
% Correct Classification ROC Statistics 
Null Model Test Model AUC (se) P-value 
GP10 57.7 74.6 0.820 (0.049) 5x10
-06
 
GP11 57.7 62.0 0.720 (0.060) 2x10
-06
 
GP13 57.7 73.2 0.841 (0.048) 1x10
-06
 
GP15 57.7 80.3 0.864 (0.044) <1x10
-06
 
DG7 57.7 77.5 0.859 (0.046) <1x10
-06
 
DG8 57.7 66.2 0.691 (0.064) 6x10
-03
 
DG9 57.7 83.1 0.889 (0.041) <1x10
-06
 
DG10 57.7 81.7 0.848 (0.050) <1x10
-06
 
DG11 57.7 78.9 0.866 (0.045) <1x10
-06
 
Full Model 57.7 85.9 0.961 (0.019) <1x10
-06
 
AUC: area under the ROC curve 




Figure 23: Receiver Operator Characteristic (ROC) Curve for full model to 
discriminate MODY3 from T2D patients. 
ROC plot for the discrimination of MODY3 (blue line) from T2D patients (green line) using 






It is acknowledged that the study design was not ideal, with MODY3 cases from Edinburgh 
and Oxford, T2D cases from Oxford and non-diabetic controls from ORCADES. It was 
attempted to get T2D cases from Edinburgh to match the Edinburgh MODY3 cases but none 
of the available cohorts were willing to contribute samples for N-glycan analysis unless the 
entire large cohort was analysed which was not feasible for this pilot study. ORCADES was 
used as it was the only British cohort with N-glycans measured that was available at the time 
despite the potential allele frequency differences due to its isolated nature. In order to 
prevent some of these potential confounders only N-glycan traits were taken forward that 
were significantly different between MODY3 cases and both the T2D cases and the age- and 
sex-matched ORCADES non-diabetic controls. In doing this, it is noted that this may have 
introduced a bias in feature selection leading to biased estimates of classification accuracy. A 
resampling approach such as bootstrap or cross validation would have been more appropriate 
however, since the main study was undertaken almost immediately after preliminary pilot 
results were presented, further work on this dataset was not pursued. 
The MODY3 biomarker pilot study showed promising results and was taken forward by 
Gaya Thanabalasingham, from Katharine Owen’s group in Oxford, to include T1D patients 
as well as patients with other types of MODY (HNF4A, GCK). N-glycan analysis was 
performed between NIBRT and Genos, Zagreb, Croatia. In contrast to the pilot study, the 
expanded study included patients with either plasma or serum measured, so not all promising 
glycan biomarkers from the pilot (which was plasma-only) could be taken forward. 
However, encouraging results were found using DG9/(DG8+DG9), which represents the 
ratio of fucosylated to nonfucosylated triantennary glycans. This “DG9-index” was able to 
distinguish between MODY3 and T2D patients (C-statistic=0.91, 88% sensitivity, 81% 
specificity) as well as T1D patients (C-statistic=0.94, 88% sensitivity, 88% specificity) 
[167].  Previous studies published by the Oxford group using the same patient samples, 
found high-sensitivity C-reactive protein (hsCRP) to discriminate very well between T2D 
and MODY3 patients (C-statistic=0.94, 83% sensitivity, 86% specificity), but it was not as 
accurate in distinguishing between T1D and MODY3 (C-statistic=0.83) [168,169]. The assay 
for measuring hsCRP is already in use in clinical laboratories, however the methodology 
required for N-glycan analysis is labour intensive and not routinely available in a clinical 
setting. Also, there is no current method for measuring just one or two N-glycan structures, 
although this is not the most time-consuming or labour-intensive step in the process. 
Therefore, the glycan measure is unlikely to be implemented in a clinical setting unless it can 




influenced by the falling cost of targeted gene sequencing so very soon it will be possible to 
simply sequence anyone who fits the typical diagnostic criteria of MODY (age of onset, 
family history of disease). 
4.5 Conclusion 
By starting from a GWAS hit, in which the disease causing gene (HNF1A) has also been 
shown to directly regulate the biomarker (N-glycan) structure, we have removed much of the 
confounding that usually surrounds biomarker discovery. These results show that regardless 
of their role in disease pathogenicity, N-glycans have the potential for use as biomarkers but 
some technical hurdles may need to be addressed before they are implemented into a clinical 




Chapter 5 - Genetic analysis of Immunoglobulin G N-
glycosylation 
5.1 Introduction 
Following on from the success of the total plasma N-glycan GWAS, it was hypothesized that 
refining the analysis to N-glycans from a single protein may increase the ability to identify 
genetic markers and make interpretation of the biological function of resulting genes more 
tractable. Using UPLC, colleagues from the Lauc laboratory in Zagreb showed exceptionally 
high individual variability in N-glycans isolated from IgG and substantial heritability of the 
observed measurements [61]. In this Chapter, I will provide the results from the first GWAS 
of the human IgG N-glycome. 
5.2 Methods 
The CROATIA-Vis, CROATIA-Korcula, ORCADES and NSPHS cohort data was used for 
the discovery study and are described in Methods Section 2.1. HapMap2 imputed dosages 
were used for the genome-wide association studies. Genotyping and imputation methods are 
described in Section 2.2.  
 IgG was isolated using protein G plates and its glycans analysed by UPLC in 2247 
individuals, using methods reported previously ([61] and in Sections 2.4.1 and 2.4.2.). 
Glycans were separated into 24 chromatographic peaks and quantified as relative 
contributions of individual peaks to the total IgG glycome. On the basis of these 24 directly 
measured glycan traits, an additional 54 derived traits were calculated. These are described 
in Appendix Table 16 and were calculated to capture further glycan structural categories that 
were not directly assayed. Extreme outliers (those with values more than 3 times the 
interquartile distances away from either the 75th or the 25
th
 percentile values) were removed 
for each glycan measure to account for errors in quantitation and to remove individuals not 
representative of normal variation within the population. After phenotype quality control, the 
number of individuals with complete phenotype and covariate information for the meta-
analysis was 2247, consisting of 906 men and 1341 women (802 from CROATIA-Vis, 851 
from CROATIA-Korcula, 415 from ORCADES, 179 from NSPHS). 
GWAS was firstly performed for each population and then combined using an inverse-
variance weighted meta-analysis for all traits. Each trait was adjusted for sex, age and 
population substructure using the first 3 principal components. The residuals were 




was used for the association test under an additive model against HapMap2 imputed 
genotype dosages. Inverse-variance weighted meta-analysis was performed using the 
MetABEL package [73] for R. All methods used for statistical analysis are described in more 
detail in the Methods Chapter (Section 2.5). 
Replication of GWAS hits was undertaken within the Leiden Longevity Study (LLS). Cohort 
and genotyping methods are described in Section 2.1.4 and 2.2.1, N-glycan measurement 
methods in Section 2.4.3 and statistical methods in Section 2.5.3. All genotyping, quality 
control, imputation, statistical analysis and IgG N-glycan measurement was performed by 
colleagues in Leiden, the Netherlands. 1848 individuals with available genotypic and IgG N-
glycan data (measured by MALDI-TOF-MS) were included in the replication sample. 
HapMap2 imputed dosages were used for analysis of all SNPs from the discovery analysis 
listed in Table 7. For the association analysis of the GWAS data, a score test was applied for 
the quantitative trait correcting for sex and age using an executable C++ program QTassoc 
(http://www.lumc.nl/uh, under GWAS Software).   
Rare variant analysis was undertaken for only the N-glycan traits which reached genome-
wide significance in the common variant GWAS using Exome Chip genotypes. This data 
was available in CROATIA-Korcula only (n=855). Analysis was performed using the 
seqMeta package (v1.3) for R. A bidirectional burden test (SKAT) at a 5% MAF threshold 
and unidirectional burden tests using a 5% (T5) or 1% (T1) MAF threshold were performed. 
A Bonferroni corrected gene-based p-value threshold of 1.85x10
-06
 was used for burden tests 
(0.05/26,965 genes). See Sections 2.2.3 and 2.5.5 for more detailed information on the 
genotyping chip and statistical methods. 
A table describing which samples contributed to which analysis is found in Appendix Table 
22. 
5.3 Results 
5.3.1 Genome-wide association study and meta-analysis 
Quantitative measurements of 77 IgG N-glycan structures were performed using ultra 
performance liquid chromatography (UPLC) in 2247 individuals from four European 
discovery populations (CROATIA-Vis, CROATIA-Korcula, ORCADES, NSPHS).  A 
description of these traits is presented in Appendix Table 16. This list comprises of 23 
directly measured quantitative IgG glycosylation traits and 54 derived traits. Descriptive 




N-glycan traits (adjusted for sex and age) were variable between populations, just like those 
measured from total plasma. Again, all traits had at least one population displaying a 
heritability > 0.2, with most having at least one population in which heritability was > 0.4. In 
fact, the mean heritability across all traits and all populations was 0.42. Due to the small 
samples sizes in both NSPHS and ORCADES, the heritability estimates for these 
populations may not accurately reflect the true heritabilites.  
Aiming to identify genetic loci involved in IgG N-glycosylation, I performed a GWAS on all 
measures.  Associations at 9 loci reached genome-wide significance (p < 2.27x10
-09
) in the 
discovery meta-analysis and a further 7 loci were strongly suggestive (2.27 x10
-09 
< p < 
5x10
-08
) (Table 7). Summary data for all SNPs achieving a P-value<1x10
-07
 are presented in 
Appendix Table 25. 
Among the nine loci that passed the genome-wide significance threshold, four contained 
genes encoding glycosyltransferases (ST6GAL1, B4GALT1, FUT8 and MGAT3), while the 
remaining five loci contained genes that have not previously been implicated in protein 
glycosylation. In general, the implicated genes were associated with several IgG N-glycan 
traits. Summary data for each gene region showing genome-wide association or found to be 
strongly suggestive are presented in Table 7. The structures for these associated traits are 
found in Figure 24, where possible. Summary data for all single-nucleotide polymorphisms 
(SNPs) and traits with suggestive associations (p<1x10
-07
) are presented in Table 25. All 
analyses were checked for inflation remaining within reasonable limits (meta-analysis 
range=0.96-1.02, mean=1.00). NSPHS was a bit more variable (range=0.87-1.01) which is 
not surprising due to the small sample size.  
The most statistically significant association was observed in a region on chromosome 3 
containing the gene ST6 beta-galactosamide (alpha-2,6)-sialyltranferase 1 (ST6GAL1, 
Entrez GeneID: 6480) (Figure 25). ST6GAL1 codes for the enzyme sialyltransferase 6 which 
adds sialic acid to galactose-containing residues on various glycoproteins including IgG 
glycans, and is therefore a biologically plausible candidate. In this region of about 70 
kilobases (kb) we identified 37 genome-wide significant SNPs associated with 14 different 
IgG glycosylation traits, generally reflecting sialylation of different glycan structures. The 
strongest association was observed for the percentage of  monosialylation of fucosylated 
digalactosylated structures in total IgG glycans (IGP29), with SNP rs11710456 explaining 
17%, 16%, 19% and 3.5% of the trait variation for CROATIA-Vis, CROATIA-Korcula, 
ORCADES and NSPHS respectively (meta-analysis p =6.12x10
-75
). NSPHS had a very small 




Table 6: Mean, standard deviation and heritabilities for IgG N-glycan traits. 








Vis 918 56.36 15.54 NA NA NA 
Korcula 898 56.27 13.94 NA NA NA 
ORCADES 889 53.49 15.73 NA NA NA 
NSPHS 656 46.98 20.70 NA NA NA 
IGP1 
Vis 785 0.22 0.18 0.2776 0.0889 1.80E-03 
Korcula 839 0.17 0.10 0.5202 0.0713 3.07E-13 
ORCADES 404 0.17 0.08 1.01E-08 1.49E-08 5.00E-01 
NSPHS 174 0.26 0.15 1.17E-08 1.73E-08 5.00E-01 
IGP2 
Vis 794 0.84 0.45 0.3261 0.0846 1.17E-04 
Korcula 842 0.82 0.47 0.4510 0.1096 3.86E-05 
ORCADES 409 0.81 0.44 0.7377 0.1390 1.11E-07 
NSPHS 178 0.90 0.63 0.7415 0.1354 4.34E-08 
IGP3 
Vis 802 20.93 6.28 0.2479 0.0914 6.66E-03 
Korcula 851 20.38 5.92 0.5761 0.1130 3.41E-07 
ORCADES 414 20.65 6.10 0.0571 0.0603 3.43E-01 
NSPHS 179 24.81 8.06 0.4289 0.1639 8.88E-03 
IGP4 
Vis 797 0.32 0.11 1.53E-08 2.27E-08 5.00E-01 
Korcula 842 0.31 0.11 0.4727 0.1243 1.43E-04 
ORCADES 405 0.28 0.07 0.2057 0.1092 5.97E-02 
NSPHS 175 0.35 0.14 1.16E-08 1.73E-08 5.00E-01 
IGP5 
Vis 801 5.42 1.61 0.2628 0.0960 6.22E-03 
Korcula 851 5.59 1.61 0.4006 0.1140 4.44E-04 
ORCADES 415 5.08 1.61 0.2962 0.1484 4.60E-02 
NSPHS 179 5.75 1.95 0.5941 0.1690 4.39E-04 
IGP6 
Vis 797 0.77 0.42 0.2104 0.0763 5.83E-03 
Korcula 845 0.75 0.37 0.6217 0.1124 3.14E-08 
ORCADES 413 0.52 0.24 0.5980 0.1365 1.18E-05 
NSPHS 179 0.66 0.33 0.3545 0.1056 7.87E-04 
IGP7 
Vis 802 16.35 1.92 0.1789 0.0760 1.86E-02 
Korcula 851 16.10 1.88 0.5698 0.1028 3.00E-08 
ORCADES 415 18.05 1.79 0.6371 0.1375 3.63E-06 
NSPHS 179 18.49 2.27 0.2922 0.1870 1.18E-01 
IGP8 
Vis 802 7.91 1.15 0.1941 0.0879 2.73E-02 
Korcula 851 7.99 1.26 0.6201 0.1043 2.76E-09 
ORCADES 415 8.94 1.24 0.6423 0.1490 1.62E-05 
NSPHS 179 8.75 1.54 0.3835 0.1736 2.71E-02 
IGP9 
Vis 801 4.72 0.91 0.2964 0.1114 7.77E-03 
Korcula 851 4.67 0.93 0.6427 0.1119 9.33E-09 
ORCADES 414 4.58 0.87 0.6877 0.1354 3.77E-07 
NSPHS 179 4.55 0.90 0.6201 0.1725 3.24E-04 
IGP10 
Vis 801 0.76 0.15 0.3512 0.1042 7.49E-04 
Korcula 847 0.78 0.16 0.4426 0.1079 4.13E-05 
ORCADES 415 0.78 0.15 0.5147 0.1322 9.84E-05 
NSPHS 177 0.68 0.15 0.6359 0.1832 5.17E-04 
IGP11 
Vis 798 1.06 0.51 0.1812 0.0754 1.62E-02 
Korcula 844 1.10 0.54 0.7184 0.1230 5.22E-09 
ORCADES 412 0.89 0.44 0.4803 0.1662 3.85E-03 
NSPHS 179 1.16 0.64 0.6072 0.1336 5.45E-06 
IGP12 
Vis 793 0.29 0.15 0.2180 0.0876 1.28E-02 
Korcula 848 0.23 0.06 0.5256 0.1119 2.62E-06 
ORCADES 406 0.24 0.06 0.1767 0.1135 1.19E-01 












Vis 802 11.39 3.55 0.3572 0.0970 2.30E-04 
Korcula 851 11.24 3.41 0.6376 0.1264 4.59E-07 
ORCADES 415 12.51 3.67 0.3795 0.1223 1.91E-03 
NSPHS 179 12.37 4.34 0.3106 0.1685 6.53E-02 
IGP14 
Vis 802 1.44 0.35 0.2812 0.0946 2.97E-03 
Korcula 851 1.54 0.34 0.4569 0.1231 2.06E-04 
ORCADES 415 1.67 0.32 0.3170 0.1148 5.78E-03 
NSPHS 179 1.52 0.38 0.5514 0.1712 1.28E-03 
IGP15 
Vis 802 3.19 0.50 0.3612 0.1025 4.27E-04 
Korcula 851 3.23 0.45 0.6169 0.1022 1.57E-09 
ORCADES 415 3.24 0.47 0.5797 0.1476 8.57E-05 
NSPHS 178 2.84 0.50 0.3004 0.1699 7.70E-02 
IGP16 
Vis 794 3.05 1.53 0.0763 0.0512 1.36E-01 
Korcula 838 2.80 1.34 0.2799 0.0935 2.76E-03 
ORCADES 410 1.65 0.42 0.3894 0.1446 7.09E-03 
NSPHS 179 1.22 0.37 0.5021 0.1352 2.04E-04 
IGP17 
Vis 802 8.88 2.54 0.2287 0.0897 1.08E-02 
Korcula 851 9.30 2.58 0.5762 0.1190 1.28E-06 
ORCADES 415 9.59 2.62 0.3323 0.1257 8.21E-03 
NSPHS 179 8.14 3.00 0.4546 0.1784 1.08E-02 
IGP18 
Vis 799 2.49 0.51 0.3777 0.1019 2.09E-04 
Korcula 850 2.48 0.50 0.5331 0.1029 2.20E-07 
ORCADES 413 2.42 0.43 0.3756 0.1377 6.38E-03 
NSPHS 177 2.03 0.50 0.4588 0.1768 9.45E-03 
IGP19 
Vis 791 0.50 0.34 0.0018 0.0026 4.88E-01 
Korcula 842 0.69 0.39 0.4446 0.0910 1.02E-06 
ORCADES 407 0.54 0.20 0.1188 0.0886 1.80E-01 
NSPHS 175 0.33 0.12 0.2229 0.1159 5.46E-02 
IGP20 
Vis 792 3.88 1.98 0.0889 0.0567 1.17E-01 
Korcula 842 3.96 2.36 0.2206 0.1079 4.09E-02 
ORCADES 407 1.72 0.61 0.1254 0.0978 2.00E-01 
NSPHS 179 0.83 0.32 0.3500 0.1273 5.98E-03 
IGP21 
Vis 800 0.40 0.17 0.1621 0.0696 1.99E-02 
Korcula 847 0.32 0.11 0.5516 0.1032 9.16E-08 
ORCADES 413 0.31 0.11 0.4413 0.1262 4.71E-04 
NSPHS 179 0.24 0.10 0.3891 0.1111 4.63E-04 
IGP22 
Vis 801 2.03 0.59 0.1529 0.0771 4.75E-02 
Korcula 851 2.32 0.64 0.3436 0.1116 2.07E-03 
ORCADES 415 2.32 0.64 0.3450 0.1373 1.20E-02 
NSPHS 179 1.67 0.68 0.7021 0.2140 1.03E-03 
IGP23 
Vis 799 2.75 0.62 0.4302 0.0925 3.33E-06 
Korcula 848 2.80 0.61 0.3791 0.0940 5.52E-05 
ORCADES 413 2.66 0.52 0.6782 0.1441 2.51E-06 
NSPHS 179 2.04 0.70 0.2980 0.1750 8.86E-02 
IGP24 
Vis 801 28.20 3.31 0.1501 0.0752 4.59E-02 
Korcula 851 29.48 3.33 0.4830 0.1042 3.57E-06 
ORCADES 415 27.55 2.96 0.6397 0.1418 6.43E-06 
NSPHS 178 23.94 3.74 0.5930 0.1846 1.32E-03 
IGP25 
Vis 801 43.08 6.50 0.2642 0.0969 6.41E-03 
Korcula 851 43.04 5.88 0.4492 0.1205 1.93E-04 
ORCADES 413 42.09 5.41 0.5210 0.1368 1.40E-04 
NSPHS 179 37.43 7.60 0.6419 0.1721 1.92E-04 
IGP26 
Vis 801 19.95 4.10 0.1666 0.0817 4.15E-02 











ORCADES 415 20.08 3.93 0.3701 0.1371 6.95E-03 
NSPHS 179 16.38 4.65 0.5664 0.1880 2.59E-03 
IGP27 
Vis 801 30.07 6.01 0.1675 0.0878 5.64E-02 
Korcula 851 29.86 5.71 0.3593 0.1191 2.54E-03 
ORCADES 415 29.95 5.47 0.2673 0.1257 3.34E-02 
NSPHS 179 24.88 6.50 0.6641 0.1802 2.28E-04 
IGP28 
Vis 800 11.69 1.96 0.1971 0.0894 2.74E-02 
Korcula 851 11.90 1.76 0.7396 0.1145 1.04E-10 
ORCADES 415 10.75 1.54 0.6117 0.1443 2.26E-05 
NSPHS 178 9.48 1.68 0.3001 0.1585 5.83E-02 
IGP29 
Vis 802 39.81 2.42 0.3511 0.1041 7.40E-04 
Korcula 851 40.69 2.36 0.4905 0.1049 2.90E-06 
ORCADES 414 39.37 2.45 0.8013 0.1314 1.07E-09 
NSPHS 178 36.65 2.97 0.3513 0.1458 1.60E-02 
IGP30 
Vis 800 9.41 2.73 0.3184 0.0976 1.11E-03 
Korcula 850 10.48 2.78 0.4844 0.1115 1.40E-05 
ORCADES 414 9.73 2.21 0.4694 0.1225 1.28E-04 
NSPHS 179 7.76 2.59 0.3649 0.1879 5.21E-02 
IGP31 
Vis 802 37.22 3.51 0.3354 0.1095 2.19E-03 
Korcula 851 36.30 3.30 0.5103 0.0984 2.14E-07 
ORCADES 415 35.82 2.97 0.3589 0.1327 6.82E-03 
NSPHS 178 36.40 3.80 0.4903 0.1771 5.63E-03 
IGP32 
Vis 802 40.94 4.39 0.5241 0.0975 7.64E-08 
Korcula 851 40.92 4.11 0.3274 0.0911 3.24E-04 
ORCADES 413 39.27 3.49 0.5465 0.1327 3.84E-05 
NSPHS 179 35.54 6.06 0.0806 0.0906 3.74E-01 
IGP33 
Vis 801 3.13 0.63 0.3699 0.0906 4.47E-05 
Korcula 850 2.99 0.54 0.5106 0.1060 1.46E-06 
ORCADES 414 3.10 0.54 0.3580 0.1317 6.55E-03 
NSPHS 178 3.74 1.11 0.0492 0.0599 4.12E-01 
IGP34 
Vis 801 6.24 1.54 0.2224 0.0913 1.48E-02 
Korcula 850 5.62 1.28 0.4888 0.1169 2.88E-05 
ORCADES 414 5.72 1.20 0.3502 0.1305 7.30E-03 
NSPHS 178 7.16 2.38 0.4529 0.1967 2.13E-02 
IGP35 
Vis 799 0.92 0.14 0.5397 0.1089 7.22E-07 
Korcula 851 0.90 0.13 0.4184 0.0909 4.11E-06 
ORCADES 415 0.92 0.12 0.5004 0.1453 5.73E-04 
NSPHS 178 1.05 0.21 1.20E-08 1.78E-08 5.00E-01 
IGP36 
Vis 801 0.39 0.10 0.5524 0.1085 3.57E-07 
Korcula 850 0.37 0.09 0.5699 0.1040 4.24E-08 
ORCADES 412 0.35 0.09 0.5885 0.1492 8.04E-05 
NSPHS 177 0.34 0.12 0.1991 0.1239 1.08E-01 
IGP37 
Vis 800 0.22 0.06 0.5325 0.1170 5.37E-06 
Korcula 850 0.21 0.06 0.6132 0.1029 2.56E-09 
ORCADES 414 0.20 0.06 0.3951 0.1416 5.28E-03 
NSPHS 177 0.20 0.07 0.3147 0.1566 4.45E-02 
IGP38 
Vis 801 0.18 0.04 0.5404 0.1170 3.85E-06 
Korcula 850 0.17 0.04 0.5777 0.1021 1.52E-08 
ORCADES 415 0.16 0.04 0.4107 0.1477 5.41E-03 
NSPHS 177 0.16 0.05 0.3074 0.1581 5.18E-02 
IGP39 
Vis 801 1.42 0.35 0.2881 0.0962 2.76E-03 
Korcula 849 1.26 0.33 0.2646 0.0968 6.25E-03 
ORCADES 414 1.21 0.32 0.6311 0.1532 3.81E-05 












Vis 802 0.58 0.06 0.2992 0.0973 2.11E-03 
Korcula 851 0.55 0.06 0.2719 0.0973 5.18E-03 
ORCADES 415 0.54 0.06 0.5739 0.1521 1.61E-04 
NSPHS 179 0.56 0.09 0.4870 0.1602 2.36E-03 
IGP41 
Vis 782 0.30 0.24 0.2784 0.0932 2.81E-03 
Korcula 839 0.24 0.14 0.5169 0.0719 6.32E-13 
ORCADES 403 0.23 0.11 1.47E-08 2.18E-08 5.00E-01 
NSPHS 172 0.31 0.18 1.08E-08 1.60E-08 5.00E-01 
IGP42 
Vis 795 1.15 0.59 0.2941 0.0845 4.98E-04 
Korcula 843 1.14 0.63 0.4882 0.1082 6.46E-06 
ORCADES 409 1.07 0.56 0.7596 0.1405 6.42E-08 
NSPHS 178 1.11 0.75 0.7296 0.1294 1.73E-08 
IGP43 
Vis 802 28.57 7.34 0.2939 0.0935 1.67E-03 
Korcula 851 28.14 6.96 0.6549 0.1120 5.03E-09 
ORCADES 415 27.21 7.09 0.1099 0.0901 2.23E-01 
NSPHS 179 30.42 8.55 0.3807 0.1575 1.56E-02 
IGP44 
Vis 797 0.45 0.17 0.0538 0.0504 2.85E-01 
Korcula 838 0.43 0.17 0.4000 0.1229 1.13E-03 
ORCADES 405 0.38 0.10 0.2622 0.1139 2.13E-02 
NSPHS 173 0.43 0.16 0.0740 0.0663 2.64E-01 
IGP45 
Vis 802 7.42 1.91 0.3128 0.0986 1.51E-03 
Korcula 851 7.73 1.93 0.4628 0.1136 4.64E-05 
ORCADES 415 6.68 1.87 0.4502 0.1697 7.97E-03 
NSPHS 179 7.06 2.16 0.5360 0.1572 6.49E-04 
IGP46 
Vis 792 1.06 0.56 0.1539 0.0724 3.35E-02 
Korcula 843 1.06 0.53 0.5946 0.1136 1.66E-07 
ORCADES 414 0.70 0.33 0.5813 0.1405 3.50E-05 
NSPHS 179 0.82 0.42 0.3381 0.0987 6.17E-04 
IGP47 
Vis 802 22.59 2.62 0.3178 0.0996 1.42E-03 
Korcula 851 22.48 2.48 0.5617 0.1016 3.28E-08 
ORCADES 415 24.01 2.69 0.4979 0.1364 2.61E-04 
NSPHS 179 23.04 3.27 0.5230 0.2607 4.48E-02 
IGP48 
Vis 802 10.92 1.52 0.1978 0.0984 4.44E-02 
Korcula 851 11.14 1.63 0.5773 0.1015 1.27E-08 
ORCADES 415 11.88 1.64 0.5485 0.1464 1.80E-04 
NSPHS 179 10.87 1.87 0.4434 0.1683 8.43E-03 
IGP49 
Vis 801 6.51 1.18 0.3562 0.1167 2.27E-03 
Korcula 851 6.51 1.22 0.6657 0.1111 2.07E-09 
ORCADES 414 6.07 1.12 0.7325 0.1329 3.58E-08 
NSPHS 179 5.66 1.12 0.6510 0.1924 7.14E-04 
IGP50 
Vis 801 1.06 0.22 0.1912 0.0998 5.55E-02 
Korcula 841 1.09 0.25 0.3905 0.1035 1.62E-04 
ORCADES 414 1.04 0.19 0.5239 0.1302 5.72E-05 
NSPHS 177 0.84 0.17 0.6364 0.1785 3.63E-04 
IGP51 
Vis 798 1.48 0.74 0.1240 0.0690 7.24E-02 
Korcula 846 1.57 0.82 0.6697 0.1203 2.63E-08 
ORCADES 409 1.18 0.58 0.4217 0.1622 9.30E-03 
NSPHS 178 1.44 0.82 0.5667 0.1239 4.76E-06 
IGP52 
Vis 786 0.40 0.20 0.2126 0.0964 2.74E-02 
Korcula 848 0.32 0.09 0.4958 0.1146 1.51E-05 
ORCADES 406 0.33 0.09 0.2045 0.1167 7.97E-02 
NSPHS 176 0.35 0.12 0.2707 0.1059 1.06E-02 
IGP53 
Vis 802 15.91 5.46 0.3645 0.0938 1.02E-04 











ORCADES 415 16.81 5.51 0.3179 0.1198 7.98E-03 
NSPHS 179 15.60 6.10 0.3738 0.1788 3.65E-02 
IGP54 
Vis 802 2.01 0.54 0.2524 0.0929 6.58E-03 
Korcula 851 2.17 0.55 0.4670 0.1220 1.28E-04 
ORCADES 415 2.24 0.51 0.3030 0.1153 8.60E-03 
NSPHS 179 1.90 0.54 0.5821 0.1772 1.02E-03 
IGP55 
Vis 802 37.50 8.95 0.3032 0.0936 1.20E-03 
Korcula 851 37.31 8.45 0.5860 0.1208 1.24E-06 
ORCADES 415 35.27 8.68 0.1577 0.1043 1.31E-01 
NSPHS 179 38.97 10.34 0.3456 0.1705 4.27E-02 
IGP56 
Vis 801 42.21 3.51 0.2482 0.0989 1.21E-02 
Korcula 851 42.33 3.30 0.4275 0.1047 4.41E-05 
ORCADES 411 43.80 3.07 0.3927 0.1342 3.44E-03 
NSPHS 178 41.33 4.09 0.5875 0.2103 5.20E-03 
IGP57 
Vis 802 19.85 6.34 0.3393 0.0944 3.27E-04 
Korcula 851 19.92 6.18 0.6181 0.1224 4.37E-07 
ORCADES 415 20.60 6.28 0.2473 0.1158 3.27E-02 
NSPHS 179 19.33 7.13 0.5140 0.1891 6.55E-03 
IGP58 
Vis 799 95.37 1.88 0.1809 0.0741 1.46E-02 
Korcula 848 95.41 1.80 0.7308 0.1146 1.83E-10 
ORCADES 412 96.28 1.40 0.6320 0.1496 2.41E-05 
NSPHS 179 95.76 1.81 0.5307 0.1111 1.77E-06 
IGP59 
Vis 798 96.87 1.48 0.2945 0.0831 3.96E-04 
Korcula 848 96.86 1.66 0.6095 0.1053 7.02E-09 
ORCADES 411 96.90 1.48 0.7740 0.1617 1.69E-06 
NSPHS 178 97.17 1.68 0.8115 0.1343 1.54E-09 
IGP60 
Vis 792 97.48 1.37 0.1476 0.0730 4.31E-02 
Korcula 842 97.50 1.27 0.6121 0.1151 1.04E-07 
ORCADES 413 98.40 0.75 0.5930 0.1352 1.15E-05 
NSPHS 179 97.99 1.05 0.3523 0.1026 5.98E-04 
IGP61 
Vis 801 90.12 4.02 0.1465 0.0681 3.15E-02 
Korcula 848 90.38 3.34 0.6438 0.1187 5.90E-08 
ORCADES 415 92.35 2.86 0.6803 0.1415 1.52E-06 
NSPHS 179 90.44 3.50 0.5317 0.1194 8.54E-06 
IGP62 
Vis 802 78.33 3.33 0.1775 0.0890 4.62E-02 
Korcula 850 77.87 3.55 0.7191 0.1122 1.49E-10 
ORCADES 415 80.17 3.31 0.5647 0.1449 9.76E-05 
NSPHS 179 80.29 3.63 0.7180 0.1417 4.01E-07 
IGP63 
Vis 802 76.86 4.04 0.2136 0.1003 3.31E-02 
Korcula 850 75.92 4.67 0.7762 0.1025 3.56E-14 
ORCADES 414 77.79 4.22 0.4430 0.1595 5.49E-03 
NSPHS 179 78.88 4.69 0.5488 0.1175 3.01E-06 
IGP64 
Vis 802 79.39 3.31 0.1613 0.0909 7.58E-02 
Korcula 851 79.37 3.39 0.5980 0.1064 1.89E-08 
ORCADES 415 81.99 3.18 0.6865 0.1444 2.00E-06 
NSPHS 179 82.11 3.21 0.8743 0.1967 8.79E-06 
IGP65 
Vis 801 79.68 4.73 0.1548 0.0698 2.66E-02 
Korcula 851 79.03 4.53 0.5635 0.1224 4.18E-06 
ORCADES 415 80.99 4.19 0.5321 0.1326 6.03E-05 
NSPHS 179 80.01 4.76 0.4622 0.1249 2.14E-04 
IGP66 
Vis 802 17.01 2.51 0.3072 0.1074 4.23E-03 
Korcula 851 17.51 2.73 0.6316 0.1175 7.61E-08 
ORCADES 415 16.06 2.68 0.6655 0.1498 8.84E-06 












Vis 802 19.97 3.27 0.2328 0.1062 2.83E-02 
Korcula 851 20.91 3.65 0.7315 0.1020 7.55E-13 
ORCADES 415 19.07 3.27 0.4770 0.1610 3.05E-03 
NSPHS 179 18.25 3.55 0.5009 0.1357 2.23E-04 
IGP68 
 
Vis 802 18.00 2.83 0.2872 0.1063 6.90E-03 
Korcula 851 18.04 3.04 0.6377 0.1181 6.66E-08 
ORCADES 414 16.35 2.98 0.9379 0.1473 1.91E-10 
NSPHS 179 15.87 2.95 0.7327 0.1963 1.89E-04 
IGP69 
 
Vis 801 10.42 1.75 0.4648 0.1083 1.76E-05 
Korcula 849 11.26 2.30 0.4652 0.1219 1.35E-04 
ORCADES 415 11.36 2.49 0.4976 0.1423 4.71E-04 
NSPHS 178 10.37 2.24 0.4267 0.1964 2.98E-02 
IGP70 
 
Vis 802 0.22 0.04 0.2441 0.1027 1.75E-02 
Korcula 851 0.23 0.05 0.6686 0.1149 5.92E-09 
ORCADES 415 0.20 0.04 0.6188 0.1493 3.40E-05 
NSPHS 179 0.19 0.04 0.7108 0.1557 4.99E-06 
IGP71 
 
Vis 802 17.85 2.69 0.2782 0.1054 8.30E-03 
Korcula 851 18.38 2.95 0.6649 0.1168 1.24E-08 
ORCADES 415 16.70 2.85 0.6217 0.1472 2.39E-05 
NSPHS 179 16.18 2.98 0.7018 0.1620 1.48E-05 
IGP72 
Vis 802 4.61 0.85 0.2715 0.1054 9.98E-03 
Korcula 851 4.50 0.89 0.6719 0.1163 7.67E-09 
ORCADES 414 5.05 1.03 0.6003 0.1502 6.44E-05 
NSPHS 179 5.26 1.14 0.7386 0.1641 6.75E-06 
IGP73 
Vis 786 4.25 2.14 0.2159 0.0961 2.47E-02 
Korcula 847 3.38 0.97 0.5260 0.1146 4.44E-06 
ORCADES 407 3.39 0.95 0.1990 0.1181 9.20E-02 
NSPHS 176 3.68 1.33 0.2817 0.1068 8.38E-03 
IGP74 
Vis 800 0.13 0.03 0.3415 0.0991 5.67E-04 
Korcula 846 0.14 0.04 0.4360 0.1225 3.73E-04 
ORCADES 414 0.14 0.04 0.5597 0.1435 9.63E-05 
NSPHS 178 0.13 0.03 0.3529 0.1806 5.07E-02 
IGP75 
Vis 800 11.59 2.12 0.3317 0.0973 6.55E-04 
Korcula 849 12.50 2.70 0.4650 0.1253 2.07E-04 
ORCADES 415 12.34 2.83 0.4396 0.1340 1.04E-03 
NSPHS 179 11.58 2.79 0.3788 0.1860 4.17E-02 
IGP76 
Vis 802 6.58 1.55 0.2742 0.0860 1.43E-03 
Korcula 851 6.39 1.58 0.5120 0.1220 2.70E-05 
ORCADES 415 6.54 1.65 0.3697 0.1266 3.50E-03 
NSPHS 179 6.86 1.94 0.3958 0.1848 3.22E-02 
IGP77 
Vis 783 24.00 12.67 0.1734 0.0831 3.69E-02 
Korcula 846 18.96 6.05 0.4856 0.1178 3.74E-05 
ORCADES 410 18.34 6.20 0.2352 0.1166 4.36E-02 
NSPHS 177 21.83 8.00 0.1186 0.0885 1.80E-01 
N: number of samples with both genotype and trait data available; Mean: trait mean, SD: trait 
standard deviation; h
2
: heritability estimate; se(h
2
): standarad error of the heritability 
estimate; p(h
2
): p-value for heritability estimate  





Table 7: Genome-wide significant (p<2.27x10-09) or strongly suggestive (p<5x10-08) SNP associations with IgG N-glycans 



























 0.64 (0.04) 0.30 0.880 20 14 ST6GAL1 IGP29 
IGP14
$
, IGP15, IGP17, 














 0.29 (0.04) 0.16 0.847 4 6 IL6ST; ANKRD55 IGP53 

























 0.31 (0.05) 0.12 0.906 3 4 
ABCF2; 
SMARCD3 
IGP2 IGP5, IGP42, IGP45 
9 rs12342831 2.70x10
-11
 -0.24 (0.04) 0.26 0.971 28 11 B4GALT1 IGP17 
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 0.19 (0.03) 0.35 0.976 1 2 HLA-DQB2 IGP42 IGP2 
6 rs404256 7.49x10
-09
 -0.21 (0.04) 0.44 0.699 1 1 BACH2 IGP7 – 
7 rs2072209 1.16x10
-08
 -0.37 (0.07) 0.06 0.971 1 1 DLD; LAMB1 IGP69 – 
9 rs4878639 3.51x10
-08
 -0.20 (0.04) 0.26 0.953 1 1 RECK IGP17 – 
12 rs12828421 4.48x10
-08
 -0.18 (0.03) 0.49 0.916 2 1 PEX5 IGP41 – 
17 rs7224668 3.33x10
-08
 0.17 (0.03) 0.48 0.945 2 1 SLC38A10 IGP31 – 
nHits:number of SNPs with GW-significant or strongly suggestive association; nTraits:number of N-glycan traits associated with the region at GW-
significant level, MAF: minor allele frequency, Mean RSq: average imputation quality (RSq) across meta-analysis populations 
*
 effect size is for the minor allele in standard deviation units after adjustment for sex, age and first 3 principle components 
+
 description of the traits provided in Table 16 
$





Figure 24: Structures for top associated N-glycan traits. 
N-glycan structures for most significantly associated traits. These are shown only for traits 
that had one structure. For some structures, more than one configuration is possible so both 
have been shown. IGP17: FA2G2S1; IGP53: FA2G2; IGP2: A2; IGP41: FA1; IGP7: 
FA2[6]G1. GlcNAc: N-acetylglucosamine. F at the start of the abbreviation indicates a core 
fucose α1-6 linked to the inner GlcNAc; Ax, number of antenna (GlcNAc) on trimannosyl 
core; A2, biantennary with both GlcNAcs as β1-2 linked; B, bisecting GlcNAc linked β1-4 to 
β1-3 mannose; Gx, number (x) of β1-4 linked galactose on antenna; [6]G1 indicates that the 












Figure 25: Significance (a) and Forest (b) plots for chromosome 3 region of 
the IGP29 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 







Figure 26: Significance plot for chromosome 3 region of the IGP29 meta-
analysis after conditioning on rs11710456. 
 -Log10 of the p-values are plotted against chromosome position. The most significant SNP is 
labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown based 







variance explained in this particular population. All variance explained are after adjusting the 
trait for age, sex and the first 3 principal components. After analysis conditioning on the top 
SNP (rs11710456) in this region, the SNP rs7652995 still reached genome-wide significance 
(p = 4.15x10
-13
) (Figure 26). It explained an extra 0.2 - 6.1% of the trait variance on top of 
rs11710456 in these populations. After adjusting for this additional SNP, the association 
peak was completely removed. This suggests that there are several genetic factors underlying 
this association. Conditional analysis of all other significant and suggestive regions resulted 
in the complete removal of their respective association peaks.  
Twenty-eight SNPs were significantly associated with 11 IgG glycosylation traits (2.70x10
-11 
< p < 4.73x10
-08
) at a locus on chromosome 9 spanning over 60 kb (Figure 27). This region 
includes UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 (B4GALT1, 
Entrez GeneID: 2683), which encodes one of the galactosyltransferase responsible for the 
addition of galactose to IgG glycans. The most significant trait associated in this region was 
IGP17 which describes the percentage of FA2G2S1 in the total fraction (Figure 24). The top 
SNP, rs12342831, explains 1.3, 2.1, 3.3 and 0.8% of the IGP17 trait variance in CROATIA-
Vis, CROATIA-Korcula, ORCADES and NSPHS. 
A large (541 kb) region on chromosome 14 harbouring the fucosyltranferase 8 (FUT8, 
Entrez GeneID: 2530) gene contained 167 SNPs showing significant associations with 12 
IgG glycosylation traits reflecting fucosylation of IgG glycans (Figure 28). FUT8 codes for 
an enzyme responsible for the addition of fucose to the core of an N-glycan. The strongest 
association (P= 1.08x10
-22
) was observed with IGP59. This trait describes the percentage of 
fucosylation of agalactosylated structures. Although the top trait is not the same as was 
associated with total plasma N-glycans by GWAS (Chapter 3), that structure was also 
associated (IGP2). The top SNP, rs11847263, explains 2.0, 8.1, 4.0 & 7.7% of the IGP59 
trait variance in CROATIA-Vis, CROATIA-Korcula, ORCADES and NSPHS. This is fairly 
close to the percentage of trait variance explained by the same top SNP in the total plasma N-
glycan GWAS (2.8, 9.2, 3.0 and 4.1%). 
On chromosome 22, two loci were associated with IgG glycosylation. The first region 
spanned over 233 kb and contained several genes. This region contains 60 significant SNPs 
associated with 17 IgG glycosylation traits (Figure 29). Association was strongest between 
SNP rs909674 and IGP40, a trait which describes the incidence of bisecting GlcNAc in all 
fucosylated disialylated structures (P= 9.66x10
-25
). Of the genes in this region, mannosyl 
(beta-1,4-)-glycoprotein (beta-1,4)-N-acetylglucosaminyltransferase (MGAT3, Entrez 










Figure 27: Significance (a) and Forest (b) plots for chromosome 9 region of 
the IGP17 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 









Figure 28: Significance (a) and Forest (b) plots for chromosome 14 region of 
the IGP59 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 









Figure 29: Significance (a) and Forest (b) plots for chromosome 22 region of 
the IGP40 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 




glycans, thus is the most biologically plausible candidate. The top SNP, rs909674, is located 
within an intron of MGAT3 and explains 4.0, 4.9, 4.9 and 3.9 % of the IGP40 trait variance 
in CROATIA-Vis, CROATIA-Korcula, ORCADES and NSPHS. 
The glycosyltranferase genes at the four GWAS loci - ST6GAL1, B4GALT1, FUT8, and 
MGAT3 – are responsible for adding sialic acid, galactose, fucose and bisecting GlcNAc to 
N-glycans and are associated with N-glycan structures containing these linkages that are 
present on IgG, thus demonstrating the proof of principle that GWAS was able to identify 
biologically relevant genes.  
In addition to these four loci encoding known glycosylation enzymes, five novel associations 
showed genome-wide significance. A second region on chromosome 22 reached genome-
wide significance which spanned 49 kb and contained the genes SWI/SNF related, matrix 
associated, actin dependent regulator of chromatin, subfamily b, member 1 (SMARCB1, 
Entrez GeneID: 6598) and derlin 3 (DERL3, Entrez GeneID: 91319) (Figure 30). The 
strongest association (P=8.63x10
-17
) was observed between SNP rs2186369 and IGP72, the 
ratio of fucosylated non-bisecting GlcNAc structures and all structures with bisecting 
GlcNAc. rs2186369 is an intronic SNP within SMARCB1 and explains 2.6-3.7% of the 
variance in IGP72 across the four populations analysed. Although DERL3 is the most 
biologically plausible gene in the region as its protein product, derlin 3, plays a role in the 
degradation of misfolded glycoproteins in the ER [170], SMARCB1 cannot be ruled out. 
Most of the strongly associated SNPs fall in a region of high LD encompassing SMARCB1 
and the protein product is a core component of a major transcriptional complex thereby also 
giving a strong biologically plausible role to this gene. 
Chromosome 5 SNP rs17348299, located in a region containing interleukin 6 signal 
transducer (IL6ST, Entrez GeneID: 3572) and ankyrin repeat domain 55 (ANKRD55, Entrez 
GeneID: 79722) was significantly associated with six IgG glycosylation traits. The most 
significantly associated trait was IGP53 (P = 6.88x10
-11
) which measured the amount of 
FA2G2 in the neutral fraction (Figure 24, Figure 31). IL6ST is part of the cytokine receptor 
complex and its activation is dependent on the binding of these cytokines to their receptor. It 
is a signal transducer shared by many cytokines, including interleukin 6 (IL6), ciliary 
neurotrophic factor (CNTF), leukaemia inhibitory factor (LIF), and oncostatin M (OSM). 
Due to its role in immune function it is the most biologically relevant gene in this region. In 
addition, the large recombination spike towards the 3’ end of ANKRD55 seems to indicate 
that the top SNP is tagging an association around IL6ST rather than ANKRD55.  The top SNP 










Figure 30: Significance (a) and Forest (b) plots for chromosome 22 region of 
the IGP72 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 










Figure 31: Significance (a) and Forest (b) plots for chromosome 5 region of 
the IGP53 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 




Two regions on chromosome 7 showed genome-wide significant associations. The first, 
spanning 26kb contained 11 SNPs, and was associated with 13 IgG glycosylation traits 
(Figure 32). The strongest association (P = 1.87x10
-13
) was observed between SNP 
rs6421315 located in IKAROS family zinc finger 1 (Ikaros) (IKZF1, Entrez GeneID: 10320) 
and the percentage of fucosylation of agalactosylated structures without bisecting GlcNAc 
(IGP63). IKZF1’s encoded protein Ikaros is a DNA-binding protein which acts as a 
transcriptional regulator and is associated with chromatin remodelling. It is an important 
regulator of lymphocyte differentiation and has been shown to influence effector pathways 
through control of class switch recombination [171], thus representing a promising 
functional candidate [172]. The top SNP explains 1.1-3.6% of the variance in IGP63 across 
the study populations.  
The second region on chromosome 7 contains ATP-binding cassette, sub-family F, member 2 
(ABCF2, Entrez GeneID: 10061) and SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily d, member 3 (SMARCD3, Entrez GeneID: 6604). The best 
signal in this region was between SNP rs1122979 and IGP2 (P= 2.10x10
-10
) (Figure 33). 
IGP2 represents the percentage of A2 glycan in the total fraction (Figure 24) and rs1122979 
explains 1.1, 1.1, 2.9, and 6.2% of the trait variance across CROATIA-Vis, CROATIA-
Korcula, ORCADES and NSPHS. The function of ABCF2 is not well understood but it is 
known to be involved in molecular transport across extra- and intracellular membranes. 
SMARCD3 is part of the ATP-dependent chromatin remodelling complex. 
Finally, the chromosome 11 SNP rs4930561, located in a region containing the genes 
suppressor of variegation 4-20 homolog 1 (SUV420H1, Entrez GeneID: 51111) and choline 
kinase alpha (CHKA, Entrez GeneID: 1119), was associated with percentage of FA1 in the 
neutral fraction (IGP41; p = 8.88x10
-10
) (Figure 24, Figure 34). This SNP explains 0.2, 2.9, 
2.7 and 1.4% of the variance in IGP41 across CROATIA-Vis, CROATIA-Korcula, 
ORCADES and NSPHS. SUV420H1 encodes a histone-lysine N-methyltransferase which 
specifically trimethylates lysine 20 of histone H4 and could therefore affects activity of 
many different genes. It is thought to be involved in proviral silencing in somatic and germ 
line cells through epigenetic mechanisms [173]. CHKA has a key role in phospholipid 
biosynthesis and may contribute to tumour cell growth. This is the intial enzyme in the CDP-
choline pathway for the biosynthesis of phosphatidylcholine. A recent paper from other 
collaborators within this project reported a number of strong associations between lipidomics 
and glycomics traits in human plasma [174], therefore an enzyme involved in phospholipid 










Figure 32: Significance (a) and Forest (b) plots for chromosome 7 region of 
the IGP63 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 











Figure 33: Significance (a) and Forest (b) plots for chromosome 7 region of 
the IGP2 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 










Figure 34: Significance (a) and Forest (b) plots for chromosome 11 region of 
the IGP41 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 




Strongly suggestive associations were observed for several regions on chromosome 6 and 
single regions on chromosomes 7, 9, 12 and 17 (Figure 35 - Figure 40). Another signal on 
chromosome 6 was discarded due to a significant heterogeneity P-value (Figure 41). The 
most interesting of these is the suggestive association between rs404256 in the BTB and 
CNC homology 1, basic leucine zipper transcription factor 2 (BACH2, Entrez GeneID: 
60468) on chromosome 6 and IGP7, defined as the percentage of FA2[6]G1 in the total 
fraction (p = 7.49x10
-09
) (Figure 24, Figure 36). BACH2 is a B-cell specific transcription 
factor that can act as a suppressor or promoter of B-cell activation. It has been shown to 
orchestrate the transcriptional activation of B-cells, modify the cytotoxic effects of 
anticancer drugs and regulate IL-2 expression in umbilical cord blood CD4+ T cells [175]. 
The top SNP explains 2.0, 0.9, 0.9 and 2.3% of the trait variance in CROATIA-Vis, 
CROATIA-Korcula, ORCADES and NSPHS respectively.  
5.3.2 Replication of GWAS Findings 
Replication was sought for all genome-wide significant and strongly suggestive signals 
identified in the discovery analysis. The replication effort was undertaken by the Leiden 
Longevity Study (LLS) and was based on a different N-glycan quantitation method 
(MALDI-TOF-MS). While UPLC separates glycans according to structural similarities, MS 
groups them by mass. Furthermore, MS analysis focused on Fc glycans while UPLC 
measures both Fc and Fab glycans, thus all traits measured by the two methods could not be 
directly compared. Glycosylation patterns of IgG1 and IgG2 were investigated by analysis of 
tryptic glycopeptides, with six glycoforms per IgG subclass measured. The intensities of all 
glycoforms were related to the monogalactosylated, core-fucosylated biantennary species, 
providing five relative intensities registered per IgG subclass (Table 8). Structural diagrams 
for these glycans are contained in Figure 42. MS-measured traits from LLS were tested for 
association with the most significantly associated SNP in the gene regions from Table 7. A 
Bonferroni correction was applied based on the number of SNPs tested within each trait (e.g. 
For IGP3, 2 SNPs were tested, therefore 0.05/2 = 0.025, is the significance threshold for this 
trait). Not all associations were able to be tested because the equivalent structure was not 
measured in LLS. Replication was achieved for three regions, B4GALT1 (FA2G2, P= 
5.35x10
-08
), SMARCB1; DERL3 (FA2BG1, P= 1.56x10
-07
; FA2BG2, P= 1.06x10
-03
), and 
MGAT3 (FA2BG1, P= 1.62x10
-10











Figure 35: Significance (a) and Forest (b) plots for chromosome 6 region of 
the IGP42 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 











Figure 36: Significance (a) and Forest (b) plots for chromosome 6 region of 
the IGP7 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 











Figure 37: Significance (a) and Forest (b) plots for chromosome 7 region of 
the IGP69 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 











Figure 38: Significance (a) and Forest (b) plots for chromosome 9 region of 
the IGP17 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 










Figure 39: Significance (a) and Forest (b) plots for chromosome 12 region of 
the IGP41 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 









Figure 40: Significance (a) and Forest (b) plots for chromosome 17 region of 
the IGP31 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 









Figure 41: Significance (a) and Forest (b) plots for chromosome 6 region of 
the IGP23 meta-analysis. 
(a) -Log10 of the p-values are plotted against chromosome position. The most significant 
SNP is labelled with a purple diamond. Gene information and regional LD (r
2
) are also shown 
based on “1000 Genomes Mar 2012 EUR”.(b)The estimate of effect size (BETA) and 
standard error for each population and the pool is shown, in which the size of the square for 
each individual cohort represents it’s weighting for the estimate of the pooled effect size. The 
effect size presented is the β-coefficient (BETA), which represents a change in IgG N-glycan 
level per copy of the minor allele in standard deviation units (after adjustment for age, sex 




Table 8: Description of N-glycan traits measured by MS and their descriptive 
statistics in LLS. 
LLS MS IgG  
N-Glycan 
Trait 
Formula Median IQR Min Max 
Analogous 
UPLC IgG  
N-Glycan Trait 
IgG1 FA2 log(FA2/FA2G1) 4.40 0.35 3.38 5.61 IGP3 
IgG1 FA2B log(FA2B/FA2G1) 3.75 0.30 2.71 4.68 IGP5 
IgG1 FA2BG1 log(FA2BG1/FA2G1) 2.80 0.46 1.56 4.42 IGP9 + IGP10 
IgG1 FA2G2 log(FA2G2/FA2G1) 3.05 0.32 2.07 4.31 IGP13 
IgG1 FA2BG2 log(FA2BG2/FA2G1) 1.25 0.40 0.12 3.83 IGP14 
IQR: trait interquartile range; Min: trait minimum; Max: trait maximum 
 
Table 9: Replication results for IgG N-Glycan traits in LLS. 
UPCL 
Trait 
MS Trait Gene Region SNP Tested 
P-Value 
Discovery Replication 







































































































Figure 42: N-glycan structures available for replication in Leiden Longevity 
Study. 
N-glycan structures available for replication in LLS as measured by MALDI-TOF-MS. 
GlcNAc: N-acetylglucosamine. F at the start of the abbreviation indicates a core fucose α1-6 
linked to the inner GlcNAc; Ax, number of antenna (GlcNAc) on trimannosyl core; A2, 
biantennary with both GlcNAcs as β1-2 linked; B, bisecting GlcNAc linked β1-4 to β1-3 





5.3.3 Rare Variant Analysis 
Rare variant burden tests were successfully run for all 13 IgG N-glycan traits which gave 
genome-wide significant or strongly suggestive P-values in the common variant GWAS 
(both IGP17 and IGP41 associated with two regions each). There were approximately 770 
people with both genotype and phenotype information (depending on the phenotype) which 
is approximately 80 people less than available for the common variant HapMap2 GWAS.  
No genes achieve the Bonferroni-corrected threshold for any trait or analysis. When looking 
only at the genes that achieved a P-value < 5x10
-08
 in the common variant GWAS, again, 
only FUT8 achieved a p-value < 0.05, with the same single SNP with MAF < 5% 
(rs2229678, MAF= 0.031, P= 1.01x10
-03
) showing association. The P-value was moderately 
more significant than in the total plasma N-glycan rare variant analysis presented in Chapter 
3, most likely due to a decrease in phenotypic noise since the glycans were isolated from one 
protein. Conditional analysis produced the same results as in Chapter 3.  
5.3.4 Analysis of Pleiotropy within IgG N-Glycan Associated Genes 
Many of the genes that were found in this GWAS have been associated with quantitative 
traits or disease. The NHGRI GWAS Catalog [7] was used to determine gene associations 
for all regions achieving a p-value < 5x10
-08
 in the discovery analysis and SNAP was used to 
calculated LD between the top disease associated SNP and the top SNP from the IgG N-
glycan GWAS. Only studies achieving a P-value < 5x10
-08
 are reported unless the finding 
was replicated within the study or by another study. 
Despite many of the same genes being associated with quantitative traits or diseases, the top 
SNPs tended to not be in high LD, therefore were unlikely to be tagging the same association 
signals (Table 10). Three associations did appear to be in high LD with the IgG N-glycan 
associated SNP, including an ABCF2; SMARCD3 association with bone mineral density and 
B4GALT1 association with serum urate concentrations. The urate paper also identified 





Table 10: Analysis of pleiotropy between IgG N-glycan associated loci and quantitative trait or disease loci. 
Gene 
Region 




Top QT or 
Disease 
SNP 



















Daly et al., Nat Genet, 
2009 
European 0.017 1 - - 
Type 2 diabetes rs16861329 3x10
-08
 


















Rheumatiod arthritis rs6859219 1x10
-11
 
Stahl et al., Nat Genet, 
2010 
European 0.044 1 - - 
Crohn’s disease rs10065637 4x10
-12
 
Jostins et al., Nature, 
2012 




Teslovich et al., Nature, 
2010 
European NA NA - - 





Zhernakova et al., PLoS 
Genet, 2011 






Sherva et al. Alzheimers 
Dement, 2013 
European 0.001 0.034 - - 
Urate levels (women) rs456867 3x10
-06
 
Kottgen et al., Nat 
Genet, 2012 







Trevino et al., Nat 
Genet, 2009 






Papaemmanuil et al., 
Nat Genet, 2009 






Ganesh et al., Nat Genet, 
2009 










0.053 0.277 0.097 0.4 
Crohn’s disease rs1456896 1x10
-08
 
Franke et al., Nat Genet, 
2010 










Top QT or 
Disease 
SNP 



















Jostins et al., Nature, 
2012 
European 0 0.007 - - 
Red blood cell traits rs12718598 2x10
-13
 
van der Harst et al., 
Nature, 2012 






















0.012 0.13 0.087 0.518 
HDL Cholesterol rs4917014 1x10
-08
 
Willer et al., Nat Genet, 
2013 
European 0.053 0.277 - - 
ABCF2; 
SMARCD3 
rs1122979 Bone Mineral Density rs7812088 7x10
-09
 
Estrada et al., Nat Genet, 
2012 
European 1 1 - - 
B4GALT1 rs12342831 Urate levels rs10813960 4x10
-07
 
Kottgen et al., Nat 
Genet, 2012 











Jostins et al., Nature, 
2012 






& the WTCC2 et al., 
Biol Psychiatry, 2012 




Kawasaki disease rs2857151 5x10
-11
 
Onouchi et al., Nat 
Genet, 2012 







Vijai et al., PLoS Genet, 
2013 
European 0.227 0.762 - - 
Hepatitis B rs7453920 5x10
-37
 




0.967 1 0.181 0.443 
BACH2 rs404256 Type 1 diabetes rs3757247 1x10
-06
 
Grant et al., Diabetes, 
2008 










Top QT or 
Disease 
SNP 














Type 1 diabetes rs11755527 5x10
-12
 
Cooper et al., Nat Genet, 
2008 
European 0.031 0.179 - - 
Type 1 diabetes rs11755527 5x10
-08
 
Barrett et al., Nat Genet, 
2009 
European 0.031 0.179 - - 
Celiac disease rs10806425 4x10
-10
 
Dubois et al., Nat Genet, 
2010 
European 0.006 0.09 - - 
Crohn’s disease rs1847472 5x10
-09
 
Franke et al., Nat Genet, 
2010 
European 0.009 0.124 - - 





Plagnol et al., PLoS 
Genet, 2011 
European 0.031 0.179 - - 
Muliple sclerosis rs12212193 4x10
-08
 
Sawcer et al., Nature, 
2011 
European 0.027 0.166 - - 
Graves’ disease rs370409 2x10
-06
 
Chu et al., Nat Genet, 
2011 




Jin et al., Nat Genet, 
2012 














Ulcerative colitis rs4598195 1x10
-06
 
Silverberg et al., Nat 
Genet, 2009 
European 0.115 1 - - 
Ulcerative colitis rs4598195 8x10
-08
 
McGovern et al., Nat 
Genet, 2010 
European 0.115 1 - - 
Ulcerative colitis rs4380874 2x10
-26
 
Jostins et al., Nature, 
2012 
European 0.070 1 - - 
Ulcerative colitis rs886774 3x10
-08
 
Barrett et al., Nat Genet, 
2009 
European 0.067 1 - - 
Associations reported are from the NHGRI GWAS Catalog [7] (accessed 08/07/2014) and LD has been calculated using SNAP[104]. LD information is 
not available in SNAP for the HLA region so HapMap2 (release 22) data was used for HLA-DQB2. QT: quantitative trait 
*
 Linkage disequilibrium from 1000 Genomes Pilot 1 CEU data (corresponding to ethnicity of the study populations for IgG N-glycan GWAS) 
**
 Linkage disequilibrium from 1000 Genomes Pilot 1 data for the ethnic group most closely corresponding to ethnicity of the QT or disease study 





The results presented in this chapter further demonstrate that the recent developments in 
high-throughput glycomics and genomics now allow identification of genetic loci that 
control N-glycosylation using a GWAS approach. In Chapter 3 I reported the results of the 
first GWAS of the total plasma N-glycome as measured by HPLC. Although the study was 
of a comparable sample size (N~2000) to the IgG GWAS, it only identified six genome-wide 
significant and four strongly suggestive assocations [111,112] compared with nine genome-
wide significant and six strongly suggestive associtions in this IgG N-glycan GWAS. It is 
possible that the power of the study presented in Chapter 3 was reduced because N-glycans 
in total plasma originate from different glycoproteins where they have different functions 
and undergo protein-specific or tissue-specific glycosylation. As well, individual protein N-
glycan associations may be diluted and lost among the great many plasma N-glycan carrying 
proteins. In this study the largest percentage of variance explained by a single association 
was 16–18% whereas in the total N-glycan study this was 2–9%. Also, concentrations of 
individual glycoproteins in plasma vary in many physiological processes, introducing 
substantial noise to the quantitation of the total plasma N-glycome.  
In this study both problems were avoided by isolating a single protein from plasma (IgG), 
which is produced by a single cell type (B lymphocytes), thus effectively excluding 
differential regulation of gene expression in different tissues, and the noise introduced by 
variation in plasma IgG concentration and by N-glycans on other plasma proteins. It was 
expected that this should increase the power of the study to detect genome-wide associations 
substantially. This study yielded more genome-wide association signals, which were also 
much more significant, in comparison to the total plasma N-glycome GWAS in the same 
cohorts (in fact, with a slightly reduced sample size). Fifteen loci were identified to be 
associated with IgG N-glycan traits with P-values < 5x10
-08
 and nine reached the multiple 
testing significance threshold of 2.27x10
-09
. During the replication effort in the LLS cohort 
using MS quantitation we replicated three of the eight loci that were able to be tested. We 
were unable to attempt to replicate associations for the remaining loci because those 
glycosylation structures were not measured. Failure to replicate many of the GWAS signals 
where the structure could be measured may be due to the different N-glycan measurement 
method used between the discovery cohorts (UPLC) and the replication study (MALDI-
TOF-MS). The method used by the replication cohort was only able to quantify structures 
with core fucose and only from one subtype of IgG (IgG1) therefore there were very few hits 




glycan trait could not be measured therefore one with a lesser signal was used. In the results 
which will be presented in Chapter 6, it was found that MALDI-TOF-MS produced the worst 
results of all N-glycan quantitation methods as compared by GWAS. In addition, the 
discovery cohorts were all population isolates, whereas the replication was a general 
population so it is possible that population-specific allele frequency differences reduced 
power to detect association, but as most SNPs were common, this is less likely. 
The potential batch effects discussed in Chapter 3 are also present in the data analysed here 
but batch-corrected data only became available in the week prior to submission of this thesis 
so was not possible to include. Preliminary reports suggest that they have a minimal impact 
on GWAS meta-analysis p-values but may impact heritability estimates as discussed in 
Chapter 3. 
Among the nine loci that reached genome-wide statistical significance, four involved genes 
encoding glycosyltransferases known to glycosylate IgG (ST6GAL1, B4GALT1, FUT8, 
MGAT3). The enzyme beta1,4-galactosyltransferase 1 is responsible for the addition of 
galactose to IgG glycans. Interestingly, variants in B4GALT1 did not affect the main 
measures of IgG galactosylation, but instead differences in sialylation and the percentage of 
bisecting GlcNAc. These associations are still biologically plausible, because galactosylation 
is a prerequisite for sialylation, and enzymes which add galactose and bisecting GlcNAc 
compete for the same substrate [176].  
Core-fucosylation of IgG has been intensively studied due to its role in antibody-dependent 
cell-mediated cytotoxicity (ADCC). ADCC is a process whereby effector cells of the 
immune system (natural killer cells, macrophages, neutrophils and eosinophils) bind to and 
kill target cells which have been bound by antibodies. This is one of the major pathways by 
which the immune system prevents infection but requires prior knowledge that the target cell 
is dangerous in order to have antibodies against it [50]. This mechanism is the basis of 
antibody-based therapeutics against tumours. Core-fucose is critically important to regulate 
this process, in fact IgGs without core fucose on the Fc glycan have been found to have 
ADCC activity enhanced by up to 100-fold [177]. Alpha-(1,6)-fucosyltransferase 
(fucosyltransferase 8) catalyses the transfer of fucose from GDP-fucose to N-linked type 
complex glycopeptides, and is encoded by the FUT8 gene. In Chapter 3, SNPs located near 
this gene were found to influence overall levels of fucosylation in the total plasma N-
glycome. This was also the case with IgG N-glycans, with the same top SNP explaining a 
similar amount of trait variance with similar structures, only isolated exclusively from IgG 




strongly associated with SNPs in the FUT8 region consisted of A2, and, less strongly, A2G1 
and A2G2. These associations are biologically plausible as these glycans serve as substrates 
for fucosyltransferase 8. Interestingly, SNPs located near the IKZF1 gene influenced 
fucosylation of a specific subset of glycans, especially those without bisecting GlcNAc, and 
were also related to the ratio of fucosylated structures with and without bisecting GlcNAc. 
This suggests the IKZF1 gene encoding Ikaros may be a potential indirect regulator of 
fucosylation in B-lymphocytes by promoting the addition of bisecting GlcNAc, which then 
inhibits fucosylation. This is difficult to confirm however as Ikaros is heavily involved 
throughout B-cell development, so any gene-level modifications to IKZF1 will have 
implications for more than just IgG glycosylation. 
Again, rare variant analyses yielded few results but suffers from the same power issues 
mentioned in Chapter 3. Further studies, with much larger samples sizes and more careful 
SNP inclusion criteria, may yield more promising results regarding the effect of rare variants 
on the genomic regulation of IgG N-glycans. 
Nearly all genome-wide significant loci in our study have already been clearly demonstrated 
to be associated with autoimmune diseases, haematologic cancers, and some of them are also 
associated with chronic inflammation and/or neuropsychiatric disorders. Although the 
literature on those associations is extensive, I have looked only at those associations that 
were identified through GWAS (Table 10). The table implies abundant pleiotropy at the gene 
level between loci that control IgG N-glycosylation and loci that have been implicated in 
many human diseases. Autoimmune diseases (including SLE, RA, UC and over 80 others) 
are thought to be triggered by aggressive responses of the adaptive immune system to self 
antigens, thereby resulting in tissue damage and pathogenicity [178]. Among other 
mechanisms, IgG autoantibodies are responsible for the chronic inflammation and 
destruction of healthy tissues by cross-linking Fc receptors on innate immune effector cells 
[179]. Class and glycosylation of IgG are important for pathogenicity of autoantibodies in 
autoimmune diseases (reviewed in [180]). Removal of IgG glycans leads to the loss of the 
proinflammatory activity, suggesting that in vivo modulation of antibody glycosylation might 
be a strategy to interfere with autoimmune processes [179]. Indeed, the removal of IgG 
glycans by injections of EndoS in vivo interfered with autoantibody-mediated 
proinflammatory processes in a variety of autoimmune models [179]. Although the 
associated SNPs are not in high LD with the majority of loci associated with disease, causal 
disease variants that substantially dimish expression or alter protein structure may still have 




disease because although they may or may not be causal, they may still be altered in a 
disease state. 
The results from this study suggest that IgG N-glycome composition is regulated through the 
interaction of genes directly involved in glycosylation and those that may have a higher-level 
regulatory function and that these loci may affect many different N-glycan structures. SNPs 
at several different loci in this GWAS showed genome-wide significant associations with the 
same or similar IgG N-glycosylation traits. For example, SNPs at loci on chromosomes 9 
(B4GALT1 region) and 3 (ST6GAL1 region) both influenced the percentage of sialylation of 
galactosylated fucosylated structures (without bisecting GlcNAc) in the same direction. 
SNPs at these loci also influenced the ratio of fucosylated monosialylated structures (with 
and without bisecting GlcNAc) in the opposite direction. SNPs at the locus on chromosome 
9 (B4GALT1), and two loci on chromosome 22 (MGAT3 and SMARCB1; DERL3 region) 
both influenced the ratio of fucosylated disialylated structures with and without bisecting 
GlcNAc. SNPs at loci on chromosome 7 (IKZF1 region) and 14 (FUT8 region) influenced an 
overlapping range of traits: percentage of A2 and A2G1 glycans, and, in the opposite 
direction, the percentage of fucosylation of agalactosylated structures. 
Finally, I have demonstrated that findings from hypothesis-free GWAS, when targeted at a 
well-defined biological phenotype of likely relevance to human health and disease (such as 
N-glycans of a single plasma protein), illuminate new biological mechanisms. The 
unexpected pleiotropy of the implicated loci that linked them to diseases can change this 
study from hypothesis-free to hypothesis-driven [181], and allow the exploration of potential 
biomarkers using N-glycan traits for the prediction of a specific disease. This study offers 
many additional opportunities to investigate both the function of newly associated genes 
with no previous ties to glycosylation, as well as the investigation of further N-glycan 
biomarkers for diseases identified through gene-level pleiotropy. 
5.5 Conclusions 
New understanding of the genetic regulation of IgG N-glycan synthesis has been revealed by 
this study. Enzymes directly responsible for the addition of galactose, fucose and bisecting 
GlcNAc may not have primary responsibility for the final IgG N-glycan structures. For all 
three processes, genes that are not directly involved in glycosylation showed the most 
significant associations: IL6ST; ANKRD55 for galactosylation; IKZF1 for fucosylation; and 
SMARCB1; DERL3 for the addition of bisecting GlcNAc. This study identified 9 loci that are 




N-glycosylation and several further loci that show suggestive association with glycan traits 
and merit further study. Genetic variants in several of these genes were previously associated 
with a number of inflammatory and neoplastic diseases across ethnically diverse populations, 
all of which could benefit from earlier and more accurate diagnosis based on molecular 
biomarkers. Variations in individual SNPs have relatively small effects, but when several 
polymorphisms are combined in a complex pathway like N-glycosylation, the final product 
of the pathway - in this case IgG N-glycan - can be significantly different, with consequences 





Chapter 6 - Comparative performance of four methods for 
high-throughput glycosylation analysis of immunoglobulin G 
in genetic and epidemiological research 
6.1 Introduction 
Rapid advances of technologies for high-throughput genome analysis in the past decade have 
enabled large-scale genome-wide association studies (GWAS). GWAS has become a reliable 
tool for identification of associations between genetic polymorphisms and various human 
diseases and quantitative traits [2]. Thousands of GWAS have been conducted in recent 
years, but these have not included the study of glycan traits until recently with the analyses 
discussed in Chapters 3 & 5 comprising three of the four published papers. The main reason 
was the absence of reliable tools for high-throughput quantitative analysis of glycans that 
could match the measurements of genomic, proteomic, lipidomic, metabolomic or other 
“omic” methods in their cost, precision and reproducibility. However, several promising 
high-throughput technologies for analysis of N-glycans have recently been developed 
[34,61,63,64,66,182,183]. Successful implementation of high-throughput analytical 
techniques for glycan analysis resulted in publication of four initial GWAS of the human 
glycome [111,112,184,185]. The final paper was looking for loci associated with 
carbohydrate deficient-transferrin so can only loosely be termed a “human glycome” GWAS. 
In this Chapter, I have compared the results of ultra-performance liquid chromatography 
(UPLC) with fluorescence detection, multiplex capillary gel electrophoresis with laser 
induced fluorescence detection (xCGE-LIF), matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF-MS) and nano liquid chromatography 
electrospray mass spectrometry (LC-ESI-MS) as tools for mid-to-high-throughput glycomics 
and glycoproteomics. Colleagues in Zagreb, Leiden, and Magdeburg have analysed IgG N-
glycans by all four methods in 1,201 individuals from the CROATIA-Vis and CROATIA-
Korcula studies. Correlation analysis was undertaken, as well as GWAS, to identify the 
analytical method that shows the strongest potential to uncover biological mechanisms 
underlying protein N-glycosylation. 
6.2 Methods 
Participants from the CROATIA-Vis and CROATIA-Korcula studies were involved in this 
analysis. IgG was isolated from the plasma of 1821 individuals as described in Section 2.4.1 




laboratories for N-glycosylation analysis by UPLC, MALDI-TOF-MS, LC-ESI-MS or 
xCGE-LIF as described in Sections 2.4.2 – 2.4.4. UPLC measurements were performed by 
colleagues from Genos (Zagreb, Croatia), MS measurements by colleagues from Dr. 
Manfred Wuhrer’s laboratory at the LUMC (Leiden, Netherlands), and xCGE-LIF 
measurements by colleagues from Dr. Erdmann Rapp’s laboratory at MPI and glyXera 
(Magdaburg, Germany).  Glycan analysis was successful for 1653 individuals (802 Vis, 851 
Korcula) for UPLC, 1552 individuals (702 Vis, 850 Korcula) for MALDI-TOF-MS, 1595 
individuals (708 Vis, 887 Korcula) for LC-ESI-MS, and 1440 individuals (610 Vis, 830 
Korcula) for xCGE-LIF.  A total of 1201 individuals were successfully measured by all four 
methods. Since not all structures could be measured by all four methods, a “minimal trait” 
dataset was defined which included 15 structures that were able to be directly measured or 
derived for all four analytical methods. A list of these glycan traits is found in Table 11 and 
diagrams of these structures are provided in Figure 43. Due to methodological differences, 
UPLC and xCGE-LIF gave values from total IgG for these structures, where as the MS-
based methods gave results from both IgG1 and IgG2/IgG3 separately. Also, some structures 
that resulted in one peak from MS-based methods were found in two peaks using UPLC and 
xCGE-LIF. 
Correlation coefficients were computed and compared for the same structure from the 
minimal dataset measure by different methods (see Section 2.5.7 for detailed methods). Not 
all individuals with glycan measurements had been successfully genotyped so the final 
sample size for comparative analysis was 1100 (445 Vis, 655 Korcula). GWAS was 
undertaken on directly genotyped SNP data using GenABEL. Each trait was adjusted for sex 
and age and the residuals transformed to ensure their normal distribution using quantile 
normalisation. Meta-analysis was performed using the inverse variance method implemented 
with the MetABEL package for R [73]. The threshold for a SNP reaching genome-wide 
significance was set at p < 5x10
-08
. These methods are described in more detail in Section 2.5 





Table 11: Minimal trait dataset for IgG N-glycan method comparison. 
Glycan Class Glycan Trait UPLC* 
MALDI-TOF-MS* nanoLC-ESI-MS* 
xCGE-LIF* 
IgG1 IgG2 & IgG3 IgG1 IgG2 & IgG3 
Total IgG 
Glycans 
FA2 IGP3 MS_IGP42 MS_IGP86 LC_IGP1 LC_IGP87 CGE_IGP14 
FA2B IGP5 MS_IGP43 MS_IGP87 LC_IGP4 LC_IGP90 CGE_IGP17 
FA2G1 
IGP7 





MS_IGP47 MS_IGP90 LC_IGP5 LC_IGP91 
CGE_IGP21 
IGP10 CGE_IGP22 
FA2G2 IGP13 MS_IGP52 MS_IGP93 LC_IGP3 LC_IGP89 CGE_IGP24 
FA2BG2 IGP14 MS_IGP53 MS_IGP94 LC_IGP6 LC_IGP92 CGE_IGP25 
FA2G1S1 IGP15 MS_IGP50 MS_IGP92 LC_IGP7 LC_IGP93 CGE_IGP7 





FGS/(FG+FGS) IGP24 MS_IGP66 MS_IGP100 LC_IGP34 LC_IGP120 CGE_IGP26 
FGS/(F+FG+FGS) IGP26 MS_IGP67 MS_IGP101 LC_IGP35 LC_IGP121 CGE_IGP28 
FG1S1/(FG1+FG1S1) IGP28 MS_IGP68 MS_IGP102 LC_IGP36 LC_IGP122 CGE_IGP30 





G0n IGP55 MS_IGP13 MS_IGP78 LC_IGP58 LC_IGP144 CGE_IGP56 
G1n IGP56 MS_IGP14 MS_IGP79 LC_IGP59 LC_IGP145 CGE_IGP57 
G2n IGP57 MS_IGP15 MS_IGP80 LC_IGP60 LC_IGP146 CGE_IGP58 
n= neutral; F at the start of the abbreviation indicates a core fucose α1-6 linked to the inner GlcNAc; Ax, number of antenna (GlcNAc) on trimannosyl 
core; A2, biantennary with both GlcNAcs as β1-2 linked; B, bisecting GlcNAc linked β1-4 to β1-3 mannose; Gx, number (x) of β1-4 linked galactose on 
antenna; F(x), number (x) of fucose linked α1-3 to antenna GlcNAc; Sx, number (x) of sialic acids linked to galactose. 





Figure 43: Structures for N-
glycans from minimal trait 
dataset.  
N-glycan structures traits in minimal 
trait dataset in Table 11. For some 
structures, more than one 
configuration is possible so both 
have been shown. GlcNAc: N-
acetylglucosamine. F at the start of 
the abbreviation indicates a core 
fucose α1-6 linked to the inner 
GlcNAc; Ax, number of antenna 
(GlcNAc) on trimannosyl core; A2, 
biantennary with both GlcNAcs as 
β1-2 linked; B, bisecting GlcNAc 
linked β1-4 to β1-3 mannose; Gx, 
number (x) of β1-4 linked galactose 
on antenna; Sx, number (x) of sialic 






IgG N-glycosylation profiling was performed for 1201 individuals using four different 
analytical approaches: UPLC, xCGE-LIF, MALDI-TOF-MS and LC-ESI-MS. An important 
difference between UPLC and xCGE-LIF, versus MS-based methods, on the other hand, is 
that UPLC and xCGE-LIF analyse IgG glycosylation at the level of released glycans (and 
therefore include glycans on both Fab and Fc parts of IgG), while MS-based methods 
included in this study analyse glycopeptides (therefore only capture the Fc region). Although 
in-depth analysis of released glycans may provide a detailed picture of the glycan structure, 
no information on the original glycan attachment site is provided with the methods used 
here. Such site-specific information can be obtained by the direct analysis of glycopeptides. 
Since different IgG subclasses have different amino acid sequences around the glycosylation 
site, by analysing glycans at the glycopeptide level MS-based methods are able to measure 
subclass-specific Fc glycosylation. However, unlike the MS-based methods used in this 
study, UPLC and xCGE-LIF provide branch-specific information i.e. separation between the 
3-arm and 6-arm isomers of glycan species (e.g. FA2[3]G1 and FA2[6]G1, see Figure 43) 
due to a slightly higher retention of the 3-arm isomer. There are other factors that impact N-
glycan quantitation due to methodological and technical differences between methods that 
were beyond the scope of this thesis. These are discussed in more detail in [83].  
In addition to the directly measured glycan structures, a number of derived traits that 
represent common biologically meaningful features (e.g. galactosylation, fucosylation, etc.) 
shared among several measured glycans were calculated as described previously [61,90]. A 
full list of traits and a description of how they were calculated is available in Appendix Table 
16, 12, 15 and 16. Due to the methodological differences, the information provided by the 
four used methods is similar, but not identical. To enable comparison of data measured by 
different methods, a shared “minimal” set of glycan features common to all four methods 
was defined (Table 11, Figure 43). Descriptive statistics for this minimal trait dataset is 
found in Table 12. Since the mean of the traits cannot be directly compared, the coefficient 
of variation (COV; standard deviation/mean) is provided which describes the variability of 
each measure. 
Pearson correlation coefficients were calculated for each minimal dataset structure to obtain 
pairwise comparisons of all methods. These are presented in Appendix Table 26 - Table 39. 
Through this analysis I was able to identify a structure which had been incorrectly annotated 




methods. The correct peak containing this structure was identified and was subsequently 
used for all analyses presented here.  
The N-glycan structures measured by MALDI-TOF-MS seemed to have a much higher COV 
than the other three methods which produced more similar results. This was also apparent 
through the lower correlation coefficients when comparing the same structure measured by 
the other three methods. However, even methods based on fluorescent dye quantification 
(UPLC and xCGE-LIF) had lower correlation coeffiecients for certain structures (for 
example: FG1S1/(FG1+FG1S1); Table 35). This indicates that in addition to different 
response factors in MS-based methods (which distort quantification), sample preparation and 
clean-up procedures (which can lead to selective loss or enrichment of some glycans) can 
also alter final results. Overall though, the correlation coefficients tended to be moderate to 
high (most >0.6), especially for directly measured structures. 
At the moment there is no “gold standard” method to analyse protein glycosylation with 
absolute precision, therefore it is not possible to decide which of the methods we used most 
accurately reflects the real biological state. Aiming to evaluate the precision of the four 
methods, I performed GWAS on the minimal trait data set to compare results for the same 
structure across methods. Since glycome composition was shown to be under strong genetic 
influence as evidenced by the results of Chapters 3 and 5, it was believed that a GWAS 
approach would be a good tool to comparatively assess the power of detecting associations 
between SNPs and IgG N-glycans measured by each of the four methods. The aim was to 
look for consistant SNP associations across methods but it was also assumed that the most 
precise method would show the strongest associations due to reduced noise caused by 
experimental variability. In order to have an unbiased approach, GWAS was performed on 
the minimal trait dataset using only data from individuals whose glycosylation traits were 
successfully measured by all four methods (n=1100). The results are presented in Table 13. 
Genome-wide significant association with SNPs in two genomic loci were obtained using all 
four methods across six N-glycan structures. Both regions were associated with IgG N-
glycans in the previous chapter and all structures that were significant here were also 
significant with the same genes in the previous chapter. It is only due to the lower sample 
size that some regions previously associated do not reach the genome-wide threshold here, 
for structures measured by UPLC. LC-ESI-MS analysis uncovered all six of these glycan 
traits, UPLC and xCGE-LIF found five, and four of the traits were observed with MALDI-




GWAS comparison, which also corresponded with lower correlation coefficients and higher 
COV. 
Table 12: Descriptive statistics for IgG N-glycan minimal trait dataset for 
CROATIA-Vis (n=445) and CROATIA-Korcula (n=655). 




Mean SD CV Mean SD CV 
FA2 
UPLC Total 26.23 7.27 0.277 25.18 6.78 0.263 
MALDI 
IgG1 35.01 10.72 0.306 35.69 10.49 0.294 
IgG2&3 48.88 11.50 0.235 47.42 11.15 0.235 
LC-MS 
IgG1 21.83 6.77 0.310 21.88 6.40 0.293 
IgG2&3 32.24 8.32 0.258 31.36 7.86 0.251 
xCGE Total 26.27 7.64 0.291 25.74 7.11 0.276 
FA2B 
UPLC Total 6.79 1.86 0.275 6.88 1.93 0.281 
MALDI 
IgG1 5.54 1.92 0.347 5.83 2.37 0.407 
IgG2&3 5.69 1.93 0.339 6.00 2.16 0.361 
LC-MS 
IgG1 8.04 2.54 0.316 8.04 2.73 0.340 
IgG2&3 8.49 2.40 0.282 8.59 2.50 0.292 
xCGE Total 5.32 1.78 0.335 5.55 1.90 0.343 
FA2G1* 
UPLC Total 
20.34 1.96 0.096 20.13 1.79 0.089 
9.76 1.20 0.122 9.80 1.32 0.135 
MALDI 
IgG1 39.46 5.98 0.152 38.59 6.37 0.165 
IgG2&3 33.15 6.78 0.204 33.30 6.72 0.202 
LC-MS 
IgG1 29.66 2.63 0.089 29.14 2.75 0.094 
IgG2&3 26.64 2.88 0.108 26.34 2.90 0.110 
xCGE Total 
21.67 1.98 0.091 21.56 1.98 0.092 
10.60 1.34 0.127 10.67 1.51 0.142 
FA2BG1* 
UPLC Total 
5.86 1.08 0.185 5.78 1.07 0.185 
0.93 0.19 0.209 0.96 0.23 0.242 
MALDI 
IgG1 5.92 1.98 0.334 6.00 2.03 0.338 
IgG2&3 2.51 1.08 0.431 2.72 1.12 0.411 
LC-MS 
IgG1 11.02 2.20 0.200 10.20 2.12 0.208 
IgG2&3 5.17 1.21 0.234 5.33 1.21 0.227 
xCGE Total 
5.47 1.16 0.213 5.67 1.15 0.203 
0.59 0.13 0.224 0.62 0.14 0.227 
FA2G2 
UPLC Total 13.80 4.20 0.304 13.90 4.10 0.295 
MALDI 
IgG1 9.87 4.95 0.501 10.15 5.13 0.505 
IgG2&3 6.77 4.10 0.605 6.92 4.03 0.582 
LC-MS 
IgG1 13.61 3.98 0.292 13.86 4.00 0.289 
IgG2&3 10.00 3.17 0.317 10.14 3.18 0.314 
xCGE Total 15.40 4.62 0.300 15.31 4.55 0.297 
FA2BG2 
 
UPLC Total 1.76 0.44 0.250 1.89 0.43 0.228 
MALDI 
IgG1 0.49 0.30 0.609 0.46 0.29 0.625 
IgG2&3 0.23 0.16 0.672 0.26 0.18 0.701 
LC-MS 
IgG1 1.85 0.63 0.343 1.73 0.56 0.324 
IgG2&3 1.00 0.41 0.412 1.04 0.42 0.401 
xCGE Total 1.37 0.41 0.298 1.38 0.40 0.292 
FA2G1S1 
UPLC Total 3.87 0.65 0.167 3.96 0.57 0.143 
MALDI 
IgG1 1.75 0.93 0.532 1.27 0.71 0.559 
IgG2&3 1.20 0.47 0.392 1.51 0.54 0.356 
LC-MS 
IgG1 2.11 0.41 0.195 2.27 0.41 0.180 
IgG2&3 5.92 1.03 0.175 6.43 1.06 0.166 








Mean SD CV Mean SD CV 
FA2G2S1 
UPLC Total 10.66 3.05 0.286 11.52 3.21 0.279 
MALDI 
IgG1 1.96 1.08 0.551 2.01 1.13 0.565 
IgG2&3 1.57 1.22 0.779 1.87 1.30 0.692 
LC-MS 
IgG1 11.89 3.89 0.327 12.88 4.13 0.321 
IgG2&3 10.54 3.92 0.372 10.78 3.93 0.364 
xCGE Total 10.33 3.14 0.304 10.56 3.22 0.304 
FGS/(FG + 
FGS) 
UPLC Total 24.68 2.87 0.116 25.90 2.89 0.112 
MALDI 
IgG1 6.94 2.53 0.365 6.20 2.12 0.342 
IgG2&3 6.15 2.20 0.358 7.49 2.56 0.342 
LC-MS 
IgG1 24.08 3.88 0.161 25.70 4.23 0.165 
IgG2&3 30.59 4.42 0.144 31.69 4.73 0.149 
xCGE Total 21.57 2.86 0.132 21.90 2.93 0.134 
FGS/(F + FG 
+ FGS) 
UPLC Total 26.23 7.41 0.282 27.95 7.64 0.273 
MALDI 
IgG1 4.23 1.89 0.446 3.75 1.68 0.449 
IgG2&3 3.02 1.78 0.590 3.72 1.92 0.517 
LC-MS 
IgG1 17.63 4.58 0.260 18.85 4.70 0.249 
IgG2&3 19.24 5.20 0.270 20.17 5.14 0.255 
xCGE Total 15.22 3.59 0.236 15.54 3.60 0.231 
FG1S1/(FG1 
+ FG1S1) 
UPLC Total 11.42 1.88 0.164 11.71 1.59 0.135 
MALDI 
IgG1 4.29 2.28 0.532 3.22 1.77 0.549 
IgG2&3 2.74 0.76 0.277 3.42 1.02 0.299 
LC-MS 
IgG1 6.64 1.12 0.169 7.23 1.22 0.169 
IgG2&3 18.20 2.63 0.145 19.64 2.77 0.141 
xCGE Total 8.44 1.47 0.174 8.41 1.37 0.163 
FG2S1/(FG2 
+ FG2S1 + 
FG2S2) 
UPLC Total 43.79 3.32 0.076 45.48 3.17 0.070 
MALDI 
IgG1 16.74 4.50 0.269 16.48 3.61 0.219 
IgG2&3 18.10 4.57 0.252 20.76 5.17 0.249 
LC-MS 
IgG1 46.41 4.08 0.088 47.93 4.77 0.099 
IgG2&3 50.90 4.76 0.094 51.02 5.54 0.109 
xCGE Total 40.21 3.09 0.077 40.84 3.05 0.075 
G0n 
UPLC Total 38.35 8.91 0.232 37.65 8.40 0.223 
MALDI 
IgG1 42.00 11.84 0.282 42.81 11.84 0.277 
IgG2&3 55.96 12.23 0.219 55.12 11.99 0.218 
LC-MS 
IgG1 34.40 8.87 0.258 34.93 8.69 0.249 
IgG2&3 48.31 9.79 0.203 47.84 9.54 0.199 
xCGE Total 36.14 9.19 0.254 35.89 8.78 0.245 
G1n 
UPLC Total 43.25 3.69 0.085 43.46 3.36 0.077 
MALDI 
IgG1 47.19 7.25 0.154 46.16 7.21 0.156 
IgG2&3 36.77 8.14 0.221 37.38 7.99 0.214 
LC-MS 
IgG1 47.40 3.91 0.082 46.46 3.86 0.083 
IgG2&3 38.30 5.24 0.137 38.44 5.05 0.131 
xCGE Total 44.30 3.64 0.082 44.60 3.41 0.076 
G2n 
UPLC Total 18.39 5.99 0.326 18.89 5.96 0.315 
MALDI 
IgG1 10.81 5.49 0.508 11.03 5.65 0.513 
IgG2&3 7.27 4.52 0.622 7.50 4.48 0.598 
LC-MS 
IgG1 18.20 6.01 0.330 18.61 6.05 0.325 
IgG2&3 13.39 4.94 0.369 13.72 4.96 0.362 
xCGE Total 19.56 6.42 0.328 19.51 6.39 0.327 
SD: standard deviation, CV: coefficient of variation, MALDI: MALDI-TOF-MS, LC-MS: LC-
ESI-MS, CGE: xCGE-LIF 
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Bold text indicates that the p-value reaches genomewide significance (P<5x10
-08
). 





In this Chapter, I have compared four different methods (UPLC, xCGE-LIF, MALDI-TOF-
MS and LC-ESI-MS) for the quantitative analysis of IgG N-glycosylation by analysing the 
same 1100 IgG samples using all four methods. These four analytical methods comprise the 
majority of those that have been commonly used for glycosylation, but there is currently no 
“gold standard” method. Therefore, it was decided to use various statistical approaches to 
determine the relative accuracy of the four most widely used methods, namely correlations 
and GWAS.  
GWAS has been successfully applied in Chapters 3 and 5 to identify genetic loci that are 
associated with the regulation of protein N-glycosylation [111,112,184,186]. For this study 
we decided to use GWAS to evaluate the consistency across methods and the precision of 
each method. Association analysis was performed separately on glycan data generated by the 
four methods under the assumption that any imprecision in measurement will decrease 
power to detect the biological association between SNPs and the measured N-glycans. 
Therefore the analytical method that is the most precise is expected to show the strongest 
association at a specific locus. 
The results presented in Table 13 clearly show that all four methods generate glycan data of 
sufficiently high quality to be used to detect associations with genetic polymorphisms. In 
general, LC-ECI-MS tended to yield the most significant association, with the benefit of IgG 
class discrimination but, overall, all methods seemed to perform fairly well. In this study, not 
all previously reported genetic associations were detected but this was not unexpected since 
the number of individuals in this study was much lower. Indeed, for a GWAS of only 1100 
individuals, the fact that any genetic associations were detected at all indicates that glycans 
are under strong genetic regulation.  
This study clearly demonstrated that the relative quantification by both MALDI-TOF-MS 
and LC-ESI-MS are each very reliable, and that very strong genetic associations can be 
obtained with glycans measured by both methods, however LC-ESI-MS did perform better 
than MALDI-TOF-MS. Numeric values generated by mass spectrometry for different 
glycans or glycopeptides are not directly comparable since each molecular species has its 
own response factors in mass spectrometry [187], but this difference does not impact this 
study because the absolute numerical values were not used. This is evident from the detected 
genetic associations observed in this study. However, if derived traits (like fucosylation, 




not correspond to real biological situations because they would be distorted by different 
response factors for individual glycans/glycopeptides, and this is something that needs to be 
considered when interpreting MS-based data. Furthermore, there are various cost and 
throughput differences to take into account. These are summarised in Table 14 prepared by 
colleages at Genos and also found in Huffman et al. [83]. All of this must be taken into 
consideration when designing a study based on what analyses are planned for the resulting 
data. 
Each of the methods reveals some additional complementary information about the glycome, 
indicating that in some situations the combined analysis by different methods can yield 
additional useful information, which helps interpretation of complex biological systems. 
6.5 Conclusions 
It is increasingly recognised that variation in N-glycan structures are likely to play essential 
and ubiquitous roles in human physiology and pathophysiology. This recognition has led to 
glycomics being declared a research priority for the next decade [188], and it is expected that 
an increasing number of large clinical and population studies will include N-glycan analysis 
[20]. However, methods for high-throughput analysis have been developed only recently, 
and thorough evaluation and standardization of the analytical methods is needed before a 
significant amount of time, money and other resources should be invested in large-scale 
studies. In this study I have used several statistical methods as the evaluation criteria to 
compare four methods (UPLC, xCGE-LIF, MALDI-TOF-MS and LC-ESI-MS) that are 
currently being used to study protein N-glycosylation. All four methods delivered reliable 
quantitative data. A number of specific advantages and disadvantages of each method have 
been compiled (Table 14) in order to guide selection of the most appropriate and cost-





Table 14: Comparison of four methods for high-throughput glycomics and 
glycoproteomic analysis. 
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Chapter 7 - Conclusion 
The results presented here comprise the first GWAS of total plasma and IgG N-glycans. I 
have shown that plasma N-glycan concentrations are highly heritable and that the 
quantitation methods are accurate enough to enable GWAS. This was shown by the “positive 
control” associations of enzymes with known roles in glycosylation. In addition, associated 
loci with no previously known role in glycosylation provide new avenues for functional 
follow-up.  Successful collaborations with colleagues here in Edinburgh provided insight 
into the role of HNF1A as a master regulator of N-glycan fucosylation and several other hits 
are currently under investigation both in Edinburgh and in Croatia. The HNF1A association 
also led to promising results identifying potential N-glycan biomarkers for MODY3 which 
are also being taken forward by colleagues in Croatia and the UK as part of a European FP7 
grant (HighGlycans). Analysis of N-glycans attached to specific proteins, in this case IgG, 
illustrate an alternative approach, which led to this discovery of several other known 
glycosylation and novel genes. More loci and stronger associations were found by looking at 
N-glycans from a specific protein, rather than a pool. Finally, comparison of several different 
analytical methods for measuring N-glycans did not produce a clear winner from these 
analyses with all performing well, but information regarding other study-specific 
considerations have been outlined. 
One line of future investigation would be laboratory-based follow-up of these genes to 
confirm and characterise their role in N-glycosylation. In Lauc et al. (2010) this proved very 
successful for HNF1A [112]. Current projects are now underway for several of the genes 
associated with IgG N-glycan levels. Dr. Chloe Stanton in our laboratory is pursuing the 
IL6ST and IKZF1 associations. She is performing shRNA-mediated knockdown and 
TALEN/CRISPR-mediated knockout of IL6ST and IKZF1 in lymphoblastoid cell lines to 
look at the effect on both the IgG N-glycan profile and the transcription levels of 
glycosylation-related genes. In addition, she is performing some pharmacological 
experiments looking at IL-6 signalling in the same cell lines. Dr. Vlatka Zoldos’s laboratory 
in Zagreb, Croatia is investigating the BACH2 association by looking at methylation patterns 
and expression differences of this transcription factor in conjunction with downstream 
differences in N-glycosylation.  
A major finding was the gene-level pleiotropy observed for loci associated with N-glycans 
and other quantitative traits or diseases.  The top SNPs located in or near HNF1A and 
SLC39A8 were in LD with variants associated with many medically relevant traits, 




protein, gamma-glutamyl transferase, HDL cholesterol, diastolic & systolic blood pressure, 
mean arterial pressure, hypertension, coronary heart disease and body mass index. Top SNPs 
from the IgG N-glycan GWAS appeared to be tagging the same regions associated with bone 
mineral density (ABCF2; SMARCD3) and serum urate concentration (B4GALT1). In 
addition, genes on or close to loci from the IgG N-glycan GWAS have been associated with 
many autoimmune related diseases but the association signals did not appear to be the same, 
i.e. the associated common variants are tagging different LD blocks than those of the glycan-
associated SNPs. There is greater support for causality if the associated SNPs are in LD but 
whether these findings indicate a causal role for glycans, or simply highlight the multifaceted 
role of these genes will require further investigation beyond the scope of this project. There 
are specific methods for investigating causality within disease cohorts that additionally have 
the phenotype of interest measured (IgG N-glycans in this case), such as Mendelian 
randomization. This assesses causality under the assumption that the genetic variant is acting 
to cause disease directly through its effect on the risk factor.  Due to the lack of disease 
cohorts with IgG N-glycans measured, this was not an option available within the scope of 
this PhD. Another consideration is that regardless of the LD structure, association with 
quantitative traits inform the likely function of the genes associated with diseases. 
A mechanism for the causal role of N-glycans in disease has been proposed previously. A 
recent paper from Ohtsubo et al.[189] has implicated improper N-glycosylation in the 
development of T2D in the presence of a high fat diet. The authors showed in mouse models, 
that increased fatty acids in the diet led to decreased expression of Foxa2 and Hnf1a 
transcription factors, in pancreatic beta cells due to their decreased nuclear localization. This 
in turn led to decreased beta cell expression of Mgat4a, a glycosyltransferase, and Slc2a2 
(also known as Glut2), the main glucose transporter in mice, leading to decreased glucose 
sensitivity. Following on the fact that Mgat4a knockout mice displayed T2D [190], further 
experiments showed that GnT-4a (the protein product of Mgat4a) was required for correct 
localisation of Glut-2 in the cell membrane, otherwise it was internalised into endosomes or 
lysosomes [189,191]. Similar results were found from experiments using human pancreatic 
cell lines as well as beta cells donated from both healthy controls and T2D patients. In 
humans, GLUT1 is the main glucose transporter, not GLUT2, but both were modified in a 
similar manner in these experiments. The authors then hypothesized that this may be the 





Regardless of their pathogenic role, N-glycans provide new molecules for biomarker 
discovery. This was highlighted in the MODY3 work from Chapter 4 and was proven to be 
useful by the identification of four undocumented MODY3 cases in Thanabalasingham et al. 
[167]. Although currently UPLC methods may not be best suited for a clinical laboratory, the 
results from Chapter 6 show that different methodologies (such as MS) may be better able to 
be used at the translational stage. This work may also be taken forward to see if glycans 
structures could also be used to identify different HNF1A mutations by acting as a proxy for 
HNF1A function but this may require better sensitivity than was observed during the 
biomarker analysis. This may also explain why some of the MODY3 cases overlapped with 
T2D, T1D and non-diabetic controls for the biomarker in Thanabalasingham et al. [167].   
Although many interesting finding have been presented here, these studies were performed 
in relatively small cohorts and have not yet been replicated by other groups. The next stage 
of the project will be to measure these N-glycan traits in other population cohorts. This is 
currently underway with a larger meta-analysis planned for autumn/winter 2014. In addition, 
expanding to case/control studies may help to elucidate some of the causality issues that 
were not able to be explored in the studies presented here. Measuring glycans in other large 
cohorts, such as Generation Scotland or UK Biobank, would provide the power to look at the 
glycans in relation to many other health-related aspects. These are both studies that have, or 
will have, medical record and prescription linkage and permission to recontact participants 
(only in a subset of Generation Scotland). As participants go on to develop disease they 
could be recontacted to obtain new biological samples. This would allow the analysis of 
samples before and after diagnosis which could help with biomarker discovery. One of the 
main limitations at this point is that commercial assays for the isolation of specific proteins 
are only available for IgG so these would need to be developed to look at disease-related 
glycosylated proteins. This is currently underway for a few proteins as part of a European 
FP7 grant (HighGlycans) but would need to be deemed commercially viable in order to 
proceed on a larger scale. 
Rare variant analyses yielded very little in terms of identifying the “missing heritability” but 
this study was very under-powered so this was not an unexpected result. Looking at rare 
variants and/or structural variants in larger samples using the Exome Chip, sequencing or 
1000 Genomes imputed data will also help to expand our knowledge of the genes and 




This thesis describes the first steps in establishing the genetic contributions to the complex 
variation in protein N-glycosylation and future studies of the genes and pathways identified 
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Chapter 9 - Appendix 
9.1 Additional Methods 
9.1.1 Isolation of Immunoglobulin G 
Immunoglobulin G was isolated from plasma by affinity chromatography using 96-well 
protein G monolithic plates (BIA Separations, Ajdovščina, Slovenia). The protein G plate 
was first washed with 10 column volumes (CV) of ultrapure water and equilibrated with 10 
CV of binding buffer (1× PBS, pH 7.4; Fisher Scientific, Pittsburgh, PA, USA). Plasma 
samples (50 μl) were diluted 10× with the binding buffer, applied to the plate and instantly 
washed five times with 5 CV of binding buffer to remove unbound proteins. IgGs were 
eluted from the protein G monoliths using 5 CV of 100 mM formic acid (FA; Fisher 
Scientific, Pittsburgh, PA, USA), pH 2.5. into a 96 deep well plate and immediately 
neutralized to pH 7.0 with 1 M ammonium bicarbonate (Fisher Scientific). After each sample 
application, the plate was regenerated with the following buffers: 10 CV of 10× PBS, 
followed by 10 CV of 0.1 M FA and afterwards 10 CV of 1× PBS to re-equilibrate the 
monoliths. Each step of the isolation was done under vacuum (approx. 60 mmHg pressure 
reduction while applying the samples, 500 mmHg during elution and washing steps) using a 
manual set-up consisting of a multichannel pipette, a vacuum manifold (Beckman Coulter, 
Brea, CA, USA) and a vacuum pump (Pall Life Sciences, Ann Arbor, MI, USA).  
9.1.2 IgG N-Glycosylation by Hydrophilic Interaction Chromatography  
9.1.2.1 Glycan release and labelling  
Aliquots (1/5; 200 µl) of the protein G eluates were transferred to 96-well flat-bottomed 
microtitre plates, dried down in a vacuum concentrator and reconstituted by adding 2 µl of 
5× sample buffer (125 µl of 0.5 M Tris (Sigma-Aldrich, St, Louis, MO, USA), pH 6.6, 200 
µl of 10 % SDS (Sigma-Aldrich), and 675 µl of water), 7 µl of water, and 1 µl of 0.5 M 
dithiothreitol (DTT; Sigma-Aldrich) and incubating at 65°C for 15 min. Ultrapure water was 
used throughout. The samples were then alkylated by adding 1 µl of 100 mM iodoacetamide 
(IAA; Sigma-Aldrich) and incubated for 30 min in the dark at room temperature. Afterwards, 
the samples were immobilized in a gel block by adding 22.5 µl of 30 % (w/w) 
acrylamide/0.8 % (w/v) bis-acrylamide stock solution (37.5:1, Protogel; Sigma-Aldrich), 
11.25 µl of 1.5 M Tris, pH 8.8, 1 µl of 10 % SDS (Invitrogen, Carlsbad, CA, USA). 1 µl of 
10 % ammonium peroxodisulphate (APS; Sigma-Aldrich), and 1 µl of N,N,N,N’-tetramethyl-




protein precipitation plate and washed with 1 ml of acetonitrile with shaking on a plate 
shaker for 10 min, followed by removal of the liquid on a vacuum manifold. The washing 
was repeated twice with 1 ml of 20 mM sodium bicarbonate (NaHCO3; Sigma-Aldrich), pH 
7.2, followed by 1 ml of acetonitrile (ACN; J.T.Baker, Phillipsburg, NJ, USA). N-glycans 
were released by adding 50 µl of 2.5 mU PNGase F (ProZyme, Leandro, CA, USA) in 20 
mM NaHCO3, pH 7.2, to reswell the gel pieces for 5 min, another 50 µl of 20 mM NaHCO3, 
pH 7.2, was added and then the plates were sealed with adhesive film (USA Scientific, 
Ocala, FL, USA) and incubated over night at 37°C. The released N-glycans were collected 
into a 2-ml polypropylene 96-well plate (Waters, Milford, MA, USA) by washing the gel 
pieces with 3× 200 µl of water, 200 µl of ACN, 200 µl of water, and finally 200 µl of ACN. 
The released N-glycans were dried, redissolved in 20 µl of 1 % FA, incubated at room 
temperature for 40 min, and dried again. N-glycans were labelled with 5 µl of 2-AB labeling 
solution (55 mg of anthranilamide, 66 mg of sodium cyanoborohydride, 330 µl of glacial 
acetic acid, and 770 µl of dimethylsulfoxide (DMSO); all from Sigma-Aldrich), shaken for 5 
min, incubated for 30 min at 65°C, shaken again for 5 min, and incubated for a further 90 
min. Excess 2-AB was removed using solid-phase extraction with 1-cm square pieces of pre-
washed, dried and folded into quarters Whatman 3MM chromatography paper placed into a 
Whatman protein precipitation plate (pre-washed with 200 µl of ACN followed by 200 µl of 
water). The 5 µl of 2-AB labelled IgG N-glycans were applied to the paper and left to dry 
and bind for 15 min. The excess 2-AB was washed off the paper by shaking with 1.6 ml of 
ACN for 15 min and then removing the ACN using a vacuum manifold; this step was 
repeated four times. The labelled N-glycans were eluted from the paper by shaking with 500 
µl of water for 20 min and collected by vacuum into a 2-ml 96-well plate; this step was 
repeated two times. The eluted 2-AB IgG N-glycans were dried before resuspending in a 
known volume of water ready for analysis by UPLC-FLR. 
9.1.2.2 Hydrophilic interaction chromatography 
2-AB labelled IgG N-glycans were separated by hydrophilic interaction chromatography on a 
Waters Acquity UPLC instrument consisting of a quaternary solvent manager, sample 
manager and a FLR fluorescence detector set with excitation and emission wavelengths of 
330 and 420 nm, respectively. The instrument was under the control of Empower 2 software, 
build 2145 (Waters). Labelled N-glycans were separated on a Waters BEH Glycan 
chromatography column, 100 x 2.1 mm i.d., 1.7 µm BEH particles, with 100 mM 
ammonium formate, pH 4.4, as solvent A and ACN as solvent B. A linear gradient of 75-
62% ACN was used at flow rate of 0.4 ml/min in a 20 min analytical run. Samples were 




was calibrated using an external standard of hydrolyzed and 2-AB labelled glucose 
oligomers from which the retention times for the individual glycans were converted to 
glucose units (GU). Data processing was performed using an automatic processing method 
with a traditional integration algorithm after which each chromatogram was manually 
corrected to maintain the same intervals of integration for all the samples. The 
chromatograms obtained were all separated in the same manner into 24 peaks and the 
amount of glycans in each peak was expressed as % of total integrated area. Additional 
structures could be derived from these 24 peaks to give a total of 77 structures. All structures 
and formulas are described in Appendix Table 16 . 
9.1.3 IgG N-Glycosylation by Mass Spectrometry 
9.1.3.1 Trypsin digestion and reverse-phase solid-phase extraction (RP-SPE)  
Aliquots (1/20; 50 μl) of the protein G eluates were applied to 96-well polypropylene V-
bottom microtitre plates. TPCK trypsin (Sigma-Aldrich) was first dissolved in ice-cold 20 
mM acetic acid (Merck, Darmstadt, Germany) to a final concentration of 0.4 μg/μl after 
which it was further diluted to 0.02 μg/μl with ice-cold ultrapure water. To each sample 20 
μl of the diluted trypsin was added followed by overnight incubation at 37°C. 
For reverse-phase desalting and purification of glycopeptides, 5 mg of Chromabond C18ec 
beads (Marcherey-Nagel, Düren, Germany) were applied to each well of an OF1100 96-well 
polypropylene filter plate with a 10 μm polyethylene frit (Orochem Technologies Inc., 
Lombard, IL, USA). The RP stationary phase was activated with 3× 200 μl 80 % ACN 
containing 0.1 % trifluoroacetic acid (TFA; Fluka, Steinheim, Germany) and conditioned 
with 3× 200 μl 0.1 % TFA. The IgG digests were diluted 10× in 0.1 % TFA, loaded onto the 
C18 beads, and washed with 3× 200 μl 0.1 % TFA. The entire procedure was performed on a 
vacuum manifold (< 3 mmHg). IgG glycopeptides were eluted into a V-bottom microtitre 
plate by centrifugation at 500 rpm with 90 μl of 18 % ACN containing 0.1 % TFA. Eluates 
were dried by vacuum centrifugation, reconstituted in 20 μl MQ water and stored at -20ºC 
until analysis by MS. 
9.1.3.2 MALDI-TOF-MS  
Purified and desalted tryptic IgG glycopeptides (3 μl) were spotted onto MTP 384 polished 
steel target plates (Bruker Daltonics, Bremen, Germany) and allowed to dry at room 
temperature. Subsequently 1 μl of 5 mg/ml 4-chloro-α-cyanocinnamic acid (Cl-CCA; 95 % 
purity; Bionet Research, Camelford, Cornwall, UK) in 50 % ACN was applied on top of 




TOF/TOF mass spectrometer (Bruker Daltonics) operated in the negative-ion reflectron 
mode, since negative-ion mode has been found well-suited for the analysis of IgG 
glycopeptides and specifically for sialylated glycopeptides [84], while reflectron mode 
greatly improves the resolution and sensitivity of the analysis. Ions between m/z 1000 and 
3800 were recorded. To allow homogeneous spot sampling a random walk laser movement 
with 50 laser shots per raster spot was applied and each IgG glycopeptide sum mass 
spectrum was generated by accumulation of 2000 laser shots. Mass spectra were internally 
calibrated using a list of known glycopeptides. Data processing and evaluation were 
performed with FlexAnalysis Software (Bruker Daltonics) and Microsoft Excel, respectively. 
Structural assignment of the detected glycoforms was performed on the basis of literature 
knowledge of IgG N-glycosylation [44,85-89]. The data were baseline subtracted and the 
intensities of a defined set of 27 glycopeptides (16 glycoforms for IgG1 and 11 for IgG2&3) 
were automatically defined for each spectrum as described before [90].  
In Caucasian populations, IgG2 and IgG3 have identical peptide moieties 
(E293EQFNSTFR301) of their tryptic Fc glycopeptides and were, therefore, not distinguished 
by the profiling method [91]. Relative intensities of IgG Fc glycopeptides were obtained by 
integrating and summing four isotopic peaks followed by normalization to the total subclass 
specific glycopeptide intensities, as described previously [90]. Additional structures could be 
derived from these directly measured values to give a total of 103 structures. All structures 
and formulas are described in Appendix Table 17. The list of the assigned IgG1, IgG2&3 
and IgG4 glycopeptides as well as the charge states corresponding m/z values is given in 
Appendix Table 18.  
9.1.3.3 Reverse phase nano-LC-sheath-flow-ESI-MS (LC-ESI-MS) 
Purified and desalted tryptic IgG glycopeptides were also analysed on an Ultimate 3000 
HPLC system (Dionex Corporation, Sunnyvale, CA, USA), consisting of a degasser unit, 
binary loading pump, dual binary gradient pump, autosampler maintained at 5°C and fitted 
with a 10μl PEEK sample loop, and two column oven compartments set at 30°C. To protect 
the trap and analytical column for particulates, samples were centrifuged at 4000 rpm for 5 
min and passed through a 2 μm pore size stainless steel frit mounted between the 
autosampler transfer tubing and the trap column. Samples (250-5000 nl) were applied to a 
Dionex Acclaim PepMap100 C18 (5 mm x 300 μm i.d.) SPE trap column conditioned with 
0.1 % TFA (mobile phase A) for 1 min at 25 μl/min. After sample loading the trap column 
was switched in-line with the gradient and Ascentis Express C18 nano-LC column (50 mm x 




sample elution took place. This was followed by an off-line cleaning of the trap column with 
three full loop injections containing 5 μl 5 % isopropanol (IPA) + 0.1 % FA and 5 μl 50 % 
IPA + 0.1 % FA. On-column separation was achieved at 900 nl/min using the following 
gradient of mobile phase A and 95 % ACN (Biosolve BV, Valkenswaard, the Netherlands; 
mobile phase B): 0 min 3 % B, 2 min 5 % B, 5 min 20 % B, 6 min 30 % B, 8 min 30 % B, 9 
min 0 % B, and 14 min 0 % B. The separation was coupled to a quadrupole-TOF-MS 
(micrOTOF-Q; Bruker Daltonics, Bremen, Germany) equipped with a standard ESI source 
(Bruker Daltonics) and a sheath-flow ESI sprayer (capillary electrophoresis ESI-MS sprayer; 
Agilent Technologies, Santa Clara, USA). The column outlet tubing (20 μm i.d., 360 μm 
o.d.) was directly applied as sprayer needle. A 2 μl/min sheath-flow of 50 % IPA, 20 % 
propionic acid (PA) and 30 % ultrapure water was applied by one of the binary gradient 
pumps to reduce the TFA gas phase ion pairing and assist with ESI spray formation. A 
nitrogen stream was applied as dry gas at 4 l/min with a nebulizer pressure of 0.4 bars to 
improve mobile phase evaporation. Glycan decay during ion transfer was reduced by 
applying 2 and 4 eV quadrupole ion energy and collision energy, respectively. Scan spectra 
were recorded from m/z 300 to 2000 with 2 averaged scans at a frequency of 1 Hz. Per 
sample the total analysis time was 16 min. The software used to operate the Ultimate 3000 
HPLC system and the Bruker micrOTOF-Q were Chromeleon Client version 6.8 and 
micrOTOF control version 2.3, respectively. 
Each LC-MS dataset was calibrated internally using a list of known glycopeptides, exported 
to the open mzXML format by Bruker DataAnalysis 4.0 in batch mode [92] and aligned to a 
master dataset of a typical sample (containing many of the (glyco)peptide species shared 
between multiple samples) using msalign2 [93] and a simple warping script in AWK [94]. 
From each dataset a list of 402 pre-defined features defined as peak maximum  in an within 
mass window of + m/z 0.04 and a retention time window of +10 [95] , were extracted using 
the in-house developed “Xtractor2D” software and merged to a complete data matrix as 
described previously [65]. As input, Xtractor2D takes a dataset in the mzXML format 
aligned to the master dataset and a reference list with pre-defined features with m/z windows 
and retention times in seconds. The theoretical m/z values used to identify the glycopeptide 
features are calculated, and the retention times on the chromatographic time scale of the 
master dataset are used for the alignment. Due to the use of TFA as ion pairing reagent, all 
glycopeptides belonging to the same IgG subclass have approximately the same retention 
time, regardless of the number of N-acetylneuraminic acid residues. The software and 
ancillary scripts are freely available at www.ms-utils.org/Xtractor2D. The complete sample-




Structural assignment of the detected glycoforms was performed on the basis of literature 
knowledge of IgG N-glycosylation [44,85-89]. Relative intensities of 20 IgG1, 20 IgG2/3 
and 10 IgG4 glycopeptide species were obtained by integrating and summing the first three 
isotopic peaks of both doubly and triply charged glycopeptide species followed by 
background correction and normalization to the total IgG subclass specific glycopeptide 
intensities. The list of the assigned IgG1, IgG2&3 and IgG4 glycopeptides as well as the 
charge states corresponding m/z values is given in Appendix Table 19 as well as in [65]. 
Non-fucosylated IgG4 species were not included in this list, because of spectral overlap with 
isomeric IgG1 species. These IgG4 species are not expected to influence the IgG1 
glycopeptide abundance levels, since they elute after the IgG1 glycopeptides. There is also 
spectral overlap between several IgG2&3 and IgG4 glycopeptides, but since IgG4 elutes 
before IgG2&3 and is present at a much lower abundace, this is not expected to be a problem 
for the analysis of either of the glycopeptides. Additional structures could be derived from 
these directly measured species to give a total of 205 structures. All structures and formulas 
are described in Appendix Table 20. 
9.1.4 IgG N-Glycosylation by Multiplex Capillary Gel Electrophoresis 
with Laser-Induced Fluorescence (xCGE-LIF) 
9.1.4.1 Glycan release and labeling 
Approximately 10 μg of the protein G monolithic plate IgG eluates were redissolved in 3 μl 
1× PBS (Sigma-Aldrich) and dispensed into a 96-well microtitre plate (Greiner Bio-One, 
Solingen, Germany). IgG samples were denatured with the addition of 4 μl of 0.5 % (w/v) 
SDS (AppliChem, Darmstadt, Germany) in 1× PBS and by incubation at 60°C for 10 min. 
Subsequently, the remaining SDS was neutralized by adding 2 μl 4 % (v/v) IGEPAL (Sigma-
Aldrich) in 1× PBS. IgG N-glycans were released by adding 0.1 U PNGase F (BioReagent ≥ 
95 %, Sigma-Aldrich) in 1 μl 1× PBS. The 96-well microtitre plate was sealed with adhesive 
tape and the final sample volume of 10 μL was incubated for 3 hours at 37°C. After N-
glycan release samples were dried in a vacuum centrifuge and stored until labeling at -80°C.  
Dried samples were redissolved by adding 2 μl of 1× PBS, 2 μl of 20 mM aminopyrene-
1,3,6-trisulfonic acid (APTS; Darmstadt, Sigma-Aldrich) in 3.6 M citric acid monohydrate 
(CAaq; Merck-Millipore, Germany) and 2 μl of 0.2 M 2-picoline-borane (2-PB; Sigma-
Aldrich) solution in DMSO (Sigma-Aldrich). Ultrapure water was used throughout. The 96-
well microtitre plate was sealed using adhesive tape followed by shaking for 2 min at 900 




MS Grade ≥ 99.5 %, Sigma-Aldrich) was added and the plate was shaken for 2 min at 500 
rpm. Post derivatization sample clean-up was performed by HILIC-solid phase extraction 
(SPE). To remove free APTS, reducing agent and other impurities, 200 μl of 100 mg/ml 
BioGel P10 (Bio-Rad, Munich, Germany) suspension in water/EtOH/ACN (70:20:10 %, v/v) 
was applied to AcroPrep 96-well GHP Filter Plates (Pall Corporation, Dreieich, Germany). 
Solvent was removed by application of vacuum using a vacuum manifold (Merck-Millipore, 
Germany). All wells were prewashed with 5× 200 μl water, followed by equilibration with 
3× 200 μl 80 % ACN. The samples were applied to the wells of the GHP Filter Plate and 
shaken for 5 min at 500 rpm to enhance glycan binding. The plate was subsequently washed 
5× with 200 μl 80 % ACN containing 100 mM triethylamine (TEA; Sigma-Aldrich) adjusted 
to pH 8.5 with acetic acid (Sigma-Aldrich), followed by washing 3× 200 μl 80 % ACN. 
After addition of solvent, each washing step was followed by incubation for 2 min and 
removal of solvent by vacuum. For elution 1× 100 μl (swelling of BioGel) and 2× 200 μl of 
water were applied to each well followed by 5 min incubation at 500 rpm. The eluates were 
removed by vacuum and collected in a 96-well storage plate (Thermo Scientific, Germany). 
The combined eluates were either analysed immediately by xCGE-LIF or stored at -20°C 
until required. 
9.1.4.2 xCGE-LIF 
For xCGE-LIF measurement, 1 μl of N-glycan eluate was mixed with 1 μl GeneScan 500 
LIZ Size Standard (Life Technologies, Darmstadt, Germany; 1:50 dilution in Hi-Di 
Formamide) and 9 μl Hi-Di Formamide (Life Technologies). The mixture was transferred to 
a MicroAmp Optical 384-well Reaction Plate (Life Technologies), sealed with a 384-well 
plate septa (Life Technologies) and centrifuged at 1000 rpm for 1 min to avoid air bubbles at 
the bottom of the wells. The xCGE-LIF measurement was performed in a 3130xl Genetic 
Analyzer, equipped with a 50 cm 16-capillary array filled with POP-7 polymer (all from Life 
Technologies). After electrokinetic sample injection, samples were analysed with a running 
voltage of 15 kV. Data were collected for 45 min. Raw data files were converted to .xml file 
format using DataFileConverter (Life Technologies) and subsequently analysed using the 
MATLAB (The Mathworks, Inc., Natick, MA, USA) based glycan analysis tools glyXtool 
and glyXalign. GlyXtool was used for structural identification by patented migration time 
normalization to  an internal standard and N-glycan database driven peak annotation [96]. 
The data comparison was performed by glyXalign [97]. Additional structures could be 
derived from to give a total of 92 structures. All structures and formulas are described in 




9.2 Additional Tables 
Table 15: Total Plasma N-Glycan Features by HPLC for GWAS. 
Trait 
Code 
Glycan Structure* Trait Description / Formula 
GP1 A2 
Relative percentage of specific peak 
area/total peak area from HILIC profile 
GP2 A2B, A1G1, FA2 
GP3 M5, FA2B, A2[6]G1, A2[6]BG1 
GP4 
A2[3]G1, A2[3]BG1, M4A1G1, FA2G1, 
FA2BG1, A1G1S1, M6D1, D2 
GP5 M6D3, A2G1S1, A2G2, A2BG2 
GP6 
FA2G1S1, FA2BG1S1, M4A1G1S1, 
FA2G2, A2BG1S1 
GP7 FA2BG2, M7D3, A2G2S1, M7D1 
GP8 
A2BG2S1, M5A1G1S1, FA2G2S1, A3G3, 
FA2BG2S1 
GP9 
A2F1G2S1, M8D2, D3, A2G2S2, 
M8D1,D3 
GP10 A2BG2S2, A3BG3S1, FA2G2S2 
GP11 FA2BG2S2, M9 
GP12 A2F1G2S2, A3G3S2, A3BG3S2 
GP13 
A3G3F1S2, FA3G3S2, FA3BG3S2, 
A3G3S3 
GP14 
A3F1G3S3, FA3F1G3S3, A4G4S2, 
A4G4S3, A4F1G4S2, A4G4S3 
GP15 A4G4S4, A4F1G4S3 
GP16 
A4G4S4, A4BG4S4, FA4G4S4, 
A4F1G4S4, A4G4LacS4, A4F2G4S4, 
FA4F1G4S4 
DG1 A2 
Relative percentage of specific peak 
area/total peak area from HILIC profile 
after sialidase treatment 
DG2 A2B, A1G1, FA2 
DG3 M5, FA2B, A2[6]G1, A2[6]BG1 
DG4 
M4A1G1, A2[3]G1, A2[3]BG1, 
FA2BG1,FA2[3]G1  
DG5 M6D1, D2, M6D3, A2G2, A2BG2 
DG6 FA2G2, M5A1G1, FA2BG2 
DG7 M7D3, A2F1G2, M7D1 
DG8 
A3G3, A2F2G2, FA3G3, 
M8D2, D3,M8D1,D3 
DG9 FA3BG3, A3F1G3 
DG10 M9, FA3F1G3 
DG11 A4G4, A4BG4, A3F2G3, FA4G4 
DG12 A4F1G4 
DG13 A4G4Lac, A4F2G4, FA4F1G4 
MonoS % monosialylated 
Relative percentage of specific peak 
area/total peak area from WAX analysis 
DiS % disialylated 
TriS % trisialylated 






Glycan Structure* Trait Description / Formula 
   
C-FUC Core fucosylated glycans (DG6/(DG5+DG6))*100 
A-FUC Antennary fucosylated glycans (DG7/(DG5+DG7))*100 
A2 Biantennary nongalactosylated glycans (GP1+DG1)/2 
BA Biantennary glycans DG1+DG2+DG3+DG4+DG5+DG6+DG7 
BAMS Monosialylated biantennary glycans ((GP7+GP8)/(DG5+DG6+DG7))*100 
BADS Disialylated biantennary glycans 
((GP9+GP10+GP11)/(DG5+DG6+DG7)) 
*100 
TRIA Triantennary glycans DG8+DG9+DG10 
TA Tetra-antennary glycans DG11+DG12+DG13 
G0 Nongalactosylated glycans DG1+DG2 
G1 Monogalactosylated glycans DG3+DG4 
G2 Digalactosylated glycans DG5+DG6+DG7 
G3 Trigalactosylated glycans GP12+GP13+GP14 
G4 Tetragalactosylated glycans GP15+GP16 
* Structures for GP and DG traits taken from Knezevic et al.[36] . All N-glycans have two 
core GlcNAcs; F at the start of the abbreviation indicates a core fucose α1-6 linked to the 
inner GlcNAc; Mx, number (x) of mannose on core GlcNAcs; D1 indicates that the α1-2 
mannose is on the Manα1-6Manα1-6 arm, D2 on the Manα1-3Manα1-6 arm, D3 on the 
Manα1-3 arm of M6 and on the Manα1-2Manα1-3 arm of M7 and M8; Ax, number of antenna 
(GlcNAc) on trimannosyl core; A2, biantennary with both GlcNAcs as β1-2 linked; A3, 
triantennary with a GlcNAc linked β1-2 to both mannose and the third GlcNAc linked β1-4 to 
the α1-3 linked mannose; A4, GlcNAcs linked as A3 with additional GlcNAc β1-6 linked to 
α1-6 mannose; B, bisecting GlcNAc linked β1-4 to β1-3 mannose; Gx, number (x) of β1-4 
linked galactose on antenna; [3]G1 and [6]G1 indicates that the galactose is on the antenna 
of the α1-3 or α1-6 mannose; F(x), number (x) of fucose linked α1-3 to antenna GlcNAc; 
Lac(x), number (x) of lactosamine (Galβ1-4GlcNAc) extensions; Sx, number (x) of sialic 






Table 16:  IgG N-Glycan Features by UPLC for GWAS. 
Trait 
Code 
Glycan Trait Trait Description Formula 
IGP1 GP1 
% FA1 glycan in total  IgG 
glycans 
GP1 / GP* 100 
IGP2 GP2 % A2 glycan in total  IgG glycans GP2 / GP* 100 
IGP3 GP4 
% FA2 glycan in total  IgG 
glycans 
GP4 / GP* 100 
IGP4 GP5 
% M5 glycan in total  IgG 
glycans 
GP5 / GP* 100 
IGP5 GP6 
% FA2B glycan in total  IgG 
glycans 
GP6 / GP* 100 
IGP6 GP7 
% A2G1 glycan in total  IgG 
glycans 
GP7 / GP* 100 
IGP7 GP8 
% FA2[6]G1 glycan in total  IgG 
glycans 
GP8 / GP* 100 
IGP8 GP9 
% FA2[3]G1 glycan in total  IgG 
glycans 
GP9 / GP* 100 
IGP9 GP10 
% FA2[6]BG1 glycan in total  
IgG glycans 
GP10 / GP* 100 
IGP10 GP11 
% FA2[3]BG1 glycan in total  
IgG glycans 
GP11 / GP* 100 
IGP11 GP12 
% A2G2 glycan in total  IgG 
glycans 
GP12 / GP* 100 
IGP12 GP13 
% A2BG2 glycan in total  IgG 
glycans 
GP13 / GP* 100 
IGP13 GP14 
% FA2G2 glycan in total  IgG 
glycans 
GP14 / GP* 100 
IGP14 GP15 
% FA2BG2 glycan in total  IgG 
glycans 
GP15 / GP* 100 
IGP15 GP16 
% FA2G1S1 glycan in total  IgG 
glycans 
GP16 / GP * 100 
IGP16 GP17 
% A2G2S1  glycan in total  IgG 
glycans 
GP17/ GP * 100 
IGP17 GP18 
% FA2G2S1 glycan in total  IgG 
glycans 
GP18 / GP * 100 
IGP18 GP19 
% FA2BG2S1 glycan in total  
IgG glycans 
GP19 / GP * 100 
IGP19 GP20 Structure not determined GP20 / GP * 100 
IGP20 GP21 
% A2G2S2 glycan in total  IgG 
glycans 
GP21 / GP * 100 
IGP21 GP22 
% A2BG2S2 glycan in total  IgG 
glycans 
GP22 / GP * 100 
IGP22 GP23 
% FA2G2S2 glycan in total  IgG 
glycans 
GP23 / GP * 100 
IGP23 GP24 
% FA2BG2S2 glycan in total  
IgG glycans 






Glycan Trait Trait Description Formula 
IGP24 FGS/(FG+FGS) 
% sialylation of fucosylated 
galactosylated structures without 
bisecting GlcNAc in total IgG 
glycans 
SUM(GP16 + GP18 + 
GP23) / SUM(GP16 + 
GP18 + GP23 + GP8 + 
GP9 + GP14)* 100 
IGP25 FBGS/(FBG+FBGS) 
% sialylation of fucosylated 
galactosylated structures with 
bisecting GlcNAc in total IgG 
glycans 
SUM(GP19 + GP24) / 
SUM(GP19 + GP24 + 
GP10 + GP11 + GP15)* 
100 
IGP26 FGS/(F+FG+FGS) 
% sialylation of all fucosylated 
structures without bisecting 
GlcNAc in total IgG glycans 
SUM(GP16 + GP18 + 
GP23) / SUM(GP16 + 
GP18 + GP23 + GP4 +  
GP8 + GP9 + GP14)* 100 
IGP27 FBGS/(FB+FBG+FBGS) 
% sialylation of all fucosylated 
structures with bisecting GlcNAc 
in total IgG glycans 
SUM(GP19 + GP24) / 
SUM(GP19 + GP24 + 
GP6 + GP10 + GP11 + 
GP15)* 100 
IGP28 FG1S1/(FG1+FG1S1) 
% monosialylation of fucosylated 
monogalactosylated structures in 
total IgG glycans 
GP16 / SUM(GP16 + GP8 




% monosialylation of fucosylated 
digalactosylated structures in total 
IgG glycans 
GP18 / SUM(GP18 + 




% disialylation of fucosylated 
digalactosylated structures in total 
IgG glycans 
GP23 / SUM(GP23 + 




% monosialylation of fucosylated 
digalactosylated structures with 
bisecting GlcNAc in total IgG 
glycans 
GP19 / SUM(GP19 + 




% disialylation of fucosylated 
digalactosylated structures with 
bisecting GlcNAc in total IgG 
glycans 
GP24 / SUM(GP24 + 






Ratio of all fucosylated (+/- 
bisecting GlyNAc) 
monosyalilated and disialylated 
structures in total IgG glycans 
SUM(GP16 + GP18 + 
GP19) / SUM(GP23 + 
GP24) 
IGP34 FS1/FS2 
Ratio of fucosylated (without 
bisecting GlcNAc) 
monosialylated  and disialylated 
structures in total IgG glycans 
SUM(GP16 + GP18) / 
GP23 
IGP35 FBS1/FBS2 
Ratio of fucosylated (with 
bisecting GlcNAc) 
monosialylated  and disialylated 
structures in total IgG glycans 






Ratio of all fucosylated sialylated 
structures with and without 
bisecting GlcNAc 
SUM(GP19 + GP24) / 







Glycan Trait Trait Description Formula 
IGP37 FBS1/FS1 
Ratio of  fucosylated 
monosialylated structures with 
and without bisecting GlcNAc 
GP19 / SUM(GP16 + 
GP18) 
IGP38 FBS1/(FS1+FBS1) 
The incidence of bisecting 
GlcNAc in all fucosylated 
monosialylated structures in total 
IgG glycans 
GP19 / SUM(GP16 + 
GP18 + GP19) 
IGP39 FBS2/FS2 
Ratio of fucosylated disialylated 
structures with and without 
bisecting GlcNAc 
GP24 / GP23 
IGP40 FBS2/(FS2+FBS2) 
The incidence of bisecting 
GlcNAc in all fucosylated 
disialylated structures in total IgG 
glycans 

































































% FA2[6]G1 glycan in total 









% FA2[3]G1 glycan in total  









% FA2[6]BG1 glycan in total  









% FA2[3]BG1 glycan in total  







































% FA2BG2 glycan in total  









% agalactosylated structures in 









% monogalactosylated structures 















% digalactosylated structures in 









% all fucosylated (+/- bisecting 
GlcNAc) structures in total 
















































































% fucosylated (without bisecting 
GlcNAc) structures in total 





















% fucosylation (without bisecting 

















% fucosylation (without bisecting 














% fucosylation (without bisecting 










% fucosylated (with bisecting 
GlcNAc) structures in total 
















% fucosylation (with bisecting 
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% fucosylation (with bisecting 










Ratio of fucosylated structures 












The incidence of bisecting 
GlcNAc in all fucosylated 
















Ratio of fucosylated non-
bisecting GlcNAc structures and 






















Ratio of structures with bisecting 
GlcNAc and all fucosylated 













Ratio of fucosylated 
digalactosylated structures with 













The incidence of bisecting 
GlcNAc in all fucosylated 
digalactosylated structures in total 
















Ratio of fucosylated 
digalactosylated non-bisecting 
GlcNAc structures and all 
















Ratio of digalactosylated 
structures with bisecting GlcNAc 
and all fucosylated 

















 ); F at the start of the 
abbreviation indicates a core fucose α1-6 linked to the inner GlcNAc; Mx, number (x) of 
mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl core; A2, 
biantennary with both GlcNAcs as β1-2 linked; B, bisecting GlcNAc linked β1-4 to β1-3 
mannose; Gx, number (x) of β1-4 linked galactose on antenna; [3]G1 and [6]G1 indicates 
that the galactose is on the antenna of the α1-3 or α1-6 mannose; F(x), number (x) of fucose 










Trait Description Formula 
MS_IGP1 IgG1 G0n 
% G0 glycan in neutral IgG1 
glycans 
 
MS_IGP2 IgG1 G0Fn 
% G0F glycan in neutral IgG1 
glycans 
 
MS_IGP3 IgG1 G0FNn 
% G0FN glycan in neutral IgG1 
glycans 
 
MS_IGP4 IgG1 G0Nn 
% G0N glycan in neutral IgG1 
glycans 
 
MS_IGP5 IgG1 G1n 
% G1 glycan in neutral IgG1 
glycans 
 
MS_IGP6 IgG1 G1Fn 
% G1F glycan in neutral IgG1 
glycans 
 
MS_IGP7 IgG1 G1FNn 
% G1FN glycan in neutral IgG1 
glycans 
 
MS_IGP8 IgG1 G1Nn 
% G1N glycan in neutral IgG1 
glycans 
 
MS_IGP9 IgG1 G2n 
% G2glycan in neutral IgG1 
glycans 
 
MS_IGP10 IgG1 G2Fn 
% G2F glycan in neutral IgG1 
glycans 
 
MS_IGP11 IgG1 G2FNn 
% G2FN glycan in neutral IgG1 
glycans 
 
MS_IGP12 IgG1 G2Nn 
% G2N glycan in neutral IgG1 
glycans 
 
MS_IGP13 IgG1 G0n 
% agalactosylated structures in 
neutral IgG1 glycans 
SUM(G0n+G0Fn+G0FNn+G0N
n) 
MS_IGP14 IgG1 G1n 
% monogalactosylated structures 
in neutral  IgG1 glycans 
SUM(G1n+G1Fn+G1FNn+G1N
n) 
MS_IGP15 IgG1 G2n 
% digalactosylated structures in 
neutral IgG1 glycans 
SUM(G2n+G2Fn+G2FNn+G2N
n) 
MS_IGP16 IgG1 Fn total 
% all fucosylated (+/- bisecting 





IgG1  FG0n 
total/G0n 




IgG1  FG1n 
total/G1n 




IgG1  FG2n 
total/G2n 
% fucosylation of 
digalactosylated structures 
SUM(G2Fn+G2FNn)/G2n*100 
MS_IGP20 IgG1 Fn 
% fucosylated (without bisecting 






% fucosylation (without 














% fucosylation (without 






% fucosylation (without 
bisecting GlcNAc) of 
digalactosylated structures 
G2Fn/G2n*100 
MS_IGP24 IgG1 FBn 
% fucosylated (with bisecting 






% fucosylation (with bisecting 






% fucosylation (with bisecting 






% fucosylation (with bisecting 
GlcNAc) of digalactosylated 
structures 
G2FNn/G2n*100 
MS_IGP28 IgG1 Bn total 
The incidence of bisecting 







The incidence of bisecting 






The incidence of bisecting 






The incidence of bisecting 
GlcNAc (+/-  core Fuc)  in 
digalactosylated structures 
SUM(G2Nn+G2FNn)/G2n 
MS_IGP32 IgG1 Bn 
The incidence of bisecting 
GlcNAc (without core Fuc) in 





The incidence of bisecting 






The incidence of bisecting 






The incidence of bisecting 






The incidence of bisecting 
GlcNAc in all fucosylated 
structures in neutral glycan 
fraction 
FBn/Fn total*100 
MS_IGP37 IgG1 FBn/Fn 
Ratio of fucosylated structures 














% fucosylation in all structures 






Ratio of fucosylated non-
bisecting GlcNAc structures and 






Ratio of structures with bisecting 
GlcNAc and all fucosylated 
structures (+/- bisecting 
GlcNAc) 
Bn/Fn total*1000 
MS_IGP41 IgG1 G0 
% G0 glycan in total  IgG1 
glycans 
 
MS_IGP42 IgG1 G0F 
% G0F glycan in total  IgG1 
glycans 
 
MS_IGP43 IgG1 G0FN 
% G0FN glycan in total  IgG1 
glycans 
 
MS_IGP44 IgG1 G0N 
% G0N glycan in total  IgG1 
glycans 
 
MS_IGP45 IgG1 G1 
% G1 glycan in total  IgG1 
glycans 
 
MS_IGP46 IgG1 G1F 
% G1F glycan in total  IgG1 
glycans 
 
MS_IGP47 IgG1 G1FN 
% G1FN glycan in total  IgG1 
glycans 
 
MS_IGP48 IgG1 G1N 
% G1N glycan in total  IgG1 
glycans 
 
MS_IGP49 IgG1 G1S* 
% G1S glycan in total  IgG1 
glycans 
 
MS_IGP50 IgG1 G1FS 
% G1FS glycan in total  IgG1 
glycans 
 
MS_IGP51 IgG1 G2 
% G2 glycan in total  IgG1 
glycans 
 
MS_IGP52 IgG1 G2F 
% G2F glycan in total  IgG1 
glycans 
 
MS_IGP53 IgG1 G2FN 
% G2FN glycan in total  IgG1 
glycans 
 
MS_IGP54 IgG1 G2N 
% G2N glycan in total  IgG1 
glycans 
 
MS_IGP55 IgG1 G2S 
% G2S glycan in total  IgG1 
glycans 
 
MS_IGP56 IgG1 G2FS 
% G2FS glycan in total  IgG1 
glycans 
 
















The incidence of bisecting 
GlcNAc of IgG1 
SUM(G0N+G1N+G2N+G0FN+
G1FN+G2FN) 
MS_IGP59 IgG1 Core F % IgG1 core fucosylation 
SUM(G0F+G0FN+G1F+G1FN+
G1FS+G2F+G2FN+G2FS) 
MS_IGP60 IgG1 Sial % IgG1 sialylation SUM(G1S+G1FS+G2S+G2FS ) 
MS_IGP61 IgG1 Sial/Gal 






% sialylation of afucosylated 
galactosylated structures without 








% sialylation of all afucosylated 
structures without bisecting 







% monosialylation of 
afucosylated monogalactosylated 
(without bisecting GlcNAc) 






% monosialylation of 
afucosylated digalactosylated 
(without bisecting GlcNAc) 






% sialylation of fucosylated 
galactosylated structures without 








% sialylation of all fucosylated 
structures without bisecting 







% monosialylation of 
fucosylated monogalactosylated 
(without bisecting GlcNAc) 






% monosialylation of 
fucosylated digalactosylated 
(without bisecting GlcNAc) 
structures in total IgG1 glycans 
G2FS/SUM(G2F+G2FS)*100 
MS_IGP70 IgG2 G0n 
% G0 glycan in neutral IgG2 
glycans 
 
MS_IGP71 IgG2 G0Fn 
% G0F glycan in neutral IgG2 
glycans 
 
MS_IGP72 IgG2 G0FNn 
% G0FN glycan in neutral IgG2 
glycans 
 
MS_IGP73 IgG2 G0Nn 
% G0N glycan in neutral IgG2 
glycans 
 
MS_IGP74 IgG2 G1Fn 










Trait Description Formula 
MS_IGP75 IgG2 G1FNn 
% G1FN glycan in neutral IgG2 
glycans 
 
MS_IGP76 IgG2 G2Fn 
% G2F glycan in neutral IgG2 
glycans 
 
MS_IGP77 IgG2 G2FNn 
% G2FN glycan in neutral IgG2 
glycans 
 
MS_IGP78 IgG2 G0n 
% agalactosylated structures in 
neutral IgG2 glycans 
SUM(G0n+G0Fn+G0FNn+G0N
n) 
MS_IGP79 IgG2 G1n 
% monogalactosylated structures 
in neutral  IgG2 glycans 
SUM(G1Fn+G1FNn) 
MS_IGP80 IgG2 G2n 
% digalactosylated structures in 
neutral IgG2 glycans 
SUM(G2Fn+G2FNn) 
MS_IGP81 IgG2 Bn 
The incidence of bisecting 
GlcNAc (without core Fuc) in 





The incidence of bisecting 
GlcNAc (without core Fuc)  in 
agalactosylated IgG2 structures 
G0Nn/G0n 
MS_IGP83 IgG2 Bn total 
The incidence of bisecting 
GlcNAc (+/- core Fuc) in neutral 






The incidence of bisecting 
GlcNAc (+/- core Fuc)  in 
agalactosylated IgG2 structures 
SUM(G0Nn+G0FNn)/G0n 
MS_IGP85 IgG2 G0 
% G0 glycan in total IgG2 
glycans 
 
MS_IGP86 IgG2 G0F 
% G0F glycan in total IgG2 
glycans 
 
MS_IGP87 IgG2 G0FN 
% G0FN glycan in total IgG2 
glycans 
 
MS_IGP88 IgG2 G0N 
% G0N glycan in total IgG2 
glycans 
 
MS_IGP89 IgG2 G1F 
% G1F glycan in total IgG2 
glycans 
 
MS_IGP90 IgG2 G1FN 
% G1FN glycan in total IgG2 
glycans 
 
MS_IGP91 IgG2 G1S 
% G1S glycan in total IgG2 
glycans 
 
MS_IGP92 IgG2 G1FS 
% G1FSglycan in total IgG2 
glycans 
 
MS_IGP93 IgG2 G2F 
% G2F glycan in total IgG2 
glycans 
 
MS_IGP94 IgG2 G2FN 
% G2FN glycan in total IgG2 
glycans 
 
MS_IGP95 IgG2 G2FS 










Trait Description Formula 






The incidence of bisecting 
GlcNAc of IgG2 
SUM(G0N+G0FN+G1FN+G2F
N) 
MS_IGP98 IgG2 Sial % IgG2 sialylation SUM(G1S+G1FS+G2FS) 
MS_IGP99 IgG2 Sial/Gal 






% sialylation of fucosylated 
galactosylated structures without 







% sialylation of all fucosylated 
structures without bisecting 






% of monosialylation of 
fucosylated monogalactosylated 





% monosialylation of 
fucosylated digalactosylated 
structures in total IgG2 glycans 
G2FS/SUM(G2F+G2FS)*100 
n= neutral; F at the start of the abbreviation indicates a core fucose α1-6 linked to the inner 
GlcNAc; Mx, number (x) of mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on 
trimannosyl core; A2, biantennary with both GlcNAcs as β1-2 linked; B, bisecting GlcNAc 
linked β1-4 to β1-3 mannose; Gx, number (x) of β1-4 linked galactose on antenna; [3]G1 and 
[6]G1 indicates that the galactose is on the antenna of the α1-3 or α1-6 mannose; F(x), 








































































































































































 SwissProt entry number. 
b
 Tryptic IgG glycopeptide sequence.  
c
 Glycan structural features are given in terms of number of galactoses (G0, G1, G2), fucose 
(F), bisecting N-acetylglucosamine (N), and N-acetylneuraminic acid (S). 
d1 – d5
 isomeric glycopeptide species of IgG1 and IgG4. 
e1 – e5










































595.260 397.176 579.265 386.513 587.263 391.844 
G0F 1317.527 878.687 
d1
 1301.532 868.024 1309.529 873.356 
e1
 
G1F 1398.553 932.705 
d2
 1382.558 922.042 1390.556 927.373 
e2
 
G2F 1479.58 986.722 1463.585 976.059 1471.582 981.391 
G0FN 1419.067 946.380 
d3
 1403.072 935.717 1411.069 941.049 
e3
 
G1FN 1500.093 1000.398 
d4
 1484.098 989.735 1492.096 995.066 
e4
 
G2FN 1581.119 1054.416 1565.125 1043.752 1573.122 1049.084 
G1FS 1544.101 1029.737 
d5
 1528.106 1019.073 1536.104 1024.405 
e5
 
G2FS 1625.127 1083.754 1609.133 1073.091 1617.13 1078.423 
G1FNS 1645.641 1097.430 1629.646 1086.767 1637.643 1092.098 
G2FNS 1726.667 1151.447 1710.672 1140.784 1718.67 1146.116 
G0 1244.498 830.001 1228.503 819.338 1236.501 824.67 
G1 1325.524 884.019 1309.529 873.356 
e1
 1317.527 878.687 
d1
 
G2 1406.551 938.036 1390.556 927.373 
e2
 1398.553 932.705 
d2
 
G0N 1346.038 897.694 1330.043 887.031 1338.04 892.363 
G1N 1427.064 951.712 1411.069 941.049 
e3
 1419.067 946.380 
d3
 
G2N 1508.090 1005.730 1492.096 995.066 
e4
 1500.093 1000.398 
d4
 
G1S 1471.072 981.051 1455.077 970.387 1463.075 975.719 
G2S 1552.098 1035.068 1536.104 1024.405 
e5
 1544.101 1029.737 
d5
 
G1NS 1572.612 1048.744 1556.617 1038.081 1564.614 1043.412 




 SwissProt entry number. 
b
 Tryptic IgG glycopeptide sequence.  
c
 Glycan structural features are given in terms of number of galactoses (G0, G1, G2), fucose 
(F), bisecting N-acetylglucosamine (N), and N-acetylneuraminic acid (S). 
d1 – d5
 isomeric glycopeptide species of IgG1 and IgG4. 
e1 – e5






Table 20: IgG N-Glycan Features by nano-LC-ESI-MS for GWAS. 
Trait 
Code 
Glycan Trait Trait Description Formula 
LC_IGP1 IgG1 G0F 
% G0F glycan in total  IgG1 
glycans 
 
LC_IGP2 IgG1 G1F 
% G1F glycan in total  IgG1 
glycans 
 
LC_IGP3 IgG1 G2F 
% G2F glycan in total  IgG1 
glycans 
 
LC_IGP4 IgG1 G0FN 
% G0FN glycan in total  IgG1 
glycans 
 
LC_IGP5 IgG1 G1FN 
% G1FN glycan in total  IgG1 
glycans 
 
LC_IGP6 IgG1 G2FN 
% G2FN glycan in total  IgG1 
glycans 
 
LC_IGP7 IgG1 G1FS1 
% G1FS1 glycan in total  
IgG1 glycans 
 
LC_IGP8 IgG1 G2FS1 
% G2FS1 glycan in total  
IgG1 glycans 
 
LC_IGP9 IgG1 G1FNS1 
% G1FNS1 glycan in total  
IgG1 glycans 
 
LC_IGP10 IgG1 G2FNS1 
% G2FNS1 glycan in total  
IgG1 glycans 
 
LC_IGP11 IgG1 G0 
% G0 glycan in total  IgG1 
glycans 
 
LC_IGP12 IgG1 G1 
% G1 glycan in total  IgG1 
glycans 
 
LC_IGP13 IgG1 G2 
% G2 glycan in total  IgG1 
glycans 
 
LC_IGP14 IgG1 G0N 
% G0N glycan in total  IgG1 
glycans 
 
LC_IGP15 IgG1 G1N 
% G1N glycan in total  IgG1 
glycans 
 
LC_IGP16 IgG1 G2N 
% G2N glycan in total  IgG1 
glycans 
 
LC_IGP17 IgG1 G1S1 
% G1S1 glycan in total  IgG1 
glycans 
 
LC_IGP18 IgG1 G2S1 
% G2S1 glycan in total  IgG1 
glycans 
 
LC_IGP19 IgG1 G1NS1 
% G1NS1 glycan in total  
IgG1 glycans 
 
LC_IGP20 IgG1 G2NS1 




















The incidence of bisecting 













LC_IGP24 IgG1 Sialylation 






IgG1 SA per 
Gal 
The number of sialic acid 
moieties on galactose moieties 






% monosialylation of 
afucosylated galactosylated 
structures without bisecting 







% monosialylation of all 
afucosylated structures 
without bisecting GlcNAc in 







% monosialylation of 
afucosylated 
monogalactosylated (without 
bisecting GlcNAc) structures 






% monosialylation of 
afucosylated digalactosylated 
(without bisecting GlcNAc) 







% monosialylation of 
afucosylated galactosylated 
structures with bisecting 








% monosialylation of all 
afucosylated structures with 









% monosialylation of 
afucosylated 
monogalactosylated (with 
bisecting GlcNAc) structures 







% monosialylation of 
afucosylated digalactosylated 
(with bisecting GlcNAc) 














% monosialylation of 
fucosylated galactosylated 
structures without bisecting 







% monosialylation of all 
fucosylated structures without 









% monosialylation of 
fucosylated 
monogalactosylated (without 
bisecting GlcNAc) structures 







% monosialylation of 
fucosylated digalactosylated 
(without bisecting GlcNAc) 








% monosialylation of 
fucosylated galactosylated 
structures with bisecting 








% monosialylation of all 
fucosylated structures with 









% monosialylation of 
fucosylated 
monogalactosylated (with 
bisecting GlcNAc) structures 







% monosialylation of 
fucosylated digalactosylated 
(with bisecting GlcNAc) 




LC_IGP42 IgG1 BS1/S1 
Ratio of afucosylated 
monosialylated structures with 
and without bisecting GlcNAc 
in total IgG1 glycans 
SUM(G1NS1+G2NS1)/SUM(G
1S1+G2S1) 
LC_IGP43 IgG1 FBS1/FS1 
Ratio of fucosylated 
monosialylated structures with 
and without bisecting GlcNAc 






The incidence of bisecting 
GlcNAc in all afucosylated 
monosialylated structures in 













The incidence of bisecting 
GlcNAc in all fucosylated 
monosialylated structures in 




LC_IGP46 IgG1 G0Fn 
% G0F glycan in neutral IgG1 
glycans 
 
LC_IGP47 IgG1 G1Fn 
% G1F glycan in neutral IgG1 
glycans 
 
LC_IGP48 IgG1 G2Fn 
% G2F glycan in neutral IgG1 
glycans 
 
LC_IGP49 IgG1 G0FNn 
% G0FN glycan in neutral 
IgG1 glycans 
 
LC_IGP50 IgG1 G1FNn 
% G1FN glycan in neutral 
IgG1 glycans 
 
LC_IGP51 IgG1 G2FNn 
% G2FN glycan in neutral 
IgG1 glycans 
 
LC_IGP52 IgG1 G0n 
% G0 glycan in neutral IgG1 
glycans 
 
LC_IGP53 IgG1 G1n 
% G1 glycan in neutral IgG1 
glycans 
 
LC_IGP54 IgG1 G2n 
% G2 glycan in neutral IgG1 
glycans 
 
LC_IGP55 IgG1 G0Nn 
% G0N glycan in neutral IgG1 
glycans 
 
LC_IGP56 IgG1 G1Nn 
% G1N glycan in neutral IgG1 
glycans 
 
LC_IGP57 IgG1 G2Nn 
% G2N glycan in neutral IgG1 
glycans 
 
LC_IGP58 IgG1 G0n 
% agalactosylated structures 
in neutral IgG1 glycan fraction 
SUM(G0n+G0Fn+G0FNn+G0
Nn) 
LC_IGP59 IgG1 G1n 
% monogalactosylated 




LC_IGP60 IgG1 G2n 
% digalactosylated structures 
in neutral IgG1 glycan fraction 
SUM(G2n+G2Fn+G2FNn+G2
Nn) 
LC_IGP61 IgG1 Fn total 
% all fucosylated (+/- 
bisecting GlcNAc) structures 




IgG1  FG0n 
total/G0n 
% fucosylation of 
agalactosylated structures in 
neutral IgG1 glycan fraction 
SUM(G0Fn+G0FNn)/G0n*100 
LC_IGP63 
IgG1  FG1n 
total/G1n 
% fucosylation of 
monogalactosylated structures 
in neutral IgG1 glycan fraction 
SUM(G1Fn+G1FNn)/G1n*100 
LC_IGP64 
IgG1  FG2n 
total/G2n 
% fucosylation of 
digalactosylated structures in 







Glycan Trait Trait Description Formula 
LC_IGP65 IgG1 Fn 
% fucosylated (without 
bisecting GlcNAc) structures i 
in neutral IgG1 glycan fraction 
SUM(G0Fn+G1Fn+G2Fn) 
LC_IGP66 IgG2 FG0n/G0n 
% fucosylation (without 
bisecting GlcNAc) of 
agalactosylated structures in 
neutral IgG1 glycan fraction 
G0Fn/G0n*100 
LC_IGP67 IgG2 FG1n/G1n 
% fucosylation (without 
bisecting GlcNAc) of 
monogalactosylated structures 
in neutral IgG1 glycan fraction 
G1Fn/G1n*100 
LC_IGP68 IgG2 FG2n/G2n 
% fucosylation (without 
bisecting GlcNAc) of 
digalactosylated structures in 
neutral IgG1 glycan fraction 
G2Fn/G2n*100 
LC_IGP69 IgG2 FBn 
% fucosylated (with bisecting 
GlcNAc) structures in neutral 





% fucosylation (with bisecting 
GlcNAc) of agalactosylated 






% fucosylation (with bisecting 
GlcNAc) of 
monogalactosylated structures 





% fucosylation (with bisecting 
GlcNAc) of digalactosylated 
structures in neutral IgG1 
glycan fraction 
G2FNn/G2n*100 
LC_IGP73 IgG1 Bn total 
The incidence of bisecting 
GlcNAc (+/- core Fuc) in 






The incidence of bisecting 
GlcNAc (+/- core Fuc)  in 
agalactosylated structures in 





The incidence of bisecting 
GlcNAc (+/- core Fuc)  in  
monogalactosylated structures 





The incidence of bisecting 
GlcNAc (+/-  core Fuc)  in 
digalactosylated structures in 
neutral IgG1 glycan fraction 
SUM(G2Nn+G2FNn)/G2n*100 
LC_IGP77 IgG1 Bn 
The incidence of bisecting 
GlcNAc (without core Fuc) in 







Glycan Trait Trait Description Formula 
LC_IGP78 IgG1 BG0n/G0n 
The incidence of bisecting 
GlcNAc (without core Fuc)  in 
agalactosylated structures in 
neutral IgG1 glycan fraction 
G0Nn/G0n*100 
LC_IGP79 IgG1 BG1n/G1n 
The incidence of bisecting 
GlcNAc (without core Fuc) in 
monogalactosylated structures 
in neutral IgG1 glycan fraction 
G1Nn/G1n*100 
LC_IGP80 IgG1 BG2n/G2n 
The incidence of bisecting 
GlcNAc (without core Fuc)  in 
digalactosylated structures in 
neutral IgG1 glycan fraction 
G2Nn/G2n*100 
LC_IGP81 IgG1 Fn/Bn 
Ratio of fucosylated structures 
without bisecting GlcNAc and 
afucosylated structures with 
bisecting GlcNAc in neutral 
IgG1 glycan fraction 
Fn/Bn 
LC_IGP82 IgG1 FBn/Fn 
Ratio of fucosylated structures 
with and without bisecting 






The incidence of bisecting 
GlcNAc in all fucosylated 






% fucosylation in all 
structures with bisecting 






Ratio of fucosylated non-
bisecting GlcNAc structures 
and all structures with 
bisecting GlcNAc in neutral 





Ratio of structures with 
bisecting GlcNAc and all 
fucosylated structures (+/- 
bisecting GlcNAc) in neutral 
IgG1 glycan fraction 
Bn/Fn total*1000 
LC_IGP87 IgG2 G0F 
The percentage of G0F glycan 
in total  IgG2 glycans 
 
LC_IGP88 IgG2 G1F 
The percentage of G1F glycan 
in total  IgG2 glycans 
 
LC_IGP89 IgG2 G2F 
The percentage of G2F glycan 
in total  IgG2 glycans 
 
LC_IGP90 IgG2 G0FN 
The percentage of G0FN 
glycan in total  IgG2 glycans 
 
LC_IGP91 IgG2 G1FN 
The percentage of G1FN 







Glycan Trait Trait Description Formula 
LC_IGP92 IgG2 G2FN 
The percentage of G2FN 
glycan in total  IgG2 glycans 
 
LC_IGP93 IgG2 G1FS1 
The percentage of G1FS1 
glycan in total  IgG2 glycans 
 
LC_IGP94 IgG2 G2FS1 
The percentage of G2FS1 
glycan in total  IgG2 glycans 
 
LC_IGP95 IgG2 G1FNS1 
The percentage of G1FNS1 
glycan in total  IgG2 glycans  
 
LC_IGP96 IgG2 G2FNS1 
The percentage of G2FNS1 
glycan in total  IgG2 glycans  
 
LC_IGP97 IgG2 G0 
The percentage of G0 glycan 
in total  IgG2 glycans  
 
LC_IGP98 IgG2 G1 
The percentage of G1 glycan 
in total  IgG2 glycans  
 
LC_IGP99 IgG2 G2 
The percentage of G2 glycan 
in total  IgG2 glycans  
 
LC_IGP100 IgG2 G0N 
The percentage of G0N glycan 
in total  IgG2 glycans  
 
LC_IGP101 IgG2 G1N 
The percentage of G1N glycan 
in total  IgG2 glycans  
 
LC_IGP102 IgG2 G2N 
The percentage of G2N glycan 
in total  IgG2 glycans  
 
LC_IGP103 IgG2 G1S1 
The percentage of G1S1 
glycan in total  IgG2 glycans  
 
LC_IGP104 IgG2 G2S1 
The percentage of G2S1 
glycan in total  IgG2 glycans  
 
LC_IGP105 IgG2 G1NS1 
The percentage of G1NS1 
glycan in total  IgG2 glycans  
 
LC_IGP106 IgG2 G2NS1 
The percentage of G2NS1 













The incidence of bisecting 














LC_IGP110 IgG2 Sialylation 






IgG2 SA per 
Gal 
The number of sialic acid 
moieties on galactose moieties 












The percentage of 
monosialylation of 
afucosylated galactosylated 
structures without bisecting 







The percentage of 
monosialylation of all 
afucosylated structures 
without bisecting GlcNAc in 











bisecting GlcNAc) structures 






The percentage of 
monosialylation of 
afucosylated digalactosylated 
(without bisecting GlcNAc) 







The percentage of 
monosialylation of 
afucosylated galactosylated 
structures with bisecting 








The percentage of 
monosialylation of all 
afucosylated structures with 













bisecting GlcNAc) structures 







The percentage of 
monosialylation of 
afucosylated digalactosylated 
(with bisecting GlcNAc) 








The percentage of 
monosialylation of 
fucosylated galactosylated 
structures without bisecting 













The percentage of 
monosialylation of all 
fucosylated structures without 













bisecting GlcNAc) structures 







The percentage of 
monosialylation of 
fucosylated digalactosylated 
(without bisecting GlcNAc) 








The percentage of 
monosialylation of 
fucosylated galactosylated 
structures with bisecting 








The percentage of 
monosialylation of all 
fucosylated structures with 













bisecting GlcNAc) structures 







The percentage of 
monosialylation of 
fucosylated digalactosylated 
(with bisecting GlcNAc) 




LC_IGP128 IgG2 BS1/S1 
Ratio of afucosylated 
monosialylated structures with 
and without bisecting GlcNAc 
in total IgG2 glycans 
SUM(G1NS1+G2NS1)/SUM(G
1S1+G2S1) 
LC_IGP129 IgG2 FBS1/FS1 
Ratio of fucosylated 
monosialylated structures with 
and without bisecting GlcNAc 






The incidence of bisecting 
GlcNAc in all afucosylated 
monosialylated structures in 













The incidence of bisecting 
GlcNAc in all fucosylated 
monosialylated structures in 




LC_IGP132 IgG2 G0Fn 
The percentage of G0F glycan 
in neutral IgG2 glycans  
 
LC_IGP133 IgG2 G1Fn 
The percentage of G1F glycan 
in neutral IgG2 glycans  
 
LC_IGP134 IgG2 G2Fn 
The percentage of G2F glycan 
in neutral IgG2 glycans  
 
LC_IGP135 IgG2 G0FNn 
The percentage of G0FN 
glycan in neutral IgG2 glycans  
 
LC_IGP136 IgG2 G1FNn 
The percentage of G1FN 
glycan in neutral IgG2 glycans  
 
LC_IGP137 IgG2 G2FNn 
The percentage of G2FN 
glycan in neutral IgG2 glycans  
 
LC_IGP138 IgG2 G0n 
The percentage of G0 glycan 
in neutral IgG2 glycans  
 
LC_IGP139 IgG2 G1n 
The percentage of G1 glycan 
in neutral IgG2 glycans  
 
LC_IGP140 IgG2 G2n 
The percentage of G2 glycan 
in neutral IgG2 glycans  
 
LC_IGP141 IgG2 G0Nn 
The percentage of G0N glycan 
in neutral IgG2 glycans  
 
LC_IGP142 IgG2 G1Nn 
The percentage of G1N glycan 
in neutral IgG2 glycans  
 
LC_IGP143 IgG2 G2Nn 
The percentage of G2N glycan 
in neutral IgG2 glycans  
 
LC_IGP144 IgG2 G0n 
The percentage of 
agalactosylated structures in 
neutral IgG2 glycan fraction 
SUM(G0n+G0Fn+G0FNn+G0
Nn) 
LC_IGP145 IgG2 G1n 
The percentage of 
monogalactosylated structures 




LC_IGP146 IgG2 G2n 
The percentage of 
digalactosylated structures in 
neutral IgG2 glycan fraction 
SUM(G2n+G2Fn+G2FNn+G2
Nn) 
LC_IGP147 IgG2 Fn total 
The percentage of all 
fucosylated (+/- bisecting 
GlcNAc) structures in neutral 




IgG2  FG0n 
total/G0n 
The percentage of 
fucosylation of 
agalactosylated structures in 







Glycan Trait Trait Description Formula 
LC_IGP149 
IgG2  FG1n 
total/G1n 
The percentage of 
fucosylation of 
monogalactosylated structures 
in neutral IgG2 glycan fraction 
SUM(G1Fn+G1FNn)/G1n*100 
LC_IGP150 
IgG2  FG2n 
total/G2n 
The percentage of 
fucosylation of 
digalactosylated structures in 
neutral IgG2 glycan fraction 
SUM(G2Fn+G2FNn)/G2n*100 
LC_IGP151 IgG2 Fn 
The percentage of fucosylated 
(without bisecting GlcNAc) 
structures in neutral IgG2 
glycan fraction 
SUM(G0Fn+G1Fn+G2Fn) 
LC_IGP152 IgG2 FG0n/G0n 
The percentage of 
fucosylation (without 
bisecting GlcNAc) of 
agalactosylated structures in 
neutral IgG2 glycan fraction 
G0Fn/G0n*100 
LC_IGP153 IgG2 FG1n/G1n 
The percentage of 
fucosylation (without 
bisecting GlcNAc) of 
monogalactosylated structures 
in neutral IgG2 glycan fraction 
G1Fn/G1n*100 
LC_IGP154 IgG2 FG2n/G2n 
The percentage of 
fucosylation (without 
bisecting GlcNAc) of 
digalactosylated structures in 
neutral IgG2 glycan fraction 
G2Fn/G2n*100 
LC_IGP155 IgG2 FBn 
The percentage of fucosylated 
(with bisecting GlcNAc) 






The percentage of 
fucosylation (with bisecting 
GlcNAc) of agalactosylated 






The percentage of 
fucosylation (with bisecting 
GlcNAc) of 
monogalactosylated structures 





The percentage of 
fucosylation (with bisecting 
GlcNAc) of digalactosylated 
structures in neutral IgG2 
glycan fraction 
G2FNn/G2n*100 
LC_IGP159 IgG2 Bn total 
The incidence of bisecting 
GlcNAc (+/- core Fuc) in 












The incidence of bisecting 
GlcNAc (+/- core Fuc)  in 
agalactosylated structures in 





The incidence of bisecting 
GlcNAc (+/- core Fuc)  in  
monogalactosylated structures 





The incidence of bisecting 
GlcNAc (+/-  core Fuc)  in 
digalactosylated structures in 
neutral IgG2 glycan fraction 
SUM(G2Nn+G2FNn)/G2n*100 
LC_IGP163 IgG2 Bn 
The incidence of bisecting 
GlcNAc (without core Fuc)  in 
neutral IgG2 glycan fraction 
SUM(G0Nn+G1Nn+G2Nn) 
LC_IGP164 IgG2 BG0n/G0n 
The incidence of bisecting 
GlcNAc (without core Fuc)  in 
agalactosylated structures in 
neutral IgG2 glycan fraction 
G0Nn/G0n*100 
LC_IGP165 IgG2 BG1n/G1n 
The incidence of bisecting 
GlcNAc (without core Fuc)  in  
monogalactosylated structures 
in neutral IgG2 glycan fraction 
G1Nn/G1n*100 
LC_IGP166 IgG2 BG2n/G2n 
The incidence of bisecting 
GlcNAc (without core Fuc)  in 
digalactosylated structures in 
neutral IgG2 glycan fraction 
G2Nn/G2n*100 
LC_IGP167 IgG2 Fn/Bn 
Ratio of fucosylated structures 
without bisecting GlcNAc and 
afucosylated structures with 
bisecting GlcNAc in neutral 
IgG2 glycan fraction 
Fn/Bn 
LC_IGP168 IgG2 FBn/Fn 
Ratio of fucosylated structures 
with and without bisecting 






The incidence of bisecting 
GlcNAc in all fucosylated 
structures in neutral IgG2 
glycan fraction 




The percentage of 
fucosylation in all structures 
with bisecting GlcNAc in 
neutral IgG2 glycan fraction 




Ratio of fucosylated non-
bisecting GlcNAc structures 
and all structures with 
bisecting GlcNAc in neutral 







Glycan Trait Trait Description Formula 
LC_IGP172 
IgG2 Bn/Fn 
total ‰  
Ratio of structures with 
bisecting GlcNAc and all 
fucosylated structures (+/- 
bisecting GlcNAc) in neutral 
IgG2 glycan fraction 
Bn/Fn total*1000 
LC_IGP173 IgG4 G0F 
The percentage of G0F glycan 
in total  IgG4 glycans  
 
LC_IGP174 IgG4 G1F 
The percentage of G1F glycan 
in total  IgG4 glycans  
 
LC_IGP175 IgG4 G2F 
The percentage of G2F glycan 
in total  IgG4 glycans  
 
LC_IGP176 IgG4 G0FN 
The percentage of G0FN 
glycan in total  IgG4 glycans  
 
LC_IGP177 IgG4 G1FN 
The percentage of G1FN 
glycan in total  IgG4 glycans  
 
LC_IGP178 IgG4 G2FN 
The percentage of G2FN 
glycan in total  IgG4 glycans  
 
LC_IGP179 IgG4 G1FS1 
The percentage of G1FS1 
glycan in total  IgG4 glycans  
 
LC_IGP180 IgG4 G2FS1 
The percentage of G2FS1 
glycan in total  IgG4 glycans  
 
LC_IGP181 IgG4 G1FNS1 
The percentage of G1FNS1 
glycan in total  IgG4 glycans  
 
LC_IGP182 IgG4 G2FNS1 
The percentage of G2FNS1 





The incidence of bisecting 










LC_IGP185 IgG4 Sialylation 





IgG4 SA per 
Gal 
The number of sialic acid 
moieties on galactose moieties 







The percentage of 
monosialylation of 
fucosylated galactosylated 
structures without bisecting 







The percentage of 
monosialylation of all 
fucosylated structures without 



















bisecting GlcNAc) structures 







The percentage of 
monosialylation of 
fucosylated digalactosylated 
(without bisecting GlcNAc) 








The percentage of 
monosialylation of 
fucosylated galactosylated 
structures with bisecting 








The percentage of 
monosialylation of all 
fucosylated structures with 













bisecting GlcNAc) structures 







The percentage of 
monosialylation of 
fucosylated digalactosylated 
(with bisecting GlcNAc) 




LC_IGP195 IgG4 FBS1/FS1 
Ratio of fucosylated 
monosialylated structures with 
and without bisecting GlcNAc 







The incidence of bisecting 
GlcNAc in all fucosylated 
monosialylated structures in 




LC_IGP197 IgG4 G0Fn 
The percentage of G0F glycan 
in neutral IgG4 glycans  
 
LC_IGP198 IgG4 G1Fn 
The percentage of G1F glycan 
in neutral IgG4 glycans  
 
LC_IGP199 IgG4 G2Fn 
The percentage of G2F glycan 
in neutral IgG4 glycans  
 
LC_IGP200 IgG4 G0FNn 
The percentage of G0FN 







Glycan Trait Trait Description Formula 
LC_IGP201 IgG4 G1FNn 
The percentage of G1FN 
glycan in neutral IgG4 glycans  
 
LC_IGP202 IgG4 G2FNn 
The percentage of G2FN 
glycan in neutral IgG4 glycans  
 
LC_IGP203 IgG4 G0n 
The percentage of 
agalactosylated structures in 
neutral IgG4 glycan fraction 
SUM(G0F+G0FN) 
LC_IGP204 IgG4 G1n 
The percentage of 
monogalactosylated structures 
in neutral  IgG4 glycan 
fraction 
SUM(G1F+G1FN) 
LC_IGP205 IgG4 G2n 
The percentage of 
digalactosylated structures in 
neutral IgG4 glycan fraction 
SUM(G2F+G2FN) 
n= neutral; F at the start of the abbreviation indicates a core fucose α1-6 linked to the inner 
GlcNAc; Mx, number (x) of mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on 
trimannosyl core; A2, biantennary with both GlcNAcs as β1-2 linked; B, bisecting GlcNAc 
linked β1-4 to β1-3 mannose; Gx, number (x) of β1-4 linked galactose on antenna; [3]G1 and 
[6]G1 indicates that the galactose is on the antenna of the α1-3 or α1-6 mannose; F(x), 






Table 21: IgG N-Glycan Features by xCGE-LIF for GWAS. 
Trait Code Glycan Trait Trait Description Formula 
CGE_IGP1 P1 
















% FA2BG2S2 glycan in 
total  IgG glycans 
P5 /Ptotal*100 
CGE_IGP6 P6 
% A2G1S1[3] glycan in 
total  IgG glycans 
P6 /Ptotal*100 
CGE_IGP7 P7 
% FA2G1S1[3] glycan in 
total  IgG glycans 
P7 /Ptotal*100 
CGE_IGP8 P8 
% A2G2S1[3] glycan in 
total  IgG glycans 
P8 /Ptotal*100 
CGE_IGP9 P9 












% FA2BG2S1 glycan in 
total  IgG glycans 
P12 /Ptotal*100 
CGE_IGP13 P13 
































% FA2[6]BG1 glycan in 
total  IgG glycans 
P21 /Ptotal*100 
CGE_IGP22 P22 
% FA2[3]BG1 glycan in 
total  IgG glycans 
P22 /Ptotal*100 
CGE_IGP23 P23 






Trait Code Glycan Trait Trait Description Formula 
CGE_IGP24 P24 








% sialylation of fucosylated 
galactosylated structures 
without bisecting GlcNAc in 






% sialylation of fucosylated 
galactosylated structures 
with bisecting GlcNAc in 






% sialylation of all 
fucosylated structures 
without bisecting GlcNAc in 






% sialylation of all 
fucosylated structures with 







% monosialylation of 
fucosylated 
monogalactosylated 
structures without bisecting 





% monosialylation of 
fucosylated digalactosylated 
structures without bisecting 





% disialylation of 
fucosylated digalactosylated 
structures without bisecting 






% monosialylation of 
fucosylated digalactosylated 
structures with bisecting 






% disialylation of 
fucosylated digalactosylated 
structures with bisecting 





Ratio of all fucosylated 
monosialylated and 
disialylated structures (+/- 





Ratio of fucosylated 
monosialylated  and 
disialylated structures 
(without bisecting GlcNAc) 





Trait Code Glycan Trait Trait Description Formula 
CGE_IGP37 FBS1/FBS2 
Ratio of fucosylated  
monosialylated  and 
disialylated structures (with 




Ratio of all fucosylated 
sialylated structures with 
and without bisecting 




Ratio of  fucosylated 
monosialylated structures 
with and without bisecting 





The incidence of bisecting 
GlcNAc in all fucosylated 
monosialylated structures in 




Ratio of fucosylated 
disialylated structures with 
and without bisecting 





The incidence of bisecting 
GlcNAc in all fucosylated 
disialylated structures in 
total IgG glycans 
P5/SUM(P5+P4)*100 
CGE_IGP43 P13n 
% A2B glycan in total 
neutral IgG glycans (Pn) 
P13n/Pntotal*100 
CGE_IGP44 P14n 
% FA2 glycan in total 
neutral IgG glycans (Pn) 
P14n/Pntotal*100 
CGE_IGP45 P15n 
% A2[6]G1 glycan in total 
neutral IgG glycans (Pn) 
P15n/Pntotal*100 
CGE_IGP46 P16n 
% A2[3]G1 glycan in total 
neutral IgG glycans (Pn) 
P16n/Pntotal*100 
CGE_IGP47 P17n 
% FA2B glycan in total 
neutral IgG glycans (Pn) 
P17n/Pntotal*100 
CGE_IGP48 P18n 
% A2BG1 glycan in total 
neutral IgG glycans (Pn) 
P18n/Pntotal*100 
CGE_IGP49 P19n 
% FA2[6]G1 glycan in total 
neutral IgG glycans (Pn) 
P19n/Pntotal*100 
CGE_IGP50 P20n 
% FA2[3]G1 glycan in total 
neutral IgG glycans (Pn) 
P20n/Pntotal*100 
CGE_IGP51 P21n 
% FA2[6]BG1 glycan in 




% FA2[3]BG1 glycan in 




% A2BG2 glycan in total 





Trait Code Glycan Trait Trait Description Formula 
CGE_IGP54 P24n 
% FA2G2 glycan in total 
neutral IgG glycans (Pn) 
P24n/Pntotal*100 
CGE_IGP55 P25n 
% FA2BG2 glycan in total 
neutral IgG glycans (Pn) 
P25n/Pntotal*100 
CGE_IGP56 G0n 
% agalactosylated structures 










structures in total neutral 
IgG glycans 
SUM(P23n+P24n+P25n) 
CGE_IGP59 Fn total 
% all fucosylated structures  
(+/- bisecting GlcNAc) in 
total neutral IgG glycans 
SUM(P14n+P17n+P19n+P20n+P
21n+P22n+P24n+P25n) 
CGE_IGP60 FG0n total/G0n 
% fucosylation of 
agalactosylated structures in 
total neutral IgG glycans 
SUM(P14n+P17n)/G0n*100 
CGE_IGP61 FG1n total/G1n 
% fucosylation of 
monogalactosylated 




CGE_IGP62 FG2n total /G2n 
% fucosylation of 
digalactosylated structures in 
total neutral IgG glycans 
SUM(P24n+P25n)/G2n*100 
CGE_IGP63 Fn 
% fucosylated  structures 
(without bisecting GlcNAc) 
in total neutral IgG glycans 
SUM(P14n+P19n+P20n+P24n) 
CGE_IGP64 FG0n/G0n 
% fucosylation of 
agalactosylated structures 
(without bisecting GlcNAc) 
in total neutral IgG glycans 
P14n/G0n*100 
CGE_IGP65 FG1n/G1n 
% fucosylation of 
monogalactosylated 
structures (without bisecting 




% fucosylation of 
digalactosylated structures 
(without bisecting GlcNAc) 
in total neutral IgG glycans 
P24n/G2n*100 
CGE_IGP67 FBn 
% fucosylated structures 
(with bisecting GlcNAc) in 
total neutral IgG glycans 
SUM(P17n+P21n+P22n+P25n) 
CGE_IGP68 FBG0n/G0n 
% fucosylation of 
agalactosylated structures 
(with bisecting GlcNAc) in 





Trait Code Glycan Trait Trait Description Formula 
CGE_IGP69 FBG1n/G1n 
% fucosylation of 
monogalactosylated 
structures (with bisecting 




% fucosylation of 
digalactosylated structures 
(with bisecting GlcNAc) in 
total neutral IgG glycans 
P25n/G2n*100 
CGE_IGP71 Bn 
The incidence of bisecting 
GlcNAc (without core Fuc) 
in total neutral IgG glycans 
SUM(P13n+P18n+P23n) 
CGE_IGP72 BG0n/G0n 
The incidence of bisecting 
GlcNAc (without core Fuc)  
in agalactosylated structures 
in total neutral IgG glycans 
P13n/G0n*100 
CGE_IGP73 BG1n/G1n 
The incidence of bisecting 
GlcNAc (without core Fuc) 
in monogalactosylated 




The incidence of bisecting 
GlcNAc (without core Fuc)  
in digalactosylated structures 
in total neutral IgG glycans 
P23n/G2n*100 
CGE_IGP75 Bn total 
The incidence of bisecting 
GlcNAc (+/- core Fuc) in 
total neutral IgG glycans 
SUM(P13n+P17n+P18n+P21n+P
22n+P23n+P25n) 
CGE_IGP76 BG0n total/G0n 
The incidence of bisecting 
GlcNAc (+/- core Fuc)  in 
agalactosylated structures in 
total neutral IgG glycans 
SUM(P13n+P17n)/G0n*100 
CGE_IGP77 BG1n total/G1n 
The incidence of bisecting 
GlcNAc (+/- core Fuc)  in  
monogalactosylated 




CGE_IGP78 BG2n total /G2n 
The incidence of bisecting 
GlcNAc (+/-  core Fuc)  in 
digalactosylated structures in 
total neutral IgG glycans 
SUM(P23n+P25n)/G2n*100 
CGE_IGP79 Fn/Bn 
Ratio of fucosylated 
structures without bisecting 
GlcNAc and afucosylated 
structures with bisecting 
GlcNAc in neutral IgG1 
glycan fraction 
Fn/Bn 
CGE_IGP80 Fn/Bn total 
Ratio of fucosylated non-
bisecting GlcNAc structures 
and all structures with 
bisecting GlcNAc in total 





Trait Code Glycan Trait Trait Description Formula 
CGE_IGP81 FBn/Fn 
Ratio of fucosylated 
structures with and without 
bisecting GlcNAc in total 
neutral IgG glycans 
FBn/Fn 
CGE_IGP82 Bn/Fn total 
Ratio of structures with 
bisecting GlcNAc and all 
fucosylated structures (+/- 
bisecting GlcNAc) in total 
neutral IgG glycans 
Bn/Fn total*1000 
CGE_IGP83 FBn/Fn total 
The incidence of bisecting 
GlcNAc in all fucosylated 
structures in total neutral 
IgG glycans 
FBn/Fn total*100 
CGE_IGP84 FBn/Bn total 
% fucosylation in all 
structures with bisecting 




Ratio of fucosylated 
agalactosylated structures 
with and without bisecting 





+ FBG0n ) 
The incidence of bisecting 
GlcNAc in all fucosylated 
agalactosylated structures in 
total neutral IgG glycans 
P17n/SUM(P14n+P17n)*100 
CGE_IGP87 FBG1n/FG1n 
Ratio of fucosylated 
monogalactosylated 
structures with and without 
bisecting GlcNAc in total 





+ FBG1n ) 
The incidence of bisecting 
GlcNAc in all fucosylated 
monogalactosylated 





Ratio of fucosylated 
digalactosylated structures 
with and without bisecting 





+ FBG2n ) 
The incidence of bisecting 
GlcNAc in all fucosylated 
digalactosylated structures in 
total neutral IgG glycans 
P25n/SUM(P24n+P25n)*100 
CGE_IGP91 BG1n/G1n 
Ratio of afucosylated 
monogalactosylated 
structures with and without 
bisecting GlcNAc in total 





Trait Code Glycan Trait Trait Description Formula 
CGE_IGP92 
BG1n /(G1n + 
BG1n ) 
The incidence of bisecting 
GlcNAc in all afucosylated 
monogalactosylated 




Ptotal = SUM(P1:P25), Pntotal = SUM(P13n:P25n); n= neutral; F at the start of the 
abbreviation indicates a core fucose α1-6 linked to the inner GlcNAc; Mx, number (x) of 
mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl core; A2, 
biantennary with both GlcNAcs as β1-2 linked; B, bisecting GlcNAc linked β1-4 to β1-3 
mannose; Gx, number (x) of β1-4 linked galactose on antenna; [3]G1 and [6]G1 indicates 
that the galactose is on the antenna of the α1-3 or α1-6 mannose; F(x), number (x) of fucose 





Table 22: Overview of samples and methods used for all N-glycan analyses presented in this thesis. 
 





















MODY3 cases from Edinburgh 
(14) and Oxford (19) 
T2D cases from Oxford(41) 





































Hum Mol Genet 
(2011) [111] 
Thesis Chapter 3 
Thesis 
Chapter 3 




Thesis Chapter 5 
Thesis 
Chapter 5 
Mol Cell Proteomics 
(2014) [83] 
 
Thesis Chapter 6 




Table 23: Testing for effect size differences between men and women for 
significant total N-glycan SNPs. 





Females only Males only 
P-
value  
Beta* SE Beta* SE 
FUT6 GP14 rs3760776 G,A (0.13) -0.293 0.052 -0.342 0.058 0.53 
FUT6 DG7 rs3760776 G,A (0.13) -0.314 0.051 -0.425 0.059 0.16 
FUT6 DG9 rs3760776 G,A (0.13) -0.427 0.052 -0.445 0.058 0.82 
FUT6 DG12 rs3760776 G,A (0.13) -0.375 0.051 -0.298 0.058 0.32 
FUT6 A-FUC rs3760776 G,A (0.13) -0.305 0.051 -0.408 0.059 0.18 
FUT8 GP1 rs7159888 G,A (0.45) 0.249 0.034 0.260 0.040 0.83 
FUT8 GP10 rs10483776 A,G (0.21) -0.282 0.042 -0.215 0.049 0.30 
FUT8 DG1 rs11621121 A,G (0.43) 0.281 0.034 0.248 0.041 0.53 
FUT8 DG6 rs10483776 A,G (0.21) -0.228 0.042 -0.150 0.049 0.23 
FUT8 DG10 rs10483776 A,G (0.21) -0.158 0.043 -0.191 0.048 0.61 
FUT8 C-FUC rs10483776 A,G (0.21) -0.203 0.042 -0.150 0.049 0.42 
FUT8 A2 rs7159888 G,A (0.45) 0.248 0.034 0.280 0.041 0.55 
HNF1A GP13 rs735396 A,G (0.40) 0.169 0.035 0.179 0.040 0.85 
HNF1A GP15 rs735396 A,G (0.40) 0.140 0.035 0.149 0.040 0.87 
HNF1A DG7 rs735396 A,G (0.39) -0.169 0.035 -0.206 0.041 0.49 
HNF1A DG9 rs7953249 A,G (0.47) -0.153 0.034 -0.207 0.039 0.30 
HNF1A DG11 rs735396 A,G (0.39) 0.157 0.035 0.163 0.040 0.91 
HNF1A A-FUC rs735396 A,G (0.40) -0.146 0.034 -0.187 0.041 0.44 
MGAT5 DG11 rs1257220 G,A (0.26) 0.220 0.037 0.146 0.045 0.20 
MGAT5 TA rs1257220 G,A (0.26) 0.221 0.037 0.136 0.045 0.14 
B3GAT1 DG13 rs7928758 A,C (0.12) -0.271 0.053 -0.169 0.061 0.20 
SLC9A9 TetraS rs4839604 G,A (0.23) 0.203 0.041 0.253 0.046 0.42 
MAF: minor allele frequency; SE: standard error of beta 





Table 24: SNP associations with P-value<1E-07 in total plasma N-glycans 
GWAS analysed by HPLC. 
Trait SNP Chr Position EA EAF RSq Beta* SE P 
GP1 rs3094093 6 30787607 T 0.10 0.76 0.247 0.044 1.69E-08 
GP1 rs1256519 14 64806077 G 0.44 0.89 -0.178 0.027 8.78E-11 
GP1 rs7159888 14 64828395 G 0.55 0.99 -0.248 0.026 5.12E-21 
GP1 rs12431963 14 64829447 C 0.92 0.93 -0.340 0.050 8.82E-12 
GP1 rs1256540 14 64833822 C 0.42 1.00 0.217 0.026 2.52E-16 
GP1 rs4902383 14 64834326 C 0.19 0.94 0.255 0.033 2.95E-14 
GP1 rs1269068 14 64837086 C 0.58 1.00 -0.217 0.026 2.28E-16 
GP1 rs1760978 14 64840800 G 0.43 0.98 0.257 0.027 3.29E-22 
GP1 rs10144975 14 64843735 C 0.80 0.98 -0.259 0.032 6.40E-16 
GP1 rs17102587 14 64844230 C 0.20 0.98 0.263 0.032 2.69E-16 
GP1 rs8017974 14 64844940 C 0.20 0.99 0.264 0.032 1.97E-16 
GP1 rs11847263 14 64845448 G 0.39 0.99 0.289 0.027 1.12E-26 
GP1 rs10132229 14 64847313 G 0.10 1.00 0.308 0.043 6.54E-13 
GP1 rs4902386 14 64848043 C 0.80 0.99 -0.263 0.032 1.85E-16 
GP1 rs10147958 14 64848586 C 0.10 1.00 0.308 0.043 6.36E-13 
GP1 rs8019473 14 64848881 G 0.80 0.99 -0.263 0.032 1.80E-16 
GP1 rs10138662 14 64849235 G 0.20 1.00 0.264 0.032 1.71E-16 
GP1 rs10134589 14 64850987 T 0.20 0.94 0.268 0.033 8.11E-16 
GP1 rs7151212 14 64851375 C 0.80 1.00 -0.264 0.032 1.59E-16 
GP1 rs11158587 14 64852465 G 0.80 1.00 -0.264 0.032 1.56E-16 
GP1 rs8019767 14 64852538 G 0.80 1.00 -0.264 0.032 1.55E-16 
GP1 rs6573598 14 64852772 C 0.20 1.00 0.264 0.032 1.52E-16 
GP1 rs6573599 14 64852880 C 0.80 1.00 -0.264 0.032 1.44E-16 
GP1 rs10144503 14 64853862 G 0.90 1.00 -0.309 0.043 5.15E-13 
GP1 rs6573602 14 64854363 C 0.20 1.00 0.264 0.032 1.38E-16 
GP1 rs17102598 14 64854613 G 0.80 1.00 -0.264 0.032 1.36E-16 
GP1 rs12436299 14 64854947 G 0.90 1.00 -0.309 0.043 4.92E-13 
GP1 rs6573604 14 64857694 C 0.20 1.00 0.264 0.032 1.33E-16 
GP1 rs9635250 14 64869101 T 0.10 1.00 0.310 0.043 4.51E-13 
GP1 rs12881755 14 64871564 G 0.66 0.96 -0.197 0.029 5.30E-12 
GP1 rs747541 14 64875163 C 0.44 0.97 0.230 0.027 8.93E-18 
GP1 rs1954052 14 64875462 T 0.43 0.99 0.230 0.027 8.07E-18 
GP1 rs12436465 14 64876630 C 0.73 0.98 -0.170 0.030 1.34E-08 
GP1 rs12886005 14 64879000 C 0.44 0.87 0.222 0.028 3.72E-15 
GP1 rs12886168 14 64879039 C 0.44 0.98 0.230 0.027 8.00E-18 
GP1 rs11623920 14 64889067 C 0.57 1.00 -0.230 0.027 6.80E-18 
GP1 rs11621121 14 64892246 C 0.43 1.00 0.229 0.027 6.91E-18 
GP1 rs10148907 14 64903125 C 0.70 0.98 -0.270 0.029 3.11E-20 
GP1 rs4902393 14 64909267 C 0.57 0.99 -0.227 0.027 2.55E-17 
GP1 rs11621604 14 64910527 G 0.58 0.98 -0.220 0.027 3.33E-16 
GP1 rs12882269 14 64916897 G 0.58 0.98 -0.217 0.027 7.93E-16 
GP1 rs11158591 14 64925515 C 0.42 0.98 0.214 0.027 1.49E-15 
GP1 rs11158592 14 64929721 G 0.48 0.99 0.219 0.026 4.08E-17 
GP1 rs11158593 14 64929737 G 0.49 0.99 0.219 0.026 3.26E-17 
GP1 rs10138570 14 64929791 G 0.51 0.99 -0.219 0.026 3.32E-17 
GP1 rs10138671 14 64929845 G 0.59 0.99 -0.146 0.026 3.22E-08 
GP1 rs4587890 14 64933537 T 0.41 0.99 0.146 0.026 3.29E-08 
GP1 rs2411823 14 64934819 C 0.41 0.99 0.146 0.026 3.38E-08 
GP1 rs17246007 14 64935424 C 0.08 0.99 0.277 0.049 1.57E-08 
GP1 rs11844747 14 64939881 C 0.08 0.99 0.277 0.049 1.51E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
GP1 rs2411822 14 64948148 G 0.49 1.00 -0.198 0.026 2.73E-14 
GP1 rs1953416 14 64948560 C 0.51 1.00 0.198 0.026 2.39E-14 
GP1 rs1953417 14 64948662 C 0.92 1.00 -0.279 0.049 1.25E-08 
GP1 rs883081 14 64950374 C 0.51 1.00 0.198 0.026 2.24E-14 
GP1 rs883082 14 64950693 G 0.49 1.00 -0.198 0.026 2.54E-14 
GP1 rs7145574 14 64954155 C 0.92 1.00 -0.279 0.049 1.25E-08 
GP1 rs867972 14 64965514 C 0.50 0.97 -0.199 0.026 3.76E-14 
GP1 rs11851576 14 64970036 C 0.55 0.99 -0.175 0.026 3.61E-11 
GP1 rs12879971 14 64971357 G 0.51 0.99 0.201 0.026 1.12E-14 
GP1 rs12892058 14 64973194 C 0.49 0.99 -0.203 0.026 6.55E-15 
GP1 rs10483776 14 64984620 G 0.21 1.00 0.204 0.033 4.88E-10 
GP1 rs17826580 14 64985015 C 0.08 1.00 0.280 0.049 1.07E-08 
GP1 rs2184602 14 64985425 G 0.08 1.00 0.280 0.049 1.07E-08 
GP1 rs2152375 14 64985531 C 0.08 1.00 0.280 0.049 1.07E-08 
GP1 rs12589698 14 64990188 G 0.50 0.98 0.208 0.026 2.16E-15 
GP1 rs4899179 14 64996501 G 0.50 0.99 -0.208 0.026 1.79E-15 
GP1 rs2184603 14 65000423 C 0.50 0.99 -0.208 0.026 1.72E-15 
GP1 rs11850847 14 65003551 C 0.92 1.00 -0.280 0.049 1.06E-08 
GP1 rs12434585 14 65008121 G 0.08 1.00 0.280 0.049 1.06E-08 
GP1 rs3825640 14 65030957 C 0.50 1.00 0.208 0.026 1.30E-15 
GP1 rs11627084 14 65048589 G 0.50 1.00 -0.207 0.026 1.57E-15 
GP1 rs10483780 14 65049923 C 0.51 1.00 -0.207 0.026 2.22E-15 
GP1 rs2149841 14 65080072 C 0.50 0.99 0.207 0.026 1.69E-15 
GP1 rs7153679 14 65082707 G 0.08 1.00 0.282 0.049 8.72E-09 
GP1 rs11621680 14 65084434 G 0.51 1.00 -0.205 0.026 4.29E-15 
GP1 rs11851013 14 65085965 G 0.08 1.00 0.282 0.049 8.68E-09 
GP1 rs11623662 14 65090945 G 0.61 0.99 -0.157 0.027 3.89E-09 
GP1 rs11851772 14 65091800 C 0.92 1.00 -0.282 0.049 8.56E-09 
GP1 rs9972106 14 65092884 T 0.61 0.99 -0.157 0.027 4.00E-09 
GP1 rs11158601 14 65095116 G 0.50 1.00 -0.204 0.026 4.32E-15 
GP1 rs7146742 14 65102687 G 0.41 0.99 0.188 0.027 2.29E-12 
GP1 rs1958561 14 65106514 G 0.50 1.00 -0.204 0.026 3.75E-15 
GP1 rs12887134 14 65115296 C 0.50 1.00 -0.205 0.026 3.03E-15 
GP1 rs7155541 14 65115995 C 0.50 1.00 -0.205 0.026 3.00E-15 
GP1 rs6573615 14 65116287 G 0.39 0.99 0.157 0.027 4.27E-09 
GP1 rs7160780 14 65122466 G 0.39 1.00 0.160 0.027 1.89E-09 
GP1 rs7161123 14 65122654 G 0.50 1.00 0.208 0.026 1.21E-15 
GP1 rs2411356 14 65122914 G 0.39 1.00 0.160 0.027 1.86E-09 
GP1 rs12433827 14 65125363 G 0.92 1.00 -0.281 0.049 9.77E-09 
GP1 rs4581615 14 65125696 C 0.50 1.00 0.208 0.026 1.21E-15 
GP1 rs8005309 14 65126261 T 0.92 1.00 -0.281 0.049 9.80E-09 
GP1 rs17753508 14 65127205 G 0.21 1.00 0.206 0.033 4.06E-10 
GP1 rs3783709 14 65128417 T 0.50 1.00 0.208 0.026 1.21E-15 
GP1 rs12889002 14 65133335 C 0.50 1.00 0.208 0.026 1.21E-15 
GP1 rs743085 14 65137886 G 0.50 1.00 -0.208 0.026 1.21E-15 
GP1 rs17826724 14 65138073 C 0.08 1.00 0.280 0.049 1.15E-08 
GP1 rs11849252 14 65139522 G 0.92 1.00 -0.280 0.049 1.16E-08 
GP1 rs7140341 14 65140170 C 0.33 1.00 0.152 0.028 4.87E-08 
GP1 rs11158603 14 65141793 C 0.33 1.00 0.152 0.028 4.87E-08 
GP1 rs17826736 14 65151955 C 0.08 1.00 0.280 0.049 1.21E-08 
GP1 rs2073294 14 65152246 C 0.92 1.00 -0.280 0.049 1.21E-08 
GP1 rs8012278 14 65152326 G 0.50 1.00 -0.211 0.026 4.51E-16 
GP1 rs8019762 14 65156931 G 0.67 1.00 -0.153 0.028 4.67E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
GP1 rs11849862 14 65167778 G 0.08 1.00 0.279 0.049 1.25E-08 
GP1 rs10873191 14 65180381 C 0.67 1.00 -0.153 0.028 4.59E-08 
GP1 rs7144345 14 65181594 C 0.67 1.00 -0.153 0.028 4.44E-08 
GP1 rs2268957 14 65182986 C 0.92 1.00 -0.279 0.049 1.30E-08 
GP1 rs12890902 14 65186375 T 0.50 1.00 0.211 0.026 3.65E-16 
GP1 rs2300865 14 65189768 C 0.50 1.00 -0.211 0.026 3.60E-16 
GP1 rs7144971 14 65190403 G 0.33 1.00 0.153 0.028 4.36E-08 
GP1 rs10143206 14 65190428 C 0.33 1.00 0.153 0.028 4.41E-08 
GP1 rs11627184 14 65191196 C 0.50 1.00 0.211 0.026 3.61E-16 
GP1 rs12435908 14 65191221 C 0.92 1.00 -0.279 0.049 1.30E-08 
GP1 rs11627185 14 65191245 G 0.50 1.00 -0.211 0.026 3.61E-16 
GP1 rs1998035 14 65195983 G 0.08 1.00 0.279 0.049 1.30E-08 
GP1 rs2268958 14 65197991 T 0.08 1.00 0.279 0.049 1.30E-08 
GP1 rs7142651 14 65202474 C 0.50 1.00 0.211 0.026 5.21E-16 
GP1 rs1998036 14 65207952 C 0.50 1.00 -0.210 0.026 5.38E-16 
GP1 rs2268959 14 65215071 C 0.79 1.00 -0.208 0.033 2.05E-10 
GP1 rs2268960 14 65215253 G 0.07 0.98 0.298 0.051 6.06E-09 
GP1 rs2268961 14 65216518 C 0.50 1.00 -0.210 0.026 5.55E-16 
GP1 rs2268962 14 65217026 G 0.50 1.00 -0.210 0.026 5.57E-16 
GP1 rs2300871 14 65217447 C 0.08 1.00 0.279 0.049 1.30E-08 
GP1 rs2300872 14 65217514 G 0.08 1.00 0.278 0.049 1.51E-08 
GP1 rs2064694 14 65217999 G 0.50 1.00 0.207 0.026 1.39E-15 
GP1 rs12588838 14 65232391 G 0.50 1.00 0.207 0.026 1.46E-15 
GP1 rs8019491 14 65237863 G 0.08 1.00 0.278 0.049 1.59E-08 
GP1 rs11628765 14 65238202 C 0.50 1.00 -0.207 0.026 1.53E-15 
GP1 rs2411351 14 65241294 C 0.50 1.00 -0.207 0.026 1.64E-15 
GP1 rs11846546 14 65246146 G 0.14 0.99 0.208 0.037 2.01E-08 
GP1 rs8018278 14 65249841 G 0.50 1.00 -0.207 0.026 1.61E-15 
GP1 rs11627067 14 65252706 G 0.50 1.00 -0.207 0.026 1.57E-15 
GP1 rs4143898 14 65258635 T 0.43 0.99 0.190 0.026 7.63E-13 
GP1 rs11622829 14 65261535 T 0.49 1.00 0.206 0.026 2.43E-15 
GP1 rs11624104 14 65265890 G 0.51 1.00 -0.205 0.026 2.77E-15 
GP1 rs1535173 14 65268892 C 0.49 1.00 0.206 0.026 1.94E-15 
GP1 rs3742597 14 65269930 G 0.28 1.00 0.266 0.030 2.28E-19 
GP1 rs927004 14 65270664 C 0.51 1.00 -0.206 0.026 1.89E-15 
GP1 rs1950557 14 65271510 C 0.72 1.00 -0.267 0.030 2.02E-19 
GP1 rs8010876 14 65276729 G 0.51 1.00 -0.207 0.026 1.66E-15 
GP1 rs1054218 14 65278943 C 0.39 1.00 0.216 0.027 7.65E-16 
GP1 rs761830 14 65282739 G 0.39 1.00 0.216 0.027 7.57E-16 
GP1 rs10483785 14 65289270 G 0.49 1.00 0.211 0.026 4.15E-16 
GP1 rs6573624 14 65296638 G 0.50 0.98 0.214 0.026 2.89E-16 
GP1 rs2411405 14 65301839 G 0.53 0.98 -0.222 0.026 2.46E-17 
GP1 rs743084 14 65302355 C 0.53 0.97 -0.223 0.026 2.68E-17 
GP1 rs11625362 14 65302622 G 0.47 0.98 0.222 0.026 2.43E-17 
GP1 rs4080329 14 65303243 C 0.63 0.97 -0.235 0.027 6.73E-18 
GP1 rs11627605 14 65304066 G 0.47 0.98 0.223 0.026 2.39E-17 
GP1 rs11627578 14 65304201 C 0.47 0.98 0.223 0.026 2.38E-17 
GP1 rs11628840 14 65305395 G 0.53 0.98 -0.223 0.026 2.39E-17 
GP1 rs1003401 14 65307473 G 0.38 0.98 0.233 0.027 6.66E-18 
GP1 rs4902416 14 65307843 C 0.53 0.98 -0.222 0.026 2.48E-17 
GP1 rs1984855 14 65309010 C 0.62 0.97 -0.233 0.027 6.61E-18 
GP1 rs730807 14 65309043 C 0.47 0.97 0.223 0.026 2.44E-17 
GP1 rs2411404 14 65309154 C 0.47 0.97 0.223 0.026 2.43E-17 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
GP1 rs7157449 14 65309890 G 0.53 0.97 -0.223 0.026 2.43E-17 
GP1 rs6573625 14 65310387 C 0.63 0.97 -0.235 0.027 7.52E-18 
GP1 rs6573626 14 65310448 C 0.53 0.97 -0.223 0.026 2.57E-17 
GP1 rs7158556 14 65310482 T 0.37 0.97 0.235 0.027 7.33E-18 
GP1 rs12894466 14 65310520 G 0.47 0.97 0.223 0.026 2.55E-17 
GP1 rs11625882 14 65314952 G 0.47 0.97 0.223 0.026 2.66E-17 
GP1 rs2236067 14 65317765 G 0.62 0.97 -0.233 0.027 7.08E-18 
GP1 rs968540 14 65318817 G 0.63 0.97 -0.236 0.027 6.05E-18 
GP1 rs7142165 14 65319985 G 0.53 0.97 -0.224 0.026 2.19E-17 
GP1 rs7143026 14 65320709 G 0.39 0.95 0.227 0.027 1.04E-16 
GP1 rs6573627 14 65322079 C 0.52 0.97 -0.217 0.026 2.01E-16 
GP1 rs4400971 14 65324331 C 0.42 0.98 0.193 0.027 3.70E-13 
GP1 rs7151846 14 65325534 C 0.51 0.98 -0.213 0.026 4.41E-16 
GP1 rs4073416 14 65329147 C 0.42 0.98 0.193 0.027 3.76E-13 
GP1 rs4073415 14 65329283 G 0.51 0.98 -0.213 0.026 4.58E-16 
GP1 rs11850120 14 65330132 C 0.41 0.97 0.194 0.027 4.75E-13 
GP1 rs8018379 14 65331690 C 0.57 0.95 -0.204 0.027 4.63E-14 
GP1 rs8007846 14 65332716 G 0.47 0.98 0.145 0.026 4.86E-08 
GP1 rs8006608 14 65336577 G 0.96 0.81 -0.410 0.074 2.73E-08 
GP1 rs10140750 14 65339625 G 0.12 0.78 -0.250 0.043 4.52E-09 
GP1 rs3924222 14 65343491 C 0.41 0.80 -0.180 0.029 8.88E-10 
GP1 rs10149325 14 65347120 G 0.41 0.79 -0.180 0.029 8.16E-10 
GP4 rs1984769 1 159824353 G 0.77 0.48 0.237 0.043 2.54E-08 
GP5 rs13107325 4 103407732 C 0.92 0.90 -0.284 0.048 4.73E-09 
GP7 rs1820248 16 70597106 G 0.29 0.95 0.155 0.029 8.36E-08 
GP7 rs3213423 16 70600326 G 0.75 1.00 -0.190 0.030 1.60E-10 
GP7 rs1424241 16 70636408 G 0.79 0.99 -0.173 0.032 4.76E-08 
GP7 rs217181 16 70671503 C 0.81 0.92 0.198 0.033 2.72E-09 
GP10 rs1794265 6 32782715 C 0.96 0.69 0.341 0.063 7.48E-08 
GP10 rs12207186 6 162234911 T 0.06 0.85 -0.303 0.057 9.66E-08 
GP10 rs17102601 14 64859324 C 0.18 0.97 -0.188 0.035 8.02E-08 
GP10 rs12436465 14 64876630 C 0.73 0.98 0.201 0.030 1.94E-11 
GP10 rs10148907 14 64903125 C 0.70 0.98 0.171 0.029 5.17E-09 
GP10 rs7150448 14 64941255 C 0.35 1.00 -0.167 0.027 1.22E-09 
GP10 rs8013442 14 64941614 G 0.66 1.00 0.172 0.028 4.02E-10 
GP10 rs7147536 14 64944451 C 0.36 1.00 -0.167 0.027 6.95E-10 
GP10 rs7145500 14 64953965 G 0.35 1.00 -0.164 0.027 1.91E-09 
GP10 rs7145759 14 64954290 C 0.35 1.00 -0.165 0.027 1.81E-09 
GP10 rs7151561 14 64960356 C 0.65 0.99 0.165 0.027 1.66E-09 
GP10 rs2210805 14 64962477 C 0.35 0.99 -0.166 0.027 1.62E-09 
GP10 rs2184601 14 64967121 T 0.34 0.99 -0.166 0.027 1.49E-09 
GP10 rs11851576 14 64970036 C 0.55 0.99 0.154 0.026 5.10E-09 
GP10 rs7157109 14 64970186 C 0.34 0.99 -0.167 0.028 1.34E-09 
GP10 rs1999725 14 64973990 G 0.35 0.98 -0.173 0.027 2.77E-10 
GP10 rs11158595 14 64976122 G 0.67 0.98 0.178 0.028 2.07E-10 
GP10 rs11844682 14 64980597 C 0.67 0.98 0.178 0.028 2.05E-10 
GP10 rs10483776 14 64984620 G 0.21 1.00 -0.246 0.033 6.16E-14 
GP10 rs1953418 14 64984979 G 0.33 0.98 -0.178 0.028 2.00E-10 
GP10 rs12885842 14 64988405 C 0.34 0.98 -0.175 0.028 2.27E-10 
GP10 rs7140695 14 64998885 C 0.67 0.99 0.178 0.028 1.91E-10 
GP10 rs8010726 14 65002350 G 0.33 0.99 -0.173 0.028 5.71E-10 
GP10 rs1889731 14 65012464 C 0.68 1.00 0.177 0.028 2.08E-10 
GP10 rs1959144 14 65015804 G 0.68 1.00 0.177 0.028 2.21E-10 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
GP10 rs4902399 14 65026650 G 0.68 1.00 0.177 0.028 2.16E-10 
GP10 rs8011224 14 65039423 T 0.33 1.00 -0.172 0.028 6.09E-10 
GP10 rs2898818 14 65042337 C 0.68 1.00 0.177 0.028 2.08E-10 
GP10 rs7141536 14 65057065 T 0.33 1.00 -0.173 0.028 5.76E-10 
GP10 rs1953415 14 65057787 G 0.68 1.00 0.178 0.028 1.98E-10 
GP10 rs12147233 14 65064702 C 0.90 0.63 0.310 0.055 1.73E-08 
GP10 rs10144979 14 65067391 G 0.33 1.00 -0.173 0.028 5.57E-10 
GP10 rs1113962 14 65075551 C 0.33 1.00 -0.173 0.028 5.53E-10 
GP10 rs7147636 14 65080937 C 0.67 0.96 0.166 0.028 4.18E-09 
GP10 rs2411815 14 65089824 T 0.68 1.00 0.179 0.028 1.60E-10 
GP10 rs2898814 14 65093714 C 0.67 1.00 0.174 0.028 4.45E-10 
GP10 rs3783711 14 65098199 G 0.68 1.00 0.179 0.028 1.53E-10 
GP10 rs3825639 14 65098258 C 0.68 1.00 0.179 0.028 1.53E-10 
GP10 rs12433597 14 65098600 C 0.68 1.00 0.179 0.028 1.54E-10 
GP10 rs9323461 14 65101158 C 0.68 1.00 0.179 0.028 1.55E-10 
GP10 rs7147002 14 65102299 C 0.68 1.00 0.179 0.028 1.56E-10 
GP10 rs7146742 14 65102687 G 0.41 0.99 -0.154 0.027 9.35E-09 
GP10 rs7158153 14 65104339 C 0.32 1.00 -0.179 0.028 1.59E-10 
GP10 rs2183277 14 65105182 C 0.68 1.00 0.179 0.028 1.60E-10 
GP10 rs10142283 14 65113882 G 0.33 1.00 -0.174 0.028 4.70E-10 
GP10 rs8007497 14 65114229 C 0.68 1.00 0.179 0.028 1.63E-10 
GP10 rs6573616 14 65116569 G 0.69 0.95 0.183 0.029 2.15E-10 
GP10 rs4902404 14 65116775 C 0.68 1.00 0.179 0.028 1.67E-10 
GP10 rs10152007 14 65117187 T 0.68 1.00 0.178 0.028 1.95E-10 
GP10 rs7146993 14 65118625 C 0.32 1.00 -0.178 0.028 1.96E-10 
GP10 rs17753508 14 65127205 G 0.21 1.00 -0.246 0.033 7.19E-14 
GP10 rs12587057 14 65136128 C 0.32 1.00 -0.178 0.028 2.06E-10 
GP10 rs7140341 14 65140170 C 0.33 1.00 -0.178 0.028 1.73E-10 
GP10 rs11158603 14 65141793 C 0.33 1.00 -0.178 0.028 1.73E-10 
GP10 rs2092914 14 65148868 C 0.34 0.99 -0.178 0.028 9.37E-11 
GP10 rs8019762 14 65156931 G 0.67 1.00 0.178 0.028 1.73E-10 
GP10 rs2268956 14 65159898 G 0.33 1.00 -0.178 0.028 1.73E-10 
GP10 rs11158605 14 65177673 T 0.34 0.99 -0.178 0.028 9.67E-11 
GP10 rs10873191 14 65180381 C 0.67 1.00 0.178 0.028 1.74E-10 
GP10 rs11158607 14 65180550 G 0.66 0.99 0.178 0.027 9.79E-11 
GP10 rs7144345 14 65181594 C 0.67 1.00 0.178 0.028 1.75E-10 
GP10 rs7144971 14 65190403 G 0.33 1.00 -0.178 0.028 1.77E-10 
GP10 rs10143206 14 65190428 C 0.33 1.00 -0.178 0.028 1.73E-10 
GP10 rs2268959 14 65215071 C 0.79 1.00 0.245 0.033 7.10E-14 
GP10 rs1956010 14 65220843 G 0.35 0.99 -0.183 0.027 2.01E-11 
GP10 rs1121885 14 65226667 G 0.67 1.00 0.181 0.028 8.43E-11 
GP10 rs4143898 14 65258635 T 0.43 0.99 -0.161 0.026 1.18E-09 
GP10 rs3742597 14 65269930 G 0.28 1.00 -0.172 0.030 5.72E-09 
GP10 rs1950557 14 65271510 C 0.72 1.00 0.172 0.030 5.70E-09 
GP10 rs1054218 14 65278943 C 0.39 1.00 -0.144 0.027 7.08E-08 
GP10 rs761830 14 65282739 G 0.39 1.00 -0.144 0.027 7.07E-08 
GP10 rs4080329 14 65303243 C 0.63 0.97 0.150 0.027 3.78E-08 
GP10 rs1003401 14 65307473 G 0.38 0.98 -0.154 0.027 1.35E-08 
GP10 rs1984855 14 65309010 C 0.62 0.97 0.154 0.027 1.35E-08 
GP10 rs6573625 14 65310387 C 0.63 0.97 0.150 0.027 3.61E-08 
GP10 rs7158556 14 65310482 T 0.37 0.97 -0.150 0.027 3.63E-08 
GP10 rs2236067 14 65317765 G 0.62 0.97 0.154 0.027 1.26E-08 
GP10 rs968540 14 65318817 G 0.63 0.97 0.151 0.027 3.33E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
GP10 rs4400971 14 65324331 C 0.42 0.98 -0.158 0.027 2.81E-09 
GP10 rs4073416 14 65329147 C 0.42 0.98 -0.157 0.027 2.85E-09 
GP10 rs11850120 14 65330132 C 0.41 0.97 -0.153 0.027 1.00E-08 
GP13 rs7953249 12 119888107 G 0.47 1.00 0.146 0.026 2.70E-08 
GP13 rs7979473 12 119904643 G 0.55 0.94 -0.159 0.027 3.72E-09 
GP13 rs7979478 12 119904646 G 0.55 0.94 -0.159 0.027 3.67E-09 
GP13 rs1183910 12 119905190 G 0.60 0.94 -0.147 0.027 7.57E-08 
GP13 rs2393791 12 119908339 C 0.45 0.94 0.159 0.027 3.51E-09 
GP13 rs2393775 12 119908957 G 0.45 0.94 0.159 0.027 3.46E-09 
GP13 rs7310409 12 119909244 G 0.55 0.94 -0.159 0.027 3.47E-09 
GP13 rs1169300 12 119915608 G 0.63 1.00 -0.154 0.027 1.46E-08 
GP13 rs2259820 12 119919725 C 0.63 1.00 -0.154 0.027 1.67E-08 
GP13 rs2464196 12 119919810 G 0.63 1.00 -0.153 0.027 2.11E-08 
GP13 rs2464195 12 119919858 G 0.60 1.00 -0.167 0.027 4.55E-10 
GP13 rs2259816 12 119919970 G 0.60 1.00 -0.167 0.027 4.52E-10 
GP13 rs1169303 12 119920759 C 0.51 1.00 0.142 0.026 4.72E-08 
GP13 rs1169306 12 119922694 C 0.60 0.97 -0.172 0.027 2.18E-10 
GP13 rs735396 12 119923227 C 0.40 1.00 0.169 0.027 2.72E-10 
GP13 rs1169310 12 119923816 G 0.60 1.00 -0.169 0.027 2.72E-10 
GP13 rs1169312 12 119925844 G 0.60 1.00 -0.169 0.027 2.70E-10 
GP13 rs1169313 12 119927053 C 0.40 1.00 0.170 0.027 2.66E-10 
GP13 rs2257764 12 119930829 T 0.37 1.00 0.155 0.027 1.35E-08 
GP13 rs2258287 12 119938696 C 0.61 0.98 -0.150 0.027 3.30E-08 
GP13 rs1182933 12 119939005 C 0.63 0.98 -0.156 0.027 1.28E-08 
GP13 rs3213545 12 119955720 G 0.64 0.87 -0.156 0.029 8.11E-08 
GP13 rs217181 16 70671503 C 0.81 0.92 -0.182 0.034 6.25E-08 
GP13 rs3760775 19 5792356 G 0.92 0.79 -0.431 0.052 2.31E-16 
GP14 rs8101385 19 5789595 C 0.88 0.91 0.368 0.042 2.49E-18 
GP14 rs3760776 19 5790746 G 0.88 0.93 0.367 0.042 1.89E-18 
GP14 rs3760775 19 5792356 G 0.92 0.79 0.517 0.053 6.88E-23 
GP15 rs7979473 12 119904643 G 0.55 0.94 -0.148 0.027 4.03E-08 
GP15 rs7979478 12 119904646 G 0.55 0.94 -0.148 0.027 3.99E-08 
GP15 rs2393791 12 119908339 C 0.45 0.94 0.148 0.027 3.92E-08 
GP15 rs2393775 12 119908957 G 0.45 0.94 0.148 0.027 3.93E-08 
GP15 rs7310409 12 119909244 G 0.55 0.94 -0.148 0.027 3.96E-08 
GP15 rs2464195 12 119919858 G 0.60 1.00 -0.146 0.027 4.60E-08 
GP15 rs2259816 12 119919970 G 0.60 1.00 -0.146 0.027 4.56E-08 
GP15 rs1169306 12 119922694 C 0.60 0.97 -0.151 0.027 2.61E-08 
GP15 rs735396 12 119923227 C 0.40 1.00 0.148 0.027 3.09E-08 
GP15 rs1169310 12 119923816 G 0.60 1.00 -0.148 0.027 3.09E-08 
GP15 rs1169312 12 119925844 G 0.60 1.00 -0.148 0.027 3.11E-08 
GP15 rs1169313 12 119927053 C 0.40 1.00 0.148 0.027 3.12E-08 
GP16 rs9344613 6 87210387 C 0.15 0.91 0.196 0.037 9.31E-08 
DG1 rs1256519 14 64806077 G 0.44 0.90 -0.192 0.028 3.93E-12 
DG1 rs7159888 14 64828395 G 0.55 0.99 -0.262 0.027 5.71E-23 
DG1 rs12431963 14 64829447 C 0.92 0.93 -0.386 0.050 8.09E-15 
DG1 rs1256540 14 64833822 C 0.42 1.00 0.237 0.027 3.47E-19 
DG1 rs4902383 14 64834326 C 0.19 0.94 0.283 0.034 4.25E-17 
DG1 rs1269068 14 64837086 C 0.58 1.00 -0.237 0.026 3.72E-19 
DG1 rs10135194 14 64840731 C 0.94 0.87 -0.359 0.059 9.29E-10 
DG1 rs1760978 14 64840800 G 0.43 0.98 0.282 0.027 3.88E-26 
DG1 rs10144975 14 64843735 C 0.80 0.98 -0.291 0.032 1.75E-19 
DG1 rs17102587 14 64844230 C 0.20 0.98 0.294 0.032 1.01E-19 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
DG1 rs11847263 14 64845448 G 0.39 0.99 0.314 0.027 7.57E-31 
DG1 rs10132229 14 64847313 G 0.10 1.00 0.349 0.043 3.55E-16 
DG1 rs4902386 14 64848043 C 0.80 0.99 -0.292 0.032 1.09E-19 
DG1 rs10147958 14 64848586 C 0.10 1.00 0.349 0.043 3.41E-16 
DG1 rs8019473 14 64848881 G 0.80 0.99 -0.292 0.032 1.05E-19 
DG1 rs10138662 14 64849235 G 0.20 1.00 0.292 0.032 9.89E-20 
DG1 rs10134589 14 64850987 T 0.20 0.94 0.300 0.033 2.52E-19 
DG1 rs7151212 14 64851375 C 0.80 1.00 -0.293 0.032 9.07E-20 
DG1 rs11158587 14 64852465 G 0.80 1.00 -0.293 0.032 8.91E-20 
DG1 rs8019767 14 64852538 G 0.80 1.00 -0.293 0.032 8.81E-20 
DG1 rs6573598 14 64852772 C 0.20 1.00 0.293 0.032 8.63E-20 
DG1 rs6573599 14 64852880 C 0.80 1.00 -0.293 0.032 8.08E-20 
DG1 rs10144503 14 64853862 G 0.90 1.00 -0.351 0.043 2.51E-16 
DG1 rs6573602 14 64854363 C 0.20 1.00 0.293 0.032 7.66E-20 
DG1 rs17102598 14 64854613 G 0.80 1.00 -0.293 0.032 7.58E-20 
DG1 rs12436299 14 64854947 G 0.90 1.00 -0.351 0.043 2.34E-16 
DG1 rs6573604 14 64857694 C 0.20 1.00 0.293 0.032 7.38E-20 
DG1 rs9635250 14 64869101 T 0.10 1.00 0.352 0.043 2.14E-16 
DG1 rs12881755 14 64871564 G 0.66 0.96 -0.224 0.029 4.60E-15 
DG1 rs747541 14 64875163 C 0.44 0.97 0.271 0.027 5.06E-24 
DG1 rs1954052 14 64875462 T 0.43 0.99 0.273 0.027 2.28E-24 
DG1 rs12436465 14 64876630 C 0.73 0.98 -0.210 0.030 3.04E-12 
DG1 rs12886005 14 64879000 C 0.44 0.87 0.273 0.028 6.34E-22 
DG1 rs12886168 14 64879039 C 0.44 0.98 0.271 0.027 4.60E-24 
DG1 rs11623920 14 64889067 C 0.57 1.00 -0.273 0.027 1.99E-24 
DG1 rs11621121 14 64892246 C 0.43 1.00 0.272 0.027 2.03E-24 
DG1 rs10148907 14 64903125 C 0.70 0.98 -0.312 0.029 2.43E-26 
DG1 rs4902393 14 64909267 C 0.57 0.98 -0.271 0.027 7.47E-24 
DG1 rs11621604 14 64910527 G 0.58 0.98 -0.265 0.027 1.15E-22 
DG1 rs12882269 14 64916897 G 0.58 0.98 -0.262 0.027 3.14E-22 
DG1 rs11845794 14 64917871 C 0.92 0.98 -0.275 0.049 1.59E-08 
DG1 rs11850160 14 64917876 C 0.08 0.98 0.275 0.049 1.62E-08 
DG1 rs11850163 14 64917898 T 0.92 0.98 -0.275 0.049 1.63E-08 
DG1 rs10083421 14 64920911 C 0.08 0.98 0.275 0.049 1.63E-08 
DG1 rs10083525 14 64921309 C 0.08 0.98 0.275 0.049 1.65E-08 
DG1 rs17826448 14 64921770 G 0.92 0.99 -0.274 0.049 1.67E-08 
DG1 rs17826466 14 64921923 G 0.92 0.99 -0.274 0.049 1.68E-08 
DG1 rs10083488 14 64923099 C 0.08 0.99 0.274 0.049 1.69E-08 
DG1 rs12433416 14 64923928 G 0.92 0.99 -0.274 0.049 1.70E-08 
DG1 rs12433423 14 64923990 C 0.08 0.99 0.274 0.049 1.71E-08 
DG1 rs8017202 14 64924711 G 0.08 0.99 0.274 0.049 1.71E-08 
DG1 rs11158591 14 64925515 C 0.42 0.98 0.259 0.027 7.07E-22 
DG1 rs11158592 14 64929721 G 0.48 0.99 0.253 0.026 3.52E-22 
DG1 rs11158593 14 64929737 G 0.49 0.99 0.253 0.026 2.82E-22 
DG1 rs10138570 14 64929791 G 0.51 0.99 -0.253 0.026 2.91E-22 
DG1 rs10138671 14 64929845 G 0.59 0.99 -0.176 0.027 2.83E-11 
DG1 rs4587890 14 64933537 T 0.41 0.99 0.176 0.027 2.90E-11 
DG1 rs2411823 14 64934819 C 0.41 0.99 0.176 0.027 2.98E-11 
DG1 rs17246007 14 64935424 C 0.08 0.99 0.290 0.049 3.26E-09 
DG1 rs11844747 14 64939881 C 0.08 0.99 0.290 0.049 3.18E-09 
DG1 rs17246035 14 64943883 G 0.08 1.00 0.292 0.049 2.52E-09 
DG1 rs7147536 14 64944451 C 0.36 1.00 0.148 0.027 5.66E-08 
DG1 rs2411822 14 64948148 G 0.49 1.00 -0.233 0.026 4.89E-19 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
DG1 rs1953417 14 64948662 C 0.92 1.00 -0.292 0.049 2.42E-09 
DG1 rs883081 14 64950374 C 0.51 1.00 0.233 0.026 4.41E-19 
DG1 rs883082 14 64950693 G 0.49 1.00 -0.233 0.026 4.65E-19 
DG1 rs7145500 14 64953965 G 0.35 1.00 0.151 0.027 4.05E-08 
DG1 rs7145574 14 64954155 C 0.92 1.00 -0.292 0.049 2.42E-09 
DG1 rs7145759 14 64954290 C 0.35 1.00 0.152 0.028 3.51E-08 
DG1 rs7151561 14 64960356 C 0.65 0.99 -0.153 0.028 2.98E-08 
DG1 rs2210805 14 64962477 C 0.35 0.99 0.153 0.028 2.84E-08 
DG1 rs867972 14 64965514 C 0.50 0.97 -0.235 0.026 4.72E-19 
DG1 rs2184601 14 64967121 T 0.35 0.99 0.154 0.028 2.42E-08 
DG1 rs11851576 14 64970036 C 0.55 0.99 -0.203 0.027 1.88E-14 
DG1 rs7157109 14 64970186 C 0.35 0.99 0.155 0.028 1.94E-08 
DG1 rs12879971 14 64971357 G 0.51 0.99 0.236 0.026 1.91E-19 
DG1 rs12892058 14 64973194 C 0.49 0.99 -0.238 0.026 1.23E-19 
DG1 rs1999725 14 64973990 G 0.35 0.98 0.157 0.028 1.28E-08 
DG1 rs11158595 14 64976122 G 0.67 0.98 -0.170 0.028 1.51E-09 
DG1 rs11844682 14 64980597 C 0.67 0.98 -0.170 0.028 1.43E-09 
DG1 rs10483776 14 64984620 G 0.21 1.00 0.249 0.033 3.65E-14 
DG1 rs1953418 14 64984979 G 0.33 0.98 0.170 0.028 1.30E-09 
DG1 rs17826580 14 64985015 C 0.08 1.00 0.294 0.049 2.01E-09 
DG1 rs2184602 14 64985425 G 0.08 1.00 0.294 0.049 2.01E-09 
DG1 rs2152375 14 64985531 C 0.08 1.00 0.294 0.049 2.01E-09 
DG1 rs12885842 14 64988405 C 0.34 0.98 0.167 0.028 1.67E-09 
DG1 rs12589698 14 64990188 G 0.50 0.98 0.242 0.026 2.97E-20 
DG1 rs4899179 14 64996501 G 0.50 0.99 -0.243 0.026 2.37E-20 
DG1 rs7140695 14 64998885 C 0.67 0.99 -0.172 0.028 8.39E-10 
DG1 rs2184603 14 65000423 C 0.50 0.99 -0.243 0.026 2.28E-20 
DG1 rs8010726 14 65002350 G 0.33 0.99 0.172 0.028 8.86E-10 
DG1 rs11850847 14 65003551 C 0.92 1.00 -0.294 0.049 2.00E-09 
DG1 rs12434585 14 65008121 G 0.08 1.00 0.294 0.049 2.00E-09 
DG1 rs1889731 14 65012464 C 0.67 1.00 -0.173 0.028 6.89E-10 
DG1 rs1959144 14 65015804 G 0.67 1.00 -0.173 0.028 6.98E-10 
DG1 rs2411820 14 65016497 C 0.33 1.00 0.172 0.028 7.36E-10 
DG1 rs4902399 14 65026650 G 0.67 1.00 -0.173 0.028 6.65E-10 
DG1 rs3825640 14 65030957 C 0.50 1.00 0.242 0.026 2.03E-20 
DG1 rs8011224 14 65039423 T 0.33 1.00 0.172 0.028 7.58E-10 
DG1 rs2898818 14 65042337 C 0.67 1.00 -0.173 0.028 6.94E-10 
DG1 rs11627084 14 65048589 G 0.50 1.00 -0.242 0.026 2.25E-20 
DG1 rs10483780 14 65049923 C 0.51 1.00 -0.242 0.026 2.37E-20 
DG1 rs7141536 14 65057065 T 0.33 1.00 0.172 0.028 8.20E-10 
DG1 rs1953415 14 65057787 G 0.67 1.00 -0.173 0.028 7.46E-10 
DG1 rs12147233 14 65064702 C 0.90 0.63 -0.297 0.055 7.41E-08 
DG1 rs10144979 14 65067391 G 0.33 1.00 0.172 0.028 8.85E-10 
DG1 rs1113962 14 65075551 C 0.33 1.00 0.171 0.028 9.01E-10 
DG1 rs2149841 14 65080072 C 0.50 0.99 0.241 0.026 2.68E-20 
DG1 rs7153679 14 65082707 G 0.08 1.00 0.296 0.049 1.61E-09 
DG1 rs11621680 14 65084434 G 0.51 1.00 -0.240 0.026 4.82E-20 
DG1 rs11851013 14 65085965 G 0.08 1.00 0.296 0.049 1.60E-09 
DG1 rs2411815 14 65089824 T 0.68 1.00 -0.170 0.028 1.35E-09 
DG1 rs11623662 14 65090945 G 0.61 0.99 -0.187 0.027 2.60E-12 
DG1 rs11851772 14 65091800 C 0.92 1.00 -0.296 0.049 1.58E-09 
DG1 rs9972106 14 65092884 T 0.61 0.99 -0.187 0.027 2.67E-12 
DG1 rs2898814 14 65093714 C 0.67 1.00 -0.168 0.028 2.04E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
DG1 rs3783711 14 65098199 G 0.68 1.00 -0.169 0.028 1.86E-09 
DG1 rs3825639 14 65098258 C 0.68 1.00 -0.169 0.028 1.79E-09 
DG1 rs12433597 14 65098600 C 0.68 1.00 -0.169 0.028 1.78E-09 
DG1 rs9323461 14 65101158 C 0.68 1.00 -0.169 0.028 1.74E-09 
DG1 rs7147002 14 65102299 C 0.68 1.00 -0.169 0.028 1.71E-09 
DG1 rs7146742 14 65102687 G 0.41 0.99 0.218 0.027 5.75E-16 
DG1 rs7158153 14 65104339 C 0.32 1.00 0.169 0.028 1.64E-09 
DG1 rs2183277 14 65105182 C 0.68 1.00 -0.169 0.028 1.63E-09 
DG1 rs1958561 14 65106514 G 0.51 1.00 -0.239 0.026 5.87E-20 
DG1 rs1958560 14 65106548 G 0.41 1.00 0.159 0.027 2.11E-09 
DG1 rs10142283 14 65113882 G 0.33 1.00 0.169 0.028 1.72E-09 
DG1 rs8007497 14 65114229 C 0.68 1.00 -0.170 0.028 1.51E-09 
DG1 rs12887134 14 65115296 C 0.50 1.00 -0.239 0.026 5.21E-20 
DG1 rs7155541 14 65115995 C 0.50 1.00 -0.239 0.026 5.16E-20 
DG1 rs6573615 14 65116287 G 0.39 0.99 0.187 0.027 2.92E-12 
DG1 rs6573616 14 65116569 G 0.69 0.95 -0.174 0.029 1.88E-09 
DG1 rs4902404 14 65116775 C 0.68 1.00 -0.170 0.028 1.45E-09 
DG1 rs10152007 14 65117187 T 0.68 1.00 -0.174 0.028 6.21E-10 
DG1 rs7146993 14 65118625 C 0.32 1.00 0.174 0.028 6.16E-10 
DG1 rs1958559 14 65121808 C 0.41 1.00 0.162 0.026 8.72E-10 
DG1 rs7160780 14 65122466 G 0.39 1.00 0.190 0.027 1.16E-12 
DG1 rs7161123 14 65122654 G 0.50 1.00 0.242 0.026 1.85E-20 
DG1 rs2411356 14 65122914 G 0.39 1.00 0.190 0.027 1.14E-12 
DG1 rs12433827 14 65125363 G 0.92 1.00 -0.295 0.049 1.82E-09 
DG1 rs4581615 14 65125696 C 0.50 1.00 0.242 0.026 1.85E-20 
DG1 rs8005309 14 65126261 T 0.92 1.00 -0.295 0.049 1.83E-09 
DG1 rs17753508 14 65127205 G 0.21 1.00 0.251 0.033 2.76E-14 
DG1 rs3783709 14 65128417 T 0.50 1.00 0.242 0.026 1.85E-20 
DG1 rs12889002 14 65133335 C 0.50 1.00 0.242 0.026 1.85E-20 
DG1 rs12587057 14 65136128 C 0.33 1.00 0.174 0.028 5.87E-10 
DG1 rs2064695 14 65136841 G 0.59 1.00 -0.162 0.026 8.40E-10 
DG1 rs743085 14 65137886 G 0.50 1.00 -0.242 0.026 1.86E-20 
DG1 rs17826724 14 65138073 C 0.08 1.00 0.293 0.049 2.27E-09 
DG1 rs11849252 14 65139522 G 0.92 1.00 -0.293 0.049 2.30E-09 
DG1 rs7140341 14 65140170 C 0.33 1.00 0.176 0.028 3.53E-10 
DG1 rs11158603 14 65141793 C 0.33 1.00 0.176 0.028 3.55E-10 
DG1 rs17826736 14 65151955 C 0.08 1.00 0.293 0.049 2.43E-09 
DG1 rs2073294 14 65152246 C 0.92 1.00 -0.292 0.049 2.44E-09 
DG1 rs8012278 14 65152326 G 0.50 1.00 -0.243 0.026 1.12E-20 
DG1 rs8019762 14 65156931 G 0.67 1.00 -0.175 0.028 3.70E-10 
DG1 rs2268955 14 65159762 T 0.41 1.00 0.165 0.026 5.00E-10 
DG1 rs2268956 14 65159898 G 0.33 1.00 0.175 0.028 3.72E-10 
DG1 rs11849862 14 65167778 G 0.08 1.00 0.292 0.049 2.56E-09 
DG1 rs10873191 14 65180381 C 0.67 1.00 -0.175 0.028 3.83E-10 
DG1 rs7144345 14 65181594 C 0.67 1.00 -0.175 0.028 3.80E-10 
DG1 rs2268957 14 65182986 C 0.92 1.00 -0.292 0.049 2.73E-09 
DG1 rs12890902 14 65186375 T 0.50 1.00 0.243 0.026 1.18E-20 
DG1 rs2300865 14 65189768 C 0.50 1.00 -0.243 0.026 1.19E-20 
DG1 rs7144971 14 65190403 G 0.33 1.00 0.175 0.028 3.92E-10 
DG1 rs10143206 14 65190428 C 0.33 1.00 0.175 0.028 3.97E-10 
DG1 rs11627184 14 65191196 C 0.50 1.00 0.243 0.026 1.21E-20 
DG1 rs12435908 14 65191221 C 0.92 1.00 -0.292 0.049 2.73E-09 
DG1 rs11627185 14 65191245 G 0.50 1.00 -0.243 0.026 1.21E-20 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
DG1 rs2268958 14 65197991 T 0.08 1.00 0.292 0.049 2.74E-09 
DG1 rs7142651 14 65202474 C 0.50 1.00 0.242 0.026 1.82E-20 
DG1 rs1998036 14 65207952 C 0.50 1.00 -0.242 0.026 1.90E-20 
DG1 rs2268959 14 65215071 C 0.79 1.00 -0.250 0.033 2.62E-14 
DG1 rs2268960 14 65215253 G 0.07 0.98 0.311 0.051 1.19E-09 
DG1 rs2268961 14 65216518 C 0.50 1.00 -0.242 0.026 2.03E-20 
DG1 rs2268962 14 65217026 G 0.50 1.00 -0.242 0.026 2.05E-20 
DG1 rs2300871 14 65217447 C 0.08 1.00 0.292 0.049 2.76E-09 
DG1 rs2300872 14 65217514 G 0.08 1.00 0.291 0.049 3.06E-09 
DG1 rs2064694 14 65217999 G 0.50 1.00 0.239 0.026 5.72E-20 
DG1 rs1121885 14 65226667 G 0.67 1.00 -0.170 0.028 1.18E-09 
DG1 rs12588838 14 65232391 G 0.50 1.00 0.238 0.026 6.11E-20 
DG1 rs8019491 14 65237863 G 0.08 1.00 0.291 0.049 3.22E-09 
DG1 rs11628765 14 65238202 C 0.50 1.00 -0.238 0.026 6.57E-20 
DG1 rs2411351 14 65241294 C 0.50 1.00 -0.238 0.026 7.22E-20 
DG1 rs11846546 14 65246146 G 0.14 0.99 0.231 0.037 5.64E-10 
DG1 rs8018278 14 65249841 G 0.50 1.00 -0.238 0.026 7.15E-20 
DG1 rs11627067 14 65252706 G 0.50 1.00 -0.238 0.026 7.08E-20 
DG1 rs4143898 14 65258635 T 0.43 0.99 0.215 0.027 6.45E-16 
DG1 rs11622829 14 65261535 T 0.49 1.00 0.237 0.026 1.04E-19 
DG1 rs11624104 14 65265890 G 0.51 1.00 -0.235 0.026 2.11E-19 
DG1 rs1535173 14 65268892 C 0.49 1.00 0.235 0.026 2.22E-19 
DG1 rs3742597 14 65269930 G 0.28 1.00 0.302 0.030 2.47E-24 
DG1 rs927004 14 65270664 C 0.51 1.00 -0.235 0.026 2.20E-19 
DG1 rs1950557 14 65271510 C 0.72 1.00 -0.303 0.030 2.09E-24 
DG1 rs8010876 14 65276729 G 0.51 1.00 -0.236 0.026 1.90E-19 
DG1 rs1054218 14 65278943 C 0.40 1.00 0.239 0.027 5.97E-19 
DG1 rs761830 14 65282739 G 0.40 1.00 0.239 0.027 5.87E-19 
DG1 rs10483785 14 65289270 G 0.49 1.00 0.239 0.026 3.71E-20 
DG1 rs6573624 14 65296638 G 0.49 0.98 0.243 0.026 2.24E-20 
DG1 rs2411405 14 65301839 G 0.53 0.98 -0.251 0.026 1.60E-21 
DG1 rs743084 14 65302355 C 0.53 0.97 -0.253 0.026 1.11E-21 
DG1 rs11625362 14 65302622 G 0.47 0.98 0.251 0.026 1.56E-21 
DG1 rs4080329 14 65303243 C 0.63 0.98 -0.259 0.027 2.48E-21 
DG1 rs11627605 14 65304066 G 0.47 0.98 0.251 0.026 1.51E-21 
DG1 rs11627578 14 65304201 C 0.47 0.98 0.252 0.026 1.50E-21 
DG1 rs11628840 14 65305395 G 0.53 0.98 -0.252 0.026 1.50E-21 
DG1 rs1003401 14 65307473 G 0.38 0.98 0.256 0.027 3.71E-21 
DG1 rs4902416 14 65307843 C 0.53 0.98 -0.251 0.026 1.57E-21 
DG1 rs1984855 14 65309010 C 0.62 0.98 -0.256 0.027 3.66E-21 
DG1 rs730807 14 65309043 C 0.47 0.98 0.252 0.026 1.53E-21 
DG1 rs2411404 14 65309154 C 0.47 0.97 0.252 0.026 1.51E-21 
DG1 rs1075566 14 65309210 C 0.47 0.97 0.252 0.026 1.50E-21 
DG1 rs7157449 14 65309890 G 0.53 0.97 -0.252 0.026 1.50E-21 
DG1 rs6573625 14 65310387 C 0.63 0.97 -0.259 0.027 2.53E-21 
DG1 rs6573626 14 65310448 C 0.53 0.97 -0.252 0.026 1.51E-21 
DG1 rs7158556 14 65310482 T 0.37 0.97 0.260 0.027 2.45E-21 
DG1 rs12894466 14 65310520 G 0.47 0.97 0.252 0.026 1.49E-21 
DG1 rs11625882 14 65314952 G 0.47 0.97 0.252 0.026 1.51E-21 
DG1 rs2236067 14 65317765 G 0.62 0.97 -0.257 0.027 3.53E-21 
DG1 rs968540 14 65318817 G 0.63 0.97 -0.261 0.027 1.89E-21 
DG1 rs7142165 14 65319985 G 0.53 0.97 -0.253 0.026 1.26E-21 
DG1 rs7143026 14 65320709 G 0.39 0.95 0.250 0.027 7.20E-20 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
DG1 rs4400971 14 65324331 C 0.42 0.98 0.215 0.027 6.79E-16 
DG1 rs7151846 14 65325534 C 0.52 0.98 -0.240 0.026 7.00E-20 
DG1 rs4073416 14 65329147 C 0.42 0.98 0.215 0.027 6.96E-16 
DG1 rs4073415 14 65329283 G 0.52 0.98 -0.240 0.026 7.13E-20 
DG1 rs11850120 14 65330132 C 0.41 0.97 0.217 0.027 5.49E-16 
DG1 rs8018379 14 65331690 C 0.57 0.95 -0.247 0.027 1.03E-19 
DG1 rs8007846 14 65332716 G 0.47 0.98 0.199 0.027 8.20E-14 
DG1 rs8006608 14 65336577 G 0.96 0.81 -0.403 0.075 7.15E-08 
DG1 rs4078408 14 65342587 G 0.29 0.85 -0.173 0.031 2.72E-08 
DG1 rs3924222 14 65343491 C 0.41 0.79 -0.210 0.029 8.10E-13 
DG1 rs10149325 14 65347120 G 0.41 0.79 -0.211 0.029 7.57E-13 
DG1 rs10149555 14 65347410 G 0.56 0.98 -0.152 0.026 6.08E-09 
DG1 rs12878546 14 65348273 C 0.56 0.97 -0.153 0.026 5.78E-09 
DG1 rs8009488 14 65349289 C 0.56 0.96 -0.153 0.026 6.50E-09 
DG3 rs2592781 2 23039477 G 0.45 1.00 -0.144 0.026 3.74E-08 
DG3 rs2681019 2 23041009 C 0.45 0.99 -0.144 0.026 3.73E-08 
DG3 rs2681005 2 23046536 C 0.45 0.99 -0.145 0.026 3.75E-08 
DG3 rs2681008 2 23047436 G 0.45 0.98 -0.145 0.026 3.77E-08 
DG3 rs2272406 2 27745527 T 0.22 0.96 -0.170 0.032 8.72E-08 
DG3 rs13023094 2 27764210 C 0.22 0.97 -0.170 0.032 7.35E-08 
DG3 rs13030973 2 27782301 C 0.22 0.99 -0.173 0.031 3.22E-08 
DG3 rs6727388 2 27786091 G 0.22 0.99 -0.173 0.031 3.18E-08 
DG3 rs4616435 2 27787146 C 0.78 0.99 0.173 0.031 3.13E-08 
DG3 rs6727215 2 27788235 G 0.78 0.99 0.173 0.031 3.09E-08 
DG3 rs13023194 2 27820764 C 0.20 0.92 -0.196 0.033 3.64E-09 
DG3 rs13030345 2 27856678 G 0.81 0.87 0.210 0.035 2.66E-09 
DG3 rs2305929 2 27967415 G 0.19 0.98 -0.192 0.033 6.27E-09 
DG6 rs12436465 14 64876630 C 0.73 0.98 0.171 0.030 1.12E-08 
DG6 rs7150448 14 64941255 C 0.35 1.00 -0.149 0.027 5.45E-08 
DG6 rs8013442 14 64941614 G 0.66 1.00 0.154 0.027 2.14E-08 
DG6 rs7147536 14 64944451 C 0.36 1.00 -0.149 0.027 4.01E-08 
DG6 rs7145500 14 64953965 G 0.35 1.00 -0.147 0.027 7.51E-08 
DG6 rs7145759 14 64954290 C 0.35 1.00 -0.147 0.027 7.84E-08 
DG6 rs7151561 14 64960356 C 0.65 0.99 0.147 0.027 7.75E-08 
DG6 rs2210805 14 64962477 C 0.35 0.99 -0.147 0.027 7.74E-08 
DG6 rs2184601 14 64967121 T 0.35 0.99 -0.147 0.027 7.74E-08 
DG6 rs7157109 14 64970186 C 0.35 0.99 -0.148 0.027 7.68E-08 
DG6 rs1999725 14 64973990 G 0.35 0.98 -0.152 0.027 3.14E-08 
DG6 rs11158595 14 64976122 G 0.67 0.98 0.152 0.028 5.21E-08 
DG6 rs11844682 14 64980597 C 0.67 0.98 0.152 0.028 5.29E-08 
DG6 rs10483776 14 64984620 G 0.21 1.00 -0.202 0.033 7.05E-10 
DG6 rs1953418 14 64984979 G 0.33 0.98 -0.152 0.028 5.43E-08 
DG6 rs12885842 14 64988405 C 0.34 0.98 -0.148 0.028 8.75E-08 
DG6 rs7140695 14 64998885 C 0.67 0.99 0.151 0.028 6.15E-08 
DG6 rs1889731 14 65012464 C 0.67 1.00 0.150 0.028 7.47E-08 
DG6 rs1959144 14 65015804 G 0.67 1.00 0.150 0.028 8.01E-08 
DG6 rs4902399 14 65026650 G 0.67 1.00 0.150 0.028 7.81E-08 
DG6 rs2898818 14 65042337 C 0.67 1.00 0.150 0.028 7.60E-08 
DG6 rs1953415 14 65057787 G 0.67 1.00 0.150 0.028 7.32E-08 
DG6 rs2411815 14 65089824 T 0.68 1.00 0.151 0.028 6.25E-08 
DG6 rs3783711 14 65098199 G 0.68 1.00 0.151 0.028 6.04E-08 
DG6 rs3825639 14 65098258 C 0.68 1.00 0.151 0.028 6.07E-08 
DG6 rs12433597 14 65098600 C 0.68 1.00 0.151 0.028 6.09E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
DG6 rs7147002 14 65102299 C 0.68 1.00 0.151 0.028 6.16E-08 
DG6 rs7158153 14 65104339 C 0.32 1.00 -0.151 0.028 6.23E-08 
DG6 rs2183277 14 65105182 C 0.68 1.00 0.151 0.028 6.25E-08 
DG6 rs8007497 14 65114229 C 0.68 1.00 0.151 0.028 6.35E-08 
DG6 rs6573616 14 65116569 G 0.69 0.95 0.155 0.029 7.77E-08 
DG6 rs4902404 14 65116775 C 0.68 1.00 0.151 0.028 6.45E-08 
DG6 rs10152007 14 65117187 T 0.68 1.00 0.150 0.028 7.55E-08 
DG6 rs7146993 14 65118625 C 0.32 1.00 -0.150 0.028 7.58E-08 
DG6 rs17753508 14 65127205 G 0.21 1.00 -0.201 0.033 7.97E-10 
DG6 rs12587057 14 65136128 C 0.33 1.00 -0.150 0.028 7.85E-08 
DG6 rs7140341 14 65140170 C 0.33 1.00 -0.153 0.028 4.11E-08 
DG6 rs11158603 14 65141793 C 0.33 1.00 -0.153 0.028 4.05E-08 
DG6 rs2092914 14 65148868 C 0.34 0.99 -0.147 0.027 9.00E-08 
DG6 rs8019762 14 65156931 G 0.67 1.00 0.154 0.028 3.43E-08 
DG6 rs2268956 14 65159898 G 0.33 1.00 -0.154 0.028 3.36E-08 
DG6 rs11158605 14 65177673 T 0.34 0.99 -0.148 0.027 7.64E-08 
DG6 rs10873191 14 65180381 C 0.67 1.00 0.154 0.028 3.05E-08 
DG6 rs11158607 14 65180550 G 0.66 0.99 0.148 0.027 7.17E-08 
DG6 rs7144345 14 65181594 C 0.67 1.00 0.154 0.028 2.89E-08 
DG6 rs7144971 14 65190403 G 0.33 1.00 -0.155 0.028 2.64E-08 
DG6 rs10143206 14 65190428 C 0.33 1.00 -0.155 0.028 2.59E-08 
DG6 rs2268959 14 65215071 C 0.79 1.00 0.207 0.033 2.22E-10 
DG6 rs1956010 14 65220843 G 0.35 0.99 -0.152 0.027 2.48E-08 
DG6 rs1121885 14 65226667 G 0.67 1.00 0.158 0.028 1.37E-08 
DG7 rs2649999 12 119864927 C 0.59 0.84 0.180 0.029 4.33E-10 
DG7 rs2650000 12 119873345 C 0.57 1.00 0.164 0.027 5.90E-10 
DG7 rs7953249 12 119888107 G 0.47 1.00 -0.177 0.026 1.43E-11 
DG7 rs2251468 12 119889509 C 0.43 0.99 -0.166 0.027 3.60E-10 
DG7 rs10774579 12 119889593 C 0.44 0.99 0.150 0.026 9.70E-09 
DG7 rs1169288 12 119901033 C 0.40 0.95 -0.183 0.027 1.49E-11 
DG7 rs2244608 12 119901371 G 0.40 0.95 -0.184 0.027 1.48E-11 
DG7 rs1169286 12 119903439 C 0.49 0.94 -0.150 0.027 1.65E-08 
DG7 rs7979473 12 119904643 G 0.55 0.94 0.197 0.027 2.81E-13 
DG7 rs7979478 12 119904646 G 0.55 0.94 0.197 0.027 2.78E-13 
DG7 rs1183910 12 119905190 G 0.60 0.94 0.188 0.027 7.27E-12 
DG7 rs11065385 12 119907769 G 0.61 0.88 0.188 0.028 4.35E-11 
DG7 rs2393791 12 119908339 C 0.45 0.94 -0.197 0.027 2.70E-13 
DG7 rs2393775 12 119908957 G 0.44 0.94 -0.197 0.027 2.64E-13 
DG7 rs7310409 12 119909244 G 0.56 0.94 0.198 0.027 2.63E-13 
DG7 rs1169300 12 119915608 G 0.63 1.00 0.184 0.027 1.56E-11 
DG7 rs2259820 12 119919725 C 0.63 1.00 0.183 0.027 1.78E-11 
DG7 rs2464196 12 119919810 G 0.63 1.00 0.182 0.027 2.25E-11 
DG7 rs2464195 12 119919858 G 0.61 1.00 0.186 0.027 4.01E-12 
DG7 rs2259816 12 119919970 G 0.61 1.00 0.186 0.027 3.97E-12 
DG7 rs1169306 12 119922694 C 0.60 0.97 0.190 0.027 2.52E-12 
DG7 rs735396 12 119923227 C 0.39 1.00 -0.188 0.027 2.48E-12 
DG7 rs1169310 12 119923816 G 0.61 1.00 0.188 0.027 2.47E-12 
DG7 rs1169312 12 119925844 G 0.61 1.00 0.188 0.027 2.44E-12 
DG7 rs1169313 12 119927053 C 0.39 1.00 -0.188 0.027 2.38E-12 
DG7 rs2257764 12 119930829 T 0.37 1.00 -0.185 0.027 1.29E-11 
DG7 rs2258287 12 119938696 C 0.61 0.98 0.170 0.027 3.92E-10 
DG7 rs1182933 12 119939005 C 0.63 0.98 0.187 0.027 9.17E-12 
DG7 rs3213545 12 119955720 G 0.64 0.87 0.204 0.029 2.60E-12 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
DG7 rs3760776 19 5790746 G 0.88 0.93 0.403 0.042 3.84E-22 
DG7 rs3760775 19 5792356 G 0.92 0.79 0.632 0.052 1.75E-33 
DG7 rs874232 19 5794609 C 0.41 0.85 -0.171 0.028 1.14E-09 
DG8 rs7979473 12 119904643 G 0.55 0.94 -0.145 0.027 7.89E-08 
DG8 rs7979478 12 119904646 G 0.55 0.94 -0.145 0.027 7.81E-08 
DG8 rs2393791 12 119908339 C 0.45 0.94 0.145 0.027 7.57E-08 
DG8 rs2393775 12 119908957 G 0.44 0.94 0.146 0.027 7.34E-08 
DG8 rs7310409 12 119909244 G 0.56 0.94 -0.146 0.027 7.29E-08 
DG8 rs2464195 12 119919858 G 0.61 1.00 -0.148 0.027 4.02E-08 
DG8 rs2259816 12 119919970 G 0.61 1.00 -0.148 0.027 3.99E-08 
DG8 rs1169306 12 119922694 C 0.60 0.97 -0.152 0.027 2.37E-08 
DG8 rs735396 12 119923227 C 0.39 1.00 0.150 0.027 2.52E-08 
DG8 rs1169310 12 119923816 G 0.61 1.00 -0.150 0.027 2.52E-08 
DG8 rs1169312 12 119925844 G 0.61 1.00 -0.150 0.027 2.50E-08 
DG8 rs1169313 12 119927053 C 0.39 1.00 0.150 0.027 2.45E-08 
DG8 rs217181 16 70671503 C 0.81 0.92 -0.200 0.034 3.36E-09 
DG8 rs8101385 19 5789595 C 0.88 0.91 -0.243 0.042 8.54E-09 
DG8 rs3760776 19 5790746 G 0.88 0.93 -0.240 0.042 1.03E-08 
DG8 rs3760775 19 5792356 G 0.92 0.79 -0.447 0.053 1.87E-17 
DG9 rs2649999 12 119864927 C 0.59 0.84 0.173 0.029 2.22E-09 
DG9 rs2650000 12 119873345 C 0.57 1.00 0.157 0.027 3.83E-09 
DG9 rs7953249 12 119888107 G 0.47 1.00 -0.175 0.026 2.99E-11 
DG9 rs2251468 12 119889509 C 0.43 0.99 -0.161 0.027 1.72E-09 
DG9 rs10774579 12 119889593 C 0.44 0.99 0.146 0.026 3.06E-08 
DG9 rs1169288 12 119901033 C 0.40 0.95 -0.177 0.027 9.91E-11 
DG9 rs2244608 12 119901371 G 0.40 0.95 -0.177 0.027 1.01E-10 
DG9 rs7979473 12 119904643 G 0.55 0.94 0.193 0.027 1.01E-12 
DG9 rs7979478 12 119904646 G 0.55 0.94 0.193 0.027 9.99E-13 
DG9 rs1183910 12 119905190 G 0.60 0.94 0.180 0.028 6.73E-11 
DG9 rs11065385 12 119907769 G 0.61 0.88 0.181 0.029 2.88E-10 
DG9 rs2393791 12 119908339 C 0.45 0.94 -0.194 0.027 9.65E-13 
DG9 rs2393775 12 119908957 G 0.44 0.94 -0.193 0.027 1.03E-12 
DG9 rs7310409 12 119909244 G 0.56 0.94 0.193 0.027 1.06E-12 
DG9 rs1169300 12 119915608 G 0.63 1.00 0.161 0.027 4.15E-09 
DG9 rs2259820 12 119919725 C 0.63 1.00 0.160 0.027 4.71E-09 
DG9 rs2464196 12 119919810 G 0.63 1.00 0.160 0.027 5.78E-09 
DG9 rs2464195 12 119919858 G 0.61 1.00 0.170 0.027 3.02E-10 
DG9 rs2259816 12 119919970 G 0.61 1.00 0.170 0.027 3.02E-10 
DG9 rs1169306 12 119922694 C 0.60 0.97 0.173 0.027 2.52E-10 
DG9 rs735396 12 119923227 C 0.39 1.00 -0.170 0.027 2.81E-10 
DG9 rs1169310 12 119923816 G 0.61 1.00 0.170 0.027 2.80E-10 
DG9 rs1169312 12 119925844 G 0.61 1.00 0.170 0.027 2.78E-10 
DG9 rs1169313 12 119927053 C 0.39 1.00 -0.171 0.027 2.70E-10 
DG9 rs2257764 12 119930829 T 0.37 1.00 -0.160 0.027 5.07E-09 
DG9 rs2258287 12 119938696 C 0.61 0.98 0.147 0.027 7.12E-08 
DG9 rs1182933 12 119939005 C 0.63 0.98 0.163 0.028 3.96E-09 
DG9 rs3213545 12 119955720 G 0.64 0.87 0.177 0.029 1.42E-09 
DG9 rs778805 19 5783209 G 0.66 0.93 0.150 0.028 9.93E-08 
DG9 rs8101385 19 5789595 C 0.88 0.91 0.486 0.042 1.51E-30 
DG9 rs3760776 19 5790746 G 0.88 0.93 0.480 0.042 2.71E-30 
DG9 rs3760775 19 5792356 G 0.92 0.79 0.744 0.053 2.92E-45 
DG9 rs874232 19 5794609 C 0.41 0.85 -0.176 0.028 4.60E-10 
DG10 rs10148907 14 64903125 C 0.70 0.98 0.159 0.029 5.74E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
DG10 rs17753508 14 65127205 G 0.21 1.00 -0.191 0.033 6.53E-09 
DG10 rs2268959 14 65215071 C 0.79 1.00 0.187 0.033 1.26E-08 
DG11 rs1257189 2 134718008 C 0.73 0.88 -0.167 0.031 5.48E-08 
DG11 rs2593704 2 134721747 C 0.75 0.90 -0.193 0.031 7.55E-10 
DG11 rs1257196 2 134722302 G 0.27 0.89 0.167 0.031 5.55E-08 
DG11 rs1257197 2 134724206 G 0.73 0.87 -0.193 0.031 6.54E-10 
DG11 rs2442046 2 134730548 C 0.74 0.98 -0.184 0.030 6.09E-10 
DG11 rs2460382 2 134730586 G 0.26 0.98 0.184 0.030 6.13E-10 
DG11 rs2460383 2 134730596 C 0.74 0.98 -0.183 0.030 6.19E-10 
DG11 rs1257220 2 134731817 G 0.74 0.99 -0.183 0.030 6.56E-10 
DG11 rs1257221 2 134733088 C 0.71 0.88 -0.181 0.030 2.00E-09 
DG11 rs7953249 12 119888107 G 0.47 1.00 0.140 0.026 7.67E-08 
DG11 rs7979473 12 119904643 G 0.55 0.94 -0.154 0.027 1.01E-08 
DG11 rs7979478 12 119904646 G 0.55 0.94 -0.154 0.027 9.98E-09 
DG11 rs2393791 12 119908339 C 0.45 0.94 0.154 0.027 9.56E-09 
DG11 rs2393775 12 119908957 G 0.44 0.94 0.154 0.027 9.24E-09 
DG11 rs7310409 12 119909244 G 0.56 0.94 -0.154 0.027 9.16E-09 
DG11 rs2464195 12 119919858 G 0.61 1.00 -0.155 0.027 6.95E-09 
DG11 rs2259816 12 119919970 G 0.61 1.00 -0.155 0.027 6.89E-09 
DG11 rs1169306 12 119922694 C 0.60 0.97 -0.158 0.027 4.85E-09 
DG11 rs1169307 12 119922765 C 0.62 1.00 0.143 0.027 8.37E-08 
DG11 rs735396 12 119923227 C 0.39 1.00 0.157 0.027 4.19E-09 
DG11 rs1169310 12 119923816 G 0.61 1.00 -0.157 0.027 4.18E-09 
DG11 rs1169312 12 119925844 G 0.61 1.00 -0.157 0.027 4.15E-09 
DG11 rs1169313 12 119927053 C 0.39 1.00 0.157 0.027 4.09E-09 
DG11 rs217181 16 70671503 C 0.81 0.92 -0.184 0.034 4.64E-08 
DG11 rs3760775 19 5792356 G 0.92 0.79 -0.327 0.052 4.28E-10 
DG12 rs8101385 19 5789595 C 0.88 0.91 0.379 0.042 2.12E-19 
DG12 rs3760776 19 5790746 G 0.88 0.93 0.375 0.042 3.14E-19 
DG12 rs3760775 19 5792356 G 0.92 0.79 0.615 0.053 1.11E-31 
DG13 rs11223780 11 133766360 G 0.11 0.92 -0.238 0.044 4.86E-08 
DG13 rs7948031 11 133774301 C 0.12 0.93 -0.233 0.042 3.93E-08 
MonoS rs217181 16 70671503 C 0.81 0.92 0.187 0.034 2.71E-08 
TriS rs217181 16 70671503 C 0.81 0.92 -0.248 0.033 1.25E-13 
TetraS rs1372288 3 144384227 C 0.25 1.00 0.214 0.030 9.54E-13 
TetraS rs920570 3 144403114 C 0.24 0.98 0.216 0.030 1.08E-12 
TetraS rs6785254 3 144408513 G 0.76 0.98 -0.216 0.030 9.35E-13 
TetraS rs990739 3 144409455 G 0.76 0.98 -0.217 0.030 9.13E-13 
TetraS rs9842703 3 144417383 G 0.24 0.97 0.224 0.030 1.58E-13 
TetraS rs894175 3 144419283 C 0.31 0.96 0.191 0.028 1.09E-11 
TetraS rs6775385 3 144421193 G 0.24 0.97 0.224 0.030 1.43E-13 
TetraS rs4553947 3 144421904 T 0.24 0.97 0.224 0.030 1.42E-13 
TetraS rs9879103 3 144422465 C 0.76 0.97 -0.224 0.030 1.42E-13 
TetraS rs9829667 3 144426857 G 0.76 0.97 -0.225 0.030 1.25E-13 
TetraS rs985247 3 144432690 C 0.77 0.98 -0.229 0.031 1.31E-13 
TetraS rs10470450 3 144435495 C 0.77 0.98 -0.229 0.031 1.23E-13 
TetraS rs17470684 3 144438749 C 0.87 0.62 -0.282 0.046 8.97E-10 
TetraS rs7631070 3 144439114 G 0.77 0.99 -0.224 0.031 3.08E-13 
TetraS rs4839604 3 144442963 C 0.77 1.00 -0.223 0.031 3.49E-13 
TetraS rs13317029 3 144443913 G 0.23 0.99 0.224 0.031 3.44E-13 
TetraS rs4602353 3 144445234 G 0.77 0.99 -0.225 0.031 3.35E-13 
TetraS rs4307732 11 125750165 G 0.88 0.84 -0.229 0.043 9.40E-08 
C-FUC rs10483776 14 64984620 G 0.21 1.00 -0.190 0.033 6.12E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
C-FUC rs2268959 14 65215071 C 0.79 1.00 0.195 0.033 2.37E-09 
A-FUC rs2649999 12 119864927 C 0.59 0.84 0.170 0.029 3.40E-09 
A-FUC rs2650000 12 119873345 C 0.57 1.00 0.153 0.027 8.40E-09 
A-FUC rs7953249 12 119888107 G 0.47 1.00 -0.166 0.026 2.46E-10 
A-FUC rs2251468 12 119889509 C 0.43 0.99 -0.155 0.027 5.72E-09 
A-FUC rs1169288 12 119901033 C 0.40 0.95 -0.169 0.027 5.74E-10 
A-FUC rs2244608 12 119901371 G 0.40 0.95 -0.169 0.027 5.80E-10 
A-FUC rs7979473 12 119904643 G 0.55 0.94 0.183 0.027 1.29E-11 
A-FUC rs7979478 12 119904646 G 0.55 0.94 0.183 0.027 1.29E-11 
A-FUC rs1183910 12 119905190 G 0.60 0.94 0.172 0.027 3.66E-10 
A-FUC rs11065385 12 119907769 G 0.61 0.88 0.169 0.029 2.94E-09 
A-FUC rs2393791 12 119908339 C 0.45 0.94 -0.183 0.027 1.28E-11 
A-FUC rs2393775 12 119908957 G 0.44 0.94 -0.183 0.027 1.29E-11 
A-FUC rs7310409 12 119909244 G 0.56 0.94 0.183 0.027 1.31E-11 
A-FUC rs1169300 12 119915608 G 0.63 1.00 0.160 0.027 4.50E-09 
A-FUC rs2259820 12 119919725 C 0.63 1.00 0.159 0.027 5.34E-09 
A-FUC rs2464196 12 119919810 G 0.63 1.00 0.158 0.027 7.11E-09 
A-FUC rs2464195 12 119919858 G 0.61 1.00 0.166 0.027 5.94E-10 
A-FUC rs2259816 12 119919970 G 0.61 1.00 0.166 0.027 5.89E-10 
A-FUC rs1169306 12 119922694 C 0.60 0.97 0.170 0.027 3.82E-10 
A-FUC rs735396 12 119923227 C 0.39 1.00 -0.169 0.027 3.44E-10 
A-FUC rs1169310 12 119923816 G 0.61 1.00 0.169 0.027 3.43E-10 
A-FUC rs1169312 12 119925844 G 0.61 1.00 0.169 0.027 3.41E-10 
A-FUC rs1169313 12 119927053 C 0.39 1.00 -0.169 0.027 3.36E-10 
A-FUC rs2257764 12 119930829 T 0.37 1.00 -0.161 0.027 4.04E-09 
A-FUC rs2258287 12 119938696 C 0.61 0.98 0.146 0.027 7.10E-08 
A-FUC rs1182933 12 119939005 C 0.63 0.98 0.162 0.027 3.49E-09 
A-FUC rs3213545 12 119955720 G 0.64 0.87 0.174 0.029 2.27E-09 
A-FUC rs8101385 19 5789595 C 0.88 0.91 0.398 0.042 2.95E-21 
A-FUC rs3760776 19 5790746 G 0.88 0.93 0.393 0.042 4.73E-21 
A-FUC rs3760775 19 5792356 G 0.92 0.79 0.593 0.052 1.34E-29 
A-FUC rs874232 19 5794609 C 0.41 0.85 -0.180 0.028 1.72E-10 
A2 rs3094093 6 30787607 T 0.10 0.75 0.240 0.044 5.70E-08 
A2 rs1270077 14 64776511 G 0.30 0.92 0.160 0.030 7.96E-08 
A2 rs1256519 14 64806077 G 0.44 0.89 -0.192 0.028 4.51E-12 
A2 rs7159888 14 64828395 G 0.55 0.99 -0.261 0.027 1.15E-22 
A2 rs12431963 14 64829447 C 0.92 0.93 -0.376 0.050 6.44E-14 
A2 rs1256540 14 64833822 C 0.42 1.00 0.235 0.027 1.34E-18 
A2 rs4902383 14 64834326 C 0.19 0.94 0.280 0.034 1.27E-16 
A2 rs1269068 14 64837086 C 0.58 1.00 -0.235 0.027 1.32E-18 
A2 rs10135194 14 64840731 C 0.94 0.87 -0.341 0.059 7.17E-09 
A2 rs1760978 14 64840800 G 0.43 0.98 0.277 0.027 5.86E-25 
A2 rs10144975 14 64843735 C 0.80 0.98 -0.286 0.032 1.05E-18 
A2 rs17102587 14 64844230 C 0.20 0.98 0.289 0.033 5.95E-19 
A2 rs8017974 14 64844940 C 0.20 0.99 0.288 0.032 6.07E-19 
A2 rs11847263 14 64845448 G 0.39 0.99 0.310 0.027 8.86E-30 
A2 rs10132229 14 64847313 G 0.10 1.00 0.341 0.043 2.70E-15 
A2 rs4902386 14 64848043 C 0.80 0.99 -0.287 0.032 6.19E-19 
A2 rs10147958 14 64848586 C 0.10 1.00 0.341 0.043 2.61E-15 
A2 rs8019473 14 64848881 G 0.80 0.99 -0.287 0.032 6.02E-19 
A2 rs10138662 14 64849235 G 0.20 1.00 0.288 0.032 5.68E-19 
A2 rs10134589 14 64850987 T 0.20 0.94 0.294 0.034 2.46E-18 
A2 rs7151212 14 64851375 C 0.80 1.00 -0.288 0.032 5.24E-19 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
A2 rs8019767 14 64852538 G 0.80 1.00 -0.288 0.032 5.10E-19 
A2 rs6573598 14 64852772 C 0.20 1.00 0.288 0.032 5.01E-19 
A2 rs6573599 14 64852880 C 0.80 1.00 -0.288 0.032 4.71E-19 
A2 rs10144503 14 64853862 G 0.90 1.00 -0.343 0.043 1.95E-15 
A2 rs6573602 14 64854363 C 0.20 1.00 0.288 0.032 4.48E-19 
A2 rs17102598 14 64854613 G 0.80 1.00 -0.288 0.032 4.44E-19 
A2 rs12436299 14 64854947 G 0.90 1.00 -0.343 0.043 1.82E-15 
A2 rs6573604 14 64857694 C 0.20 1.00 0.288 0.032 4.34E-19 
A2 rs9635250 14 64869101 T 0.10 1.00 0.344 0.043 1.66E-15 
A2 rs12881755 14 64871564 G 0.66 0.96 -0.217 0.029 4.47E-14 
A2 rs747541 14 64875163 C 0.44 0.97 0.257 0.027 1.73E-21 
A2 rs1954052 14 64875462 T 0.43 0.99 0.258 0.027 1.29E-21 
A2 rs12436465 14 64876630 C 0.73 0.98 -0.192 0.030 1.92E-10 
A2 rs12886005 14 64879000 C 0.44 0.87 0.254 0.029 6.06E-19 
A2 rs12886168 14 64879039 C 0.44 0.98 0.257 0.027 1.55E-21 
A2 rs11623920 14 64889067 C 0.57 1.00 -0.257 0.027 1.10E-21 
A2 rs11621121 14 64892246 C 0.43 1.00 0.257 0.027 1.12E-21 
A2 rs10148907 14 64903125 C 0.70 0.98 -0.300 0.030 3.67E-24 
A2 rs4902393 14 64909267 C 0.57 0.98 -0.254 0.027 5.57E-21 
A2 rs11621604 14 64910527 G 0.58 0.98 -0.247 0.027 1.16E-19 
A2 rs12882269 14 64916897 G 0.58 0.98 -0.243 0.027 3.31E-19 
A2 rs11845794 14 64917871 C 0.92 0.98 -0.277 0.049 1.47E-08 
A2 rs11850160 14 64917876 C 0.08 0.98 0.277 0.049 1.49E-08 
A2 rs11850163 14 64917898 T 0.92 0.98 -0.277 0.049 1.49E-08 
A2 rs10083421 14 64920911 C 0.08 0.98 0.277 0.049 1.49E-08 
A2 rs10083525 14 64921309 C 0.08 0.98 0.277 0.049 1.51E-08 
A2 rs17826448 14 64921770 G 0.92 0.99 -0.277 0.049 1.53E-08 
A2 rs17826466 14 64921923 G 0.92 0.99 -0.277 0.049 1.54E-08 
A2 rs10083488 14 64923099 C 0.08 0.99 0.277 0.049 1.54E-08 
A2 rs12433416 14 64923928 G 0.92 0.99 -0.277 0.049 1.55E-08 
A2 rs12433423 14 64923990 C 0.08 0.99 0.276 0.049 1.56E-08 
A2 rs8017202 14 64924711 G 0.08 0.99 0.276 0.049 1.56E-08 
A2 rs11158591 14 64925515 C 0.42 0.98 0.241 0.027 7.24E-19 
A2 rs11158592 14 64929721 G 0.48 0.99 0.240 0.026 7.53E-20 
A2 rs11158593 14 64929737 G 0.49 0.99 0.241 0.026 5.02E-20 
A2 rs10138570 14 64929791 G 0.51 0.99 -0.241 0.026 5.14E-20 
A2 rs10138671 14 64929845 G 0.59 0.99 -0.162 0.027 1.38E-09 
A2 rs4587890 14 64933537 T 0.41 0.99 0.162 0.027 1.42E-09 
A2 rs2411823 14 64934819 C 0.41 0.99 0.161 0.027 1.46E-09 
A2 rs17246007 14 64935424 C 0.08 0.99 0.296 0.049 1.97E-09 
A2 rs11844747 14 64939881 C 0.08 0.99 0.296 0.049 1.89E-09 
A2 rs17246035 14 64943883 G 0.08 1.00 0.297 0.049 1.53E-09 
A2 rs2411822 14 64948148 G 0.49 1.00 -0.219 0.026 7.97E-17 
A2 rs1953416 14 64948560 C 0.51 1.00 0.219 0.026 6.27E-17 
A2 rs1953417 14 64948662 C 0.92 1.00 -0.298 0.049 1.46E-09 
A2 rs883081 14 64950374 C 0.51 1.00 0.220 0.026 5.89E-17 
A2 rs883082 14 64950693 G 0.49 1.00 -0.219 0.026 7.44E-17 
A2 rs7145574 14 64954155 C 0.92 1.00 -0.298 0.049 1.45E-09 
A2 rs867972 14 64965514 C 0.50 0.97 -0.221 0.027 7.15E-17 
A2 rs11851576 14 64970036 C 0.55 0.99 -0.194 0.027 3.34E-13 
A2 rs12879971 14 64971357 G 0.51 0.99 0.222 0.026 3.19E-17 
A2 rs12892058 14 64973194 C 0.49 0.99 -0.224 0.026 1.81E-17 
A2 rs11158595 14 64976122 G 0.67 0.98 -0.159 0.028 1.96E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
A2 rs10483776 14 64984620 G 0.21 1.00 0.228 0.033 5.81E-12 
A2 rs1953418 14 64984979 G 0.33 0.98 0.159 0.028 1.69E-08 
A2 rs17826580 14 64985015 C 0.08 1.00 0.299 0.049 1.20E-09 
A2 rs2184602 14 64985425 G 0.08 1.00 0.299 0.049 1.20E-09 
A2 rs2152375 14 64985531 C 0.08 1.00 0.299 0.049 1.20E-09 
A2 rs12885842 14 64988405 C 0.34 0.98 0.156 0.028 2.48E-08 
A2 rs12589698 14 64990188 G 0.50 0.98 0.229 0.026 4.74E-18 
A2 rs4899179 14 64996501 G 0.50 0.99 -0.228 0.026 4.77E-18 
A2 rs7140695 14 64998885 C 0.67 0.99 -0.161 0.028 1.15E-08 
A2 rs2184603 14 65000423 C 0.50 0.99 -0.228 0.026 4.59E-18 
A2 rs8010726 14 65002350 G 0.33 0.99 0.161 0.028 1.07E-08 
A2 rs11850847 14 65003551 C 0.92 1.00 -0.299 0.049 1.19E-09 
A2 rs12434585 14 65008121 G 0.08 1.00 0.299 0.049 1.19E-09 
A2 rs1889731 14 65012464 C 0.67 1.00 -0.162 0.028 9.63E-09 
A2 rs1959144 14 65015804 G 0.67 1.00 -0.162 0.028 9.77E-09 
A2 rs2411820 14 65016497 C 0.33 1.00 0.162 0.028 9.02E-09 
A2 rs4902399 14 65026650 G 0.67 1.00 -0.162 0.028 9.30E-09 
A2 rs3825640 14 65030957 C 0.50 1.00 0.229 0.026 3.34E-18 
A2 rs8011224 14 65039423 T 0.33 1.00 0.162 0.028 9.33E-09 
A2 rs2898818 14 65042337 C 0.67 1.00 -0.162 0.028 9.77E-09 
A2 rs11627084 14 65048589 G 0.50 1.00 -0.228 0.026 4.55E-18 
A2 rs10483780 14 65049923 C 0.51 1.00 -0.229 0.026 3.18E-18 
A2 rs7141536 14 65057065 T 0.33 1.00 0.161 0.028 1.02E-08 
A2 rs1953415 14 65057787 G 0.68 1.00 -0.161 0.028 1.06E-08 
A2 rs10144979 14 65067391 G 0.33 1.00 0.161 0.028 1.11E-08 
A2 rs1113962 14 65075551 C 0.33 1.00 0.161 0.028 1.13E-08 
A2 rs2149841 14 65080072 C 0.50 0.99 0.228 0.026 4.53E-18 
A2 rs7153679 14 65082707 G 0.08 1.00 0.301 0.049 9.43E-10 
A2 rs11621680 14 65084434 G 0.51 1.00 -0.227 0.026 6.89E-18 
A2 rs11851013 14 65085965 G 0.08 1.00 0.301 0.049 9.37E-10 
A2 rs2411815 14 65089824 T 0.68 1.00 -0.159 0.028 1.99E-08 
A2 rs11623662 14 65090945 G 0.61 0.99 -0.172 0.027 1.83E-10 
A2 rs11851772 14 65091800 C 0.92 1.00 -0.302 0.049 9.22E-10 
A2 rs9972106 14 65092884 T 0.61 0.99 -0.171 0.027 1.89E-10 
A2 rs2898814 14 65093714 C 0.67 1.00 -0.157 0.028 2.65E-08 
A2 rs11158601 14 65095116 G 0.50 1.00 -0.224 0.026 1.48E-17 
A2 rs3783711 14 65098199 G 0.68 1.00 -0.157 0.028 2.77E-08 
A2 rs3825639 14 65098258 C 0.68 1.00 -0.157 0.028 2.67E-08 
A2 rs12433597 14 65098600 C 0.68 1.00 -0.157 0.028 2.65E-08 
A2 rs9323461 14 65101158 C 0.68 1.00 -0.157 0.028 2.59E-08 
A2 rs7147002 14 65102299 C 0.68 1.00 -0.157 0.028 2.54E-08 
A2 rs7146742 14 65102687 G 0.41 0.99 0.209 0.027 1.17E-14 
A2 rs7158153 14 65104339 C 0.32 1.00 0.157 0.028 2.44E-08 
A2 rs2183277 14 65105182 C 0.68 1.00 -0.158 0.028 2.42E-08 
A2 rs1958561 14 65106514 G 0.50 1.00 -0.224 0.026 1.27E-17 
A2 rs1958560 14 65106548 G 0.41 1.00 0.144 0.027 7.34E-08 
A2 rs10142283 14 65113882 G 0.33 1.00 0.158 0.028 2.22E-08 
A2 rs8007497 14 65114229 C 0.68 1.00 -0.158 0.028 2.24E-08 
A2 rs12887134 14 65115296 C 0.50 1.00 -0.226 0.026 9.12E-18 
A2 rs7155541 14 65115995 C 0.50 1.00 -0.226 0.026 9.02E-18 
A2 rs6573615 14 65116287 G 0.39 0.99 0.171 0.027 2.05E-10 
A2 rs6573616 14 65116569 G 0.69 0.95 -0.163 0.029 2.25E-08 
A2 rs4902404 14 65116775 C 0.68 1.00 -0.158 0.028 2.14E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
A2 rs7146993 14 65118625 C 0.32 1.00 0.162 0.028 9.02E-09 
A2 rs1958559 14 65121808 C 0.41 1.00 0.148 0.027 2.98E-08 
A2 rs7160780 14 65122466 G 0.39 1.00 0.175 0.027 8.10E-11 
A2 rs7161123 14 65122654 G 0.50 1.00 0.228 0.026 3.63E-18 
A2 rs2411356 14 65122914 G 0.39 1.00 0.175 0.027 7.97E-11 
A2 rs12433827 14 65125363 G 0.92 1.00 -0.300 0.049 1.07E-09 
A2 rs4581615 14 65125696 C 0.50 1.00 0.228 0.026 3.63E-18 
A2 rs8005309 14 65126261 T 0.92 1.00 -0.300 0.049 1.08E-09 
A2 rs17753508 14 65127205 G 0.21 1.00 0.229 0.033 4.63E-12 
A2 rs3783709 14 65128417 T 0.50 1.00 0.228 0.026 3.64E-18 
A2 rs12889002 14 65133335 C 0.50 1.00 0.228 0.026 3.64E-18 
A2 rs12587057 14 65136128 C 0.33 1.00 0.162 0.028 8.58E-09 
A2 rs2064695 14 65136841 G 0.59 1.00 -0.148 0.027 2.86E-08 
A2 rs743085 14 65137886 G 0.50 1.00 -0.228 0.026 3.64E-18 
A2 rs17826724 14 65138073 C 0.08 1.00 0.299 0.049 1.31E-09 
A2 rs11849252 14 65139522 G 0.92 1.00 -0.299 0.049 1.33E-09 
A2 rs7140341 14 65140170 C 0.33 1.00 0.165 0.028 4.46E-09 
A2 rs11158603 14 65141793 C 0.33 1.00 0.165 0.028 4.48E-09 
A2 rs17826736 14 65151955 C 0.08 1.00 0.299 0.049 1.39E-09 
A2 rs2073294 14 65152246 C 0.92 1.00 -0.299 0.049 1.40E-09 
A2 rs8012278 14 65152326 G 0.50 1.00 -0.230 0.026 1.63E-18 
A2 rs8019762 14 65156931 G 0.67 1.00 -0.165 0.028 4.48E-09 
A2 rs2268955 14 65159762 T 0.41 1.00 0.151 0.027 1.42E-08 
A2 rs2268956 14 65159898 G 0.33 1.00 0.165 0.028 4.49E-09 
A2 rs11849862 14 65167778 G 0.08 1.00 0.298 0.049 1.46E-09 
A2 rs10873191 14 65180381 C 0.67 1.00 -0.165 0.028 4.53E-09 
A2 rs7144345 14 65181594 C 0.67 1.00 -0.165 0.028 4.43E-09 
A2 rs2268957 14 65182986 C 0.92 1.00 -0.298 0.049 1.54E-09 
A2 rs12890902 14 65186375 T 0.50 1.00 0.231 0.026 1.50E-18 
A2 rs2300865 14 65189768 C 0.50 1.00 -0.230 0.026 1.49E-18 
A2 rs7144971 14 65190403 G 0.33 1.00 0.165 0.028 4.46E-09 
A2 rs10143206 14 65190428 C 0.33 1.00 0.165 0.028 4.52E-09 
A2 rs11627184 14 65191196 C 0.50 1.00 0.230 0.026 1.51E-18 
A2 rs12435908 14 65191221 C 0.92 1.00 -0.298 0.049 1.55E-09 
A2 rs11627185 14 65191245 G 0.50 1.00 -0.230 0.026 1.52E-18 
A2 rs1998035 14 65195983 G 0.08 1.00 0.298 0.049 1.55E-09 
A2 rs2268958 14 65197991 T 0.08 1.00 0.298 0.049 1.55E-09 
A2 rs7142651 14 65202474 C 0.50 1.00 0.229 0.026 2.35E-18 
A2 rs1998036 14 65207952 C 0.50 1.00 -0.229 0.026 2.46E-18 
A2 rs2268959 14 65215071 C 0.79 1.00 -0.231 0.033 3.10E-12 
A2 rs2268960 14 65215253 G 0.07 0.98 0.318 0.051 6.34E-10 
A2 rs2268961 14 65216518 C 0.50 1.00 -0.229 0.026 2.63E-18 
A2 rs2268962 14 65217026 G 0.50 1.00 -0.229 0.026 2.65E-18 
A2 rs2300871 14 65217447 C 0.08 1.00 0.298 0.049 1.56E-09 
A2 rs2300872 14 65217514 G 0.08 1.00 0.297 0.049 1.77E-09 
A2 rs2064694 14 65217999 G 0.50 1.00 0.226 0.026 7.66E-18 
A2 rs1121885 14 65226667 G 0.67 1.00 -0.160 0.028 1.46E-08 
A2 rs12588838 14 65232391 G 0.50 1.00 0.225 0.026 8.17E-18 
A2 rs8019491 14 65237863 G 0.08 1.00 0.297 0.049 1.87E-09 
A2 rs11628765 14 65238202 C 0.50 1.00 -0.225 0.026 8.74E-18 
A2 rs2411351 14 65241294 C 0.50 1.00 -0.225 0.026 9.57E-18 
A2 rs11846546 14 65246146 G 0.14 0.99 0.225 0.038 2.00E-09 
A2 rs8018278 14 65249841 G 0.50 1.00 -0.225 0.026 9.43E-18 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
A2 rs4143898 14 65258635 T 0.43 0.99 0.206 0.027 1.20E-14 
A2 rs11622829 14 65261535 T 0.49 1.00 0.224 0.026 1.49E-17 
A2 rs11624104 14 65265890 G 0.51 1.00 -0.223 0.026 2.23E-17 
A2 rs1535173 14 65268892 C 0.49 1.00 0.223 0.026 1.88E-17 
A2 rs3742597 14 65269930 G 0.28 1.00 0.291 0.030 2.50E-22 
A2 rs927004 14 65270664 C 0.51 1.00 -0.223 0.026 1.84E-17 
A2 rs1950557 14 65271510 C 0.72 1.00 -0.291 0.030 2.14E-22 
A2 rs8010876 14 65276729 G 0.51 1.00 -0.224 0.026 1.59E-17 
A2 rs1054218 14 65278943 C 0.40 1.00 0.232 0.027 9.20E-18 
A2 rs761830 14 65282739 G 0.40 1.00 0.232 0.027 9.06E-18 
A2 rs10483785 14 65289270 G 0.49 1.00 0.228 0.026 3.02E-18 
A2 rs6573624 14 65296638 G 0.49 0.98 0.231 0.026 1.95E-18 
A2 rs2411405 14 65301839 G 0.53 0.98 -0.239 0.027 2.21E-19 
A2 rs743084 14 65302355 C 0.53 0.97 -0.240 0.027 1.89E-19 
A2 rs11625362 14 65302622 G 0.47 0.98 0.239 0.027 2.16E-19 
A2 rs4080329 14 65303243 C 0.63 0.97 -0.251 0.027 7.39E-20 
A2 rs11627605 14 65304066 G 0.47 0.98 0.239 0.027 2.11E-19 
A2 rs11627578 14 65304201 C 0.47 0.98 0.239 0.027 2.09E-19 
A2 rs11628840 14 65305395 G 0.53 0.98 -0.239 0.027 2.10E-19 
A2 rs1003401 14 65307473 G 0.38 0.98 0.247 0.027 1.64E-19 
A2 rs4902416 14 65307843 C 0.53 0.98 -0.239 0.027 2.19E-19 
A2 rs1984855 14 65309010 C 0.62 0.97 -0.247 0.027 1.62E-19 
A2 rs730807 14 65309043 C 0.47 0.98 0.239 0.027 2.15E-19 
A2 rs2411404 14 65309154 C 0.47 0.97 0.239 0.027 2.13E-19 
A2 rs1075566 14 65309210 C 0.47 0.97 0.239 0.027 2.11E-19 
A2 rs7157449 14 65309890 G 0.53 0.97 -0.239 0.027 2.11E-19 
A2 rs6573625 14 65310387 C 0.63 0.97 -0.251 0.028 7.94E-20 
A2 rs6573626 14 65310448 C 0.53 0.97 -0.239 0.027 2.17E-19 
A2 rs7158556 14 65310482 T 0.37 0.97 0.251 0.028 7.71E-20 
A2 rs12894466 14 65310520 G 0.47 0.97 0.239 0.027 2.14E-19 
A2 rs11625882 14 65314952 G 0.47 0.97 0.239 0.027 2.20E-19 
A2 rs2236067 14 65317765 G 0.62 0.97 -0.247 0.027 1.67E-19 
A2 rs968540 14 65318817 G 0.63 0.97 -0.252 0.028 6.33E-20 
A2 rs7142165 14 65319985 G 0.53 0.97 -0.240 0.027 1.82E-19 
A2 rs7143026 14 65320709 G 0.39 0.95 0.241 0.028 1.90E-18 
A2 rs6573627 14 65322079 C 0.52 0.97 -0.232 0.027 2.71E-18 
A2 rs4400971 14 65324331 C 0.42 0.98 0.206 0.027 1.60E-14 
A2 rs7151846 14 65325534 C 0.51 0.98 -0.228 0.026 7.69E-18 
A2 rs4073416 14 65329147 C 0.42 0.98 0.205 0.027 1.63E-14 
A2 rs4073415 14 65329283 G 0.51 0.98 -0.228 0.026 7.92E-18 
A2 rs11850120 14 65330132 C 0.41 0.97 0.209 0.027 9.77E-15 
A2 rs8018379 14 65331690 C 0.57 0.95 -0.230 0.027 4.14E-17 
A2 rs8007846 14 65332716 G 0.47 0.98 0.176 0.027 5.48E-11 
A2 rs8006608 14 65336577 G 0.96 0.81 -0.426 0.075 1.36E-08 
A2 rs3924222 14 65343491 C 0.41 0.79 -0.199 0.030 1.75E-11 
A2 rs10149325 14 65347120 G 0.41 0.79 -0.199 0.030 1.56E-11 
A2 rs10149555 14 65347410 G 0.56 0.98 -0.145 0.026 3.38E-08 
A2 rs12878546 14 65348273 C 0.56 0.97 -0.147 0.027 3.16E-08 
A2 rs8009488 14 65349289 C 0.56 0.96 -0.147 0.027 3.51E-08 
BA rs217181 16 70671503 C 0.81 0.92 0.220 0.034 5.82E-11 
BAMS rs1820248 16 70597106 G 0.29 0.95 0.187 0.029 1.53E-10 
BAMS rs3213423 16 70600326 G 0.75 1.00 -0.203 0.030 1.35E-11 
BAMS rs152828 16 70681387 C 0.90 0.99 -0.231 0.042 3.99E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
BAMS rs30433 16 70702905 C 0.90 0.90 -0.250 0.045 2.14E-08 
TRIA rs217181 16 70671503 C 0.81 0.92 -0.225 0.034 2.47E-11 
TA rs1257189 2 134718008 C 0.73 0.88 -0.176 0.031 7.77E-09 
TA rs2593704 2 134721747 C 0.75 0.90 -0.194 0.031 4.84E-10 
TA rs1257196 2 134722302 G 0.27 0.89 0.176 0.030 7.69E-09 
TA rs1257197 2 134724206 G 0.73 0.87 -0.196 0.031 2.44E-10 
TA rs2442046 2 134730548 C 0.74 0.98 -0.187 0.029 1.79E-10 
TA rs2460382 2 134730586 G 0.26 0.98 0.187 0.029 1.80E-10 
TA rs2460383 2 134730596 C 0.74 0.98 -0.187 0.029 1.81E-10 
TA rs1257220 2 134731817 G 0.74 0.99 -0.187 0.029 1.87E-10 
TA rs1257221 2 134733088 C 0.71 0.88 -0.191 0.030 1.82E-10 
G3 rs2878404 16 70602687 C 0.32 0.99 0.153 0.028 2.62E-08 
G3 rs1465457 16 70603769 C 0.68 0.99 -0.154 0.028 2.36E-08 
G3 rs217181 16 70671503 C 0.81 0.92 -0.257 0.034 2.49E-14 
G3 rs2023929 16 70794457 G 0.88 0.99 -0.216 0.040 5.21E-08 
Chr= chromosome; Position= position (build 36); EA= effect allele; EAF= effect allele 
frequency; RSq= average imputation quality (RSq) across meta-analysis populations; SE= 
standard error of beta 






Table 25: SNP associations with P-value<1E-07 in IgG N-glycans GWAS 
analysed by UPLC. 
Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP1 rs1894204 11 67686247 C 0.59 0.88 0.179 0.033 4.28E-08 
IGP1 rs10896298 11 67688035 C 0.51 1.00 0.171 0.030 1.31E-08 
IGP1 rs4930561 11 67688337 G 0.51 1.00 0.171 0.030 1.30E-08 
IGP1 rs7931502 11 67716183 C 0.59 0.89 0.178 0.032 4.47E-08 
IGP1 rs4930564 11 67739857 G 0.41 0.86 -0.181 0.033 4.45E-08 
IGP2 rs1049110 6 32834781 C 0.35 0.98 0.185 0.034 4.44E-08 
IGP2 rs7782210 7 50319291 G 0.38 0.98 -0.187 0.032 4.12E-09 
IGP2 rs6583437 7 50320813 G 0.64 0.98 0.193 0.032 1.56E-09 
IGP2 rs7789913 7 50323241 C 0.62 1.00 0.185 0.032 4.23E-09 
IGP2 rs6421315 7 50325753 C 0.37 0.95 -0.190 0.032 4.25E-09 
IGP2 rs1122979 7 150546004 G 0.88 0.91 0.313 0.049 2.10E-10 
IGP2 rs7812088 7 150550762 G 0.87 0.98 0.298 0.047 2.72E-10 
IGP2 rs7781265 7 150581873 G 0.88 0.92 0.299 0.050 2.40E-09 
IGP2 rs1256519 14 64806077 G 0.44 0.89 -0.191 0.033 4.31E-09 
IGP2 rs7159888 14 64828395 G 0.55 0.99 -0.251 0.031 1.22E-15 
IGP2 rs12431963 14 64829447 C 0.92 0.92 -0.406 0.059 6.08E-12 
IGP2 rs1256540 14 64833822 C 0.43 1.00 0.251 0.031 1.16E-15 
IGP2 rs4902383 14 64834326 C 0.19 0.94 0.261 0.040 6.39E-11 
IGP2 rs1269068 14 64837086 C 0.57 1.00 -0.251 0.031 1.25E-15 
IGP2 rs10135194 14 64840731 C 0.94 0.84 -0.417 0.071 3.87E-09 
IGP2 rs1760978 14 64840800 G 0.43 0.98 0.280 0.031 5.17E-19 
IGP2 rs10144975 14 64843735 C 0.80 0.98 -0.275 0.038 7.11E-13 
IGP2 rs17102587 14 64844230 C 0.20 0.97 0.283 0.039 2.22E-13 
IGP2 rs8017974 14 64844940 C 0.20 0.99 0.284 0.038 1.29E-13 
IGP2 rs11847263 14 64845448 G 0.39 0.98 0.291 0.032 7.93E-20 
IGP2 rs10132229 14 64847313 G 0.10 1.00 0.373 0.051 2.69E-13 
IGP2 rs4902386 14 64848043 C 0.81 0.99 -0.284 0.038 1.16E-13 
IGP2 rs10147958 14 64848586 C 0.10 1.00 0.373 0.051 2.66E-13 
IGP2 rs8019473 14 64848881 G 0.81 0.99 -0.284 0.038 1.14E-13 
IGP2 rs10138662 14 64849235 G 0.19 0.99 0.284 0.038 1.10E-13 
IGP2 rs10134589 14 64850987 T 0.19 0.94 0.306 0.040 1.10E-14 
IGP2 rs7151212 14 64851375 C 0.81 0.99 -0.284 0.038 1.05E-13 
IGP2 rs11158587 14 64852465 G 0.81 0.99 -0.285 0.038 1.03E-13 
IGP2 rs8019767 14 64852538 G 0.81 1.00 -0.285 0.038 1.02E-13 
IGP2 rs6573598 14 64852772 C 0.19 1.00 0.285 0.038 1.01E-13 
IGP2 rs6573599 14 64852880 C 0.81 1.00 -0.285 0.038 9.79E-14 
IGP2 rs10144503 14 64853862 G 0.90 1.00 -0.374 0.051 2.43E-13 
IGP2 rs6573602 14 64854363 C 0.19 1.00 0.285 0.038 9.51E-14 
IGP2 rs17102598 14 64854613 G 0.81 1.00 -0.285 0.038 9.44E-14 
IGP2 rs12436299 14 64854947 G 0.90 1.00 -0.374 0.051 2.39E-13 
IGP2 rs6573604 14 64857694 C 0.19 1.00 0.285 0.038 9.26E-14 
IGP2 rs9635250 14 64869101 T 0.10 1.00 0.374 0.051 2.33E-13 
IGP2 rs12881755 14 64871564 G 0.65 0.96 -0.240 0.033 8.12E-13 
IGP2 rs747541 14 64875163 C 0.45 0.98 0.274 0.032 6.21E-18 
IGP2 rs1954052 14 64875462 T 0.44 0.99 0.274 0.032 5.35E-18 
IGP2 rs12436465 14 64876630 C 0.72 0.98 -0.202 0.035 1.05E-08 
IGP2 rs12886005 14 64879000 C 0.45 0.87 0.279 0.034 1.32E-16 
IGP2 rs12886168 14 64879039 C 0.45 0.98 0.274 0.032 6.16E-18 
IGP2 rs11623920 14 64889067 C 0.56 1.00 -0.274 0.032 5.30E-18 
IGP2 rs11621121 14 64892246 C 0.44 1.00 0.274 0.032 5.36E-18 
IGP2 rs10148907 14 64903125 C 0.69 0.98 -0.274 0.034 1.80E-15 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP2 rs11621604 14 64910527 G 0.56 0.98 -0.271 0.032 2.07E-17 
IGP2 rs12882269 14 64916897 G 0.56 0.97 -0.270 0.032 3.30E-17 
IGP2 rs11158591 14 64925515 C 0.44 0.97 0.268 0.032 4.29E-17 
IGP2 rs11158592 14 64929721 G 0.50 0.99 0.248 0.031 9.38E-16 
IGP2 rs11158593 14 64929737 G 0.50 0.99 0.250 0.031 4.68E-16 
IGP2 rs10138570 14 64929791 G 0.50 0.99 -0.250 0.031 4.73E-16 
IGP2 rs10138671 14 64929845 G 0.58 0.99 -0.173 0.031 3.18E-08 
IGP2 rs4587890 14 64933537 T 0.42 0.99 0.173 0.031 3.22E-08 
IGP2 rs2411823 14 64934819 C 0.42 0.99 0.173 0.031 3.27E-08 
IGP2 rs2411822 14 64948148 G 0.48 1.00 -0.233 0.031 3.88E-14 
IGP2 rs1953416 14 64948560 C 0.53 1.00 0.236 0.031 2.12E-14 
IGP2 rs883081 14 64950374 C 0.53 1.00 0.236 0.031 2.20E-14 
IGP2 rs883082 14 64950693 G 0.48 1.00 -0.233 0.031 4.07E-14 
IGP2 rs867972 14 64965514 C 0.48 0.97 -0.237 0.031 3.30E-14 
IGP2 rs11851576 14 64970036 C 0.54 0.99 -0.203 0.031 7.89E-11 
IGP2 rs12879971 14 64971357 G 0.52 0.99 0.236 0.031 2.63E-14 
IGP2 rs12892058 14 64973194 C 0.47 0.99 -0.239 0.031 1.19E-14 
IGP2 rs10483776 14 64984620 G 0.22 1.00 0.218 0.038 1.41E-08 
IGP2 rs12589698 14 64990188 G 0.52 0.98 0.244 0.031 3.92E-15 
IGP2 rs4899179 14 64996501 G 0.49 0.99 -0.242 0.031 6.33E-15 
IGP2 rs2184603 14 65000423 C 0.49 0.99 -0.242 0.031 6.21E-15 
IGP2 rs3825640 14 65030957 C 0.51 0.99 0.244 0.031 3.21E-15 
IGP2 rs11627084 14 65048589 G 0.49 1.00 -0.241 0.031 5.89E-15 
IGP2 rs10483780 14 65049923 C 0.50 0.99 -0.237 0.031 1.97E-14 
IGP2 rs2149841 14 65080072 C 0.51 0.99 0.244 0.031 3.13E-15 
IGP2 rs11621680 14 65084434 G 0.50 0.99 -0.237 0.031 1.87E-14 
IGP2 rs11623662 14 65090945 G 0.60 0.99 -0.180 0.032 1.24E-08 
IGP2 rs9972106 14 65092884 T 0.60 0.99 -0.180 0.032 1.22E-08 
IGP2 rs11158601 14 65095116 G 0.49 1.00 -0.241 0.031 5.75E-15 
IGP2 rs7146742 14 65102687 G 0.43 0.99 0.214 0.032 1.61E-11 
IGP2 rs1958561 14 65106514 G 0.49 1.00 -0.241 0.031 6.10E-15 
IGP2 rs12887134 14 65115296 C 0.49 0.99 -0.243 0.031 3.37E-15 
IGP2 rs7155541 14 65115995 C 0.49 0.99 -0.243 0.031 3.39E-15 
IGP2 rs6573615 14 65116287 G 0.40 0.99 0.180 0.032 1.25E-08 
IGP2 rs7160780 14 65122466 G 0.40 0.99 0.181 0.032 9.88E-09 
IGP2 rs7161123 14 65122654 G 0.51 1.00 0.240 0.031 5.95E-15 
IGP2 rs2411356 14 65122914 G 0.40 0.99 0.181 0.032 9.91E-09 
IGP2 rs4581615 14 65125696 C 0.51 1.00 0.240 0.031 5.94E-15 
IGP2 rs17753508 14 65127205 G 0.22 1.00 0.221 0.039 9.43E-09 
IGP2 rs3783709 14 65128417 T 0.51 1.00 0.240 0.031 5.95E-15 
IGP2 rs12889002 14 65133335 C 0.51 1.00 0.240 0.031 5.94E-15 
IGP2 rs743085 14 65137886 G 0.49 1.00 -0.240 0.031 5.94E-15 
IGP2 rs8012278 14 65152326 G 0.49 1.00 -0.246 0.031 1.64E-15 
IGP2 rs12890902 14 65186375 T 0.51 1.00 0.247 0.031 1.12E-15 
IGP2 rs2300865 14 65189768 C 0.49 1.00 -0.247 0.031 1.09E-15 
IGP2 rs11627184 14 65191196 C 0.51 1.00 0.247 0.031 1.01E-15 
IGP2 rs11627185 14 65191245 G 0.49 1.00 -0.247 0.031 9.67E-16 
IGP2 rs7142651 14 65202474 C 0.51 1.00 0.248 0.031 8.91E-16 
IGP2 rs1998036 14 65207952 C 0.49 0.99 -0.248 0.031 8.51E-16 
IGP2 rs2268959 14 65215071 C 0.78 1.00 -0.228 0.038 2.90E-09 
IGP2 rs2268960 14 65215253 G 0.07 0.97 0.327 0.061 8.97E-08 
IGP2 rs2268961 14 65216518 C 0.49 0.99 -0.249 0.031 6.84E-16 
IGP2 rs2268962 14 65217026 G 0.49 1.00 -0.249 0.031 6.68E-16 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP2 rs12588838 14 65232391 G 0.51 1.00 0.248 0.031 7.88E-16 
IGP2 rs11628765 14 65238202 C 0.49 1.00 -0.248 0.031 7.35E-16 
IGP2 rs2411351 14 65241294 C 0.49 1.00 -0.249 0.031 7.10E-16 
IGP2 rs11846546 14 65246146 G 0.14 0.99 0.251 0.045 2.22E-08 
IGP2 rs8018278 14 65249841 G 0.49 1.00 -0.249 0.031 7.06E-16 
IGP2 rs11627067 14 65252706 G 0.49 1.00 -0.249 0.031 7.03E-16 
IGP2 rs4143898 14 65258635 T 0.44 0.99 0.221 0.031 2.13E-12 
IGP2 rs11622829 14 65261535 T 0.50 1.00 0.248 0.031 9.74E-16 
IGP2 rs11624104 14 65265890 G 0.50 1.00 -0.245 0.031 2.03E-15 
IGP2 rs1535173 14 65268892 C 0.50 1.00 0.245 0.031 2.17E-15 
IGP2 rs3742597 14 65269930 G 0.29 1.00 0.281 0.035 5.60E-16 
IGP2 rs927004 14 65270664 C 0.50 1.00 -0.244 0.031 2.42E-15 
IGP2 rs1950557 14 65271510 C 0.71 1.00 -0.281 0.035 5.64E-16 
IGP2 rs8010876 14 65276729 G 0.50 1.00 -0.244 0.031 2.35E-15 
IGP2 rs1054218 14 65278943 C 0.40 1.00 0.235 0.032 1.52E-13 
IGP2 rs761830 14 65282739 G 0.40 1.00 0.235 0.032 1.53E-13 
IGP2 rs10483785 14 65289270 G 0.50 1.00 0.244 0.031 2.54E-15 
IGP2 rs6573624 14 65296638 G 0.50 0.98 0.245 0.031 3.12E-15 
IGP2 rs2411405 14 65301839 G 0.53 0.97 -0.242 0.031 8.45E-15 
IGP2 rs743084 14 65302355 C 0.52 0.97 -0.241 0.031 1.61E-14 
IGP2 rs11625362 14 65302622 G 0.47 0.97 0.242 0.031 8.70E-15 
IGP2 rs4080329 14 65303243 C 0.62 0.97 -0.237 0.032 2.66E-13 
IGP2 rs11627605 14 65304066 G 0.47 0.97 0.242 0.031 8.98E-15 
IGP2 rs11627578 14 65304201 C 0.47 0.97 0.242 0.031 9.00E-15 
IGP2 rs11628840 14 65305395 G 0.53 0.97 -0.242 0.031 9.05E-15 
IGP2 rs1003401 14 65307473 G 0.39 0.97 0.239 0.032 1.08E-13 
IGP2 rs4902416 14 65307843 C 0.53 0.97 -0.242 0.031 9.35E-15 
IGP2 rs1984855 14 65309010 C 0.61 0.97 -0.239 0.032 1.09E-13 
IGP2 rs730807 14 65309043 C 0.47 0.97 0.242 0.031 9.55E-15 
IGP2 rs2411404 14 65309154 C 0.47 0.97 0.242 0.031 9.64E-15 
IGP2 rs1075566 14 65309210 C 0.47 0.97 0.242 0.031 9.74E-15 
IGP2 rs7157449 14 65309890 G 0.53 0.97 -0.242 0.031 9.97E-15 
IGP2 rs6573625 14 65310387 C 0.62 0.97 -0.236 0.032 3.18E-13 
IGP2 rs6573626 14 65310448 C 0.53 0.97 -0.242 0.031 1.14E-14 
IGP2 rs7158556 14 65310482 T 0.38 0.97 0.236 0.032 3.23E-13 
IGP2 rs12894466 14 65310520 G 0.47 0.97 0.242 0.031 1.17E-14 
IGP2 rs11625882 14 65314952 G 0.47 0.97 0.241 0.031 1.31E-14 
IGP2 rs2236067 14 65317765 G 0.61 0.97 -0.238 0.032 1.43E-13 
IGP2 rs968540 14 65318817 G 0.62 0.96 -0.236 0.032 4.03E-13 
IGP2 rs7142165 14 65319985 G 0.53 0.96 -0.240 0.031 1.74E-14 
IGP2 rs7143026 14 65320709 G 0.40 0.95 0.220 0.033 1.38E-11 
IGP2 rs6573627 14 65322079 C 0.51 0.98 -0.226 0.031 5.67E-13 
IGP2 rs4400971 14 65324331 C 0.42 0.99 0.188 0.032 2.27E-09 
IGP2 rs7151846 14 65325534 C 0.51 0.99 -0.219 0.031 2.17E-12 
IGP2 rs4073416 14 65329147 C 0.42 0.99 0.188 0.032 2.37E-09 
IGP2 rs4073415 14 65329283 G 0.51 0.99 -0.219 0.031 2.20E-12 
IGP2 rs11850120 14 65330132 C 0.42 0.98 0.185 0.032 6.39E-09 
IGP2 rs8018379 14 65331690 C 0.56 0.95 -0.231 0.032 6.50E-13 
IGP2 rs8007846 14 65332716 G 0.48 0.98 0.186 0.031 3.00E-09 
IGP2 rs3924222 14 65343491 C 0.41 0.80 -0.244 0.035 2.68E-12 
IGP2 rs10149325 14 65347120 G 0.41 0.80 -0.245 0.035 2.17E-12 
IGP3 rs17348299 5 55358652 C 0.84 0.85 -0.266 0.045 2.39E-09 
IGP3 rs16884711 5 55360559 C 0.19 0.91 0.218 0.040 6.53E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP5 rs7812088 7 150550762 G 0.87 0.98 0.279 0.047 2.67E-09 
IGP5 rs7781265 7 150581873 G 0.88 0.92 0.286 0.050 9.71E-09 
IGP5 rs5757647 22 38104993 C 0.33 1.00 0.181 0.033 3.00E-08 
IGP5 rs4821890 22 38107469 G 0.34 0.99 0.179 0.033 4.13E-08 
IGP5 rs1010169 22 38108113 G 0.67 1.00 -0.181 0.033 2.98E-08 
IGP5 rs1010170 22 38108273 C 0.67 1.00 -0.181 0.033 3.02E-08 
IGP5 rs5757650 22 38108365 C 0.67 1.00 -0.181 0.033 3.02E-08 
IGP5 rs9611169 22 38112973 C 0.33 1.00 0.181 0.033 3.02E-08 
IGP5 rs9611170 22 38114791 C 0.66 0.99 -0.177 0.033 5.76E-08 
IGP5 rs2413590 22 38120137 C 0.67 1.00 -0.179 0.033 4.28E-08 
IGP5 rs5750808 22 38120933 G 0.33 1.00 0.179 0.033 4.38E-08 
IGP5 rs5750811 22 38123012 G 0.67 1.00 -0.178 0.033 4.52E-08 
IGP5 rs5750812 22 38123025 G 0.34 0.99 0.177 0.033 6.00E-08 
IGP5 rs5757655 22 38127124 C 0.66 0.99 -0.177 0.033 5.99E-08 
IGP5 rs4821893 22 38127725 G 0.33 1.00 0.179 0.033 4.05E-08 
IGP5 rs5750814 22 38127933 C 0.67 1.00 -0.179 0.033 3.95E-08 
IGP5 rs5757657 22 38128375 G 0.33 1.00 0.178 0.033 4.23E-08 
IGP5 rs5750815 22 38128395 C 0.67 1.00 -0.178 0.033 4.23E-08 
IGP5 rs4337572 22 38130650 C 0.33 1.00 0.178 0.033 4.26E-08 
IGP5 rs4821894 22 38139766 C 0.67 1.00 -0.178 0.033 4.28E-08 
IGP5 rs5750816 22 38140325 C 0.33 1.00 0.178 0.033 4.33E-08 
IGP5 rs5757659 22 38142355 G 0.66 1.00 -0.178 0.033 4.34E-08 
IGP5 rs6001587 22 38148954 C 0.66 1.00 -0.178 0.033 4.33E-08 
IGP5 rs5750818 22 38150831 G 0.66 1.00 -0.178 0.033 4.31E-08 
IGP5 rs5757665 22 38151587 G 0.66 1.00 -0.178 0.033 4.29E-08 
IGP5 rs4821895 22 38152961 G 0.66 1.00 -0.178 0.033 4.27E-08 
IGP5 rs739141 22 38154396 C 0.36 1.00 0.181 0.032 1.97E-08 
IGP5 rs5750820 22 38155268 G 0.67 0.97 -0.191 0.033 7.08E-09 
IGP5 rs5750822 22 38156734 G 0.34 1.00 0.179 0.033 4.01E-08 
IGP5 rs7949 22 38157499 G 0.34 0.99 0.179 0.033 3.72E-08 
IGP5 rs5757670 22 38159682 G 0.34 0.99 0.180 0.033 3.52E-08 
IGP5 rs5750825 22 38161224 G 0.71 0.98 -0.214 0.034 4.13E-10 
IGP5 rs1972280 22 38161932 T 0.29 0.98 0.215 0.034 3.43E-10 
IGP5 rs4821897 22 38165533 G 0.71 0.97 -0.216 0.034 3.27E-10 
IGP5 rs5750830 22 38170774 C 0.29 0.98 0.218 0.034 1.81E-10 
IGP5 rs5757676 22 38171646 C 0.78 0.96 -0.199 0.037 9.08E-08 
IGP5 rs8137426 22 38174296 G 0.71 0.98 -0.218 0.034 1.80E-10 
IGP5 rs5757683 22 38180120 G 0.29 0.98 0.218 0.034 1.78E-10 
IGP5 rs1557541 22 38181916 C 0.29 0.98 0.218 0.034 1.77E-10 
IGP5 rs1557542 22 38182296 C 0.71 0.98 -0.218 0.034 1.75E-10 
IGP5 rs5995735 22 38184367 C 0.29 0.98 0.218 0.034 1.73E-10 
IGP5 rs738289 22 38185829 C 0.29 0.98 0.218 0.034 1.70E-10 
IGP5 rs909674 22 38189115 C 0.30 0.99 0.218 0.034 1.10E-10 
IGP6 rs7782210 7 50319291 G 0.38 0.98 -0.176 0.032 2.49E-08 
IGP6 rs6583437 7 50320813 G 0.64 0.98 0.182 0.032 1.13E-08 
IGP6 rs7789913 7 50323241 C 0.62 1.00 0.175 0.031 2.72E-08 
IGP6 rs6421315 7 50325753 C 0.37 0.95 -0.181 0.032 1.95E-08 
IGP6 rs7159888 14 64828395 G 0.55 0.99 -0.212 0.031 8.72E-12 
IGP6 rs1256540 14 64833822 C 0.43 1.00 0.185 0.031 2.96E-09 
IGP6 rs4902383 14 64834326 C 0.19 0.94 0.244 0.040 7.13E-10 
IGP6 rs1269068 14 64837086 C 0.57 1.00 -0.184 0.031 3.42E-09 
IGP6 rs1760978 14 64840800 G 0.43 0.98 0.214 0.031 7.37E-12 
IGP6 rs10144975 14 64843735 C 0.80 0.98 -0.243 0.038 1.81E-10 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP6 rs8017974 14 64844940 C 0.20 0.99 0.255 0.038 2.01E-11 
IGP6 rs11847263 14 64845448 G 0.39 0.98 0.248 0.032 4.69E-15 
IGP6 rs10132229 14 64847313 G 0.10 1.00 0.276 0.050 4.27E-08 
IGP6 rs4902386 14 64848043 C 0.80 0.99 -0.255 0.038 1.75E-11 
IGP6 rs10147958 14 64848586 C 0.10 1.00 0.276 0.050 4.15E-08 
IGP6 rs8019473 14 64848881 G 0.80 0.99 -0.256 0.038 1.73E-11 
IGP6 rs10138662 14 64849235 G 0.20 0.99 0.256 0.038 1.65E-11 
IGP6 rs10134589 14 64850987 T 0.20 0.94 0.263 0.039 2.15E-11 
IGP6 rs7151212 14 64851375 C 0.80 0.99 -0.256 0.038 1.57E-11 
IGP6 rs11158587 14 64852465 G 0.80 0.99 -0.256 0.038 1.55E-11 
IGP6 rs8019767 14 64852538 G 0.80 1.00 -0.256 0.038 1.55E-11 
IGP6 rs6573598 14 64852772 C 0.20 1.00 0.256 0.038 1.54E-11 
IGP6 rs6573599 14 64852880 C 0.80 1.00 -0.256 0.038 1.46E-11 
IGP6 rs10144503 14 64853862 G 0.90 1.00 -0.278 0.050 3.29E-08 
IGP6 rs6573602 14 64854363 C 0.20 1.00 0.256 0.038 1.42E-11 
IGP6 rs17102598 14 64854613 G 0.80 1.00 -0.256 0.038 1.42E-11 
IGP6 rs12436299 14 64854947 G 0.90 1.00 -0.279 0.050 3.11E-08 
IGP6 rs6573604 14 64857694 C 0.20 1.00 0.256 0.038 1.41E-11 
IGP6 rs9635250 14 64869101 T 0.10 1.00 0.279 0.050 3.03E-08 
IGP6 rs747541 14 64875163 C 0.45 0.98 0.208 0.032 4.29E-11 
IGP6 rs1954052 14 64875462 T 0.44 0.99 0.205 0.031 6.85E-11 
IGP6 rs12886005 14 64879000 C 0.45 0.87 0.220 0.033 4.93E-11 
IGP6 rs12886168 14 64879039 C 0.45 0.98 0.208 0.031 4.28E-11 
IGP6 rs11623920 14 64889067 C 0.56 1.00 -0.205 0.031 6.84E-11 
IGP6 rs11621121 14 64892246 C 0.44 1.00 0.205 0.031 6.83E-11 
IGP6 rs10148907 14 64903125 C 0.69 0.98 -0.207 0.034 1.23E-09 
IGP6 rs4902393 14 64909267 C 0.56 0.99 -0.205 0.032 8.41E-11 
IGP6 rs11621604 14 64910527 G 0.56 0.98 -0.200 0.032 2.52E-10 
IGP6 rs12882269 14 64916897 G 0.56 0.97 -0.199 0.032 3.60E-10 
IGP6 rs11158591 14 64925515 C 0.44 0.97 0.198 0.032 4.39E-10 
IGP6 rs11158592 14 64929721 G 0.50 0.99 0.176 0.031 9.59E-09 
IGP6 rs11158593 14 64929737 G 0.50 0.99 0.175 0.031 1.25E-08 
IGP6 rs10138570 14 64929791 G 0.50 0.99 -0.174 0.031 1.26E-08 
IGP6 rs2411822 14 64948148 G 0.47 1.00 -0.172 0.031 1.91E-08 
IGP6 rs1953416 14 64948560 C 0.53 1.00 0.171 0.031 2.53E-08 
IGP6 rs883081 14 64950374 C 0.53 1.00 0.171 0.031 2.58E-08 
IGP6 rs883082 14 64950693 G 0.47 1.00 -0.172 0.031 1.96E-08 
IGP6 rs12879971 14 64971357 G 0.52 0.99 0.175 0.031 1.39E-08 
IGP6 rs12892058 14 64973194 C 0.47 0.99 -0.175 0.031 1.47E-08 
IGP6 rs12589698 14 64990188 G 0.52 0.98 0.179 0.031 6.75E-09 
IGP6 rs4899179 14 64996501 G 0.49 0.99 -0.181 0.031 4.00E-09 
IGP6 rs2184603 14 65000423 C 0.49 0.99 -0.181 0.031 3.91E-09 
IGP6 rs3825640 14 65030957 C 0.51 0.99 0.180 0.031 4.49E-09 
IGP6 rs11627084 14 65048589 G 0.49 1.00 -0.181 0.031 3.37E-09 
IGP6 rs10483780 14 65049923 C 0.50 0.99 -0.174 0.031 1.65E-08 
IGP6 rs2149841 14 65080072 C 0.51 0.99 0.180 0.031 4.69E-09 
IGP6 rs11621680 14 65084434 G 0.50 0.99 -0.173 0.031 1.85E-08 
IGP6 rs11158601 14 65095116 G 0.49 1.00 -0.180 0.031 4.23E-09 
IGP6 rs1958561 14 65106514 G 0.49 1.00 -0.180 0.031 4.25E-09 
IGP6 rs12887134 14 65115296 C 0.49 0.99 -0.179 0.031 5.74E-09 
IGP6 rs7155541 14 65115995 C 0.49 0.99 -0.179 0.031 5.74E-09 
IGP6 rs7161123 14 65122654 G 0.51 1.00 0.180 0.031 3.88E-09 
IGP6 rs4581615 14 65125696 C 0.51 1.00 0.180 0.031 3.87E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP6 rs12889002 14 65133335 C 0.51 1.00 0.180 0.031 3.86E-09 
IGP6 rs743085 14 65137886 G 0.49 1.00 -0.180 0.031 3.86E-09 
IGP6 rs8012278 14 65152326 G 0.49 1.00 -0.182 0.031 2.53E-09 
IGP6 rs12890902 14 65186375 T 0.51 1.00 0.183 0.031 2.40E-09 
IGP6 rs2300865 14 65189768 C 0.49 1.00 -0.183 0.031 2.39E-09 
IGP6 rs11627184 14 65191196 C 0.51 1.00 0.183 0.031 2.35E-09 
IGP6 rs11627185 14 65191245 G 0.49 1.00 -0.183 0.031 2.31E-09 
IGP6 rs7142651 14 65202474 C 0.51 1.00 0.183 0.031 2.50E-09 
IGP6 rs1998036 14 65207952 C 0.49 0.99 -0.183 0.031 2.49E-09 
IGP6 rs2268961 14 65216518 C 0.49 0.99 -0.183 0.031 2.35E-09 
IGP6 rs2268962 14 65217026 G 0.49 1.00 -0.183 0.031 2.34E-09 
IGP6 rs2064694 14 65217999 G 0.51 1.00 0.181 0.031 3.38E-09 
IGP6 rs12588838 14 65232391 G 0.51 1.00 0.181 0.031 3.38E-09 
IGP6 rs11628765 14 65238202 C 0.49 1.00 -0.181 0.031 3.35E-09 
IGP6 rs2411351 14 65241294 C 0.49 1.00 -0.181 0.031 3.37E-09 
IGP6 rs8018278 14 65249841 G 0.49 1.00 -0.181 0.031 3.45E-09 
IGP6 rs11627067 14 65252706 G 0.49 1.00 -0.181 0.031 3.50E-09 
IGP6 rs11622829 14 65261535 T 0.50 1.00 0.176 0.031 9.39E-09 
IGP6 rs11624104 14 65265890 G 0.50 1.00 -0.176 0.031 1.06E-08 
IGP6 rs1535173 14 65268892 C 0.50 1.00 0.175 0.031 1.08E-08 
IGP6 rs3742597 14 65269930 G 0.29 1.00 0.206 0.034 2.13E-09 
IGP6 rs927004 14 65270664 C 0.50 1.00 -0.175 0.031 1.23E-08 
IGP6 rs1950557 14 65271510 C 0.71 1.00 -0.206 0.034 2.23E-09 
IGP6 rs8010876 14 65276729 G 0.50 1.00 -0.175 0.031 1.25E-08 
IGP6 rs10483785 14 65289270 G 0.50 1.00 0.172 0.031 2.15E-08 
IGP6 rs6573624 14 65296638 G 0.50 0.98 0.171 0.031 3.19E-08 
IGP6 rs2411405 14 65301839 G 0.52 0.97 -0.177 0.031 1.09E-08 
IGP6 rs743084 14 65302355 C 0.52 0.97 -0.181 0.031 6.46E-09 
IGP6 rs11625362 14 65302622 G 0.48 0.97 0.177 0.031 1.16E-08 
IGP6 rs11627605 14 65304066 G 0.48 0.97 0.177 0.031 1.21E-08 
IGP6 rs11627578 14 65304201 C 0.48 0.97 0.177 0.031 1.22E-08 
IGP6 rs11628840 14 65305395 G 0.52 0.97 -0.177 0.031 1.23E-08 
IGP6 rs4902416 14 65307843 C 0.52 0.97 -0.177 0.031 1.27E-08 
IGP6 rs730807 14 65309043 C 0.48 0.97 0.177 0.031 1.30E-08 
IGP6 rs2411404 14 65309154 C 0.48 0.97 0.176 0.031 1.32E-08 
IGP6 rs1075566 14 65309210 C 0.48 0.97 0.176 0.031 1.32E-08 
IGP6 rs7157449 14 65309890 G 0.52 0.97 -0.176 0.031 1.35E-08 
IGP6 rs6573626 14 65310448 C 0.52 0.97 -0.176 0.031 1.48E-08 
IGP6 rs12894466 14 65310520 G 0.48 0.97 0.176 0.031 1.50E-08 
IGP6 rs11625882 14 65314952 G 0.48 0.97 0.176 0.031 1.60E-08 
IGP6 rs7142165 14 65319985 G 0.52 0.96 -0.175 0.031 1.90E-08 
IGP6 rs8006608 14 65336577 G 0.96 0.81 -0.478 0.086 2.64E-08 
IGP7 rs404256 6 90714504 C 0.56 0.70 -0.209 0.036 7.49E-09 
IGP9 rs17630758 22 22466542 G 0.83 0.99 0.298 0.041 4.85E-13 
IGP9 rs12167679 22 22471690 C 0.80 1.00 0.219 0.039 1.52E-08 
IGP9 rs17548631 22 22474125 C 0.17 0.99 -0.298 0.041 4.65E-13 
IGP9 rs9620326 22 22476629 C 0.83 0.99 0.298 0.041 4.73E-13 
IGP9 rs9624334 22 22496256 C 0.17 0.99 -0.301 0.041 3.59E-13 
IGP9 rs2186369 22 22500996 G 0.19 0.88 -0.304 0.042 3.00E-13 
IGP9 rs5757642 22 38094770 C 0.64 1.00 -0.180 0.033 3.33E-08 
IGP9 rs7286714 22 38095550 C 0.36 0.97 0.178 0.033 5.71E-08 
IGP9 rs5757644 22 38096386 C 0.36 0.97 0.178 0.033 5.69E-08 
IGP9 rs5750806 22 38096957 G 0.64 0.97 -0.178 0.033 5.72E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP9 rs4821888 22 38100543 G 0.64 0.97 -0.182 0.033 3.64E-08 
IGP9 rs5750825 22 38161224 G 0.71 0.98 -0.198 0.034 8.43E-09 
IGP9 rs1972280 22 38161932 T 0.29 0.98 0.199 0.034 7.54E-09 
IGP9 rs4821897 22 38165533 G 0.71 0.97 -0.199 0.034 7.07E-09 
IGP9 rs5750830 22 38170774 C 0.29 0.98 0.199 0.034 6.97E-09 
IGP9 rs8137426 22 38174296 G 0.71 0.98 -0.199 0.034 6.85E-09 
IGP9 rs5757683 22 38180120 G 0.29 0.98 0.199 0.034 6.80E-09 
IGP9 rs1557541 22 38181916 C 0.29 0.98 0.198 0.034 6.84E-09 
IGP9 rs1557542 22 38182296 C 0.71 0.98 -0.198 0.034 6.82E-09 
IGP9 rs5995735 22 38184367 C 0.29 0.98 0.198 0.034 6.78E-09 
IGP9 rs738289 22 38185829 C 0.29 0.98 0.198 0.034 6.78E-09 
IGP9 rs909674 22 38189115 C 0.30 0.99 0.201 0.034 2.80E-09 
IGP10 rs17630758 22 22466542 G 0.83 0.99 0.237 0.041 9.92E-09 
IGP10 rs17548631 22 22474125 C 0.17 0.99 -0.236 0.041 1.01E-08 
IGP10 rs9620326 22 22476629 C 0.83 0.99 0.236 0.041 1.01E-08 
IGP10 rs9624334 22 22496256 C 0.17 0.99 -0.235 0.042 1.52E-08 
IGP10 rs2186369 22 22500996 G 0.19 0.88 -0.256 0.042 9.32E-10 
IGP11 rs7159888 14 64828395 G 0.55 0.99 -0.208 0.031 2.43E-11 
IGP11 rs1256540 14 64833822 C 0.43 1.00 0.169 0.031 6.23E-08 
IGP11 rs4902383 14 64834326 C 0.19 0.94 0.241 0.040 1.45E-09 
IGP11 rs1269068 14 64837086 C 0.57 1.00 -0.168 0.031 7.10E-08 
IGP11 rs1760978 14 64840800 G 0.43 0.98 0.198 0.031 2.62E-10 
IGP11 rs10144975 14 64843735 C 0.80 0.98 -0.238 0.038 4.69E-10 
IGP11 rs17102587 14 64844230 C 0.20 0.97 0.245 0.038 1.79E-10 
IGP11 rs8017974 14 64844940 C 0.20 0.99 0.247 0.038 1.08E-10 
IGP11 rs11847263 14 64845448 G 0.39 0.98 0.238 0.032 7.27E-14 
IGP11 rs4902386 14 64848043 C 0.80 0.99 -0.246 0.038 1.03E-10 
IGP11 rs8019473 14 64848881 G 0.80 0.99 -0.246 0.038 1.02E-10 
IGP11 rs10138662 14 64849235 G 0.20 0.99 0.247 0.038 9.82E-11 
IGP11 rs10134589 14 64850987 T 0.19 0.94 0.259 0.039 5.28E-11 
IGP11 rs7151212 14 64851375 C 0.80 0.99 -0.247 0.038 9.45E-11 
IGP11 rs11158587 14 64852465 G 0.80 0.99 -0.247 0.038 9.43E-11 
IGP11 rs8019767 14 64852538 G 0.80 1.00 -0.247 0.038 9.47E-11 
IGP11 rs6573598 14 64852772 C 0.20 1.00 0.247 0.038 9.45E-11 
IGP11 rs6573599 14 64852880 C 0.80 1.00 -0.247 0.038 9.01E-11 
IGP11 rs6573602 14 64854363 C 0.20 1.00 0.247 0.038 8.81E-11 
IGP11 rs17102598 14 64854613 G 0.80 1.00 -0.247 0.038 8.87E-11 
IGP11 rs6573604 14 64857694 C 0.20 1.00 0.247 0.038 8.87E-11 
IGP11 rs747541 14 64875163 C 0.45 0.98 0.206 0.032 6.84E-11 
IGP11 rs1954052 14 64875462 T 0.44 0.99 0.203 0.032 1.15E-10 
IGP11 rs12886005 14 64879000 C 0.45 0.87 0.215 0.034 1.45E-10 
IGP11 rs12886168 14 64879039 C 0.45 0.98 0.206 0.032 6.66E-11 
IGP11 rs11623920 14 64889067 C 0.56 1.00 -0.203 0.032 1.12E-10 
IGP11 rs11621121 14 64892246 C 0.44 1.00 0.203 0.031 1.12E-10 
IGP11 rs10148907 14 64903125 C 0.69 0.98 -0.208 0.034 1.28E-09 
IGP11 rs4902393 14 64909267 C 0.56 0.99 -0.203 0.032 1.47E-10 
IGP11 rs11621604 14 64910527 G 0.56 0.98 -0.198 0.032 4.63E-10 
IGP11 rs12882269 14 64916897 G 0.56 0.97 -0.196 0.032 6.87E-10 
IGP11 rs11158591 14 64925515 C 0.44 0.97 0.195 0.032 8.58E-10 
IGP11 rs12879971 14 64971357 G 0.52 0.99 0.165 0.031 8.45E-08 
IGP11 rs12589698 14 64990188 G 0.52 0.98 0.174 0.031 2.06E-08 
IGP11 rs4899179 14 64996501 G 0.49 0.99 -0.176 0.031 1.12E-08 
IGP11 rs2184603 14 65000423 C 0.49 0.99 -0.177 0.031 1.04E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP11 rs11627084 14 65048589 G 0.49 1.00 -0.177 0.031 8.26E-09 
IGP11 rs10483780 14 65049923 C 0.50 0.99 -0.171 0.031 2.99E-08 
IGP11 rs2149841 14 65080072 C 0.51 0.99 0.175 0.031 1.28E-08 
IGP11 rs11621680 14 65084434 G 0.50 0.99 -0.170 0.031 3.21E-08 
IGP11 rs11158601 14 65095116 G 0.49 1.00 -0.176 0.031 9.40E-09 
IGP11 rs1958561 14 65106514 G 0.49 1.00 -0.176 0.031 9.25E-09 
IGP11 rs12887134 14 65115296 C 0.49 0.99 -0.175 0.031 1.40E-08 
IGP11 rs7155541 14 65115995 C 0.49 0.99 -0.175 0.031 1.40E-08 
IGP11 rs7161123 14 65122654 G 0.51 1.00 0.177 0.031 8.22E-09 
IGP11 rs4581615 14 65125696 C 0.51 1.00 0.177 0.031 8.23E-09 
IGP11 rs3783709 14 65128417 T 0.51 1.00 0.177 0.031 8.25E-09 
IGP11 rs12889002 14 65133335 C 0.51 1.00 0.177 0.031 8.27E-09 
IGP11 rs743085 14 65137886 G 0.49 1.00 -0.177 0.031 8.29E-09 
IGP11 rs8012278 14 65152326 G 0.49 1.00 -0.178 0.031 6.43E-09 
IGP11 rs12890902 14 65186375 T 0.51 1.00 0.178 0.031 6.86E-09 
IGP11 rs2300865 14 65189768 C 0.49 1.00 -0.178 0.031 6.89E-09 
IGP11 rs11627184 14 65191196 C 0.51 1.00 0.178 0.031 6.83E-09 
IGP11 rs11627185 14 65191245 G 0.49 1.00 -0.178 0.031 6.75E-09 
IGP11 rs7142651 14 65202474 C 0.51 1.00 0.177 0.031 7.63E-09 
IGP11 rs1998036 14 65207952 C 0.49 0.99 -0.177 0.031 7.65E-09 
IGP11 rs2268961 14 65216518 C 0.49 0.99 -0.178 0.031 7.37E-09 
IGP11 rs2268962 14 65217026 G 0.49 1.00 -0.178 0.031 7.35E-09 
IGP11 rs2064694 14 65217999 G 0.51 1.00 0.175 0.031 1.14E-08 
IGP11 rs12588838 14 65232391 G 0.51 1.00 0.175 0.031 1.14E-08 
IGP11 rs11628765 14 65238202 C 0.49 1.00 -0.175 0.031 1.14E-08 
IGP11 rs2411351 14 65241294 C 0.49 1.00 -0.175 0.031 1.16E-08 
IGP11 rs8018278 14 65249841 G 0.49 1.00 -0.175 0.031 1.20E-08 
IGP11 rs11627067 14 65252706 G 0.49 1.00 -0.175 0.031 1.24E-08 
IGP11 rs11622829 14 65261535 T 0.50 1.00 0.168 0.031 4.83E-08 
IGP11 rs11624104 14 65265890 G 0.50 1.00 -0.170 0.031 3.53E-08 
IGP11 rs1535173 14 65268892 C 0.50 1.00 0.168 0.031 4.38E-08 
IGP11 rs3742597 14 65269930 G 0.29 1.00 0.201 0.035 5.91E-09 
IGP11 rs927004 14 65270664 C 0.50 1.00 -0.167 0.031 4.94E-08 
IGP11 rs1950557 14 65271510 C 0.71 1.00 -0.201 0.035 6.09E-09 
IGP11 rs8010876 14 65276729 G 0.50 1.00 -0.167 0.031 4.96E-08 
IGP11 rs10483785 14 65289270 G 0.50 1.00 0.165 0.031 7.00E-08 
IGP11 rs6573624 14 65296638 G 0.50 0.98 0.166 0.031 7.62E-08 
IGP11 rs2411405 14 65301839 G 0.53 0.97 -0.177 0.031 1.16E-08 
IGP11 rs743084 14 65302355 C 0.52 0.97 -0.177 0.031 1.32E-08 
IGP11 rs11625362 14 65302622 G 0.47 0.97 0.177 0.031 1.20E-08 
IGP11 rs11627605 14 65304066 G 0.47 0.97 0.177 0.031 1.23E-08 
IGP11 rs11627578 14 65304201 C 0.47 0.97 0.177 0.031 1.24E-08 
IGP11 rs11628840 14 65305395 G 0.53 0.97 -0.177 0.031 1.24E-08 
IGP11 rs4902416 14 65307843 C 0.53 0.97 -0.177 0.031 1.26E-08 
IGP11 rs730807 14 65309043 C 0.47 0.97 0.177 0.031 1.27E-08 
IGP11 rs2411404 14 65309154 C 0.47 0.97 0.177 0.031 1.28E-08 
IGP11 rs1075566 14 65309210 C 0.47 0.97 0.177 0.031 1.28E-08 
IGP11 rs7157449 14 65309890 G 0.52 0.97 -0.177 0.031 1.29E-08 
IGP11 rs6573626 14 65310448 C 0.52 0.97 -0.177 0.031 1.33E-08 
IGP11 rs12894466 14 65310520 G 0.48 0.97 0.177 0.031 1.34E-08 
IGP11 rs11625882 14 65314952 G 0.48 0.97 0.177 0.031 1.37E-08 
IGP11 rs7142165 14 65319985 G 0.52 0.96 -0.177 0.031 1.44E-08 
IGP11 rs6573627 14 65322079 C 0.51 0.98 -0.171 0.031 3.99E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP11 rs4073415 14 65329283 G 0.51 0.99 -0.170 0.031 3.98E-08 
IGP13 rs17348299 5 55358652 C 0.84 0.85 0.287 0.045 1.27E-10 
IGP13 rs16884711 5 55360559 C 0.19 0.91 -0.242 0.041 2.63E-09 
IGP13 rs10454831 5 55374548 T 0.80 0.90 0.224 0.040 2.35E-08 
IGP13 rs955768 5 55374759 T 0.20 0.90 -0.225 0.040 2.32E-08 
IGP13 rs12342831 9 33114872 C 0.26 0.97 -0.193 0.036 5.19E-08 
IGP13 rs10813951 9 33118021 G 0.26 0.97 -0.193 0.036 5.19E-08 
IGP13 rs2067749 9 33120640 G 0.11 0.98 0.270 0.050 6.91E-08 
IGP13 rs10511909 9 33122518 C 0.11 0.98 0.270 0.050 7.10E-08 
IGP13 rs3780486 9 33129453 C 0.74 0.97 0.194 0.036 5.13E-08 
IGP13 rs10813957 9 33143527 G 0.74 0.96 0.196 0.036 4.73E-08 
IGP14 rs17776120 3 188215373 C 0.64 0.80 -0.216 0.035 5.98E-10 
IGP14 rs3821819 3 188215419 G 0.63 0.81 -0.213 0.035 7.02E-10 
IGP14 rs967367 3 188217160 G 0.63 0.81 -0.213 0.035 6.75E-10 
IGP14 rs278541 8 94292121 C 0.98 0.50 -0.802 0.146 4.24E-08 
IGP14 rs9624334 22 22496256 C 0.17 0.99 -0.225 0.041 4.93E-08 
IGP14 rs2186369 22 22500996 G 0.19 0.88 -0.229 0.042 3.40E-08 
IGP15 rs11923417 3 188188484 C 0.60 0.45 -0.314 0.046 1.04E-11 
IGP15 rs759602 3 188191498 G 0.78 0.98 -0.200 0.037 6.59E-08 
IGP15 rs4012171 3 188194147 C 0.75 0.75 -0.297 0.040 2.04E-13 
IGP15 rs16848727 3 188195657 G 0.25 0.71 -0.520 0.042 8.08E-36 
IGP15 rs13322676 3 188201439 C 0.28 0.87 -0.492 0.036 7.06E-42 
IGP15 rs6808800 3 188202068 G 0.51 0.85 -0.323 0.033 5.02E-23 
IGP15 rs17775791 3 188205056 C 0.28 0.89 -0.492 0.036 2.62E-42 
IGP15 rs7617523 3 188205144 G 0.34 0.89 -0.399 0.034 6.56E-32 
IGP15 rs7652995 3 188205638 G 0.18 0.83 0.391 0.044 5.43E-19 
IGP15 rs6764279 3 188206669 C 0.71 0.95 0.489 0.035 1.59E-45 
IGP15 rs6788832 3 188206913 G 0.34 0.89 -0.397 0.034 6.15E-32 
IGP15 rs3872721 3 188208185 G 0.24 0.89 0.384 0.038 3.62E-24 
IGP15 rs11710456 3 188208581 G 0.70 0.88 0.498 0.035 2.05E-45 
IGP15 rs3872722 3 188208971 C 0.41 0.89 0.328 0.033 2.09E-23 
IGP15 rs7621161 3 188209864 C 0.72 0.94 0.491 0.035 1.68E-45 
IGP15 rs10937278 3 188210509 T 0.23 0.94 0.372 0.037 2.99E-23 
IGP15 rs10937279 3 188210530 G 0.77 0.94 -0.371 0.037 3.14E-23 
IGP15 rs7619468 3 188210872 C 0.77 0.94 -0.371 0.037 3.21E-23 
IGP15 rs4686830 3 188211259 G 0.77 0.96 -0.368 0.037 4.81E-23 
IGP15 rs10804908 3 188211536 T 0.23 0.96 0.367 0.037 5.05E-23 
IGP15 rs4686834 3 188211848 G 0.77 0.97 -0.364 0.037 6.92E-23 
IGP15 rs4686835 3 188211912 C 0.23 0.97 0.364 0.037 7.40E-23 
IGP15 rs4686836 3 188212059 C 0.23 0.97 0.363 0.037 7.81E-23 
IGP15 rs4012256 3 188213035 C 0.77 0.97 -0.363 0.037 8.30E-23 
IGP15 rs4012257 3 188213090 C 0.77 0.98 -0.362 0.037 8.69E-23 
IGP15 rs7619989 3 188214443 C 0.59 0.89 -0.322 0.033 8.24E-23 
IGP15 rs17776120 3 188215373 C 0.64 0.80 0.430 0.035 2.53E-34 
IGP15 rs3821819 3 188215419 G 0.63 0.81 0.432 0.035 2.28E-35 
IGP15 rs6444193 3 188216882 G 0.23 0.99 0.359 0.037 1.31E-22 
IGP15 rs967367 3 188217160 G 0.63 0.81 0.432 0.035 2.92E-35 
IGP15 rs4686837 3 188222371 G 0.70 0.86 0.287 0.036 1.62E-15 
IGP15 rs9941987 3 188225221 G 0.18 0.79 0.364 0.045 1.18E-15 
IGP15 rs4686838 3 188225747 G 0.45 0.71 -0.233 0.036 1.12E-10 
IGP15 rs16861533 3 188237416 G 0.84 0.67 0.399 0.050 2.42E-15 
IGP15 rs2268536 3 188239602 G 0.16 0.68 -0.391 0.050 7.40E-15 
IGP15 rs9876699 3 188248791 C 0.56 0.92 -0.174 0.033 8.91E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP17 rs17775791 3 188205056 C 0.28 0.89 -0.192 0.036 9.32E-08 
IGP17 rs6764279 3 188206669 C 0.71 0.95 0.191 0.034 2.70E-08 
IGP17 rs11710456 3 188208581 G 0.70 0.88 0.200 0.035 1.18E-08 
IGP17 rs7621161 3 188209864 C 0.71 0.94 0.192 0.035 2.79E-08 
IGP17 rs3818593 9 33110706 G 0.20 1.00 -0.232 0.039 2.68E-09 
IGP17 rs10971418 9 33112024 C 0.80 0.98 0.231 0.039 3.23E-09 
IGP17 rs10113903 9 33112645 C 0.31 0.99 -0.193 0.034 1.31E-08 
IGP17 rs10738905 9 33113627 G 0.31 0.99 -0.192 0.034 1.39E-08 
IGP17 rs10971419 9 33114161 C 0.31 0.99 -0.191 0.034 1.54E-08 
IGP17 rs12342831 9 33114872 C 0.26 0.97 -0.237 0.036 2.70E-11 
IGP17 rs10758189 9 33115804 C 0.31 0.92 -0.193 0.035 3.35E-08 
IGP17 rs10813950 9 33117640 G 0.69 1.00 0.190 0.034 1.64E-08 
IGP17 rs10813951 9 33118021 G 0.26 0.97 -0.236 0.036 2.74E-11 
IGP17 rs3780490 9 33119839 G 0.31 1.00 -0.190 0.034 1.65E-08 
IGP17 rs2067749 9 33120640 G 0.11 0.98 0.283 0.050 1.53E-08 
IGP17 rs10758192 9 33121651 G 0.69 1.00 0.190 0.034 1.66E-08 
IGP17 rs10511909 9 33122518 C 0.11 0.98 0.283 0.050 1.57E-08 
IGP17 rs913214 9 33125085 G 0.69 1.00 0.190 0.034 1.68E-08 
IGP17 rs10738906 9 33125634 C 0.31 1.00 -0.190 0.034 1.69E-08 
IGP17 rs10124479 9 33126233 G 0.31 1.00 -0.190 0.034 1.70E-08 
IGP17 rs10813954 9 33127596 C 0.31 1.00 -0.190 0.034 1.71E-08 
IGP17 rs3780486 9 33129453 C 0.74 0.97 0.237 0.036 2.77E-11 
IGP17 rs7864705 9 33130352 C 0.31 1.00 -0.190 0.034 1.72E-08 
IGP17 rs7865745 9 33130976 G 0.69 1.00 0.190 0.034 1.72E-08 
IGP17 rs7873903 9 33132728 G 0.69 0.99 0.191 0.034 1.73E-08 
IGP17 rs3824458 9 33134809 C 0.69 0.99 0.191 0.034 1.66E-08 
IGP17 rs10813957 9 33143527 G 0.74 0.96 0.239 0.036 2.78E-11 
IGP17 rs10971438 9 33170308 G 0.30 0.75 -0.251 0.039 9.27E-11 
IGP17 rs10813960 9 33170362 C 0.70 0.74 0.252 0.039 9.01E-11 
IGP17 rs10971439 9 33170813 C 0.23 0.71 -0.260 0.043 2.06E-09 
IGP17 rs4878639 9 36089399 C 0.26 0.95 -0.196 0.036 3.51E-08 
IGP22 rs5750825 22 38161224 G 0.71 0.98 0.197 0.034 1.01E-08 
IGP22 rs1972280 22 38161932 T 0.29 0.98 -0.198 0.034 9.01E-09 
IGP22 rs4821897 22 38165533 G 0.71 0.97 0.198 0.034 8.68E-09 
IGP22 rs5750830 22 38170774 C 0.29 0.98 -0.203 0.034 3.45E-09 
IGP22 rs8137426 22 38174296 G 0.71 0.98 0.203 0.034 3.34E-09 
IGP22 rs5757683 22 38180120 G 0.29 0.98 -0.202 0.034 3.34E-09 
IGP22 rs1557541 22 38181916 C 0.29 0.98 -0.202 0.034 3.34E-09 
IGP22 rs1557542 22 38182296 C 0.71 0.98 0.202 0.034 3.32E-09 
IGP22 rs5995735 22 38184367 C 0.29 0.98 -0.202 0.034 3.30E-09 
IGP22 rs738289 22 38185829 C 0.29 0.98 -0.202 0.034 3.27E-09 
IGP22 rs909674 22 38189115 C 0.30 0.99 -0.210 0.034 5.33E-10 
IGP23 rs16848727 3 188195657 G 0.25 0.71 -0.227 0.041 4.39E-08 
IGP23 rs13322676 3 188201439 C 0.28 0.87 -0.218 0.036 1.58E-09 
IGP23 rs17775791 3 188205056 C 0.28 0.89 -0.220 0.036 9.07E-10 
IGP23 rs7617523 3 188205144 G 0.34 0.89 -0.202 0.034 2.11E-09 
IGP23 rs6764279 3 188206669 C 0.71 0.95 0.227 0.034 4.11E-11 
IGP23 rs6788832 3 188206913 G 0.34 0.89 -0.202 0.034 1.82E-09 
IGP23 rs11710456 3 188208581 G 0.70 0.88 0.230 0.035 5.92E-11 
IGP23 rs7621161 3 188209864 C 0.72 0.94 0.228 0.035 3.92E-11 
IGP23 rs17776120 3 188215373 C 0.64 0.80 0.203 0.035 7.64E-09 
IGP23 rs3821819 3 188215419 G 0.63 0.81 0.200 0.035 8.28E-09 
IGP23 rs967367 3 188217160 G 0.63 0.81 0.200 0.035 8.78E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP24 rs11923417 3 188188484 C 0.60 0.45 -0.258 0.046 1.72E-08 
IGP24 rs759602 3 188191498 G 0.78 0.98 -0.198 0.037 6.71E-08 
IGP24 rs4012171 3 188194147 C 0.75 0.75 -0.264 0.040 4.59E-11 
IGP24 rs16848727 3 188195657 G 0.25 0.71 -0.429 0.041 2.65E-25 
IGP24 rs13322676 3 188201439 C 0.28 0.87 -0.406 0.036 1.70E-29 
IGP24 rs6808800 3 188202068 G 0.51 0.85 -0.273 0.032 3.66E-17 
IGP24 rs17775791 3 188205056 C 0.28 0.89 -0.406 0.036 9.08E-30 
IGP24 rs7617523 3 188205144 G 0.34 0.89 -0.351 0.034 1.47E-25 
IGP24 rs7652995 3 188205638 G 0.18 0.83 0.353 0.043 4.46E-16 
IGP24 rs6764279 3 188206669 C 0.71 0.95 0.396 0.034 5.33E-31 
IGP24 rs6788832 3 188206913 G 0.34 0.89 -0.350 0.033 1.41E-25 
IGP24 rs3872721 3 188208185 G 0.24 0.89 0.300 0.038 1.15E-15 
IGP24 rs11710456 3 188208581 G 0.70 0.88 0.405 0.035 4.30E-31 
IGP24 rs3872722 3 188208971 C 0.41 0.89 0.275 0.033 3.29E-17 
IGP24 rs7621161 3 188209864 C 0.71 0.94 0.398 0.034 5.13E-31 
IGP24 rs10937278 3 188210509 T 0.23 0.94 0.293 0.037 2.70E-15 
IGP24 rs10937279 3 188210530 G 0.77 0.94 -0.292 0.037 2.77E-15 
IGP24 rs7619468 3 188210872 C 0.77 0.94 -0.292 0.037 2.80E-15 
IGP24 rs4686830 3 188211259 G 0.77 0.96 -0.290 0.037 3.01E-15 
IGP24 rs10804908 3 188211536 T 0.23 0.96 0.290 0.037 3.08E-15 
IGP24 rs4686834 3 188211848 G 0.77 0.97 -0.288 0.037 3.71E-15 
IGP24 rs4686835 3 188211912 C 0.23 0.97 0.287 0.037 3.84E-15 
IGP24 rs4686836 3 188212059 C 0.23 0.97 0.287 0.037 3.93E-15 
IGP24 rs4012256 3 188213035 C 0.77 0.97 -0.287 0.037 4.08E-15 
IGP24 rs4012257 3 188213090 C 0.77 0.98 -0.286 0.036 4.19E-15 
IGP24 rs7619989 3 188214443 C 0.59 0.89 -0.270 0.032 6.64E-17 
IGP24 rs17776120 3 188215373 C 0.64 0.80 0.355 0.035 2.52E-24 
IGP24 rs3821819 3 188215419 G 0.63 0.81 0.356 0.034 5.32E-25 
IGP24 rs6444193 3 188216882 G 0.23 0.99 0.284 0.036 5.33E-15 
IGP24 rs967367 3 188217160 G 0.63 0.81 0.355 0.035 7.07E-25 
IGP24 rs4686837 3 188222371 G 0.70 0.86 0.245 0.036 6.09E-12 
IGP24 rs9941987 3 188225221 G 0.18 0.79 0.338 0.045 4.54E-14 
IGP24 rs4686838 3 188225747 G 0.45 0.71 -0.204 0.036 1.01E-08 
IGP24 rs16861533 3 188237416 G 0.84 0.67 0.343 0.050 6.69E-12 
IGP24 rs2268536 3 188239602 G 0.16 0.68 -0.336 0.050 1.56E-11 
IGP24 rs257101 3 188261522 C 0.23 0.49 -0.346 0.050 3.94E-12 
IGP24 rs10113903 9 33112645 C 0.31 0.99 -0.202 0.034 2.23E-09 
IGP24 rs10738905 9 33113627 G 0.31 0.99 -0.202 0.034 2.35E-09 
IGP24 rs10971419 9 33114161 C 0.31 0.99 -0.201 0.034 2.57E-09 
IGP24 rs12342831 9 33114872 C 0.26 0.97 -0.223 0.035 2.70E-10 
IGP24 rs10758189 9 33115804 C 0.31 0.92 -0.200 0.035 9.83E-09 
IGP24 rs10813950 9 33117640 G 0.69 1.00 0.200 0.034 2.76E-09 
IGP24 rs10813951 9 33118021 G 0.26 0.97 -0.223 0.035 2.79E-10 
IGP24 rs3780490 9 33119839 G 0.31 1.00 -0.200 0.034 2.84E-09 
IGP24 rs10758192 9 33121651 G 0.69 1.00 0.200 0.034 2.91E-09 
IGP24 rs913214 9 33125085 G 0.69 1.00 0.199 0.034 3.14E-09 
IGP24 rs10738906 9 33125634 C 0.31 1.00 -0.199 0.034 3.21E-09 
IGP24 rs10124479 9 33126233 G 0.31 1.00 -0.199 0.034 3.26E-09 
IGP24 rs10813954 9 33127596 C 0.31 1.00 -0.199 0.034 3.38E-09 
IGP24 rs10971424 9 33128775 C 0.34 0.90 -0.184 0.034 9.46E-08 
IGP24 rs3780486 9 33129453 C 0.74 0.97 0.223 0.035 3.27E-10 
IGP24 rs7864705 9 33130352 C 0.31 1.00 -0.199 0.034 3.40E-09 
IGP24 rs7865745 9 33130976 G 0.69 1.00 0.199 0.034 3.40E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP24 rs3824458 9 33134809 C 0.69 0.99 0.200 0.034 3.35E-09 
IGP24 rs10813957 9 33143527 G 0.74 0.96 0.224 0.036 3.56E-10 
IGP24 rs10971438 9 33170308 G 0.30 0.75 -0.238 0.039 7.30E-10 
IGP24 rs10813960 9 33170362 C 0.70 0.74 0.238 0.039 7.17E-10 
IGP26 rs16848727 3 188195657 G 0.25 0.71 -0.268 0.041 1.02E-10 
IGP26 rs13322676 3 188201439 C 0.28 0.87 -0.251 0.036 3.63E-12 
IGP26 rs17775791 3 188205056 C 0.28 0.89 -0.252 0.036 2.32E-12 
IGP26 rs7617523 3 188205144 G 0.34 0.89 -0.221 0.034 5.55E-11 
IGP26 rs6764279 3 188206669 C 0.71 0.95 0.249 0.034 3.89E-13 
IGP26 rs6788832 3 188206913 G 0.34 0.89 -0.220 0.034 5.16E-11 
IGP26 rs11710456 3 188208581 G 0.70 0.88 0.256 0.035 2.47E-13 
IGP26 rs7621161 3 188209864 C 0.71 0.94 0.250 0.034 4.10E-13 
IGP26 rs17776120 3 188215373 C 0.64 0.80 0.202 0.035 7.72E-09 
IGP26 rs3821819 3 188215419 G 0.63 0.81 0.204 0.035 3.95E-09 
IGP26 rs967367 3 188217160 G 0.63 0.81 0.203 0.035 4.51E-09 
IGP26 rs3818593 9 33110706 G 0.20 1.00 -0.231 0.039 2.81E-09 
IGP26 rs10971418 9 33112024 C 0.80 0.98 0.230 0.039 3.31E-09 
IGP26 rs10113903 9 33112645 C 0.31 0.99 -0.194 0.034 9.24E-09 
IGP26 rs10738905 9 33113627 G 0.31 0.99 -0.194 0.034 9.69E-09 
IGP26 rs10971419 9 33114161 C 0.31 0.99 -0.193 0.034 1.05E-08 
IGP26 rs12342831 9 33114872 C 0.26 0.97 -0.236 0.035 2.96E-11 
IGP26 rs10758189 9 33115804 C 0.31 0.92 -0.194 0.035 2.52E-08 
IGP26 rs10813950 9 33117640 G 0.69 1.00 0.192 0.034 1.12E-08 
IGP26 rs10813951 9 33118021 G 0.26 0.97 -0.236 0.035 3.04E-11 
IGP26 rs3780490 9 33119839 G 0.31 1.00 -0.192 0.034 1.14E-08 
IGP26 rs10758192 9 33121651 G 0.69 1.00 0.192 0.034 1.16E-08 
IGP26 rs913214 9 33125085 G 0.69 1.00 0.192 0.034 1.22E-08 
IGP26 rs10738906 9 33125634 C 0.31 1.00 -0.192 0.034 1.24E-08 
IGP26 rs10124479 9 33126233 G 0.31 1.00 -0.192 0.034 1.25E-08 
IGP26 rs10813954 9 33127596 C 0.31 1.00 -0.192 0.034 1.28E-08 
IGP26 rs3780486 9 33129453 C 0.74 0.97 0.235 0.036 3.36E-11 
IGP26 rs7864705 9 33130352 C 0.31 1.00 -0.192 0.034 1.29E-08 
IGP26 rs7865745 9 33130976 G 0.69 1.00 0.192 0.034 1.29E-08 
IGP26 rs7873903 9 33132728 G 0.69 0.99 0.192 0.034 1.30E-08 
IGP26 rs3824458 9 33134809 C 0.69 0.99 0.193 0.034 1.26E-08 
IGP26 rs10813957 9 33143527 G 0.74 0.96 0.237 0.036 3.50E-11 
IGP26 rs10971438 9 33170308 G 0.30 0.75 -0.248 0.039 1.52E-10 
IGP26 rs10813960 9 33170362 C 0.70 0.74 0.248 0.039 1.49E-10 
IGP26 rs10971439 9 33170813 C 0.23 0.71 -0.260 0.043 1.93E-09 
IGP28 rs11923417 3 188188484 C 0.60 0.45 -0.302 0.046 4.37E-11 
IGP28 rs759602 3 188191498 G 0.78 0.98 -0.212 0.037 7.85E-09 
IGP28 rs4012171 3 188194147 C 0.75 0.75 -0.302 0.040 6.22E-14 
IGP28 rs16848727 3 188195657 G 0.25 0.71 -0.451 0.041 9.13E-28 
IGP28 rs13322676 3 188201439 C 0.28 0.87 -0.438 0.036 8.16E-34 
IGP28 rs6808800 3 188202068 G 0.51 0.85 -0.311 0.032 8.62E-22 
IGP28 rs17775791 3 188205056 C 0.28 0.89 -0.437 0.036 3.64E-34 
IGP28 rs7617523 3 188205144 G 0.34 0.89 -0.371 0.034 3.75E-28 
IGP28 rs7652995 3 188205638 G 0.18 0.83 0.404 0.044 2.04E-20 
IGP28 rs6764279 3 188206669 C 0.71 0.95 0.435 0.034 8.43E-37 
IGP28 rs6788832 3 188206913 G 0.34 0.89 -0.370 0.034 3.33E-28 
IGP28 rs3872721 3 188208185 G 0.24 0.89 0.363 0.038 5.22E-22 
IGP28 rs11710456 3 188208581 G 0.70 0.88 0.444 0.035 8.53E-37 
IGP28 rs3872722 3 188208971 C 0.41 0.89 0.298 0.033 8.50E-20 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP28 rs10937278 3 188210509 T 0.23 0.94 0.351 0.037 3.43E-21 
IGP28 rs10937279 3 188210530 G 0.77 0.94 -0.351 0.037 3.60E-21 
IGP28 rs7619468 3 188210872 C 0.77 0.94 -0.351 0.037 3.65E-21 
IGP28 rs4686830 3 188211259 G 0.77 0.96 -0.347 0.037 5.24E-21 
IGP28 rs10804908 3 188211536 T 0.23 0.96 0.347 0.037 5.44E-21 
IGP28 rs4686834 3 188211848 G 0.77 0.97 -0.344 0.037 7.68E-21 
IGP28 rs4686835 3 188211912 C 0.23 0.97 0.344 0.037 8.13E-21 
IGP28 rs4686836 3 188212059 C 0.23 0.97 0.343 0.037 8.51E-21 
IGP28 rs4012256 3 188213035 C 0.77 0.97 -0.343 0.037 9.05E-21 
IGP28 rs4012257 3 188213090 C 0.77 0.98 -0.342 0.037 9.43E-21 
IGP28 rs7619989 3 188214443 C 0.59 0.89 -0.293 0.033 2.33E-19 
IGP28 rs17776120 3 188215373 C 0.64 0.80 0.379 0.035 2.55E-27 
IGP28 rs3821819 3 188215419 G 0.63 0.81 0.382 0.035 1.93E-28 
IGP28 rs6444193 3 188216882 G 0.23 0.99 0.339 0.036 1.39E-20 
IGP28 rs967367 3 188217160 G 0.63 0.81 0.382 0.035 2.50E-28 
IGP28 rs4686837 3 188222371 G 0.70 0.86 0.276 0.036 1.19E-14 
IGP28 rs9941987 3 188225221 G 0.18 0.79 0.386 0.045 1.07E-17 
IGP28 rs4686838 3 188225747 G 0.45 0.71 -0.221 0.036 7.24E-10 
IGP28 rs16861533 3 188237416 G 0.84 0.67 0.333 0.050 2.99E-11 
IGP28 rs2268536 3 188239602 G 0.16 0.68 -0.326 0.050 7.02E-11 
IGP28 rs257101 3 188261522 C 0.23 0.49 -0.315 0.050 2.56E-10 
IGP29 rs11923417 3 188188484 C 0.60 0.45 -0.452 0.046 5.88E-23 
IGP29 rs759602 3 188191498 G 0.78 0.98 -0.336 0.037 4.89E-20 
IGP29 rs4012171 3 188194147 C 0.75 0.75 -0.451 0.040 3.23E-29 
IGP29 rs16848727 3 188195657 G 0.25 0.71 -0.677 0.041 3.57E-60 
IGP29 rs13322676 3 188201439 C 0.28 0.87 -0.644 0.036 6.10E-71 
IGP29 rs6808800 3 188202068 G 0.51 0.85 -0.435 0.033 1.15E-40 
IGP29 rs17775791 3 188205056 C 0.28 0.89 -0.643 0.036 1.69E-71 
IGP29 rs7617523 3 188205144 G 0.34 0.89 -0.559 0.034 2.28E-61 
IGP29 rs7652995 3 188205638 G 0.18 0.83 0.580 0.044 2.75E-40 
IGP29 rs6764279 3 188206669 C 0.72 0.95 0.627 0.034 2.53E-74 
IGP29 rs6788832 3 188206913 G 0.34 0.89 -0.557 0.034 2.24E-61 
IGP29 rs3872721 3 188208185 G 0.24 0.89 0.494 0.038 2.50E-39 
IGP29 rs11710456 3 188208581 G 0.70 0.88 0.643 0.035 6.12E-75 
IGP29 rs3872722 3 188208971 C 0.41 0.89 0.442 0.033 1.36E-41 
IGP29 rs7621161 3 188209864 C 0.72 0.94 0.631 0.035 1.95E-74 
IGP29 rs10937278 3 188210509 T 0.23 0.94 0.476 0.037 1.36E-37 
IGP29 rs10937279 3 188210530 G 0.77 0.94 -0.476 0.037 1.43E-37 
IGP29 rs7619468 3 188210872 C 0.77 0.94 -0.476 0.037 1.47E-37 
IGP29 rs4686830 3 188211259 G 0.77 0.96 -0.472 0.037 2.41E-37 
IGP29 rs10804908 3 188211536 T 0.23 0.96 0.471 0.037 2.54E-37 
IGP29 rs4686834 3 188211848 G 0.77 0.97 -0.467 0.037 4.85E-37 
IGP29 rs4686835 3 188211912 C 0.23 0.97 0.466 0.037 5.42E-37 
IGP29 rs4686836 3 188212059 C 0.23 0.97 0.466 0.037 5.86E-37 
IGP29 rs4012256 3 188213035 C 0.77 0.97 -0.465 0.037 6.48E-37 
IGP29 rs4012257 3 188213090 C 0.77 0.98 -0.465 0.037 6.85E-37 
IGP29 rs7619989 3 188214443 C 0.59 0.89 -0.434 0.033 1.17E-40 
IGP29 rs17776120 3 188215373 C 0.64 0.80 0.569 0.035 2.73E-59 
IGP29 rs3821819 3 188215419 G 0.63 0.81 0.569 0.035 1.50E-60 
IGP29 rs6444193 3 188216882 G 0.23 0.99 0.461 0.036 1.34E-36 
IGP29 rs967367 3 188217160 G 0.63 0.81 0.568 0.035 2.71E-60 
IGP29 rs4686837 3 188222371 G 0.70 0.86 0.391 0.036 1.28E-27 
IGP29 rs9941987 3 188225221 G 0.18 0.79 0.538 0.045 9.37E-33 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP29 rs16861533 3 188237416 G 0.84 0.67 0.527 0.050 1.10E-25 
IGP29 rs2268536 3 188239602 G 0.16 0.68 -0.516 0.050 8.07E-25 
IGP29 rs4686844 3 188247829 G 0.41 0.75 0.191 0.036 8.28E-08 
IGP29 rs9876699 3 188248791 C 0.56 0.92 -0.214 0.032 3.81E-11 
IGP29 rs6800338 3 188248816 C 0.56 0.94 -0.207 0.032 9.90E-11 
IGP29 rs4012245 3 188250134 G 0.44 0.98 0.191 0.031 1.30E-09 
IGP29 rs257105 3 188258413 C 0.38 0.87 0.195 0.034 1.01E-08 
IGP29 rs4012246 3 188261076 C 0.44 0.99 0.189 0.031 1.77E-09 
IGP29 rs257101 3 188261522 C 0.23 0.49 -0.509 0.050 2.74E-24 
IGP29 rs10433485 3 188263560 G 0.38 0.86 0.198 0.034 5.41E-09 
IGP30 rs17776120 3 188215373 C 0.64 0.80 0.195 0.035 2.77E-08 
IGP30 rs3821819 3 188215419 G 0.63 0.81 0.192 0.035 2.95E-08 
IGP30 rs967367 3 188217160 G 0.63 0.81 0.192 0.035 2.98E-08 
IGP31 rs16848727 3 188195657 G 0.25 0.71 0.283 0.041 8.74E-12 
IGP31 rs13322676 3 188201439 C 0.28 0.87 0.274 0.036 3.46E-14 
IGP31 rs6808800 3 188202068 G 0.51 0.85 0.186 0.033 1.07E-08 
IGP31 rs17775791 3 188205056 C 0.28 0.89 0.275 0.036 1.93E-14 
IGP31 rs7617523 3 188205144 G 0.34 0.89 0.237 0.034 2.11E-12 
IGP31 rs6764279 3 188206669 C 0.71 0.95 -0.283 0.034 1.89E-16 
IGP31 rs6788832 3 188206913 G 0.34 0.89 0.237 0.034 1.85E-12 
IGP31 rs3872721 3 188208185 G 0.24 0.89 -0.208 0.038 3.79E-08 
IGP31 rs11710456 3 188208581 G 0.70 0.88 -0.293 0.035 5.66E-17 
IGP31 rs3872722 3 188208971 C 0.41 0.89 -0.189 0.033 8.52E-09 
IGP31 rs7621161 3 188209864 C 0.72 0.94 -0.284 0.035 2.10E-16 
IGP31 rs10937278 3 188210509 T 0.23 0.94 -0.202 0.037 6.07E-08 
IGP31 rs10937279 3 188210530 G 0.77 0.94 0.202 0.037 6.17E-08 
IGP31 rs7619468 3 188210872 C 0.77 0.94 0.202 0.037 6.27E-08 
IGP31 rs4686830 3 188211259 G 0.77 0.96 0.198 0.037 9.76E-08 
IGP31 rs10804908 3 188211536 T 0.23 0.96 -0.198 0.037 9.87E-08 
IGP31 rs7619989 3 188214443 C 0.59 0.89 0.181 0.033 3.09E-08 
IGP31 rs17776120 3 188215373 C 0.64 0.80 -0.228 0.035 7.01E-11 
IGP31 rs3821819 3 188215419 G 0.63 0.81 -0.228 0.035 4.38E-11 
IGP31 rs967367 3 188217160 G 0.63 0.81 -0.227 0.035 5.51E-11 
IGP31 rs2659005 17 76833309 C 0.52 0.88 0.176 0.033 5.83E-08 
IGP31 rs7224668 17 76850383 C 0.52 0.94 0.173 0.031 3.33E-08 
IGP31 rs7223939 17 76856116 G 0.36 0.98 0.172 0.032 8.35E-08 
IGP31 rs8077394 17 76873382 G 0.49 0.93 0.171 0.031 5.33E-08 
IGP31 rs9914093 17 76875248 C 0.49 0.95 -0.171 0.031 4.80E-08 
IGP32 rs4012171 3 188194147 C 0.75 0.75 -0.273 0.040 1.23E-11 
IGP32 rs16848727 3 188195657 G 0.25 0.71 -0.462 0.041 8.24E-29 
IGP32 rs13322676 3 188201439 C 0.28 0.87 -0.443 0.036 2.12E-34 
IGP32 rs6808800 3 188202068 G 0.51 0.85 -0.252 0.033 1.32E-14 
IGP32 rs17775791 3 188205056 C 0.28 0.89 -0.443 0.036 7.36E-35 
IGP32 rs7617523 3 188205144 G 0.34 0.89 -0.371 0.034 5.17E-28 
IGP32 rs7652995 3 188205638 G 0.18 0.83 0.339 0.044 9.02E-15 
IGP32 rs6764279 3 188206669 C 0.72 0.95 0.441 0.034 1.24E-37 
IGP32 rs6788832 3 188206913 G 0.34 0.89 -0.370 0.034 4.42E-28 
IGP32 rs3872721 3 188208185 G 0.24 0.89 0.322 0.038 1.41E-17 
IGP32 rs11710456 3 188208581 G 0.70 0.88 0.448 0.035 3.13E-37 
IGP32 rs3872722 3 188208971 C 0.41 0.89 0.330 0.033 9.54E-24 
IGP32 rs7621161 3 188209864 C 0.72 0.94 0.444 0.035 1.07E-37 
IGP32 rs10937278 3 188210509 T 0.23 0.94 0.312 0.037 6.03E-17 
IGP32 rs10937279 3 188210530 G 0.77 0.94 -0.312 0.037 6.08E-17 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP32 rs4686830 3 188211259 G 0.77 0.96 -0.309 0.037 7.06E-17 
IGP32 rs10804908 3 188211536 T 0.23 0.96 0.309 0.037 7.21E-17 
IGP32 rs4686834 3 188211848 G 0.77 0.97 -0.306 0.037 9.19E-17 
IGP32 rs4686835 3 188211912 C 0.23 0.97 0.306 0.037 9.61E-17 
IGP32 rs4686836 3 188212059 C 0.23 0.97 0.306 0.037 9.86E-17 
IGP32 rs4012256 3 188213035 C 0.77 0.97 -0.305 0.037 1.03E-16 
IGP32 rs4012257 3 188213090 C 0.77 0.98 -0.305 0.037 1.04E-16 
IGP32 rs7619989 3 188214443 C 0.59 0.89 -0.325 0.033 2.45E-23 
IGP32 rs17776120 3 188215373 C 0.64 0.80 0.431 0.035 1.12E-34 
IGP32 rs3821819 3 188215419 G 0.63 0.81 0.427 0.035 1.05E-34 
IGP32 rs6444193 3 188216882 G 0.23 0.99 0.303 0.037 1.35E-16 
IGP32 rs967367 3 188217160 G 0.63 0.81 0.426 0.035 1.40E-34 
IGP32 rs4686837 3 188222371 G 0.70 0.86 0.287 0.036 1.49E-15 
IGP32 rs9941987 3 188225221 G 0.18 0.79 0.319 0.045 1.83E-12 
IGP32 rs4686838 3 188225747 G 0.45 0.71 -0.240 0.036 2.74E-11 
IGP32 rs16861533 3 188237416 G 0.84 0.67 0.389 0.050 1.05E-14 
IGP32 rs2268536 3 188239602 G 0.16 0.68 -0.383 0.050 2.41E-14 
IGP32 rs9876699 3 188248791 C 0.56 0.92 -0.174 0.033 8.41E-08 
IGP32 rs257101 3 188261522 C 0.23 0.49 -0.365 0.050 3.89E-13 
IGP34 rs5750825 22 38161224 G 0.71 0.98 -0.208 0.034 1.26E-09 
IGP34 rs1972280 22 38161932 T 0.29 0.98 0.208 0.034 1.24E-09 
IGP34 rs4821897 22 38165533 G 0.71 0.97 -0.209 0.034 1.20E-09 
IGP34 rs5750830 22 38170774 C 0.29 0.98 0.208 0.034 1.17E-09 
IGP34 rs8137426 22 38174296 G 0.71 0.98 -0.208 0.034 1.16E-09 
IGP34 rs5757683 22 38180120 G 0.29 0.98 0.208 0.034 1.17E-09 
IGP34 rs1557541 22 38181916 C 0.29 0.98 0.208 0.034 1.17E-09 
IGP34 rs1557542 22 38182296 C 0.71 0.98 -0.208 0.034 1.18E-09 
IGP34 rs5995735 22 38184367 C 0.29 0.98 0.207 0.034 1.22E-09 
IGP34 rs738289 22 38185829 C 0.29 0.98 0.207 0.034 1.23E-09 
IGP34 rs909674 22 38189115 C 0.30 0.99 0.214 0.034 2.48E-10 
IGP35 rs4012171 3 188194147 C 0.75 0.75 0.280 0.040 3.50E-12 
IGP35 rs16848727 3 188195657 G 0.25 0.71 0.490 0.041 2.72E-32 
IGP35 rs13322676 3 188201439 C 0.28 0.87 0.475 0.036 3.32E-39 
IGP35 rs6808800 3 188202068 G 0.51 0.85 0.285 0.033 2.52E-18 
IGP35 rs17775791 3 188205056 C 0.28 0.89 0.475 0.036 7.89E-40 
IGP35 rs7617523 3 188205144 G 0.34 0.89 0.398 0.034 6.87E-32 
IGP35 rs7652995 3 188205638 G 0.18 0.83 -0.366 0.044 6.84E-17 
IGP35 rs6764279 3 188206669 C 0.72 0.95 -0.478 0.034 1.11E-43 
IGP35 rs6788832 3 188206913 G 0.34 0.89 0.397 0.034 5.22E-32 
IGP35 rs3872721 3 188208185 G 0.24 0.89 -0.350 0.038 2.11E-20 
IGP35 rs11710456 3 188208581 G 0.70 0.88 -0.489 0.035 5.11E-44 
IGP35 rs3872722 3 188208971 C 0.41 0.89 -0.343 0.033 1.91E-25 
IGP35 rs7621161 3 188209864 C 0.72 0.94 -0.480 0.035 1.12E-43 
IGP35 rs10937278 3 188210509 T 0.23 0.94 -0.340 0.037 8.94E-20 
IGP35 rs10937279 3 188210530 G 0.77 0.94 0.340 0.037 9.13E-20 
IGP35 rs7619468 3 188210872 C 0.77 0.94 0.339 0.037 9.39E-20 
IGP35 rs4686830 3 188211259 G 0.77 0.96 0.335 0.037 1.67E-19 
IGP35 rs10804908 3 188211536 T 0.23 0.96 -0.335 0.037 1.71E-19 
IGP35 rs4686834 3 188211848 G 0.77 0.97 0.331 0.037 2.66E-19 
IGP35 rs4686835 3 188211912 C 0.23 0.97 -0.331 0.037 2.81E-19 
IGP35 rs4686836 3 188212059 C 0.23 0.97 -0.331 0.037 2.97E-19 
IGP35 rs4012256 3 188213035 C 0.77 0.97 0.330 0.037 3.17E-19 
IGP35 rs4012257 3 188213090 C 0.77 0.98 0.330 0.037 3.24E-19 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP35 rs17776120 3 188215373 C 0.64 0.80 -0.442 0.035 2.64E-36 
IGP35 rs3821819 3 188215419 G 0.63 0.81 -0.438 0.035 1.48E-36 
IGP35 rs6444193 3 188216882 G 0.23 0.99 -0.327 0.037 4.84E-19 
IGP35 rs967367 3 188217160 G 0.63 0.81 -0.438 0.035 2.38E-36 
IGP35 rs4686837 3 188222371 G 0.70 0.86 -0.277 0.036 1.59E-14 
IGP35 rs9941987 3 188225221 G 0.18 0.79 -0.336 0.045 1.23E-13 
IGP35 rs4686838 3 188225747 G 0.45 0.71 0.208 0.036 8.46E-09 
IGP35 rs16861533 3 188237416 G 0.84 0.67 -0.361 0.050 7.83E-13 
IGP35 rs2268536 3 188239602 G 0.16 0.68 0.353 0.050 2.03E-12 
IGP35 rs257101 3 188261522 C 0.23 0.49 0.322 0.050 1.54E-10 
IGP36 rs3818593 9 33110706 G 0.20 1.00 0.222 0.039 1.25E-08 
IGP36 rs10971418 9 33112024 C 0.80 0.98 -0.222 0.039 1.24E-08 
IGP36 rs10113903 9 33112645 C 0.31 0.99 0.193 0.034 1.39E-08 
IGP36 rs10738905 9 33113627 G 0.31 0.99 0.192 0.034 1.46E-08 
IGP36 rs10971419 9 33114161 C 0.31 0.99 0.191 0.034 1.59E-08 
IGP36 rs12342831 9 33114872 C 0.26 0.97 0.230 0.036 1.05E-10 
IGP36 rs10813950 9 33117640 G 0.69 1.00 -0.191 0.034 1.70E-08 
IGP36 rs10813951 9 33118021 G 0.26 0.97 0.230 0.036 1.07E-10 
IGP36 rs3780490 9 33119839 G 0.31 1.00 0.190 0.034 1.72E-08 
IGP36 rs10758192 9 33121651 G 0.69 1.00 -0.190 0.034 1.73E-08 
IGP36 rs913214 9 33125085 G 0.69 1.00 -0.190 0.034 1.73E-08 
IGP36 rs10738906 9 33125634 C 0.31 1.00 0.190 0.034 1.74E-08 
IGP36 rs10124479 9 33126233 G 0.31 1.00 0.190 0.034 1.74E-08 
IGP36 rs10813954 9 33127596 C 0.31 1.00 0.190 0.034 1.76E-08 
IGP36 rs3780486 9 33129453 C 0.74 0.97 -0.230 0.036 1.07E-10 
IGP36 rs7864705 9 33130352 C 0.31 1.00 0.191 0.034 1.76E-08 
IGP36 rs7865745 9 33130976 G 0.69 1.00 -0.191 0.034 1.76E-08 
IGP36 rs7873903 9 33132728 G 0.69 0.99 -0.191 0.034 1.77E-08 
IGP36 rs3824458 9 33134809 C 0.69 0.99 -0.191 0.034 1.76E-08 
IGP36 rs10813957 9 33143527 G 0.74 0.96 -0.231 0.036 1.27E-10 
IGP36 rs10971438 9 33170308 G 0.30 0.75 0.236 0.039 1.31E-09 
IGP36 rs10813960 9 33170362 C 0.70 0.74 -0.236 0.039 1.29E-09 
IGP36 rs10971439 9 33170813 C 0.23 0.71 0.245 0.043 1.73E-08 
IGP37 rs16848727 3 188195657 G 0.25 0.71 0.305 0.042 2.26E-13 
IGP37 rs13322676 3 188201439 C 0.28 0.87 0.284 0.036 5.14E-15 
IGP37 rs6808800 3 188202068 G 0.51 0.85 0.186 0.033 1.28E-08 
IGP37 rs17775791 3 188205056 C 0.28 0.89 0.283 0.036 3.83E-15 
IGP37 rs7617523 3 188205144 G 0.34 0.89 0.232 0.034 7.81E-12 
IGP37 rs7652995 3 188205638 G 0.18 0.83 -0.239 0.044 5.11E-08 
IGP37 rs6764279 3 188206669 C 0.71 0.95 -0.280 0.034 4.35E-16 
IGP37 rs6788832 3 188206913 G 0.34 0.89 0.231 0.034 7.89E-12 
IGP37 rs3872721 3 188208185 G 0.24 0.89 -0.226 0.038 2.63E-09 
IGP37 rs11710456 3 188208581 G 0.70 0.88 -0.293 0.035 8.21E-17 
IGP37 rs3872722 3 188208971 C 0.41 0.89 -0.198 0.033 1.71E-09 
IGP37 rs7621161 3 188209864 C 0.71 0.94 -0.281 0.035 4.76E-16 
IGP37 rs10937278 3 188210509 T 0.23 0.94 -0.221 0.037 3.76E-09 
IGP37 rs10937279 3 188210530 G 0.77 0.94 0.220 0.037 3.83E-09 
IGP37 rs7619468 3 188210872 C 0.77 0.94 0.220 0.037 3.88E-09 
IGP37 rs4686830 3 188211259 G 0.77 0.96 0.217 0.037 5.61E-09 
IGP37 rs10804908 3 188211536 T 0.23 0.96 -0.217 0.037 5.70E-09 
IGP37 rs4686834 3 188211848 G 0.77 0.97 0.215 0.037 6.49E-09 
IGP37 rs4686835 3 188211912 C 0.23 0.97 -0.214 0.037 6.71E-09 
IGP37 rs4686836 3 188212059 C 0.23 0.97 -0.214 0.037 6.96E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP37 rs4012257 3 188213090 C 0.77 0.98 0.213 0.037 7.20E-09 
IGP37 rs7619989 3 188214443 C 0.59 0.89 0.192 0.033 4.24E-09 
IGP37 rs17776120 3 188215373 C 0.64 0.80 -0.244 0.035 4.18E-12 
IGP37 rs3821819 3 188215419 G 0.63 0.81 -0.245 0.035 2.05E-12 
IGP37 rs6444193 3 188216882 G 0.23 0.99 -0.211 0.037 8.43E-09 
IGP37 rs967367 3 188217160 G 0.63 0.81 -0.244 0.035 2.43E-12 
IGP37 rs3818593 9 33110706 G 0.20 1.00 0.226 0.039 6.55E-09 
IGP37 rs10971418 9 33112024 C 0.80 0.98 -0.226 0.039 6.92E-09 
IGP37 rs10113903 9 33112645 C 0.31 0.99 0.195 0.034 9.01E-09 
IGP37 rs10738905 9 33113627 G 0.31 0.99 0.194 0.034 9.55E-09 
IGP37 rs10971419 9 33114161 C 0.31 0.99 0.193 0.034 1.05E-08 
IGP37 rs12342831 9 33114872 C 0.26 0.97 0.230 0.036 9.37E-11 
IGP37 rs10813950 9 33117640 G 0.69 1.00 -0.193 0.034 1.14E-08 
IGP37 rs10813951 9 33118021 G 0.26 0.97 0.230 0.036 9.58E-11 
IGP37 rs3780490 9 33119839 G 0.31 1.00 0.193 0.034 1.15E-08 
IGP37 rs10758192 9 33121651 G 0.69 1.00 -0.193 0.034 1.16E-08 
IGP37 rs913214 9 33125085 G 0.69 1.00 -0.193 0.034 1.12E-08 
IGP37 rs10738906 9 33125634 C 0.31 1.00 0.193 0.034 1.12E-08 
IGP37 rs10124479 9 33126233 G 0.31 1.00 0.193 0.034 1.11E-08 
IGP37 rs10813954 9 33127596 C 0.31 1.00 0.193 0.034 1.10E-08 
IGP37 rs3780486 9 33129453 C 0.74 0.97 -0.231 0.036 8.98E-11 
IGP37 rs7864705 9 33130352 C 0.31 1.00 0.193 0.034 1.10E-08 
IGP37 rs7865745 9 33130976 G 0.69 1.00 -0.193 0.034 1.10E-08 
IGP37 rs7873903 9 33132728 G 0.69 0.99 -0.193 0.034 1.12E-08 
IGP37 rs3824458 9 33134809 C 0.69 0.99 -0.194 0.034 1.11E-08 
IGP37 rs10813957 9 33143527 G 0.74 0.96 -0.232 0.036 1.11E-10 
IGP37 rs10971438 9 33170308 G 0.30 0.75 0.237 0.039 1.08E-09 
IGP37 rs10813960 9 33170362 C 0.70 0.74 -0.237 0.039 1.07E-09 
IGP37 rs10971439 9 33170813 C 0.23 0.71 0.247 0.043 1.19E-08 
IGP38 rs16848727 3 188195657 G 0.25 0.71 0.309 0.042 1.12E-13 
IGP38 rs13322676 3 188201439 C 0.28 0.87 0.286 0.036 2.87E-15 
IGP38 rs6808800 3 188202068 G 0.51 0.85 0.183 0.033 2.29E-08 
IGP38 rs17775791 3 188205056 C 0.28 0.89 0.286 0.036 2.24E-15 
IGP38 rs7617523 3 188205144 G 0.34 0.89 0.230 0.034 1.22E-11 
IGP38 rs7652995 3 188205638 G 0.18 0.83 -0.240 0.044 4.82E-08 
IGP38 rs6764279 3 188206669 C 0.71 0.95 -0.282 0.034 3.03E-16 
IGP38 rs6788832 3 188206913 G 0.34 0.89 0.229 0.034 1.24E-11 
IGP38 rs3872721 3 188208185 G 0.24 0.89 -0.231 0.038 1.18E-09 
IGP38 rs11710456 3 188208581 G 0.70 0.88 -0.295 0.035 5.43E-17 
IGP38 rs3872722 3 188208971 C 0.41 0.89 -0.203 0.033 6.82E-10 
IGP38 rs7621161 3 188209864 C 0.71 0.94 -0.283 0.035 3.24E-16 
IGP38 rs10937278 3 188210509 T 0.23 0.94 -0.225 0.037 1.71E-09 
IGP38 rs10937279 3 188210530 G 0.77 0.94 0.225 0.037 1.74E-09 
IGP38 rs7619468 3 188210872 C 0.77 0.94 0.225 0.037 1.77E-09 
IGP38 rs4686830 3 188211259 G 0.77 0.96 0.222 0.037 2.53E-09 
IGP38 rs10804908 3 188211536 T 0.23 0.96 -0.221 0.037 2.57E-09 
IGP38 rs4686834 3 188211848 G 0.77 0.97 0.219 0.037 2.95E-09 
IGP38 rs4686835 3 188211912 C 0.23 0.97 -0.219 0.037 3.07E-09 
IGP38 rs4686836 3 188212059 C 0.23 0.97 -0.219 0.037 3.18E-09 
IGP38 rs4012256 3 188213035 C 0.77 0.97 0.218 0.037 3.25E-09 
IGP38 rs4012257 3 188213090 C 0.77 0.98 0.218 0.037 3.29E-09 
IGP38 rs7619989 3 188214443 C 0.59 0.89 0.197 0.033 1.69E-09 
IGP38 rs17776120 3 188215373 C 0.64 0.80 -0.245 0.035 3.16E-12 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP38 rs6444193 3 188216882 G 0.23 0.99 -0.216 0.037 3.88E-09 
IGP38 rs967367 3 188217160 G 0.63 0.81 -0.245 0.035 1.86E-12 
IGP38 rs3818593 9 33110706 G 0.20 1.00 0.229 0.039 4.01E-09 
IGP38 rs10971418 9 33112024 C 0.80 0.98 -0.230 0.039 4.08E-09 
IGP38 rs10113903 9 33112645 C 0.31 0.99 0.197 0.034 6.60E-09 
IGP38 rs10738905 9 33113627 G 0.31 0.99 0.196 0.034 7.01E-09 
IGP38 rs10971419 9 33114161 C 0.31 0.99 0.195 0.034 7.75E-09 
IGP38 rs12342831 9 33114872 C 0.26 0.97 0.234 0.036 4.96E-11 
IGP38 rs10813950 9 33117640 G 0.69 1.00 -0.195 0.034 8.39E-09 
IGP38 rs10813951 9 33118021 G 0.26 0.97 0.234 0.036 5.06E-11 
IGP38 rs3780490 9 33119839 G 0.31 1.00 0.194 0.034 8.47E-09 
IGP38 rs10758192 9 33121651 G 0.69 1.00 -0.194 0.034 8.55E-09 
IGP38 rs913214 9 33125085 G 0.69 1.00 -0.195 0.034 8.42E-09 
IGP38 rs10738906 9 33125634 C 0.31 1.00 0.195 0.034 8.43E-09 
IGP38 rs10124479 9 33126233 G 0.31 1.00 0.195 0.034 8.43E-09 
IGP38 rs10813954 9 33127596 C 0.31 1.00 0.195 0.034 8.44E-09 
IGP38 rs3780486 9 33129453 C 0.74 0.97 -0.234 0.036 4.95E-11 
IGP38 rs7864705 9 33130352 C 0.31 1.00 0.195 0.034 8.44E-09 
IGP38 rs7865745 9 33130976 G 0.69 1.00 -0.195 0.034 8.45E-09 
IGP38 rs7873903 9 33132728 G 0.69 0.99 -0.195 0.034 8.56E-09 
IGP38 rs3824458 9 33134809 C 0.69 0.99 -0.195 0.034 8.56E-09 
IGP38 rs10813957 9 33143527 G 0.74 0.96 -0.235 0.036 6.39E-11 
IGP38 rs10971438 9 33170308 G 0.30 0.75 0.239 0.039 7.65E-10 
IGP38 rs10813960 9 33170362 C 0.70 0.74 -0.239 0.039 7.58E-10 
IGP38 rs10971439 9 33170813 C 0.23 0.71 0.251 0.043 7.19E-09 
IGP39 rs3818593 9 33110706 G 0.20 1.00 0.213 0.039 4.18E-08 
IGP39 rs10971418 9 33112024 C 0.80 0.98 -0.214 0.039 3.59E-08 
IGP39 rs10113903 9 33112645 C 0.31 0.99 0.207 0.034 9.65E-10 
IGP39 rs10738905 9 33113627 G 0.31 0.99 0.206 0.034 9.90E-10 
IGP39 rs10971419 9 33114161 C 0.31 0.99 0.206 0.034 1.02E-09 
IGP39 rs12342831 9 33114872 C 0.26 0.97 0.217 0.035 9.57E-10 
IGP39 rs10758189 9 33115804 C 0.31 0.92 0.204 0.035 4.84E-09 
IGP39 rs10813950 9 33117640 G 0.69 1.00 -0.205 0.034 1.04E-09 
IGP39 rs10813951 9 33118021 G 0.26 0.97 0.217 0.035 9.40E-10 
IGP39 rs3780490 9 33119839 G 0.31 1.00 0.205 0.034 1.04E-09 
IGP39 rs10758192 9 33121651 G 0.69 1.00 -0.205 0.034 1.04E-09 
IGP39 rs913214 9 33125085 G 0.69 1.00 -0.205 0.034 1.18E-09 
IGP39 rs10738906 9 33125634 C 0.31 1.00 0.205 0.034 1.23E-09 
IGP39 rs10124479 9 33126233 G 0.31 1.00 0.204 0.034 1.27E-09 
IGP39 rs10813954 9 33127596 C 0.31 1.00 0.204 0.034 1.35E-09 
IGP39 rs10971424 9 33128775 C 0.34 0.90 0.194 0.035 2.01E-08 
IGP39 rs3780486 9 33129453 C 0.74 0.97 -0.216 0.035 1.17E-09 
IGP39 rs7864705 9 33130352 C 0.31 1.00 0.204 0.034 1.34E-09 
IGP39 rs7865745 9 33130976 G 0.69 1.00 -0.204 0.034 1.34E-09 
IGP39 rs7873903 9 33132728 G 0.69 0.99 -0.204 0.034 1.35E-09 
IGP39 rs7036812 9 33133822 C 0.33 0.89 0.193 0.035 3.61E-08 
IGP39 rs3824458 9 33134809 C 0.69 0.99 -0.205 0.034 1.35E-09 
IGP39 rs10813957 9 33143527 G 0.74 0.96 -0.217 0.036 1.30E-09 
IGP39 rs10971438 9 33170308 G 0.30 0.75 0.228 0.039 3.92E-09 
IGP39 rs10813960 9 33170362 C 0.70 0.74 -0.228 0.039 3.89E-09 
IGP39 rs10971439 9 33170813 C 0.23 0.71 0.234 0.043 6.11E-08 
IGP39 rs17630758 22 22466542 G 0.83 0.99 0.260 0.041 2.61E-10 
IGP39 rs17548631 22 22474125 C 0.17 0.99 -0.260 0.041 2.26E-10 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP39 rs9624334 22 22496256 C 0.17 0.99 -0.259 0.041 3.51E-10 
IGP39 rs2186369 22 22500996 G 0.19 0.88 -0.267 0.042 1.34E-10 
IGP39 rs137682 22 38068371 C 0.78 1.00 -0.207 0.037 1.57E-08 
IGP39 rs137683 22 38068447 C 0.78 0.96 -0.219 0.037 2.73E-09 
IGP39 rs137686 22 38069584 C 0.24 0.89 0.252 0.037 1.13E-11 
IGP39 rs137699 22 38078800 G 0.69 0.89 -0.211 0.035 1.49E-09 
IGP39 rs2049986 22 38086800 C 0.69 0.88 -0.212 0.035 1.16E-09 
IGP39 rs5757636 22 38088455 G 0.87 0.77 -0.292 0.051 1.04E-08 
IGP39 rs5757637 22 38088487 G 0.87 0.77 -0.295 0.051 6.94E-09 
IGP39 rs5757642 22 38094770 C 0.64 1.00 -0.276 0.032 1.80E-17 
IGP39 rs7286714 22 38095550 C 0.36 0.97 0.280 0.033 1.07E-17 
IGP39 rs5757644 22 38096386 C 0.36 0.97 0.280 0.033 1.04E-17 
IGP39 rs5750806 22 38096957 G 0.64 0.97 -0.280 0.033 1.04E-17 
IGP39 rs1569499 22 38099764 C 0.64 0.97 -0.281 0.033 1.16E-17 
IGP39 rs4821888 22 38100543 G 0.64 0.97 -0.281 0.033 1.18E-17 
IGP39 rs5757647 22 38104993 C 0.33 1.00 0.284 0.033 4.25E-18 
IGP39 rs4821890 22 38107469 G 0.34 0.99 0.285 0.033 2.98E-18 
IGP39 rs1010169 22 38108113 G 0.67 1.00 -0.284 0.033 4.31E-18 
IGP39 rs1010170 22 38108273 C 0.67 1.00 -0.283 0.033 4.47E-18 
IGP39 rs5757650 22 38108365 C 0.67 1.00 -0.283 0.033 4.54E-18 
IGP39 rs9611169 22 38112973 C 0.33 1.00 0.283 0.033 4.67E-18 
IGP39 rs9611170 22 38114791 C 0.67 0.99 -0.282 0.033 6.34E-18 
IGP39 rs2413590 22 38120137 C 0.67 1.00 -0.280 0.033 8.90E-18 
IGP39 rs5750808 22 38120933 G 0.33 1.00 0.280 0.033 8.80E-18 
IGP39 rs5750811 22 38123012 G 0.67 1.00 -0.280 0.033 8.67E-18 
IGP39 rs5750812 22 38123025 G 0.34 0.99 0.284 0.033 3.54E-18 
IGP39 rs5757655 22 38127124 C 0.66 0.99 -0.284 0.033 3.35E-18 
IGP39 rs4821893 22 38127725 G 0.33 1.00 0.284 0.033 3.27E-18 
IGP39 rs5750814 22 38127933 C 0.67 1.00 -0.284 0.033 2.86E-18 
IGP39 rs5757657 22 38128375 G 0.33 1.00 0.284 0.033 2.75E-18 
IGP39 rs5750815 22 38128395 C 0.67 1.00 -0.284 0.033 2.59E-18 
IGP39 rs4337572 22 38130650 C 0.33 1.00 0.284 0.033 2.50E-18 
IGP39 rs4821894 22 38139766 C 0.67 1.00 -0.284 0.033 2.38E-18 
IGP39 rs5750816 22 38140325 C 0.33 1.00 0.285 0.033 2.27E-18 
IGP39 rs5757659 22 38142355 G 0.67 1.00 -0.285 0.033 2.14E-18 
IGP39 rs6001585 22 38142932 C 0.22 1.00 0.297 0.037 5.28E-16 
IGP39 rs6001587 22 38148954 C 0.67 1.00 -0.285 0.033 2.17E-18 
IGP39 rs5750818 22 38150831 G 0.67 1.00 -0.285 0.033 2.18E-18 
IGP39 rs5757665 22 38151587 G 0.67 1.00 -0.285 0.033 2.18E-18 
IGP39 rs4821895 22 38152961 G 0.67 1.00 -0.285 0.033 2.19E-18 
IGP39 rs739141 22 38154396 C 0.36 1.00 0.263 0.032 3.37E-16 
IGP39 rs5750820 22 38155268 G 0.68 0.97 -0.303 0.033 5.96E-20 
IGP39 rs5750822 22 38156734 G 0.33 1.00 0.285 0.033 1.95E-18 
IGP39 rs7949 22 38157499 G 0.33 0.99 0.286 0.033 1.71E-18 
IGP39 rs5757670 22 38159682 G 0.33 0.99 0.287 0.033 1.51E-18 
IGP39 rs5750825 22 38161224 G 0.71 0.98 -0.333 0.034 2.26E-22 
IGP39 rs1972280 22 38161932 T 0.29 0.98 0.334 0.034 1.82E-22 
IGP39 rs4821897 22 38165533 G 0.71 0.97 -0.335 0.034 1.46E-22 
IGP39 rs5750830 22 38170774 C 0.29 0.98 0.341 0.034 1.67E-23 
IGP39 rs5757676 22 38171646 C 0.78 0.96 -0.318 0.037 1.16E-17 
IGP39 rs8137426 22 38174296 G 0.71 0.98 -0.341 0.034 1.58E-23 
IGP39 rs5757683 22 38180120 G 0.29 0.98 0.341 0.034 1.51E-23 
IGP39 rs1557541 22 38181916 C 0.29 0.98 0.341 0.034 1.52E-23 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP39 rs5995735 22 38184367 C 0.29 0.98 0.341 0.034 1.54E-23 
IGP39 rs738289 22 38185829 C 0.29 0.98 0.341 0.034 1.54E-23 
IGP39 rs909674 22 38189115 C 0.30 0.99 0.339 0.034 8.87E-24 
IGP39 rs4820378 22 38199155 C 0.47 0.99 -0.177 0.031 1.40E-08 
IGP39 rs1003538 22 38202653 G 0.49 0.95 -0.191 0.032 1.62E-09 
IGP39 rs9306336 22 38203416 T 0.54 0.99 0.170 0.031 4.91E-08 
IGP39 rs5757731 22 38297731 C 0.43 0.90 -0.173 0.032 8.67E-08 
IGP39 rs3788556 22 38302108 C 0.56 0.85 0.180 0.033 4.90E-08 
IGP40 rs3818593 9 33110706 G 0.20 1.00 0.211 0.039 5.10E-08 
IGP40 rs10971418 9 33112024 C 0.80 0.98 -0.212 0.039 4.54E-08 
IGP40 rs10113903 9 33112645 C 0.31 0.99 0.209 0.034 6.07E-10 
IGP40 rs10738905 9 33113627 G 0.31 0.99 0.208 0.034 6.23E-10 
IGP40 rs10971419 9 33114161 C 0.31 0.99 0.208 0.034 6.44E-10 
IGP40 rs12342831 9 33114872 C 0.26 0.97 0.219 0.035 5.59E-10 
IGP40 rs10758189 9 33115804 C 0.31 0.92 0.204 0.035 4.02E-09 
IGP40 rs10813950 9 33117640 G 0.69 1.00 -0.207 0.034 6.59E-10 
IGP40 rs10813951 9 33118021 G 0.26 0.97 0.219 0.035 5.49E-10 
IGP40 rs3780490 9 33119839 G 0.31 1.00 0.207 0.034 6.58E-10 
IGP40 rs10758192 9 33121651 G 0.69 1.00 -0.207 0.034 6.58E-10 
IGP40 rs913214 9 33125085 G 0.69 1.00 -0.207 0.034 7.40E-10 
IGP40 rs10738906 9 33125634 C 0.31 1.00 0.206 0.034 7.71E-10 
IGP40 rs10124479 9 33126233 G 0.31 1.00 0.206 0.034 7.91E-10 
IGP40 rs10813954 9 33127596 C 0.31 1.00 0.206 0.034 8.38E-10 
IGP40 rs10971424 9 33128775 C 0.34 0.90 0.196 0.034 1.35E-08 
IGP40 rs3780486 9 33129453 C 0.74 0.97 -0.218 0.035 6.77E-10 
IGP40 rs7864705 9 33130352 C 0.31 1.00 0.206 0.034 8.35E-10 
IGP40 rs7865745 9 33130976 G 0.69 1.00 -0.206 0.034 8.35E-10 
IGP40 rs7873903 9 33132728 G 0.69 0.99 -0.206 0.034 8.42E-10 
IGP40 rs7036812 9 33133822 C 0.33 0.89 0.195 0.035 2.37E-08 
IGP40 rs3824458 9 33134809 C 0.69 0.99 -0.207 0.034 8.39E-10 
IGP40 rs10813957 9 33143527 G 0.74 0.96 -0.220 0.036 7.63E-10 
IGP40 rs10971438 9 33170308 G 0.30 0.75 0.230 0.039 2.64E-09 
IGP40 rs10813960 9 33170362 C 0.70 0.74 -0.230 0.039 2.64E-09 
IGP40 rs10971439 9 33170813 C 0.23 0.71 0.231 0.043 8.64E-08 
IGP40 rs17630758 22 22466542 G 0.83 0.99 0.260 0.041 1.86E-10 
IGP40 rs17548631 22 22474125 C 0.17 0.99 -0.261 0.041 1.62E-10 
IGP40 rs9620326 22 22476629 C 0.83 0.99 0.261 0.041 1.60E-10 
IGP40 rs9624334 22 22496256 C 0.17 0.99 -0.258 0.041 3.41E-10 
IGP40 rs2186369 22 22500996 G 0.19 0.88 -0.265 0.041 1.43E-10 
IGP40 rs137682 22 38068371 C 0.78 1.00 -0.217 0.036 2.11E-09 
IGP40 rs137683 22 38068447 C 0.78 0.96 -0.230 0.037 3.44E-10 
IGP40 rs137686 22 38069584 C 0.24 0.89 0.261 0.037 1.60E-12 
IGP40 rs137699 22 38078800 G 0.69 0.89 -0.224 0.035 9.98E-11 
IGP40 rs2049986 22 38086800 C 0.69 0.88 -0.225 0.035 7.74E-11 
IGP40 rs5757636 22 38088455 G 0.87 0.77 -0.307 0.051 1.44E-09 
IGP40 rs5757637 22 38088487 G 0.87 0.77 -0.310 0.051 9.42E-10 
IGP40 rs5757642 22 38094770 C 0.64 1.00 -0.282 0.032 2.51E-18 
IGP40 rs7286714 22 38095550 C 0.36 0.97 0.286 0.033 1.41E-18 
IGP40 rs5757644 22 38096386 C 0.36 0.97 0.286 0.033 1.37E-18 
IGP40 rs5750806 22 38096957 G 0.64 0.97 -0.286 0.033 1.36E-18 
IGP40 rs1569499 22 38099764 C 0.64 0.97 -0.287 0.033 1.53E-18 
IGP40 rs4821888 22 38100543 G 0.64 0.97 -0.287 0.033 1.55E-18 
IGP40 rs5757647 22 38104993 C 0.33 1.00 0.292 0.033 2.79E-19 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP40 rs1010169 22 38108113 G 0.67 1.00 -0.292 0.033 2.84E-19 
IGP40 rs1010170 22 38108273 C 0.67 1.00 -0.292 0.033 2.95E-19 
IGP40 rs5757650 22 38108365 C 0.67 1.00 -0.292 0.033 3.00E-19 
IGP40 rs9611169 22 38112973 C 0.33 1.00 0.291 0.033 3.08E-19 
IGP40 rs9611170 22 38114791 C 0.66 0.99 -0.290 0.032 3.73E-19 
IGP40 rs2413590 22 38120137 C 0.67 1.00 -0.289 0.032 5.35E-19 
IGP40 rs5750808 22 38120933 G 0.33 1.00 0.289 0.032 5.28E-19 
IGP40 rs5750811 22 38123012 G 0.67 1.00 -0.289 0.032 5.18E-19 
IGP40 rs5750812 22 38123025 G 0.34 0.99 0.293 0.032 2.01E-19 
IGP40 rs5757655 22 38127124 C 0.66 0.99 -0.293 0.032 1.90E-19 
IGP40 rs4821893 22 38127725 G 0.33 1.00 0.292 0.032 1.86E-19 
IGP40 rs5750814 22 38127933 C 0.67 1.00 -0.293 0.032 1.63E-19 
IGP40 rs5757657 22 38128375 G 0.33 1.00 0.293 0.032 1.57E-19 
IGP40 rs5750815 22 38128395 C 0.67 1.00 -0.293 0.032 1.47E-19 
IGP40 rs4337572 22 38130650 C 0.33 1.00 0.293 0.032 1.42E-19 
IGP40 rs4821894 22 38139766 C 0.66 1.00 -0.293 0.032 1.36E-19 
IGP40 rs5750816 22 38140325 C 0.34 1.00 0.293 0.032 1.29E-19 
IGP40 rs5757659 22 38142355 G 0.66 1.00 -0.293 0.032 1.22E-19 
IGP40 rs6001585 22 38142932 C 0.22 1.00 0.308 0.036 3.28E-17 
IGP40 rs6001587 22 38148954 C 0.66 1.00 -0.293 0.032 1.24E-19 
IGP40 rs5750818 22 38150831 G 0.66 1.00 -0.293 0.032 1.24E-19 
IGP40 rs5757665 22 38151587 G 0.66 1.00 -0.293 0.032 1.25E-19 
IGP40 rs4821895 22 38152961 G 0.66 1.00 -0.293 0.032 1.25E-19 
IGP40 rs739141 22 38154396 C 0.36 1.00 0.271 0.032 2.77E-17 
IGP40 rs5750820 22 38155268 G 0.67 0.97 -0.311 0.033 2.98E-21 
IGP40 rs5750822 22 38156734 G 0.34 1.00 0.294 0.032 1.10E-19 
IGP40 rs7949 22 38157499 G 0.34 0.99 0.295 0.032 9.53E-20 
IGP40 rs5757670 22 38159682 G 0.34 0.99 0.296 0.032 8.31E-20 
IGP40 rs5750825 22 38161224 G 0.71 0.98 -0.338 0.034 3.24E-23 
IGP40 rs1972280 22 38161932 T 0.29 0.98 0.340 0.034 2.56E-23 
IGP40 rs4821897 22 38165533 G 0.71 0.97 -0.341 0.034 2.04E-23 
IGP40 rs5750830 22 38170774 C 0.29 0.98 0.347 0.034 2.01E-24 
IGP40 rs5757676 22 38171646 C 0.78 0.96 -0.329 0.037 6.14E-19 
IGP40 rs8137426 22 38174296 G 0.71 0.98 -0.347 0.034 1.88E-24 
IGP40 rs5757683 22 38180120 G 0.29 0.98 0.347 0.034 1.81E-24 
IGP40 rs1557541 22 38181916 C 0.29 0.98 0.347 0.034 1.81E-24 
IGP40 rs1557542 22 38182296 C 0.71 0.98 -0.347 0.034 1.81E-24 
IGP40 rs5995735 22 38184367 C 0.29 0.98 0.347 0.034 1.83E-24 
IGP40 rs738289 22 38185829 C 0.29 0.98 0.346 0.034 1.82E-24 
IGP40 rs909674 22 38189115 C 0.30 0.99 0.345 0.034 9.66E-25 
IGP40 rs4820378 22 38199155 C 0.47 0.99 -0.177 0.031 1.06E-08 
IGP40 rs1003538 22 38202653 G 0.49 0.95 -0.190 0.032 1.57E-09 
IGP40 rs9306336 22 38203416 T 0.54 0.99 0.171 0.031 3.40E-08 
IGP40 rs2899319 22 38204260 C 0.66 0.99 0.174 0.033 8.91E-08 
IGP40 rs9607658 22 38287686 C 0.57 1.00 0.165 0.031 6.09E-08 
IGP40 rs5757731 22 38297731 C 0.43 0.90 -0.177 0.032 3.92E-08 
IGP40 rs3788556 22 38302108 C 0.56 0.85 0.186 0.033 1.46E-08 
IGP41 rs1894204 11 67686247 C 0.59 0.88 0.191 0.033 5.66E-09 
IGP41 rs10896298 11 67688035 C 0.51 1.00 0.185 0.030 8.90E-10 
IGP41 rs4930561 11 67688337 G 0.51 1.00 0.185 0.030 8.88E-10 
IGP41 rs7931502 11 67716183 C 0.59 0.89 0.189 0.033 6.24E-09 
IGP41 rs4930564 11 67739857 G 0.41 0.86 -0.192 0.033 6.37E-09 
IGP41 rs7973719 12 7226080 C 0.49 0.92 0.177 0.032 4.48E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP42 rs2859113 6 32805763 C 0.38 0.91 0.181 0.033 5.72E-08 
IGP42 rs7751856 6 32806966 C 0.38 0.90 0.181 0.033 6.27E-08 
IGP42 rs9276197 6 32807565 C 0.62 0.90 -0.180 0.033 6.47E-08 
IGP42 rs9276234 6 32808826 T 0.62 0.90 -0.180 0.033 6.45E-08 
IGP42 rs2859071 6 32811344 C 0.62 0.92 -0.180 0.033 6.51E-08 
IGP42 rs9276311 6 32812637 C 0.62 0.94 -0.179 0.033 6.75E-08 
IGP42 rs7773149 6 32814020 G 0.62 0.94 -0.179 0.033 7.23E-08 
IGP42 rs1049110 6 32834781 C 0.35 0.98 0.191 0.034 1.64E-08 
IGP42 rs7782210 7 50319291 G 0.38 0.98 -0.190 0.032 2.04E-09 
IGP42 rs6583437 7 50320813 G 0.64 0.98 0.197 0.032 6.66E-10 
IGP42 rs7789913 7 50323241 C 0.62 1.00 0.189 0.032 2.13E-09 
IGP42 rs6421315 7 50325753 C 0.37 0.95 -0.194 0.032 2.22E-09 
IGP42 rs1122979 7 150546004 G 0.87 0.91 0.298 0.049 1.41E-09 
IGP42 rs7812088 7 150550762 G 0.87 0.98 0.283 0.047 1.82E-09 
IGP42 rs7781265 7 150581873 G 0.88 0.92 0.281 0.050 2.01E-08 
IGP42 rs8021641 14 64782173 C 0.15 0.95 0.234 0.044 9.64E-08 
IGP42 rs1256519 14 64806077 G 0.44 0.89 -0.198 0.033 1.03E-09 
IGP42 rs1256526 14 64809658 G 0.39 1.00 0.170 0.032 9.20E-08 
IGP42 rs7159888 14 64828395 G 0.55 0.99 -0.262 0.031 5.01E-17 
IGP42 rs12431963 14 64829447 C 0.92 0.92 -0.431 0.059 2.48E-13 
IGP42 rs1256540 14 64833822 C 0.43 1.00 0.257 0.031 2.38E-16 
IGP42 rs4902383 14 64834326 C 0.19 0.94 0.274 0.040 7.17E-12 
IGP42 rs1269068 14 64837086 C 0.57 1.00 -0.257 0.031 2.51E-16 
IGP42 rs10135194 14 64840731 C 0.94 0.84 -0.434 0.071 8.50E-10 
IGP42 rs1760978 14 64840800 G 0.43 0.98 0.288 0.031 4.65E-20 
IGP42 rs10144975 14 64843735 C 0.80 0.98 -0.288 0.038 5.87E-14 
IGP42 rs17102587 14 64844230 C 0.20 0.97 0.295 0.038 1.88E-14 
IGP42 rs8017974 14 64844940 C 0.20 0.99 0.296 0.038 1.17E-14 
IGP42 rs11847263 14 64845448 G 0.39 0.98 0.303 0.032 2.76E-21 
IGP42 rs10132229 14 64847313 G 0.10 1.00 0.393 0.051 1.38E-14 
IGP42 rs4902386 14 64848043 C 0.81 0.99 -0.296 0.038 1.07E-14 
IGP42 rs10147958 14 64848586 C 0.10 1.00 0.393 0.051 1.37E-14 
IGP42 rs8019473 14 64848881 G 0.81 0.99 -0.296 0.038 1.05E-14 
IGP42 rs10138662 14 64849235 G 0.19 0.99 0.296 0.038 1.01E-14 
IGP42 rs10134589 14 64850987 T 0.19 0.94 0.318 0.040 1.04E-15 
IGP42 rs7151212 14 64851375 C 0.81 0.99 -0.296 0.038 9.63E-15 
IGP42 rs11158587 14 64852465 G 0.81 0.99 -0.296 0.038 9.51E-15 
IGP42 rs8019767 14 64852538 G 0.81 1.00 -0.296 0.038 9.41E-15 
IGP42 rs6573598 14 64852772 C 0.19 1.00 0.296 0.038 9.27E-15 
IGP42 rs6573599 14 64852880 C 0.81 1.00 -0.296 0.038 8.99E-15 
IGP42 rs10144503 14 64853862 G 0.90 1.00 -0.393 0.051 1.25E-14 
IGP42 rs6573602 14 64854363 C 0.19 1.00 0.296 0.038 8.73E-15 
IGP42 rs17102598 14 64854613 G 0.81 1.00 -0.296 0.038 8.65E-15 
IGP42 rs12436299 14 64854947 G 0.90 1.00 -0.393 0.051 1.23E-14 
IGP42 rs6573604 14 64857694 C 0.19 1.00 0.297 0.038 8.48E-15 
IGP42 rs9635250 14 64869101 T 0.10 1.00 0.394 0.051 1.20E-14 
IGP42 rs12881755 14 64871564 G 0.65 0.96 -0.245 0.033 2.24E-13 
IGP42 rs747541 14 64875163 C 0.45 0.98 0.280 0.032 1.28E-18 
IGP42 rs1954052 14 64875462 T 0.44 0.99 0.280 0.032 1.11E-18 
IGP42 rs12436465 14 64876630 C 0.72 0.98 -0.205 0.035 6.53E-09 
IGP42 rs12886005 14 64879000 C 0.45 0.87 0.283 0.034 4.17E-17 
IGP42 rs12886168 14 64879039 C 0.45 0.98 0.279 0.032 1.27E-18 
IGP42 rs11623920 14 64889067 C 0.56 1.00 -0.279 0.032 1.11E-18 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP42 rs10148907 14 64903125 C 0.69 0.98 -0.286 0.034 8.94E-17 
IGP42 rs4902393 14 64909267 C 0.56 0.99 -0.278 0.032 1.99E-18 
IGP42 rs11621604 14 64910527 G 0.56 0.98 -0.274 0.032 9.11E-18 
IGP42 rs12882269 14 64916897 G 0.56 0.97 -0.272 0.032 1.63E-17 
IGP42 rs11158591 14 64925515 C 0.44 0.97 0.270 0.032 2.39E-17 
IGP42 rs11158592 14 64929721 G 0.50 0.99 0.251 0.031 3.93E-16 
IGP42 rs11158593 14 64929737 G 0.50 0.99 0.253 0.031 1.96E-16 
IGP42 rs10138570 14 64929791 G 0.50 0.99 -0.253 0.031 1.99E-16 
IGP42 rs10138671 14 64929845 G 0.58 0.99 -0.172 0.031 3.96E-08 
IGP42 rs4587890 14 64933537 T 0.42 0.99 0.171 0.031 4.02E-08 
IGP42 rs2411823 14 64934819 C 0.42 0.99 0.171 0.031 4.10E-08 
IGP42 rs17246007 14 64935424 C 0.08 0.99 0.323 0.059 5.77E-08 
IGP42 rs11844747 14 64939881 C 0.08 0.99 0.323 0.059 5.69E-08 
IGP42 rs17246035 14 64943883 G 0.08 1.00 0.323 0.059 5.23E-08 
IGP42 rs2411822 14 64948148 G 0.48 1.00 -0.235 0.031 2.48E-14 
IGP42 rs1953416 14 64948560 C 0.53 1.00 0.237 0.031 1.36E-14 
IGP42 rs1953417 14 64948662 C 0.92 1.00 -0.323 0.059 5.11E-08 
IGP42 rs883081 14 64950374 C 0.53 1.00 0.237 0.031 1.41E-14 
IGP42 rs883082 14 64950693 G 0.48 1.00 -0.235 0.031 2.59E-14 
IGP42 rs7145574 14 64954155 C 0.92 1.00 -0.324 0.059 5.06E-08 
IGP42 rs867972 14 64965514 C 0.48 0.97 -0.237 0.031 2.86E-14 
IGP42 rs11851576 14 64970036 C 0.54 0.99 -0.206 0.031 4.51E-11 
IGP42 rs12879971 14 64971357 G 0.52 0.99 0.237 0.031 1.66E-14 
IGP42 rs12892058 14 64973194 C 0.47 0.99 -0.241 0.031 7.51E-15 
IGP42 rs10483776 14 64984620 G 0.22 1.00 0.220 0.038 1.04E-08 
IGP42 rs17826580 14 64985015 C 0.08 1.00 0.325 0.059 4.40E-08 
IGP42 rs2184602 14 64985425 G 0.08 1.00 0.325 0.059 4.40E-08 
IGP42 rs2152375 14 64985531 C 0.08 1.00 0.325 0.059 4.40E-08 
IGP42 rs12589698 14 64990188 G 0.52 0.98 0.246 0.031 2.63E-15 
IGP42 rs4899179 14 64996501 G 0.49 0.99 -0.243 0.031 4.25E-15 
IGP42 rs2184603 14 65000423 C 0.49 0.99 -0.243 0.031 4.18E-15 
IGP42 rs11850847 14 65003551 C 0.92 1.00 -0.325 0.059 4.33E-08 
IGP42 rs12434585 14 65008121 G 0.08 1.00 0.325 0.059 4.33E-08 
IGP42 rs3825640 14 65030957 C 0.51 0.99 0.245 0.031 2.19E-15 
IGP42 rs11627084 14 65048589 G 0.49 1.00 -0.243 0.031 3.98E-15 
IGP42 rs10483780 14 65049923 C 0.50 0.99 -0.239 0.031 1.14E-14 
IGP42 rs2149841 14 65080072 C 0.51 0.99 0.245 0.031 2.12E-15 
IGP42 rs7153679 14 65082707 G 0.08 0.99 0.326 0.059 4.09E-08 
IGP42 rs11621680 14 65084434 G 0.50 0.99 -0.239 0.031 1.07E-14 
IGP42 rs11851013 14 65085965 G 0.08 0.99 0.326 0.059 4.09E-08 
IGP42 rs11623662 14 65090945 G 0.60 0.99 -0.178 0.032 1.65E-08 
IGP42 rs11851772 14 65091800 C 0.92 0.99 -0.326 0.059 4.09E-08 
IGP42 rs9972106 14 65092884 T 0.60 0.99 -0.178 0.032 1.63E-08 
IGP42 rs11158601 14 65095116 G 0.49 1.00 -0.242 0.031 3.80E-15 
IGP42 rs7146742 14 65102687 G 0.43 0.99 0.217 0.032 8.53E-12 
IGP42 rs1958561 14 65106514 G 0.49 1.00 -0.242 0.031 4.03E-15 
IGP42 rs12887134 14 65115296 C 0.49 0.99 -0.245 0.031 2.24E-15 
IGP42 rs7155541 14 65115995 C 0.49 0.99 -0.245 0.031 2.25E-15 
IGP42 rs6573615 14 65116287 G 0.40 0.99 0.178 0.032 1.67E-08 
IGP42 rs7160780 14 65122466 G 0.40 0.99 0.179 0.031 1.32E-08 
IGP42 rs7161123 14 65122654 G 0.51 1.00 0.242 0.031 3.84E-15 
IGP42 rs2411356 14 65122914 G 0.40 0.99 0.179 0.031 1.32E-08 
IGP42 rs12433827 14 65125363 G 0.92 1.00 -0.327 0.059 3.96E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP42 rs8005309 14 65126261 T 0.92 1.00 -0.327 0.059 3.96E-08 
IGP42 rs17753508 14 65127205 G 0.22 1.00 0.223 0.038 6.94E-09 
IGP42 rs3783709 14 65128417 T 0.51 1.00 0.242 0.031 3.84E-15 
IGP42 rs12889002 14 65133335 C 0.51 1.00 0.242 0.031 3.84E-15 
IGP42 rs743085 14 65137886 G 0.49 1.00 -0.242 0.031 3.84E-15 
IGP42 rs17826724 14 65138073 C 0.08 1.00 0.327 0.060 3.93E-08 
IGP42 rs11849252 14 65139522 G 0.92 1.00 -0.327 0.060 3.93E-08 
IGP42 rs17826736 14 65151955 C 0.08 1.00 0.327 0.060 3.91E-08 
IGP42 rs2073294 14 65152246 C 0.92 1.00 -0.327 0.060 3.91E-08 
IGP42 rs8012278 14 65152326 G 0.49 1.00 -0.247 0.031 1.09E-15 
IGP42 rs11849862 14 65167778 G 0.07 1.00 0.327 0.060 3.91E-08 
IGP42 rs2268957 14 65182986 C 0.93 1.00 -0.327 0.060 3.92E-08 
IGP42 rs12890902 14 65186375 T 0.51 1.00 0.248 0.031 7.47E-16 
IGP42 rs2300865 14 65189768 C 0.49 1.00 -0.248 0.031 7.28E-16 
IGP42 rs11627184 14 65191196 C 0.51 1.00 0.249 0.031 6.80E-16 
IGP42 rs12435908 14 65191221 C 0.93 1.00 -0.327 0.060 3.91E-08 
IGP42 rs11627185 14 65191245 G 0.49 1.00 -0.249 0.031 6.49E-16 
IGP42 rs1998035 14 65195983 G 0.07 1.00 0.327 0.060 3.89E-08 
IGP42 rs2268958 14 65197991 T 0.07 1.00 0.327 0.060 3.88E-08 
IGP42 rs7142651 14 65202474 C 0.51 1.00 0.249 0.031 6.11E-16 
IGP42 rs1998036 14 65207952 C 0.49 0.99 -0.249 0.031 5.85E-16 
IGP42 rs2268959 14 65215071 C 0.78 1.00 -0.229 0.038 2.33E-09 
IGP42 rs2268960 14 65215253 G 0.07 0.97 0.344 0.061 1.84E-08 
IGP42 rs2268961 14 65216518 C 0.49 0.99 -0.250 0.031 4.70E-16 
IGP42 rs2268962 14 65217026 G 0.49 1.00 -0.250 0.031 4.59E-16 
IGP42 rs2300871 14 65217447 C 0.07 1.00 0.327 0.060 3.81E-08 
IGP42 rs2300872 14 65217514 G 0.07 1.00 0.328 0.060 4.03E-08 
IGP42 rs2064694 14 65217999 G 0.51 1.00 0.249 0.031 5.90E-16 
IGP42 rs12588838 14 65232391 G 0.51 1.00 0.249 0.031 5.65E-16 
IGP42 rs8019491 14 65237863 G 0.07 1.00 0.328 0.060 4.01E-08 
IGP42 rs11628765 14 65238202 C 0.49 1.00 -0.250 0.031 5.27E-16 
IGP42 rs2411351 14 65241294 C 0.49 1.00 -0.250 0.031 5.09E-16 
IGP42 rs11846546 14 65246146 G 0.14 0.99 0.259 0.045 7.31E-09 
IGP42 rs8018278 14 65249841 G 0.49 1.00 -0.250 0.031 5.06E-16 
IGP42 rs11627067 14 65252706 G 0.49 1.00 -0.250 0.031 5.04E-16 
IGP42 rs4143898 14 65258635 T 0.44 0.99 0.223 0.031 1.40E-12 
IGP42 rs11622829 14 65261535 T 0.50 1.00 0.249 0.031 7.25E-16 
IGP42 rs11624104 14 65265890 G 0.50 1.00 -0.247 0.031 1.35E-15 
IGP42 rs1535173 14 65268892 C 0.50 1.00 0.246 0.031 1.45E-15 
IGP42 rs3742597 14 65269930 G 0.29 1.00 0.288 0.035 9.84E-17 
IGP42 rs927004 14 65270664 C 0.50 1.00 -0.246 0.031 1.61E-15 
IGP42 rs1950557 14 65271510 C 0.71 1.00 -0.288 0.035 9.89E-17 
IGP42 rs8010876 14 65276729 G 0.50 1.00 -0.246 0.031 1.56E-15 
IGP42 rs1054218 14 65278943 C 0.40 1.00 0.238 0.032 6.66E-14 
IGP42 rs761830 14 65282739 G 0.40 1.00 0.238 0.032 6.68E-14 
IGP42 rs10483785 14 65289270 G 0.50 1.00 0.245 0.031 1.68E-15 
IGP42 rs6573624 14 65296638 G 0.50 0.98 0.248 0.031 1.65E-15 
IGP42 rs2411405 14 65301839 G 0.53 0.97 -0.246 0.031 3.18E-15 
IGP42 rs743084 14 65302355 C 0.52 0.97 -0.245 0.031 5.83E-15 
IGP42 rs11625362 14 65302622 G 0.47 0.97 0.246 0.031 3.22E-15 
IGP42 rs4080329 14 65303243 C 0.62 0.97 -0.243 0.032 6.35E-14 
IGP42 rs11627605 14 65304066 G 0.47 0.97 0.246 0.031 3.29E-15 
IGP42 rs11627578 14 65304201 C 0.47 0.97 0.246 0.031 3.29E-15 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP42 rs1003401 14 65307473 G 0.39 0.97 0.244 0.032 2.87E-14 
IGP42 rs4902416 14 65307843 C 0.53 0.97 -0.246 0.031 3.37E-15 
IGP42 rs1984855 14 65309010 C 0.61 0.97 -0.244 0.032 2.89E-14 
IGP42 rs730807 14 65309043 C 0.47 0.97 0.246 0.031 3.43E-15 
IGP42 rs2411404 14 65309154 C 0.47 0.97 0.246 0.031 3.46E-15 
IGP42 rs1075566 14 65309210 C 0.47 0.97 0.246 0.031 3.49E-15 
IGP42 rs7157449 14 65309890 G 0.53 0.97 -0.246 0.031 3.56E-15 
IGP42 rs6573625 14 65310387 C 0.62 0.97 -0.243 0.032 7.33E-14 
IGP42 rs6573626 14 65310448 C 0.53 0.97 -0.246 0.031 4.11E-15 
IGP42 rs7158556 14 65310482 T 0.38 0.97 0.242 0.032 7.42E-14 
IGP42 rs12894466 14 65310520 G 0.47 0.97 0.246 0.031 4.18E-15 
IGP42 rs11625882 14 65314952 G 0.47 0.97 0.245 0.031 4.74E-15 
IGP42 rs2236067 14 65317765 G 0.61 0.97 -0.244 0.032 3.78E-14 
IGP42 rs968540 14 65318817 G 0.62 0.96 -0.242 0.032 8.88E-14 
IGP42 rs7142165 14 65319985 G 0.53 0.96 -0.245 0.031 6.00E-15 
IGP42 rs7143026 14 65320709 G 0.40 0.95 0.226 0.033 3.92E-12 
IGP42 rs6573627 14 65322079 C 0.51 0.98 -0.230 0.031 2.13E-13 
IGP42 rs4400971 14 65324331 C 0.43 0.99 0.193 0.031 8.89E-10 
IGP42 rs7151846 14 65325534 C 0.51 0.99 -0.222 0.031 8.85E-13 
IGP42 rs4073416 14 65329147 C 0.43 0.99 0.193 0.031 9.27E-10 
IGP42 rs4073415 14 65329283 G 0.51 0.99 -0.223 0.031 8.96E-13 
IGP42 rs11850120 14 65330132 C 0.42 0.98 0.190 0.032 2.31E-09 
IGP42 rs8018379 14 65331690 C 0.56 0.95 -0.232 0.032 5.80E-13 
IGP42 rs8007846 14 65332716 G 0.48 0.98 0.186 0.031 3.21E-09 
IGP42 rs4078408 14 65342587 G 0.29 0.86 -0.198 0.037 8.41E-08 
IGP42 rs3924222 14 65343491 C 0.41 0.80 -0.246 0.035 1.58E-12 
IGP42 rs10149325 14 65347120 G 0.41 0.80 -0.247 0.035 1.30E-12 
IGP43 rs17348299 5 55358652 C 0.84 0.85 -0.280 0.045 3.09E-10 
IGP43 rs16884711 5 55360559 C 0.19 0.91 0.227 0.040 1.89E-08 
IGP43 rs10454831 5 55374548 T 0.80 0.90 -0.217 0.040 5.59E-08 
IGP43 rs955768 5 55374759 T 0.20 0.90 0.217 0.040 5.59E-08 
IGP45 rs1122979 7 150546004 G 0.88 0.91 0.305 0.049 6.06E-10 
IGP45 rs7812088 7 150550762 G 0.87 0.98 0.288 0.047 9.67E-10 
IGP45 rs7781265 7 150581873 G 0.88 0.92 0.287 0.050 9.22E-09 
IGP45 rs5757647 22 38104993 C 0.33 1.00 0.206 0.033 3.28E-10 
IGP45 rs4821890 22 38107469 G 0.34 0.99 0.206 0.033 3.31E-10 
IGP45 rs1010169 22 38108113 G 0.67 1.00 -0.206 0.033 3.26E-10 
IGP45 rs1010170 22 38108273 C 0.67 1.00 -0.206 0.033 3.30E-10 
IGP45 rs5757650 22 38108365 C 0.67 1.00 -0.206 0.033 3.29E-10 
IGP45 rs9611169 22 38112973 C 0.33 1.00 0.206 0.033 3.29E-10 
IGP45 rs9611170 22 38114791 C 0.66 0.99 -0.204 0.033 4.12E-10 
IGP45 rs2413590 22 38120137 C 0.67 1.00 -0.204 0.033 4.14E-10 
IGP45 rs5750808 22 38120933 G 0.33 1.00 0.204 0.033 4.21E-10 
IGP45 rs5750811 22 38123012 G 0.67 1.00 -0.204 0.033 4.32E-10 
IGP45 rs5750812 22 38123025 G 0.34 0.99 0.205 0.033 3.91E-10 
IGP45 rs5757655 22 38127124 C 0.66 0.99 -0.205 0.033 3.88E-10 
IGP45 rs4821893 22 38127725 G 0.33 1.00 0.205 0.033 3.35E-10 
IGP45 rs5750814 22 38127933 C 0.67 1.00 -0.205 0.033 3.24E-10 
IGP45 rs5757657 22 38128375 G 0.33 1.00 0.205 0.033 3.46E-10 
IGP45 rs5750815 22 38128395 C 0.67 1.00 -0.205 0.033 3.43E-10 
IGP45 rs4337572 22 38130650 C 0.33 1.00 0.205 0.033 3.45E-10 
IGP45 rs4821894 22 38139766 C 0.66 1.00 -0.205 0.033 3.46E-10 
IGP45 rs5750816 22 38140325 C 0.34 1.00 0.204 0.033 3.49E-10 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP45 rs6001585 22 38142932 C 0.22 1.00 0.212 0.037 7.63E-09 
IGP45 rs6001587 22 38148954 C 0.66 1.00 -0.204 0.033 3.48E-10 
IGP45 rs5750818 22 38150831 G 0.66 1.00 -0.204 0.033 3.46E-10 
IGP45 rs5757665 22 38151587 G 0.66 1.00 -0.204 0.033 3.45E-10 
IGP45 rs4821895 22 38152961 G 0.66 1.00 -0.204 0.033 3.43E-10 
IGP45 rs739141 22 38154396 C 0.36 1.00 0.208 0.032 1.10E-10 
IGP45 rs5750820 22 38155268 G 0.67 0.97 -0.219 0.033 3.93E-11 
IGP45 rs5750822 22 38156734 G 0.34 1.00 0.205 0.033 3.17E-10 
IGP45 rs7949 22 38157499 G 0.34 0.99 0.206 0.033 2.89E-10 
IGP45 rs5757670 22 38159682 G 0.34 0.99 0.206 0.033 2.70E-10 
IGP45 rs5750825 22 38161224 G 0.71 0.98 -0.243 0.034 1.34E-12 
IGP45 rs1972280 22 38161932 T 0.29 0.98 0.245 0.034 1.08E-12 
IGP45 rs4821897 22 38165533 G 0.71 0.97 -0.245 0.034 1.02E-12 
IGP45 rs5750830 22 38170774 C 0.29 0.98 0.250 0.034 3.24E-13 
IGP45 rs5757676 22 38171646 C 0.78 0.96 -0.227 0.037 1.14E-09 
IGP45 rs8137426 22 38174296 G 0.71 0.98 -0.249 0.034 3.21E-13 
IGP45 rs5757683 22 38180120 G 0.29 0.98 0.249 0.034 3.17E-13 
IGP45 rs1557541 22 38181916 C 0.29 0.98 0.249 0.034 3.14E-13 
IGP45 rs1557542 22 38182296 C 0.71 0.98 -0.249 0.034 3.11E-13 
IGP45 rs5995735 22 38184367 C 0.29 0.98 0.249 0.034 3.07E-13 
IGP45 rs738289 22 38185829 C 0.29 0.98 0.249 0.034 3.02E-13 
IGP45 rs909674 22 38189115 C 0.30 0.99 0.247 0.034 2.84E-13 
IGP46 rs6583437 7 50320813 G 0.64 0.98 0.174 0.032 3.95E-08 
IGP46 rs6421315 7 50325753 C 0.37 0.95 -0.173 0.032 7.38E-08 
IGP46 rs7159888 14 64828395 G 0.55 0.99 -0.200 0.031 1.06E-10 
IGP46 rs1256540 14 64833822 C 0.43 1.00 0.168 0.031 6.83E-08 
IGP46 rs4902383 14 64834326 C 0.19 0.94 0.221 0.040 2.57E-08 
IGP46 rs1269068 14 64837086 C 0.57 1.00 -0.167 0.031 7.65E-08 
IGP46 rs1760978 14 64840800 G 0.43 0.98 0.198 0.031 2.04E-10 
IGP46 rs10144975 14 64843735 C 0.80 0.98 -0.220 0.038 7.06E-09 
IGP46 rs17102587 14 64844230 C 0.20 0.97 0.228 0.038 2.70E-09 
IGP46 rs8017974 14 64844940 C 0.20 0.99 0.230 0.038 1.55E-09 
IGP46 rs11847263 14 64845448 G 0.39 0.98 0.233 0.032 1.81E-13 
IGP46 rs4902386 14 64848043 C 0.80 0.99 -0.230 0.038 1.42E-09 
IGP46 rs8019473 14 64848881 G 0.80 0.99 -0.230 0.038 1.41E-09 
IGP46 rs10138662 14 64849235 G 0.20 0.99 0.230 0.038 1.36E-09 
IGP46 rs10134589 14 64850987 T 0.19 0.94 0.239 0.039 1.20E-09 
IGP46 rs7151212 14 64851375 C 0.80 0.99 -0.231 0.038 1.30E-09 
IGP46 rs11158587 14 64852465 G 0.80 0.99 -0.231 0.038 1.29E-09 
IGP46 rs8019767 14 64852538 G 0.80 1.00 -0.231 0.038 1.28E-09 
IGP46 rs6573598 14 64852772 C 0.20 1.00 0.231 0.038 1.27E-09 
IGP46 rs6573599 14 64852880 C 0.80 1.00 -0.231 0.038 1.22E-09 
IGP46 rs6573602 14 64854363 C 0.20 1.00 0.231 0.038 1.19E-09 
IGP46 rs17102598 14 64854613 G 0.80 1.00 -0.231 0.038 1.19E-09 
IGP46 rs6573604 14 64857694 C 0.20 1.00 0.231 0.038 1.18E-09 
IGP46 rs747541 14 64875163 C 0.45 0.98 0.194 0.031 7.23E-10 
IGP46 rs1954052 14 64875462 T 0.44 0.99 0.191 0.031 1.13E-09 
IGP46 rs12886005 14 64879000 C 0.45 0.87 0.202 0.033 1.28E-09 
IGP46 rs12886168 14 64879039 C 0.45 0.98 0.193 0.031 7.15E-10 
IGP46 rs11623920 14 64889067 C 0.56 1.00 -0.191 0.031 1.12E-09 
IGP46 rs11621121 14 64892246 C 0.44 1.00 0.190 0.031 1.11E-09 
IGP46 rs10148907 14 64903125 C 0.69 0.98 -0.195 0.034 9.86E-09 
IGP46 rs4902393 14 64909267 C 0.56 0.99 -0.190 0.031 1.42E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP46 rs12882269 14 64916897 G 0.56 0.97 -0.184 0.032 5.76E-09 
IGP46 rs11158591 14 64925515 C 0.44 0.97 0.183 0.032 7.00E-09 
IGP46 rs11158592 14 64929721 G 0.50 0.99 0.167 0.031 5.00E-08 
IGP46 rs11158593 14 64929737 G 0.50 0.99 0.165 0.031 6.40E-08 
IGP46 rs10138570 14 64929791 G 0.50 0.99 -0.165 0.031 6.47E-08 
IGP46 rs2411822 14 64948148 G 0.47 1.00 -0.166 0.031 6.13E-08 
IGP46 rs1953416 14 64948560 C 0.53 1.00 0.164 0.031 8.01E-08 
IGP46 rs883081 14 64950374 C 0.53 1.00 0.164 0.031 8.13E-08 
IGP46 rs883082 14 64950693 G 0.47 1.00 -0.165 0.031 6.26E-08 
IGP46 rs12879971 14 64971357 G 0.52 0.99 0.168 0.031 4.64E-08 
IGP46 rs12892058 14 64973194 C 0.47 0.99 -0.168 0.031 4.90E-08 
IGP46 rs12589698 14 64990188 G 0.52 0.98 0.171 0.031 2.79E-08 
IGP46 rs4899179 14 64996501 G 0.49 0.99 -0.173 0.031 1.74E-08 
IGP46 rs2184603 14 65000423 C 0.49 0.99 -0.173 0.031 1.72E-08 
IGP46 rs3825640 14 65030957 C 0.51 0.99 0.172 0.031 2.01E-08 
IGP46 rs11627084 14 65048589 G 0.49 1.00 -0.173 0.031 1.55E-08 
IGP46 rs10483780 14 65049923 C 0.50 0.99 -0.165 0.031 7.59E-08 
IGP46 rs2149841 14 65080072 C 0.51 0.99 0.172 0.031 2.14E-08 
IGP46 rs11621680 14 65084434 G 0.50 0.99 -0.164 0.031 8.82E-08 
IGP46 rs11158601 14 65095116 G 0.49 1.00 -0.171 0.031 2.06E-08 
IGP46 rs1958561 14 65106514 G 0.49 1.00 -0.171 0.031 2.06E-08 
IGP46 rs12887134 14 65115296 C 0.49 0.99 -0.170 0.031 2.71E-08 
IGP46 rs7155541 14 65115995 C 0.49 0.99 -0.170 0.031 2.71E-08 
IGP46 rs7161123 14 65122654 G 0.51 1.00 0.172 0.031 1.84E-08 
IGP46 rs4581615 14 65125696 C 0.51 1.00 0.172 0.031 1.84E-08 
IGP46 rs3783709 14 65128417 T 0.51 1.00 0.172 0.031 1.83E-08 
IGP46 rs12889002 14 65133335 C 0.51 1.00 0.172 0.031 1.83E-08 
IGP46 rs743085 14 65137886 G 0.49 1.00 -0.172 0.031 1.83E-08 
IGP46 rs8012278 14 65152326 G 0.49 1.00 -0.174 0.031 1.27E-08 
IGP46 rs12890902 14 65186375 T 0.51 1.00 0.174 0.031 1.20E-08 
IGP46 rs2300865 14 65189768 C 0.49 1.00 -0.174 0.031 1.20E-08 
IGP46 rs11627184 14 65191196 C 0.51 1.00 0.174 0.031 1.18E-08 
IGP46 rs11627185 14 65191245 G 0.49 1.00 -0.174 0.031 1.17E-08 
IGP46 rs7142651 14 65202474 C 0.51 1.00 0.174 0.031 1.30E-08 
IGP46 rs1998036 14 65207952 C 0.49 0.99 -0.174 0.031 1.30E-08 
IGP46 rs2268961 14 65216518 C 0.49 0.99 -0.174 0.031 1.24E-08 
IGP46 rs2268962 14 65217026 G 0.49 1.00 -0.174 0.031 1.24E-08 
IGP46 rs2064694 14 65217999 G 0.51 1.00 0.172 0.031 1.85E-08 
IGP46 rs12588838 14 65232391 G 0.51 1.00 0.172 0.031 1.86E-08 
IGP46 rs11628765 14 65238202 C 0.49 1.00 -0.172 0.031 1.85E-08 
IGP46 rs2411351 14 65241294 C 0.49 1.00 -0.172 0.031 1.87E-08 
IGP46 rs8018278 14 65249841 G 0.49 1.00 -0.172 0.031 1.92E-08 
IGP46 rs11627067 14 65252706 G 0.49 1.00 -0.172 0.031 1.96E-08 
IGP46 rs11622829 14 65261535 T 0.50 1.00 0.166 0.031 5.64E-08 
IGP46 rs11624104 14 65265890 G 0.50 1.00 -0.166 0.031 5.95E-08 
IGP46 rs1535173 14 65268892 C 0.50 1.00 0.166 0.031 6.25E-08 
IGP46 rs3742597 14 65269930 G 0.29 1.00 0.191 0.034 2.87E-08 
IGP46 rs927004 14 65270664 C 0.50 1.00 -0.165 0.031 7.11E-08 
IGP46 rs1950557 14 65271510 C 0.71 1.00 -0.190 0.034 2.99E-08 
IGP46 rs8010876 14 65276729 G 0.50 1.00 -0.165 0.031 7.23E-08 
IGP46 rs2411405 14 65301839 G 0.52 0.97 -0.167 0.031 7.29E-08 
IGP46 rs743084 14 65302355 C 0.52 0.97 -0.171 0.031 3.69E-08 
IGP46 rs11625362 14 65302622 G 0.48 0.97 0.166 0.031 7.65E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP46 rs11627578 14 65304201 C 0.48 0.97 0.166 0.031 7.99E-08 
IGP46 rs11628840 14 65305395 G 0.52 0.97 -0.166 0.031 8.06E-08 
IGP46 rs4902416 14 65307843 C 0.52 0.97 -0.166 0.031 8.28E-08 
IGP46 rs730807 14 65309043 C 0.48 0.97 0.166 0.031 8.45E-08 
IGP46 rs2411404 14 65309154 C 0.48 0.97 0.166 0.031 8.53E-08 
IGP46 rs1075566 14 65309210 C 0.48 0.97 0.166 0.031 8.58E-08 
IGP46 rs7157449 14 65309890 G 0.52 0.97 -0.166 0.031 8.75E-08 
IGP46 rs6573626 14 65310448 C 0.52 0.97 -0.165 0.031 9.56E-08 
IGP46 rs12894466 14 65310520 G 0.48 0.97 0.165 0.031 9.70E-08 
IGP49 rs5760020 22 22463092 G 0.30 1.00 -0.185 0.034 4.77E-08 
IGP49 rs2073389 22 22463493 C 0.30 1.00 -0.185 0.034 4.52E-08 
IGP49 rs17630758 22 22466542 G 0.83 0.99 0.327 0.041 2.33E-15 
IGP49 rs5760023 22 22468301 C 0.30 1.00 -0.186 0.034 3.73E-08 
IGP49 rs12167679 22 22471690 C 0.80 1.00 0.256 0.039 3.95E-11 
IGP49 rs17548631 22 22474125 C 0.17 0.99 -0.326 0.041 2.27E-15 
IGP49 rs9620326 22 22476629 C 0.83 0.99 0.326 0.041 2.32E-15 
IGP49 rs9624334 22 22496256 C 0.17 0.99 -0.332 0.041 1.12E-15 
IGP49 rs2186369 22 22500996 G 0.19 0.88 -0.336 0.042 7.34E-16 
IGP49 rs6519476 22 22512500 G 0.76 0.99 0.215 0.036 3.56E-09 
IGP49 rs5757642 22 38094770 C 0.64 1.00 -0.182 0.033 2.54E-08 
IGP49 rs7286714 22 38095550 C 0.36 0.97 0.182 0.033 2.97E-08 
IGP49 rs5757644 22 38096386 C 0.36 0.97 0.182 0.033 2.96E-08 
IGP49 rs5750806 22 38096957 G 0.64 0.97 -0.182 0.033 2.97E-08 
IGP49 rs1569499 22 38099764 C 0.64 0.97 -0.184 0.033 2.70E-08 
IGP49 rs4821888 22 38100543 G 0.64 0.97 -0.183 0.033 2.75E-08 
IGP49 rs5750820 22 38155268 G 0.67 0.97 -0.180 0.033 5.71E-08 
IGP49 rs5750825 22 38161224 G 0.71 0.98 -0.199 0.034 6.65E-09 
IGP49 rs1972280 22 38161932 T 0.29 0.98 0.200 0.034 6.12E-09 
IGP49 rs4821897 22 38165533 G 0.71 0.97 -0.200 0.034 5.74E-09 
IGP49 rs5750830 22 38170774 C 0.29 0.98 0.201 0.034 4.37E-09 
IGP49 rs8137426 22 38174296 G 0.71 0.98 -0.201 0.034 4.32E-09 
IGP49 rs5757683 22 38180120 G 0.29 0.98 0.201 0.034 4.30E-09 
IGP49 rs1557541 22 38181916 C 0.29 0.98 0.201 0.034 4.31E-09 
IGP49 rs1557542 22 38182296 C 0.71 0.98 -0.201 0.034 4.31E-09 
IGP49 rs5995735 22 38184367 C 0.29 0.98 0.201 0.034 4.33E-09 
IGP49 rs738289 22 38185829 C 0.29 0.98 0.201 0.034 4.35E-09 
IGP49 rs909674 22 38189115 C 0.30 0.99 0.200 0.034 3.26E-09 
IGP50 rs17630758 22 22466542 G 0.83 0.99 0.239 0.041 6.21E-09 
IGP50 rs12167679 22 22471690 C 0.80 1.00 0.227 0.039 5.16E-09 
IGP50 rs17548631 22 22474125 C 0.17 0.99 -0.239 0.041 6.61E-09 
IGP50 rs9620326 22 22476629 C 0.83 0.99 0.238 0.041 6.63E-09 
IGP50 rs9624334 22 22496256 C 0.17 0.99 -0.239 0.041 7.86E-09 
IGP50 rs2186369 22 22500996 G 0.19 0.88 -0.259 0.042 5.34E-10 
IGP51 rs7159888 14 64828395 G 0.55 0.99 -0.199 0.031 1.63E-10 
IGP51 rs4902383 14 64834326 C 0.19 0.94 0.230 0.040 7.18E-09 
IGP51 rs1760978 14 64840800 G 0.43 0.98 0.190 0.031 1.25E-09 
IGP51 rs10144975 14 64843735 C 0.80 0.98 -0.230 0.038 1.73E-09 
IGP51 rs17102587 14 64844230 C 0.20 0.97 0.236 0.038 7.98E-10 
IGP51 rs8017974 14 64844940 C 0.20 0.99 0.237 0.038 5.56E-10 
IGP51 rs11847263 14 64845448 G 0.39 0.98 0.232 0.032 2.35E-13 
IGP51 rs4902386 14 64848043 C 0.80 0.99 -0.236 0.038 5.46E-10 
IGP51 rs8019473 14 64848881 G 0.80 0.99 -0.236 0.038 5.43E-10 
IGP51 rs10138662 14 64849235 G 0.20 0.99 0.236 0.038 5.24E-10 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP51 rs7151212 14 64851375 C 0.80 0.99 -0.237 0.038 5.05E-10 
IGP51 rs11158587 14 64852465 G 0.80 0.99 -0.237 0.038 5.04E-10 
IGP51 rs8019767 14 64852538 G 0.80 1.00 -0.237 0.038 5.05E-10 
IGP51 rs6573598 14 64852772 C 0.20 1.00 0.237 0.038 5.04E-10 
IGP51 rs6573599 14 64852880 C 0.80 1.00 -0.237 0.038 4.83E-10 
IGP51 rs6573602 14 64854363 C 0.20 1.00 0.237 0.038 4.73E-10 
IGP51 rs17102598 14 64854613 G 0.80 1.00 -0.237 0.038 4.76E-10 
IGP51 rs6573604 14 64857694 C 0.20 1.00 0.237 0.038 4.75E-10 
IGP51 rs747541 14 64875163 C 0.45 0.98 0.192 0.032 1.05E-09 
IGP51 rs1954052 14 64875462 T 0.44 0.99 0.190 0.031 1.65E-09 
IGP51 rs12886005 14 64879000 C 0.45 0.87 0.201 0.033 1.94E-09 
IGP51 rs12886168 14 64879039 C 0.45 0.98 0.192 0.031 1.05E-09 
IGP51 rs11623920 14 64889067 C 0.56 1.00 -0.189 0.031 1.65E-09 
IGP51 rs11621121 14 64892246 C 0.44 1.00 0.189 0.031 1.65E-09 
IGP51 rs10148907 14 64903125 C 0.69 0.98 -0.204 0.034 2.41E-09 
IGP51 rs4902393 14 64909267 C 0.56 0.99 -0.188 0.032 2.28E-09 
IGP51 rs11621604 14 64910527 G 0.56 0.98 -0.183 0.032 7.06E-09 
IGP51 rs12882269 14 64916897 G 0.56 0.97 -0.181 0.032 1.07E-08 
IGP51 rs11158591 14 64925515 C 0.44 0.97 0.180 0.032 1.33E-08 
IGP51 rs3742597 14 65269930 G 0.29 1.00 0.194 0.034 1.69E-08 
IGP51 rs1950557 14 65271510 C 0.71 1.00 -0.194 0.034 1.71E-08 
IGP53 rs17348299 5 55358652 C 0.84 0.85 0.292 0.045 6.88E-11 
IGP53 rs16884711 5 55360559 C 0.19 0.91 -0.247 0.041 1.23E-09 
IGP53 rs10454831 5 55374548 T 0.80 0.90 0.228 0.040 1.31E-08 
IGP53 rs955768 5 55374759 T 0.20 0.90 -0.229 0.040 1.31E-08 
IGP53 rs3818593 9 33110706 G 0.20 1.00 -0.215 0.039 3.48E-08 
IGP53 rs10971418 9 33112024 C 0.80 0.98 0.214 0.039 3.79E-08 
IGP53 rs12342831 9 33114872 C 0.26 0.97 -0.214 0.035 1.68E-09 
IGP53 rs10813951 9 33118021 G 0.26 0.97 -0.214 0.035 1.70E-09 
IGP53 rs2067749 9 33120640 G 0.11 0.98 0.294 0.050 3.97E-09 
IGP53 rs10511909 9 33122518 C 0.11 0.98 0.294 0.050 4.08E-09 
IGP53 rs3780486 9 33129453 C 0.74 0.97 0.214 0.036 1.74E-09 
IGP53 rs10813957 9 33143527 G 0.74 0.96 0.216 0.036 1.60E-09 
IGP53 rs10971438 9 33170308 G 0.30 0.75 -0.224 0.039 6.74E-09 
IGP53 rs10813960 9 33170362 C 0.70 0.74 0.225 0.039 6.58E-09 
IGP53 rs10971439 9 33170813 C 0.23 0.71 -0.242 0.043 2.26E-08 
IGP54 rs278541 8 94292121 C 0.98 0.50 -0.805 0.147 3.87E-08 
IGP55 rs17348299 5 55358652 C 0.84 0.85 -0.286 0.045 1.35E-10 
IGP55 rs16884711 5 55360559 C 0.19 0.91 0.239 0.040 3.59E-09 
IGP55 rs10454831 5 55374548 T 0.80 0.90 -0.225 0.040 2.03E-08 
IGP55 rs955768 5 55374759 T 0.20 0.90 0.225 0.040 2.02E-08 
IGP57 rs17348299 5 55358652 C 0.84 0.85 0.287 0.045 1.32E-10 
IGP57 rs16884711 5 55360559 C 0.19 0.91 -0.237 0.041 5.05E-09 
IGP57 rs10454831 5 55374548 T 0.80 0.90 0.223 0.040 2.73E-08 
IGP57 rs955768 5 55374759 T 0.20 0.90 -0.223 0.040 2.73E-08 
IGP57 rs3818593 9 33110706 G 0.20 1.00 -0.209 0.039 7.16E-08 
IGP57 rs10971418 9 33112024 C 0.80 0.98 0.209 0.039 7.96E-08 
IGP57 rs12342831 9 33114872 C 0.26 0.97 -0.210 0.035 3.03E-09 
IGP57 rs10813951 9 33118021 G 0.26 0.97 -0.210 0.035 3.07E-09 
IGP57 rs2067749 9 33120640 G 0.11 0.98 0.276 0.050 3.56E-08 
IGP57 rs10511909 9 33122518 C 0.11 0.98 0.275 0.050 3.64E-08 
IGP57 rs3780486 9 33129453 C 0.74 0.97 0.210 0.036 3.26E-09 
IGP57 rs10813957 9 33143527 G 0.74 0.96 0.213 0.036 2.99E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP57 rs10813960 9 33170362 C 0.70 0.74 0.218 0.039 1.81E-08 
IGP57 rs10971439 9 33170813 C 0.23 0.71 -0.234 0.043 6.36E-08 
IGP58 rs7782210 7 50319291 G 0.38 0.98 0.171 0.032 6.91E-08 
IGP58 rs6583437 7 50320813 G 0.64 0.98 -0.177 0.032 2.50E-08 
IGP58 rs7789913 7 50323241 C 0.62 1.00 -0.169 0.031 7.96E-08 
IGP58 rs6421315 7 50325753 C 0.37 0.95 0.178 0.032 3.16E-08 
IGP58 rs7159888 14 64828395 G 0.55 0.99 0.246 0.031 2.31E-15 
IGP58 rs12431963 14 64829447 C 0.92 0.92 0.357 0.058 7.41E-10 
IGP58 rs1256540 14 64833822 C 0.43 1.00 -0.213 0.031 8.16E-12 
IGP58 rs4902383 14 64834326 C 0.19 0.94 -0.290 0.040 2.37E-13 
IGP58 rs1269068 14 64837086 C 0.57 1.00 0.212 0.031 9.53E-12 
IGP58 rs10135194 14 64840731 C 0.94 0.84 0.390 0.070 2.15E-08 
IGP58 rs1760978 14 64840800 G 0.43 0.98 -0.250 0.031 1.16E-15 
IGP58 rs10144975 14 64843735 C 0.80 0.98 0.293 0.038 1.27E-14 
IGP58 rs17102587 14 64844230 C 0.20 0.97 -0.301 0.038 3.74E-15 
IGP58 rs8017974 14 64844940 C 0.20 0.99 -0.302 0.038 2.15E-15 
IGP58 rs11847263 14 64845448 G 0.39 0.98 -0.285 0.032 2.36E-19 
IGP58 rs10132229 14 64847313 G 0.10 1.00 -0.342 0.050 1.16E-11 
IGP58 rs4902386 14 64848043 C 0.80 0.99 0.302 0.038 2.03E-15 
IGP58 rs10147958 14 64848586 C 0.10 1.00 -0.342 0.050 1.13E-11 
IGP58 rs8019473 14 64848881 G 0.80 0.99 0.302 0.038 2.01E-15 
IGP58 rs10138662 14 64849235 G 0.20 0.99 -0.302 0.038 1.93E-15 
IGP58 rs10134589 14 64850987 T 0.20 0.94 -0.316 0.039 1.00E-15 
IGP58 rs7151212 14 64851375 C 0.80 0.99 0.302 0.038 1.84E-15 
IGP58 rs11158587 14 64852465 G 0.80 0.99 0.302 0.038 1.83E-15 
IGP58 rs8019767 14 64852538 G 0.80 1.00 0.302 0.038 1.83E-15 
IGP58 rs6573598 14 64852772 C 0.20 1.00 -0.302 0.038 1.81E-15 
IGP58 rs6573599 14 64852880 C 0.80 1.00 0.302 0.038 1.74E-15 
IGP58 rs10144503 14 64853862 G 0.90 1.00 0.344 0.050 8.93E-12 
IGP58 rs6573602 14 64854363 C 0.20 1.00 -0.302 0.038 1.69E-15 
IGP58 rs17102598 14 64854613 G 0.80 1.00 0.302 0.038 1.70E-15 
IGP58 rs12436299 14 64854947 G 0.90 1.00 0.344 0.050 8.47E-12 
IGP58 rs6573604 14 64857694 C 0.20 1.00 -0.302 0.038 1.68E-15 
IGP58 rs9635250 14 64869101 T 0.10 1.00 -0.345 0.050 8.19E-12 
IGP58 rs12881755 14 64871564 G 0.65 0.96 0.186 0.033 2.23E-08 
IGP58 rs747541 14 64875163 C 0.45 0.98 -0.239 0.032 3.91E-14 
IGP58 rs1954052 14 64875462 T 0.44 0.99 -0.237 0.031 4.74E-14 
IGP58 rs12886005 14 64879000 C 0.45 0.87 -0.248 0.033 1.37E-13 
IGP58 rs12886168 14 64879039 C 0.45 0.98 -0.238 0.032 3.84E-14 
IGP58 rs11623920 14 64889067 C 0.56 1.00 0.237 0.031 4.66E-14 
IGP58 rs11621121 14 64892246 C 0.44 1.00 -0.237 0.031 4.72E-14 
IGP58 rs10148907 14 64903125 C 0.69 0.98 0.244 0.034 8.51E-13 
IGP58 rs4902393 14 64909267 C 0.56 0.99 0.237 0.032 6.49E-14 
IGP58 rs11621604 14 64910527 G 0.56 0.98 0.232 0.032 2.62E-13 
IGP58 rs12882269 14 64916897 G 0.56 0.97 0.230 0.032 4.20E-13 
IGP58 rs11158591 14 64925515 C 0.44 0.97 -0.229 0.032 5.47E-13 
IGP58 rs11158592 14 64929721 G 0.50 0.99 -0.206 0.031 1.85E-11 
IGP58 rs11158593 14 64929737 G 0.50 0.99 -0.206 0.031 2.01E-11 
IGP58 rs10138570 14 64929791 G 0.50 0.99 0.205 0.031 2.04E-11 
IGP58 rs2411822 14 64948148 G 0.47 1.00 0.202 0.031 4.28E-11 
IGP58 rs1953416 14 64948560 C 0.53 1.00 -0.202 0.031 4.91E-11 
IGP58 rs883081 14 64950374 C 0.53 1.00 -0.202 0.031 4.91E-11 
IGP58 rs883082 14 64950693 G 0.47 1.00 0.202 0.031 4.29E-11 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP58 rs11851576 14 64970036 C 0.54 0.99 0.166 0.031 9.69E-08 
IGP58 rs12879971 14 64971357 G 0.52 0.99 -0.205 0.031 2.55E-11 
IGP58 rs12892058 14 64973194 C 0.47 0.99 0.206 0.031 2.26E-11 
IGP58 rs12589698 14 64990188 G 0.52 0.98 -0.212 0.031 7.27E-12 
IGP58 rs4899179 14 64996501 G 0.49 0.99 0.213 0.031 4.83E-12 
IGP58 rs2184603 14 65000423 C 0.49 0.99 0.213 0.031 4.68E-12 
IGP58 rs3825640 14 65030957 C 0.51 0.99 -0.213 0.031 4.46E-12 
IGP58 rs11627084 14 65048589 G 0.49 1.00 0.213 0.031 4.00E-12 
IGP58 rs10483780 14 65049923 C 0.50 0.99 0.205 0.031 2.39E-11 
IGP58 rs2149841 14 65080072 C 0.51 0.99 -0.212 0.031 5.16E-12 
IGP58 rs11621680 14 65084434 G 0.50 0.99 0.204 0.031 3.44E-11 
IGP58 rs11158601 14 65095116 G 0.49 1.00 0.210 0.031 7.46E-12 
IGP58 rs7146742 14 65102687 G 0.43 0.99 -0.172 0.032 5.03E-08 
IGP58 rs1958561 14 65106514 G 0.49 1.00 0.210 0.031 7.17E-12 
IGP58 rs12887134 14 65115296 C 0.49 0.99 0.210 0.031 8.02E-12 
IGP58 rs7155541 14 65115995 C 0.49 0.99 0.210 0.031 8.00E-12 
IGP58 rs7161123 14 65122654 G 0.51 1.00 -0.212 0.031 4.55E-12 
IGP58 rs4581615 14 65125696 C 0.51 1.00 -0.212 0.031 4.55E-12 
IGP58 rs3783709 14 65128417 T 0.51 1.00 -0.212 0.031 4.55E-12 
IGP58 rs12889002 14 65133335 C 0.51 1.00 -0.212 0.031 4.55E-12 
IGP58 rs743085 14 65137886 G 0.49 1.00 0.212 0.031 4.55E-12 
IGP58 rs8012278 14 65152326 G 0.49 1.00 0.215 0.031 2.39E-12 
IGP58 rs12890902 14 65186375 T 0.51 1.00 -0.215 0.031 2.27E-12 
IGP58 rs2300865 14 65189768 C 0.49 1.00 0.215 0.031 2.28E-12 
IGP58 rs11627184 14 65191196 C 0.51 1.00 -0.215 0.031 2.26E-12 
IGP58 rs11627185 14 65191245 G 0.49 1.00 0.215 0.031 2.24E-12 
IGP58 rs7142651 14 65202474 C 0.51 1.00 -0.214 0.031 3.00E-12 
IGP58 rs1998036 14 65207952 C 0.49 0.99 0.214 0.031 3.06E-12 
IGP58 rs2268961 14 65216518 C 0.49 0.99 0.214 0.031 3.01E-12 
IGP58 rs2268962 14 65217026 G 0.49 1.00 0.214 0.031 3.00E-12 
IGP58 rs2064694 14 65217999 G 0.51 1.00 -0.210 0.031 6.66E-12 
IGP58 rs12588838 14 65232391 G 0.51 1.00 -0.210 0.031 6.79E-12 
IGP58 rs11628765 14 65238202 C 0.49 1.00 0.210 0.031 6.85E-12 
IGP58 rs2411351 14 65241294 C 0.49 1.00 0.210 0.031 7.10E-12 
IGP58 rs8018278 14 65249841 G 0.49 1.00 0.210 0.031 7.25E-12 
IGP58 rs11627067 14 65252706 G 0.49 1.00 0.210 0.031 7.38E-12 
IGP58 rs4143898 14 65258635 T 0.44 0.99 -0.179 0.031 1.00E-08 
IGP58 rs11622829 14 65261535 T 0.50 1.00 -0.205 0.031 2.17E-11 
IGP58 rs11624104 14 65265890 G 0.50 1.00 0.206 0.031 2.10E-11 
IGP58 rs1535173 14 65268892 C 0.50 1.00 -0.205 0.031 2.52E-11 
IGP58 rs3742597 14 65269930 G 0.29 1.00 -0.244 0.034 1.34E-12 
IGP58 rs927004 14 65270664 C 0.50 1.00 0.204 0.031 2.88E-11 
IGP58 rs1950557 14 65271510 C 0.71 1.00 0.244 0.034 1.39E-12 
IGP58 rs8010876 14 65276729 G 0.50 1.00 0.204 0.031 2.91E-11 
IGP58 rs1054218 14 65278943 C 0.40 1.00 -0.184 0.032 5.55E-09 
IGP58 rs761830 14 65282739 G 0.40 1.00 -0.184 0.032 5.58E-09 
IGP58 rs10483785 14 65289270 G 0.50 1.00 -0.201 0.031 4.83E-11 
IGP58 rs6573624 14 65296638 G 0.50 0.98 -0.203 0.031 5.48E-11 
IGP58 rs2411405 14 65301839 G 0.52 0.97 0.208 0.031 1.93E-11 
IGP58 rs743084 14 65302355 C 0.52 0.97 0.210 0.031 1.70E-11 
IGP58 rs11625362 14 65302622 G 0.48 0.97 -0.208 0.031 2.01E-11 
IGP58 rs4080329 14 65303243 C 0.62 0.97 0.192 0.032 2.66E-09 
IGP58 rs11627605 14 65304066 G 0.48 0.97 -0.208 0.031 2.08E-11 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP58 rs11628840 14 65305395 G 0.52 0.97 0.208 0.031 2.10E-11 
IGP58 rs1003401 14 65307473 G 0.39 0.97 -0.197 0.032 6.42E-10 
IGP58 rs4902416 14 65307843 C 0.52 0.97 0.208 0.031 2.16E-11 
IGP58 rs1984855 14 65309010 C 0.61 0.97 0.197 0.032 6.49E-10 
IGP58 rs730807 14 65309043 C 0.48 0.97 -0.208 0.031 2.20E-11 
IGP58 rs2411404 14 65309154 C 0.48 0.97 -0.208 0.031 2.22E-11 
IGP58 rs1075566 14 65309210 C 0.48 0.97 -0.208 0.031 2.23E-11 
IGP58 rs7157449 14 65309890 G 0.52 0.97 0.208 0.031 2.29E-11 
IGP58 rs6573625 14 65310387 C 0.62 0.97 0.191 0.032 3.24E-09 
IGP58 rs6573626 14 65310448 C 0.52 0.97 0.207 0.031 2.59E-11 
IGP58 rs7158556 14 65310482 T 0.38 0.97 -0.191 0.032 3.28E-09 
IGP58 rs12894466 14 65310520 G 0.48 0.97 -0.207 0.031 2.63E-11 
IGP58 rs11625882 14 65314952 G 0.48 0.97 -0.207 0.031 2.90E-11 
IGP58 rs2236067 14 65317765 G 0.61 0.97 0.197 0.032 8.30E-10 
IGP58 rs968540 14 65318817 G 0.62 0.96 0.190 0.032 3.74E-09 
IGP58 rs7142165 14 65319985 G 0.52 0.96 0.207 0.031 3.22E-11 
IGP58 rs7143026 14 65320709 G 0.40 0.95 -0.180 0.032 2.39E-08 
IGP58 rs6573627 14 65322079 C 0.51 0.98 0.196 0.031 3.39E-10 
IGP58 rs7151846 14 65325534 C 0.51 0.99 0.192 0.031 5.51E-10 
IGP58 rs4073415 14 65329283 G 0.51 0.99 0.192 0.031 5.45E-10 
IGP58 rs8018379 14 65331690 C 0.56 0.95 0.196 0.032 7.68E-10 
IGP58 rs8006608 14 65336577 G 0.96 0.81 0.481 0.086 2.27E-08 
IGP58 rs3924222 14 65343491 C 0.41 0.80 0.193 0.035 2.41E-08 
IGP58 rs10149325 14 65347120 G 0.41 0.80 0.194 0.035 2.02E-08 
IGP59 rs2859113 6 32805763 C 0.38 0.91 -0.182 0.033 5.64E-08 
IGP59 rs7751856 6 32806966 C 0.38 0.90 -0.181 0.033 6.24E-08 
IGP59 rs9276197 6 32807565 C 0.62 0.89 0.181 0.033 6.50E-08 
IGP59 rs9276234 6 32808826 T 0.62 0.90 0.181 0.033 6.53E-08 
IGP59 rs2859071 6 32811344 C 0.62 0.92 0.180 0.033 6.68E-08 
IGP59 rs9276311 6 32812637 C 0.62 0.94 0.180 0.033 6.89E-08 
IGP59 rs7773149 6 32814020 G 0.62 0.94 0.179 0.033 7.40E-08 
IGP59 rs1049110 6 32834781 C 0.35 0.98 -0.182 0.034 7.97E-08 
IGP59 rs7782210 7 50319291 G 0.38 0.98 0.192 0.032 1.57E-09 
IGP59 rs6583437 7 50320813 G 0.64 0.98 -0.195 0.032 1.05E-09 
IGP59 rs7789913 7 50323241 C 0.62 1.00 -0.190 0.032 1.80E-09 
IGP59 rs6421315 7 50325753 C 0.37 0.95 0.197 0.032 1.15E-09 
IGP59 rs1256519 14 64806077 G 0.44 0.89 0.190 0.032 4.86E-09 
IGP59 rs7159888 14 64828395 G 0.55 0.99 0.270 0.031 5.34E-18 
IGP59 rs12431963 14 64829447 C 0.92 0.92 0.425 0.059 4.16E-13 
IGP59 rs1256540 14 64833822 C 0.43 1.00 -0.258 0.031 1.50E-16 
IGP59 rs4902383 14 64834326 C 0.19 0.94 -0.301 0.040 3.81E-14 
IGP59 rs1269068 14 64837086 C 0.57 1.00 0.258 0.031 1.60E-16 
IGP59 rs10135194 14 64840731 C 0.94 0.84 0.423 0.071 2.21E-09 
IGP59 rs1760978 14 64840800 G 0.43 0.98 -0.291 0.031 1.58E-20 
IGP59 rs10144975 14 64843735 C 0.80 0.98 0.309 0.038 5.13E-16 
IGP59 rs17102587 14 64844230 C 0.20 0.97 -0.315 0.038 2.39E-16 
IGP59 rs8017974 14 64844940 C 0.20 0.99 -0.314 0.038 2.23E-16 
IGP59 rs11847263 14 64845448 G 0.39 0.98 -0.312 0.032 1.08E-22 
IGP59 rs10132229 14 64847313 G 0.10 1.00 -0.387 0.051 2.91E-14 
IGP59 rs4902386 14 64848043 C 0.80 0.99 0.313 0.038 2.35E-16 
IGP59 rs10147958 14 64848586 C 0.10 1.00 -0.387 0.051 2.91E-14 
IGP59 rs8019473 14 64848881 G 0.80 0.99 0.313 0.038 2.35E-16 
IGP59 rs10138662 14 64849235 G 0.20 0.99 -0.312 0.038 2.35E-16 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP59 rs7151212 14 64851375 C 0.80 0.99 0.312 0.038 2.36E-16 
IGP59 rs11158587 14 64852465 G 0.80 0.99 0.312 0.038 2.36E-16 
IGP59 rs8019767 14 64852538 G 0.80 1.00 0.312 0.038 2.36E-16 
IGP59 rs6573598 14 64852772 C 0.20 1.00 -0.312 0.038 2.36E-16 
IGP59 rs6573599 14 64852880 C 0.80 1.00 0.312 0.038 2.38E-16 
IGP59 rs10144503 14 64853862 G 0.90 1.00 0.387 0.051 2.94E-14 
IGP59 rs6573602 14 64854363 C 0.20 1.00 -0.312 0.038 2.40E-16 
IGP59 rs17102598 14 64854613 G 0.80 1.00 0.312 0.038 2.41E-16 
IGP59 rs12436299 14 64854947 G 0.90 1.00 0.387 0.051 2.97E-14 
IGP59 rs6573604 14 64857694 C 0.20 1.00 -0.312 0.038 2.41E-16 
IGP59 rs9635250 14 64869101 T 0.10 1.00 -0.387 0.051 2.91E-14 
IGP59 rs12881755 14 64871564 G 0.65 0.96 0.236 0.033 1.55E-12 
IGP59 rs747541 14 64875163 C 0.45 0.98 -0.286 0.032 1.90E-19 
IGP59 rs1954052 14 64875462 T 0.44 0.99 -0.285 0.032 2.16E-19 
IGP59 rs12436465 14 64876630 C 0.72 0.98 0.194 0.035 3.70E-08 
IGP59 rs12886005 14 64879000 C 0.45 0.87 -0.291 0.034 5.32E-18 
IGP59 rs12886168 14 64879039 C 0.45 0.98 -0.286 0.032 1.87E-19 
IGP59 rs11623920 14 64889067 C 0.56 1.00 0.285 0.032 2.12E-19 
IGP59 rs11621121 14 64892246 C 0.44 1.00 -0.284 0.032 2.19E-19 
IGP59 rs10148907 14 64903125 C 0.69 0.98 0.286 0.034 8.00E-17 
IGP59 rs4902393 14 64909267 C 0.56 0.99 0.285 0.032 2.32E-19 
IGP59 rs11621604 14 64910527 G 0.56 0.98 0.283 0.032 7.13E-19 
IGP59 rs12882269 14 64916897 G 0.56 0.97 0.281 0.032 1.27E-18 
IGP59 rs11158591 14 64925515 C 0.44 0.97 -0.280 0.032 1.59E-18 
IGP59 rs11158592 14 64929721 G 0.50 0.99 -0.244 0.031 2.23E-15 
IGP59 rs11158593 14 64929737 G 0.50 0.99 -0.247 0.031 1.08E-15 
IGP59 rs10138570 14 64929791 G 0.50 0.99 0.247 0.031 1.08E-15 
IGP59 rs17246007 14 64935424 C 0.08 0.99 -0.318 0.059 8.18E-08 
IGP59 rs11844747 14 64939881 C 0.08 0.99 -0.318 0.059 8.05E-08 
IGP59 rs17246035 14 64943883 G 0.08 1.00 -0.319 0.059 7.15E-08 
IGP59 rs2411822 14 64948148 G 0.47 1.00 0.232 0.031 4.82E-14 
IGP59 rs1953416 14 64948560 C 0.53 1.00 -0.235 0.031 2.49E-14 
IGP59 rs1953417 14 64948662 C 0.92 1.00 0.319 0.059 6.98E-08 
IGP59 rs883081 14 64950374 C 0.53 1.00 -0.235 0.031 2.57E-14 
IGP59 rs883082 14 64950693 G 0.47 1.00 0.232 0.031 5.02E-14 
IGP59 rs7145574 14 64954155 C 0.92 1.00 0.319 0.059 6.91E-08 
IGP59 rs867972 14 64965514 C 0.48 0.97 0.232 0.031 1.07E-13 
IGP59 rs11851576 14 64970036 C 0.54 0.99 0.194 0.031 5.35E-10 
IGP59 rs12879971 14 64971357 G 0.52 0.99 -0.235 0.031 2.93E-14 
IGP59 rs12892058 14 64973194 C 0.47 0.99 0.239 0.031 1.29E-14 
IGP59 rs10483776 14 64984620 G 0.22 1.00 -0.224 0.038 4.98E-09 
IGP59 rs17826580 14 64985015 C 0.08 1.00 -0.320 0.059 6.35E-08 
IGP59 rs2184602 14 64985425 G 0.08 1.00 -0.320 0.059 6.35E-08 
IGP59 rs2152375 14 64985531 C 0.08 1.00 -0.320 0.059 6.35E-08 
IGP59 rs12589698 14 64990188 G 0.52 0.98 -0.246 0.031 2.33E-15 
IGP59 rs4899179 14 64996501 G 0.49 0.99 0.244 0.031 3.68E-15 
IGP59 rs2184603 14 65000423 C 0.49 0.99 0.244 0.031 3.54E-15 
IGP59 rs11850847 14 65003551 C 0.92 1.00 0.321 0.059 6.25E-08 
IGP59 rs12434585 14 65008121 G 0.08 1.00 -0.321 0.059 6.25E-08 
IGP59 rs3825640 14 65030957 C 0.51 0.99 -0.246 0.031 1.51E-15 
IGP59 rs11627084 14 65048589 G 0.49 1.00 0.244 0.031 2.85E-15 
IGP59 rs10483780 14 65049923 C 0.50 0.99 0.240 0.031 8.49E-15 
IGP59 rs2149841 14 65080072 C 0.51 0.99 -0.247 0.031 1.40E-15 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP59 rs11621680 14 65084434 G 0.50 0.99 0.240 0.031 7.18E-15 
IGP59 rs11851013 14 65085965 G 0.08 0.99 -0.321 0.059 5.92E-08 
IGP59 rs11623662 14 65090945 G 0.59 0.99 0.175 0.031 2.53E-08 
IGP59 rs11851772 14 65091800 C 0.92 0.99 0.321 0.059 5.91E-08 
IGP59 rs9972106 14 65092884 T 0.59 0.99 0.176 0.031 2.50E-08 
IGP59 rs11158601 14 65095116 G 0.49 1.00 0.244 0.031 2.30E-15 
IGP59 rs7146742 14 65102687 G 0.43 0.99 -0.209 0.032 4.29E-11 
IGP59 rs1958561 14 65106514 G 0.49 1.00 0.244 0.031 2.43E-15 
IGP59 rs12887134 14 65115296 C 0.49 0.99 0.247 0.031 1.31E-15 
IGP59 rs7155541 14 65115995 C 0.49 0.99 0.247 0.031 1.32E-15 
IGP59 rs6573615 14 65116287 G 0.41 0.99 -0.176 0.031 2.47E-08 
IGP59 rs7160780 14 65122466 G 0.41 0.99 -0.177 0.031 1.99E-08 
IGP59 rs7161123 14 65122654 G 0.51 1.00 -0.244 0.031 2.45E-15 
IGP59 rs2411356 14 65122914 G 0.41 0.99 -0.177 0.031 2.00E-08 
IGP59 rs12433827 14 65125363 G 0.92 1.00 0.322 0.059 5.66E-08 
IGP59 rs4581615 14 65125696 C 0.51 1.00 -0.244 0.031 2.45E-15 
IGP59 rs8005309 14 65126261 T 0.92 1.00 0.322 0.059 5.66E-08 
IGP59 rs17753508 14 65127205 G 0.22 1.00 -0.228 0.038 3.05E-09 
IGP59 rs3783709 14 65128417 T 0.51 1.00 -0.244 0.031 2.46E-15 
IGP59 rs12889002 14 65133335 C 0.51 1.00 -0.244 0.031 2.46E-15 
IGP59 rs743085 14 65137886 G 0.49 1.00 0.244 0.031 2.46E-15 
IGP59 rs17826724 14 65138073 C 0.08 1.00 -0.322 0.059 5.69E-08 
IGP59 rs11849252 14 65139522 G 0.92 1.00 0.322 0.059 5.70E-08 
IGP59 rs17826736 14 65151955 C 0.08 1.00 -0.322 0.059 5.69E-08 
IGP59 rs2073294 14 65152246 C 0.92 1.00 0.322 0.059 5.69E-08 
IGP59 rs8012278 14 65152326 G 0.49 1.00 0.248 0.031 8.28E-16 
IGP59 rs11849862 14 65167778 G 0.08 1.00 -0.322 0.059 5.71E-08 
IGP59 rs2268957 14 65182986 C 0.92 1.00 0.322 0.059 5.76E-08 
IGP59 rs12890902 14 65186375 T 0.51 1.00 -0.249 0.031 6.17E-16 
IGP59 rs2300865 14 65189768 C 0.49 1.00 0.249 0.031 6.06E-16 
IGP59 rs11627184 14 65191196 C 0.51 1.00 -0.249 0.031 5.66E-16 
IGP59 rs12435908 14 65191221 C 0.92 1.00 0.322 0.059 5.74E-08 
IGP59 rs11627185 14 65191245 G 0.49 1.00 0.249 0.031 5.40E-16 
IGP59 rs1998035 14 65195983 G 0.08 1.00 -0.322 0.059 5.72E-08 
IGP59 rs2268958 14 65197991 T 0.08 1.00 -0.322 0.059 5.71E-08 
IGP59 rs7142651 14 65202474 C 0.51 1.00 -0.250 0.031 4.77E-16 
IGP59 rs1998036 14 65207952 C 0.49 0.99 0.250 0.031 4.54E-16 
IGP59 rs2268959 14 65215071 C 0.78 1.00 0.233 0.038 1.16E-09 
IGP59 rs2268960 14 65215253 G 0.07 0.97 -0.341 0.061 2.10E-08 
IGP59 rs2268961 14 65216518 C 0.49 0.99 0.251 0.031 3.65E-16 
IGP59 rs2268962 14 65217026 G 0.49 1.00 0.251 0.031 3.56E-16 
IGP59 rs2300871 14 65217447 C 0.08 1.00 -0.322 0.059 5.62E-08 
IGP59 rs2300872 14 65217514 G 0.08 1.00 -0.321 0.059 6.53E-08 
IGP59 rs2064694 14 65217999 G 0.51 1.00 -0.250 0.031 4.18E-16 
IGP59 rs12588838 14 65232391 G 0.51 1.00 -0.250 0.031 4.00E-16 
IGP59 rs8019491 14 65237863 G 0.08 1.00 -0.321 0.060 6.58E-08 
IGP59 rs11628765 14 65238202 C 0.49 1.00 0.251 0.031 3.74E-16 
IGP59 rs2411351 14 65241294 C 0.49 1.00 0.251 0.031 3.61E-16 
IGP59 rs11846546 14 65246146 G 0.14 0.99 -0.274 0.044 7.59E-10 
IGP59 rs8018278 14 65249841 G 0.49 1.00 0.251 0.031 3.60E-16 
IGP59 rs11627067 14 65252706 G 0.49 1.00 0.251 0.031 3.59E-16 
IGP59 rs4143898 14 65258635 T 0.44 0.99 -0.214 0.031 1.02E-11 
IGP59 rs11622829 14 65261535 T 0.50 1.00 -0.249 0.031 6.13E-16 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP59 rs1535173 14 65268892 C 0.50 1.00 -0.247 0.031 1.01E-15 
IGP59 rs3742597 14 65269930 G 0.29 1.00 -0.290 0.035 6.05E-17 
IGP59 rs927004 14 65270664 C 0.50 1.00 0.247 0.031 1.16E-15 
IGP59 rs1950557 14 65271510 C 0.71 1.00 0.290 0.035 6.37E-17 
IGP59 rs8010876 14 65276729 G 0.50 1.00 0.247 0.031 1.17E-15 
IGP59 rs1054218 14 65278943 C 0.40 1.00 -0.224 0.032 1.75E-12 
IGP59 rs761830 14 65282739 G 0.40 1.00 -0.224 0.032 1.76E-12 
IGP59 rs10483785 14 65289270 G 0.50 1.00 -0.244 0.031 2.16E-15 
IGP59 rs6573624 14 65296638 G 0.50 0.98 -0.246 0.031 2.57E-15 
IGP59 rs2411405 14 65301839 G 0.52 0.97 0.249 0.031 1.25E-15 
IGP59 rs743084 14 65302355 C 0.52 0.97 0.250 0.031 1.46E-15 
IGP59 rs11625362 14 65302622 G 0.48 0.97 -0.249 0.031 1.30E-15 
IGP59 rs4080329 14 65303243 C 0.62 0.97 0.231 0.032 1.04E-12 
IGP59 rs11627605 14 65304066 G 0.48 0.97 -0.249 0.031 1.34E-15 
IGP59 rs11627578 14 65304201 C 0.48 0.97 -0.249 0.031 1.34E-15 
IGP59 rs11628840 14 65305395 G 0.52 0.97 0.249 0.031 1.35E-15 
IGP59 rs1003401 14 65307473 G 0.39 0.97 -0.232 0.032 4.76E-13 
IGP59 rs4902416 14 65307843 C 0.52 0.97 0.249 0.031 1.39E-15 
IGP59 rs1984855 14 65309010 C 0.61 0.97 0.232 0.032 4.81E-13 
IGP59 rs730807 14 65309043 C 0.48 0.97 -0.249 0.031 1.42E-15 
IGP59 rs2411404 14 65309154 C 0.48 0.97 -0.249 0.031 1.43E-15 
IGP59 rs1075566 14 65309210 C 0.48 0.97 -0.249 0.031 1.44E-15 
IGP59 rs7157449 14 65309890 G 0.52 0.97 0.249 0.031 1.48E-15 
IGP59 rs6573625 14 65310387 C 0.62 0.97 0.230 0.032 1.26E-12 
IGP59 rs6573626 14 65310448 C 0.52 0.97 0.249 0.031 1.72E-15 
IGP59 rs7158556 14 65310482 T 0.38 0.97 -0.230 0.032 1.28E-12 
IGP59 rs12894466 14 65310520 G 0.48 0.97 -0.249 0.031 1.75E-15 
IGP59 rs11625882 14 65314952 G 0.48 0.97 -0.248 0.031 1.98E-15 
IGP59 rs2236067 14 65317765 G 0.61 0.97 0.232 0.032 6.34E-13 
IGP59 rs968540 14 65318817 G 0.62 0.96 0.229 0.032 1.59E-12 
IGP59 rs7142165 14 65319985 G 0.52 0.96 0.248 0.031 2.50E-15 
IGP59 rs7143026 14 65320709 G 0.40 0.95 -0.215 0.033 4.11E-11 
IGP59 rs6573627 14 65322079 C 0.51 0.98 0.235 0.031 6.44E-14 
IGP59 rs4400971 14 65324331 C 0.43 0.99 -0.188 0.031 2.18E-09 
IGP59 rs7151846 14 65325534 C 0.51 0.99 0.228 0.031 2.13E-13 
IGP59 rs4073416 14 65329147 C 0.43 0.99 -0.188 0.031 2.28E-09 
IGP59 rs4073415 14 65329283 G 0.51 0.99 0.228 0.031 2.15E-13 
IGP59 rs11850120 14 65330132 C 0.42 0.98 -0.185 0.032 5.60E-09 
IGP59 rs8018379 14 65331690 C 0.56 0.95 0.241 0.032 5.74E-14 
IGP59 rs8007846 14 65332716 G 0.48 0.98 -0.195 0.031 4.76E-10 
IGP59 rs8006608 14 65336577 G 0.96 0.81 0.514 0.086 2.58E-09 
IGP59 rs3924222 14 65343491 C 0.41 0.80 0.240 0.035 5.30E-12 
IGP59 rs10149325 14 65347120 G 0.41 0.80 0.241 0.035 4.40E-12 
IGP60 rs17732497 7 50306619 C 0.70 0.97 -0.178 0.033 9.85E-08 
IGP60 rs7805434 7 50311296 C 0.30 0.99 0.177 0.033 9.66E-08 
IGP60 rs7781977 7 50316680 C 0.70 1.00 -0.177 0.033 8.93E-08 
IGP60 rs7782210 7 50319291 G 0.38 0.98 0.180 0.032 1.31E-08 
IGP60 rs6583437 7 50320813 G 0.64 0.98 -0.186 0.032 4.60E-09 
IGP60 rs7789913 7 50323241 C 0.62 1.00 -0.178 0.031 1.48E-08 
IGP60 rs6421315 7 50325753 C 0.37 0.95 0.185 0.032 8.55E-09 
IGP60 rs7159888 14 64828395 G 0.55 0.99 0.208 0.031 1.82E-11 
IGP60 rs1256540 14 64833822 C 0.43 1.00 -0.173 0.031 2.69E-08 
IGP60 rs4902383 14 64834326 C 0.19 0.94 -0.229 0.040 7.35E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP60 rs1760978 14 64840800 G 0.43 0.98 -0.205 0.031 4.59E-11 
IGP60 rs10144975 14 64843735 C 0.80 0.98 0.233 0.038 9.22E-10 
IGP60 rs17102587 14 64844230 C 0.20 0.97 -0.242 0.038 2.52E-10 
IGP60 rs8017974 14 64844940 C 0.20 0.99 -0.246 0.038 1.11E-10 
IGP60 rs11847263 14 64845448 G 0.39 0.98 -0.240 0.032 3.08E-14 
IGP60 rs4902386 14 64848043 C 0.80 0.99 0.246 0.038 9.57E-11 
IGP60 rs8019473 14 64848881 G 0.80 0.99 0.246 0.038 9.39E-11 
IGP60 rs10138662 14 64849235 G 0.20 0.99 -0.246 0.038 8.93E-11 
IGP60 rs10134589 14 64850987 T 0.19 0.94 -0.255 0.039 8.13E-11 
IGP60 rs7151212 14 64851375 C 0.80 0.99 0.247 0.038 8.36E-11 
IGP60 rs11158587 14 64852465 G 0.80 0.99 0.247 0.038 8.26E-11 
IGP60 rs8019767 14 64852538 G 0.80 1.00 0.247 0.038 8.23E-11 
IGP60 rs6573598 14 64852772 C 0.20 1.00 -0.247 0.038 8.13E-11 
IGP60 rs6573599 14 64852880 C 0.80 1.00 0.247 0.038 7.68E-11 
IGP60 rs6573602 14 64854363 C 0.20 1.00 -0.247 0.038 7.38E-11 
IGP60 rs17102598 14 64854613 G 0.80 1.00 0.247 0.038 7.36E-11 
IGP60 rs6573604 14 64857694 C 0.20 1.00 -0.247 0.038 7.25E-11 
IGP60 rs747541 14 64875163 C 0.45 0.98 -0.198 0.031 2.74E-10 
IGP60 rs1954052 14 64875462 T 0.44 0.99 -0.197 0.031 3.58E-10 
IGP60 rs12886005 14 64879000 C 0.45 0.87 -0.209 0.033 3.38E-10 
IGP60 rs12886168 14 64879039 C 0.45 0.98 -0.198 0.031 2.72E-10 
IGP60 rs11623920 14 64889067 C 0.56 1.00 0.196 0.031 3.55E-10 
IGP60 rs11621121 14 64892246 C 0.44 1.00 -0.196 0.031 3.53E-10 
IGP60 rs10148907 14 64903125 C 0.69 0.98 0.199 0.034 5.51E-09 
IGP60 rs4902393 14 64909267 C 0.56 0.99 0.196 0.031 4.51E-10 
IGP60 rs11621604 14 64910527 G 0.56 0.98 0.191 0.032 1.39E-09 
IGP60 rs12882269 14 64916897 G 0.56 0.97 0.189 0.032 2.05E-09 
IGP60 rs11158591 14 64925515 C 0.44 0.97 -0.188 0.032 2.52E-09 
IGP60 rs11158592 14 64929721 G 0.50 0.99 -0.177 0.031 7.21E-09 
IGP60 rs11158593 14 64929737 G 0.50 0.99 -0.175 0.031 9.87E-09 
IGP60 rs10138570 14 64929791 G 0.50 0.99 0.175 0.031 9.98E-09 
IGP60 rs2411822 14 64948148 G 0.47 1.00 0.172 0.031 1.78E-08 
IGP60 rs1953416 14 64948560 C 0.53 1.00 -0.170 0.031 2.47E-08 
IGP60 rs883081 14 64950374 C 0.53 1.00 -0.170 0.031 2.49E-08 
IGP60 rs883082 14 64950693 G 0.47 1.00 0.172 0.031 1.80E-08 
IGP60 rs12879971 14 64971357 G 0.52 0.99 -0.175 0.031 1.27E-08 
IGP60 rs12892058 14 64973194 C 0.47 0.99 0.174 0.031 1.39E-08 
IGP60 rs12589698 14 64990188 G 0.52 0.98 -0.178 0.031 7.65E-09 
IGP60 rs4899179 14 64996501 G 0.49 0.99 0.180 0.031 4.37E-09 
IGP60 rs2184603 14 65000423 C 0.49 0.99 0.180 0.031 4.31E-09 
IGP60 rs3825640 14 65030957 C 0.51 0.99 -0.179 0.031 5.29E-09 
IGP60 rs11627084 14 65048589 G 0.49 1.00 0.180 0.031 3.77E-09 
IGP60 rs10483780 14 65049923 C 0.50 0.99 0.172 0.031 2.11E-08 
IGP60 rs2149841 14 65080072 C 0.51 0.99 -0.179 0.031 5.52E-09 
IGP60 rs11621680 14 65084434 G 0.50 0.99 0.171 0.031 2.37E-08 
IGP60 rs11158601 14 65095116 G 0.49 1.00 0.179 0.031 4.68E-09 
IGP60 rs1958561 14 65106514 G 0.49 1.00 0.179 0.031 4.65E-09 
IGP60 rs12887134 14 65115296 C 0.49 0.99 0.178 0.031 6.56E-09 
IGP60 rs7155541 14 65115995 C 0.49 0.99 0.178 0.031 6.56E-09 
IGP60 rs7161123 14 65122654 G 0.51 1.00 -0.180 0.030 3.91E-09 
IGP60 rs4581615 14 65125696 C 0.51 1.00 -0.180 0.030 3.90E-09 
IGP60 rs3783709 14 65128417 T 0.51 1.00 -0.180 0.030 3.90E-09 
IGP60 rs12889002 14 65133335 C 0.51 1.00 -0.180 0.030 3.89E-09 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP60 rs8012278 14 65152326 G 0.49 1.00 0.182 0.031 2.48E-09 
IGP60 rs12890902 14 65186375 T 0.51 1.00 -0.182 0.030 2.34E-09 
IGP60 rs2300865 14 65189768 C 0.49 1.00 0.182 0.030 2.33E-09 
IGP60 rs11627184 14 65191196 C 0.51 1.00 -0.182 0.030 2.30E-09 
IGP60 rs11627185 14 65191245 G 0.49 1.00 0.182 0.031 2.28E-09 
IGP60 rs7142651 14 65202474 C 0.51 1.00 -0.182 0.031 2.58E-09 
IGP60 rs1998036 14 65207952 C 0.49 0.99 0.182 0.031 2.59E-09 
IGP60 rs2268961 14 65216518 C 0.49 0.99 0.182 0.031 2.50E-09 
IGP60 rs2268962 14 65217026 G 0.49 1.00 0.182 0.031 2.49E-09 
IGP60 rs2064694 14 65217999 G 0.51 1.00 -0.180 0.031 3.85E-09 
IGP60 rs12588838 14 65232391 G 0.51 1.00 -0.180 0.031 3.88E-09 
IGP60 rs11628765 14 65238202 C 0.49 1.00 0.180 0.031 3.88E-09 
IGP60 rs2411351 14 65241294 C 0.49 1.00 0.180 0.031 3.95E-09 
IGP60 rs8018278 14 65249841 G 0.49 1.00 0.180 0.031 4.03E-09 
IGP60 rs11627067 14 65252706 G 0.49 1.00 0.180 0.031 4.10E-09 
IGP60 rs11622829 14 65261535 T 0.50 1.00 -0.175 0.031 1.04E-08 
IGP60 rs11624104 14 65265890 G 0.50 1.00 0.175 0.031 1.17E-08 
IGP60 rs1535173 14 65268892 C 0.50 1.00 -0.174 0.031 1.26E-08 
IGP60 rs3742597 14 65269930 G 0.29 1.00 -0.198 0.034 8.83E-09 
IGP60 rs927004 14 65270664 C 0.50 1.00 0.173 0.031 1.41E-08 
IGP60 rs1950557 14 65271510 C 0.71 1.00 0.197 0.034 9.05E-09 
IGP60 rs8010876 14 65276729 G 0.50 1.00 0.173 0.031 1.41E-08 
IGP60 rs10483785 14 65289270 G 0.50 1.00 -0.171 0.031 1.97E-08 
IGP60 rs6573624 14 65296638 G 0.50 0.98 -0.171 0.031 2.62E-08 
IGP60 rs2411405 14 65301839 G 0.52 0.97 0.176 0.031 1.18E-08 
IGP60 rs743084 14 65302355 C 0.52 0.97 0.180 0.031 6.29E-09 
IGP60 rs11625362 14 65302622 G 0.48 0.97 -0.176 0.031 1.23E-08 
IGP60 rs11627605 14 65304066 G 0.48 0.97 -0.176 0.031 1.28E-08 
IGP60 rs11627578 14 65304201 C 0.48 0.97 -0.176 0.031 1.29E-08 
IGP60 rs11628840 14 65305395 G 0.52 0.97 0.176 0.031 1.30E-08 
IGP60 rs4902416 14 65307843 C 0.52 0.97 0.176 0.031 1.33E-08 
IGP60 rs730807 14 65309043 C 0.48 0.97 -0.176 0.031 1.36E-08 
IGP60 rs2411404 14 65309154 C 0.48 0.97 -0.176 0.031 1.37E-08 
IGP60 rs1075566 14 65309210 C 0.48 0.97 -0.176 0.031 1.38E-08 
IGP60 rs7157449 14 65309890 G 0.52 0.97 0.176 0.031 1.41E-08 
IGP60 rs6573626 14 65310448 C 0.52 0.97 0.175 0.031 1.55E-08 
IGP60 rs12894466 14 65310520 G 0.48 0.97 -0.175 0.031 1.57E-08 
IGP60 rs11625882 14 65314952 G 0.48 0.97 -0.175 0.031 1.69E-08 
IGP60 rs7142165 14 65319985 G 0.52 0.96 0.174 0.031 1.97E-08 
IGP60 rs8006608 14 65336577 G 0.96 0.81 0.488 0.086 1.30E-08 
IGP61 rs7159888 14 64828395 G 0.55 0.99 0.238 0.031 1.34E-14 
IGP61 rs1256540 14 64833822 C 0.43 1.00 -0.196 0.031 2.48E-10 
IGP61 rs4902383 14 64834326 C 0.19 0.94 -0.257 0.039 6.84E-11 
IGP61 rs1269068 14 64837086 C 0.57 1.00 0.195 0.031 2.92E-10 
IGP61 rs1760978 14 64840800 G 0.43 0.98 -0.227 0.031 2.99E-13 
IGP61 rs10144975 14 64843735 C 0.80 0.98 0.264 0.038 3.13E-12 
IGP61 rs17102587 14 64844230 C 0.20 0.97 -0.274 0.038 6.30E-13 
IGP61 rs8017974 14 64844940 C 0.20 0.99 -0.278 0.038 2.36E-13 
IGP61 rs11847263 14 64845448 G 0.39 0.98 -0.268 0.032 2.60E-17 
IGP61 rs10132229 14 64847313 G 0.10 1.00 -0.299 0.050 3.01E-09 
IGP61 rs4902386 14 64848043 C 0.80 0.99 0.279 0.038 1.97E-13 
IGP61 rs10147958 14 64848586 C 0.10 1.00 -0.299 0.050 2.90E-09 
IGP61 rs8019473 14 64848881 G 0.80 0.99 0.279 0.038 1.93E-13 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP61 rs10134589 14 64850987 T 0.20 0.94 -0.289 0.039 1.86E-13 
IGP61 rs7151212 14 64851375 C 0.80 0.99 0.279 0.038 1.68E-13 
IGP61 rs11158587 14 64852465 G 0.80 0.99 0.279 0.038 1.66E-13 
IGP61 rs8019767 14 64852538 G 0.80 1.00 0.279 0.038 1.65E-13 
IGP61 rs6573598 14 64852772 C 0.20 1.00 -0.279 0.038 1.63E-13 
IGP61 rs6573599 14 64852880 C 0.80 1.00 0.280 0.038 1.52E-13 
IGP61 rs10144503 14 64853862 G 0.90 1.00 0.301 0.050 2.17E-09 
IGP61 rs6573602 14 64854363 C 0.20 1.00 -0.280 0.038 1.45E-13 
IGP61 rs17102598 14 64854613 G 0.80 1.00 0.280 0.038 1.45E-13 
IGP61 rs12436299 14 64854947 G 0.90 1.00 0.302 0.050 2.04E-09 
IGP61 rs6573604 14 64857694 C 0.20 1.00 -0.280 0.038 1.42E-13 
IGP61 rs9635250 14 64869101 T 0.10 1.00 -0.302 0.050 1.96E-09 
IGP61 rs747541 14 64875163 C 0.45 0.98 -0.221 0.031 2.00E-12 
IGP61 rs1954052 14 64875462 T 0.44 0.99 -0.222 0.031 1.71E-12 
IGP61 rs12886005 14 64879000 C 0.45 0.87 -0.229 0.033 6.13E-12 
IGP61 rs12886168 14 64879039 C 0.45 0.98 -0.221 0.031 1.98E-12 
IGP61 rs11623920 14 64889067 C 0.56 1.00 0.221 0.031 1.69E-12 
IGP61 rs11621121 14 64892246 C 0.44 1.00 -0.221 0.031 1.68E-12 
IGP61 rs10148907 14 64903125 C 0.69 0.98 0.226 0.034 3.28E-11 
IGP61 rs4902393 14 64909267 C 0.56 0.99 0.222 0.031 1.59E-12 
IGP61 rs11621604 14 64910527 G 0.56 0.98 0.220 0.032 3.17E-12 
IGP61 rs12882269 14 64916897 G 0.56 0.97 0.220 0.032 3.94E-12 
IGP61 rs11158591 14 64925515 C 0.44 0.97 -0.219 0.032 4.38E-12 
IGP61 rs11158592 14 64929721 G 0.50 0.99 -0.210 0.031 6.95E-12 
IGP61 rs11158593 14 64929737 G 0.50 0.99 -0.208 0.031 1.13E-11 
IGP61 rs10138570 14 64929791 G 0.50 0.99 0.208 0.031 1.15E-11 
IGP61 rs2411822 14 64948148 G 0.47 1.00 0.207 0.031 1.24E-11 
IGP61 rs1953416 14 64948560 C 0.53 1.00 -0.205 0.031 2.04E-11 
IGP61 rs883081 14 64950374 C 0.53 1.00 -0.205 0.031 2.12E-11 
IGP61 rs883082 14 64950693 G 0.47 1.00 0.207 0.031 1.30E-11 
IGP61 rs867972 14 64965514 C 0.48 0.97 0.200 0.031 1.13E-10 
IGP61 rs11851576 14 64970036 C 0.54 0.99 0.167 0.031 6.87E-08 
IGP61 rs12879971 14 64971357 G 0.52 0.99 -0.209 0.031 9.38E-12 
IGP61 rs12892058 14 64973194 C 0.47 0.99 0.208 0.031 1.29E-11 
IGP61 rs12589698 14 64990188 G 0.52 0.98 -0.212 0.031 5.36E-12 
IGP61 rs4899179 14 64996501 G 0.49 0.99 0.215 0.031 2.82E-12 
IGP61 rs2184603 14 65000423 C 0.49 0.99 0.215 0.031 2.75E-12 
IGP61 rs3825640 14 65030957 C 0.51 0.99 -0.212 0.031 4.34E-12 
IGP61 rs11627084 14 65048589 G 0.49 1.00 0.214 0.031 2.70E-12 
IGP61 rs10483780 14 65049923 C 0.50 0.99 0.204 0.031 2.75E-11 
IGP61 rs2149841 14 65080072 C 0.51 0.99 -0.212 0.031 4.47E-12 
IGP61 rs11621680 14 65084434 G 0.50 0.99 0.204 0.031 2.93E-11 
IGP61 rs11158601 14 65095116 G 0.49 1.00 0.213 0.031 3.23E-12 
IGP61 rs7146742 14 65102687 G 0.43 0.99 -0.172 0.031 4.28E-08 
IGP61 rs1958561 14 65106514 G 0.49 1.00 0.213 0.031 3.38E-12 
IGP61 rs12887134 14 65115296 C 0.49 0.99 0.211 0.031 5.49E-12 
IGP61 rs7155541 14 65115995 C 0.49 0.99 0.211 0.031 5.51E-12 
IGP61 rs7161123 14 65122654 G 0.51 1.00 -0.212 0.031 3.77E-12 
IGP61 rs4581615 14 65125696 C 0.51 1.00 -0.212 0.031 3.77E-12 
IGP61 rs3783709 14 65128417 T 0.51 1.00 -0.212 0.031 3.77E-12 
IGP61 rs12889002 14 65133335 C 0.51 1.00 -0.212 0.031 3.77E-12 
IGP61 rs743085 14 65137886 G 0.49 1.00 0.212 0.031 3.77E-12 
IGP61 rs8012278 14 65152326 G 0.49 1.00 0.215 0.031 1.86E-12 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP61 rs2300865 14 65189768 C 0.49 1.00 0.215 0.031 1.68E-12 
IGP61 rs11627184 14 65191196 C 0.51 1.00 -0.216 0.031 1.63E-12 
IGP61 rs11627185 14 65191245 G 0.49 1.00 0.216 0.031 1.59E-12 
IGP61 rs7142651 14 65202474 C 0.51 1.00 -0.215 0.031 1.78E-12 
IGP61 rs1998036 14 65207952 C 0.49 0.99 0.216 0.031 1.76E-12 
IGP61 rs2268961 14 65216518 C 0.49 0.99 0.216 0.031 1.59E-12 
IGP61 rs2268962 14 65217026 G 0.49 1.00 0.216 0.031 1.57E-12 
IGP61 rs2064694 14 65217999 G 0.51 1.00 -0.214 0.031 2.57E-12 
IGP61 rs12588838 14 65232391 G 0.51 1.00 -0.214 0.031 2.54E-12 
IGP61 rs11628765 14 65238202 C 0.49 1.00 0.214 0.031 2.48E-12 
IGP61 rs2411351 14 65241294 C 0.49 1.00 0.214 0.031 2.49E-12 
IGP61 rs8018278 14 65249841 G 0.49 1.00 0.214 0.031 2.53E-12 
IGP61 rs11627067 14 65252706 G 0.49 1.00 0.214 0.031 2.57E-12 
IGP61 rs4143898 14 65258635 T 0.44 0.99 -0.182 0.031 4.84E-09 
IGP61 rs11622829 14 65261535 T 0.50 1.00 -0.209 0.031 7.79E-12 
IGP61 rs11624104 14 65265890 G 0.50 1.00 0.210 0.031 6.44E-12 
IGP61 rs1535173 14 65268892 C 0.50 1.00 -0.209 0.031 7.68E-12 
IGP61 rs3742597 14 65269930 G 0.29 1.00 -0.234 0.034 9.82E-12 
IGP61 rs927004 14 65270664 C 0.50 1.00 0.209 0.031 8.44E-12 
IGP61 rs1950557 14 65271510 C 0.71 1.00 0.234 0.034 9.66E-12 
IGP61 rs8010876 14 65276729 G 0.50 1.00 0.209 0.031 8.18E-12 
IGP61 rs1054218 14 65278943 C 0.40 1.00 -0.186 0.031 3.75E-09 
IGP61 rs761830 14 65282739 G 0.40 1.00 -0.186 0.031 3.74E-09 
IGP61 rs10483785 14 65289270 G 0.50 1.00 -0.209 0.031 6.88E-12 
IGP61 rs6573624 14 65296638 G 0.50 0.98 -0.213 0.031 4.94E-12 
IGP61 rs2411405 14 65301839 G 0.53 0.97 0.213 0.031 6.04E-12 
IGP61 rs743084 14 65302355 C 0.52 0.97 0.212 0.031 8.41E-12 
IGP61 rs11625362 14 65302622 G 0.47 0.97 -0.213 0.031 6.06E-12 
IGP61 rs4080329 14 65303243 C 0.62 0.97 0.192 0.032 2.10E-09 
IGP61 rs11627605 14 65304066 G 0.48 0.97 -0.213 0.031 6.11E-12 
IGP61 rs11627578 14 65304201 C 0.48 0.97 -0.213 0.031 6.11E-12 
IGP61 rs11628840 14 65305395 G 0.52 0.97 0.213 0.031 6.11E-12 
IGP61 rs1003401 14 65307473 G 0.39 0.97 -0.201 0.032 2.92E-10 
IGP61 rs4902416 14 65307843 C 0.52 0.97 0.213 0.031 6.14E-12 
IGP61 rs1984855 14 65309010 C 0.61 0.97 0.201 0.032 2.93E-10 
IGP61 rs730807 14 65309043 C 0.48 0.97 -0.213 0.031 6.19E-12 
IGP61 rs2411404 14 65309154 C 0.48 0.97 -0.213 0.031 6.22E-12 
IGP61 rs1075566 14 65309210 C 0.48 0.97 -0.213 0.031 6.25E-12 
IGP61 rs7157449 14 65309890 G 0.52 0.97 0.213 0.031 6.35E-12 
IGP61 rs6573625 14 65310387 C 0.62 0.97 0.192 0.032 2.37E-09 
IGP61 rs6573626 14 65310448 C 0.52 0.97 0.213 0.031 7.08E-12 
IGP61 rs7158556 14 65310482 T 0.38 0.97 -0.192 0.032 2.39E-09 
IGP61 rs12894466 14 65310520 G 0.48 0.97 -0.212 0.031 7.17E-12 
IGP61 rs11625882 14 65314952 G 0.48 0.97 -0.212 0.031 7.86E-12 
IGP61 rs2236067 14 65317765 G 0.61 0.97 0.200 0.032 3.64E-10 
IGP61 rs968540 14 65318817 G 0.62 0.96 0.192 0.032 2.55E-09 
IGP61 rs7142165 14 65319985 G 0.52 0.96 0.212 0.031 7.97E-12 
IGP61 rs7143026 14 65320709 G 0.40 0.95 -0.177 0.032 3.96E-08 
IGP61 rs6573627 14 65322079 C 0.51 0.98 0.200 0.031 1.12E-10 
IGP61 rs7151846 14 65325534 C 0.51 0.99 0.196 0.031 2.37E-10 
IGP61 rs4073415 14 65329283 G 0.51 0.99 0.196 0.031 2.35E-10 
IGP61 rs8018379 14 65331690 C 0.56 0.95 0.193 0.032 1.39E-09 
IGP61 rs8006608 14 65336577 G 0.96 0.81 0.483 0.086 1.70E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP61 rs10149325 14 65347120 G 0.41 0.80 0.206 0.035 2.25E-09 
IGP62 rs4917017 7 50305778 G 0.71 0.92 -0.218 0.035 3.38E-10 
IGP62 rs17732497 7 50306619 C 0.70 0.97 -0.212 0.033 2.31E-10 
IGP62 rs9886239 7 50307097 C 0.32 0.98 0.207 0.033 3.45E-10 
IGP62 rs7805434 7 50311296 C 0.30 0.99 0.210 0.033 2.04E-10 
IGP62 rs7781977 7 50316680 C 0.70 1.00 -0.210 0.033 1.92E-10 
IGP62 rs7782210 7 50319291 G 0.38 0.98 0.209 0.032 3.24E-11 
IGP62 rs6583437 7 50320813 G 0.64 0.98 -0.212 0.032 2.30E-11 
IGP62 rs7789913 7 50323241 C 0.62 1.00 -0.206 0.031 4.50E-11 
IGP62 rs6421315 7 50325753 C 0.37 0.95 0.220 0.032 8.11E-12 
IGP62 rs7802443 7 50328511 C 0.39 0.99 0.170 0.032 7.14E-08 
IGP62 rs6583440 7 50332228 G 0.63 0.99 -0.173 0.032 5.75E-08 
IGP62 rs17630758 22 22466542 G 0.83 0.99 -0.260 0.041 2.34E-10 
IGP62 rs17548631 22 22474125 C 0.17 0.99 0.260 0.041 2.18E-10 
IGP62 rs9620326 22 22476629 C 0.83 0.99 -0.260 0.041 2.17E-10 
IGP62 rs9624334 22 22496256 C 0.17 0.99 0.282 0.041 8.76E-12 
IGP62 rs2186369 22 22500996 G 0.19 0.88 0.295 0.042 1.23E-12 
IGP62 rs5757647 22 38104993 C 0.33 1.00 -0.186 0.033 1.31E-08 
IGP62 rs4821890 22 38107469 G 0.34 0.99 -0.188 0.033 9.60E-09 
IGP62 rs1010169 22 38108113 G 0.67 1.00 0.186 0.033 1.32E-08 
IGP62 rs1010170 22 38108273 C 0.67 1.00 0.186 0.033 1.35E-08 
IGP62 rs5757650 22 38108365 C 0.67 1.00 0.186 0.033 1.35E-08 
IGP62 rs9611169 22 38112973 C 0.33 1.00 -0.185 0.033 1.36E-08 
IGP62 rs9611170 22 38114791 C 0.66 0.99 0.185 0.033 1.45E-08 
IGP62 rs2413590 22 38120137 C 0.67 1.00 0.183 0.033 2.03E-08 
IGP62 rs5750808 22 38120933 G 0.33 1.00 -0.183 0.033 2.06E-08 
IGP62 rs5750811 22 38123012 G 0.67 1.00 0.183 0.033 2.11E-08 
IGP62 rs5750812 22 38123025 G 0.34 0.99 -0.185 0.033 1.36E-08 
IGP62 rs5757655 22 38127124 C 0.66 0.99 0.185 0.033 1.37E-08 
IGP62 rs4821893 22 38127725 G 0.33 1.00 -0.184 0.033 1.71E-08 
IGP62 rs5750814 22 38127933 C 0.67 1.00 0.183 0.033 1.75E-08 
IGP62 rs5757657 22 38128375 G 0.33 1.00 -0.183 0.033 1.82E-08 
IGP62 rs5750815 22 38128395 C 0.67 1.00 0.183 0.033 1.84E-08 
IGP62 rs4337572 22 38130650 C 0.33 1.00 -0.183 0.033 1.87E-08 
IGP62 rs4821894 22 38139766 C 0.67 1.00 0.183 0.033 1.90E-08 
IGP62 rs5750816 22 38140325 C 0.33 1.00 -0.183 0.032 1.95E-08 
IGP62 rs5757659 22 38142355 G 0.66 1.00 0.182 0.032 1.99E-08 
IGP62 rs6001587 22 38148954 C 0.66 1.00 0.182 0.032 1.99E-08 
IGP62 rs5750818 22 38150831 G 0.66 1.00 0.182 0.032 1.99E-08 
IGP62 rs5757665 22 38151587 G 0.66 1.00 0.182 0.032 1.99E-08 
IGP62 rs4821895 22 38152961 G 0.66 1.00 0.182 0.032 1.98E-08 
IGP62 rs739141 22 38154396 C 0.36 1.00 -0.189 0.032 4.41E-09 
IGP62 rs5750820 22 38155268 G 0.67 0.97 0.199 0.033 1.80E-09 
IGP62 rs5750822 22 38156734 G 0.34 1.00 -0.183 0.033 1.89E-08 
IGP62 rs7949 22 38157499 G 0.34 0.99 -0.183 0.033 1.81E-08 
IGP62 rs5757670 22 38159682 G 0.34 0.99 -0.184 0.033 1.73E-08 
IGP62 rs5750825 22 38161224 G 0.71 0.98 0.214 0.034 3.87E-10 
IGP62 rs1972280 22 38161932 T 0.29 0.98 -0.215 0.034 3.67E-10 
IGP62 rs4821897 22 38165533 G 0.71 0.97 0.215 0.034 3.48E-10 
IGP62 rs5750830 22 38170774 C 0.29 0.98 -0.217 0.034 2.28E-10 
IGP62 rs8137426 22 38174296 G 0.71 0.98 0.217 0.034 2.33E-10 
IGP62 rs5757683 22 38180120 G 0.29 0.98 -0.217 0.034 2.33E-10 
IGP62 rs1557541 22 38181916 C 0.29 0.98 -0.217 0.034 2.32E-10 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP62 rs5995735 22 38184367 C 0.29 0.98 -0.216 0.034 2.41E-10 
IGP62 rs738289 22 38185829 C 0.29 0.98 -0.216 0.034 2.44E-10 
IGP62 rs909674 22 38189115 C 0.30 0.99 -0.215 0.034 1.93E-10 
IGP63 rs716719 7 50296263 C 0.71 0.80 -0.198 0.037 7.01E-08 
IGP63 rs4917017 7 50305778 G 0.71 0.92 -0.217 0.035 3.52E-10 
IGP63 rs17732497 7 50306619 C 0.70 0.97 -0.207 0.033 4.99E-10 
IGP63 rs9886239 7 50307097 C 0.32 0.98 0.210 0.033 1.60E-10 
IGP63 rs7805434 7 50311296 C 0.30 0.99 0.205 0.033 4.69E-10 
IGP63 rs7781977 7 50316680 C 0.70 1.00 -0.205 0.033 4.56E-10 
IGP63 rs7782210 7 50319291 G 0.38 0.98 0.230 0.031 3.02E-13 
IGP63 rs6583437 7 50320813 G 0.64 0.98 -0.225 0.032 1.12E-12 
IGP63 rs7789913 7 50323241 C 0.62 1.00 -0.225 0.031 6.82E-13 
IGP63 rs6421315 7 50325753 C 0.37 0.95 0.236 0.032 1.87E-13 
IGP63 rs7802443 7 50328511 C 0.39 0.99 0.198 0.032 3.45E-10 
IGP63 rs6583440 7 50332228 G 0.63 0.99 -0.193 0.032 1.15E-09 
IGP63 rs11847263 14 64845448 G 0.39 0.98 -0.175 0.032 3.34E-08 
IGP63 rs300032 16 85238497 G 0.15 0.89 -0.243 0.046 9.11E-08 
IGP63 rs9624334 22 22496256 C 0.17 0.99 0.233 0.041 1.61E-08 
IGP63 rs2186369 22 22500996 G 0.19 0.88 0.244 0.041 3.68E-09 
IGP63 rs5757642 22 38094770 C 0.64 1.00 0.174 0.032 8.65E-08 
IGP63 rs7286714 22 38095550 C 0.36 0.97 -0.175 0.033 8.35E-08 
IGP63 rs5757644 22 38096386 C 0.36 0.97 -0.175 0.033 8.32E-08 
IGP63 rs5750806 22 38096957 G 0.64 0.97 0.175 0.033 8.31E-08 
IGP63 rs1569499 22 38099764 C 0.64 0.97 0.176 0.033 7.90E-08 
IGP63 rs4821888 22 38100543 G 0.64 0.97 0.176 0.033 7.97E-08 
IGP63 rs5757647 22 38104993 C 0.33 1.00 -0.199 0.033 1.02E-09 
IGP63 rs4821890 22 38107469 G 0.34 0.99 -0.200 0.033 1.02E-09 
IGP63 rs1010169 22 38108113 G 0.67 1.00 0.199 0.033 1.03E-09 
IGP63 rs1010170 22 38108273 C 0.67 1.00 0.199 0.033 1.06E-09 
IGP63 rs5757650 22 38108365 C 0.67 1.00 0.199 0.033 1.07E-09 
IGP63 rs9611169 22 38112973 C 0.33 1.00 -0.199 0.033 1.08E-09 
IGP63 rs9611170 22 38114791 C 0.66 0.99 0.198 0.033 1.19E-09 
IGP63 rs2413590 22 38120137 C 0.67 1.00 0.198 0.033 1.21E-09 
IGP63 rs5750808 22 38120933 G 0.33 1.00 -0.198 0.033 1.21E-09 
IGP63 rs5750811 22 38123012 G 0.67 1.00 0.198 0.033 1.20E-09 
IGP63 rs5750812 22 38123025 G 0.34 0.99 -0.199 0.033 9.60E-10 
IGP63 rs5757655 22 38127124 C 0.66 0.99 0.199 0.033 9.51E-10 
IGP63 rs4821893 22 38127725 G 0.33 1.00 -0.199 0.033 8.54E-10 
IGP63 rs5750814 22 38127933 C 0.67 1.00 0.199 0.033 8.48E-10 
IGP63 rs5757657 22 38128375 G 0.33 1.00 -0.199 0.032 8.49E-10 
IGP63 rs5750815 22 38128395 C 0.67 1.00 0.199 0.032 8.45E-10 
IGP63 rs4337572 22 38130650 C 0.33 1.00 -0.199 0.032 8.46E-10 
IGP63 rs4821894 22 38139766 C 0.67 1.00 0.199 0.032 8.48E-10 
IGP63 rs5750816 22 38140325 C 0.33 1.00 -0.199 0.032 8.51E-10 
IGP63 rs5757659 22 38142355 G 0.67 1.00 0.199 0.032 8.54E-10 
IGP63 rs6001587 22 38148954 C 0.67 1.00 0.199 0.032 8.58E-10 
IGP63 rs5750818 22 38150831 G 0.67 1.00 0.199 0.032 8.59E-10 
IGP63 rs5757665 22 38151587 G 0.67 1.00 0.199 0.032 8.61E-10 
IGP63 rs4821895 22 38152961 G 0.67 1.00 0.199 0.032 8.62E-10 
IGP63 rs739141 22 38154396 C 0.36 1.00 -0.207 0.032 1.30E-10 
IGP63 rs5750820 22 38155268 G 0.67 0.97 0.218 0.033 3.84E-11 
IGP63 rs5750822 22 38156734 G 0.33 1.00 -0.199 0.032 8.39E-10 
IGP63 rs7949 22 38157499 G 0.33 0.99 -0.200 0.033 8.15E-10 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP63 rs5750825 22 38161224 G 0.71 0.98 0.238 0.034 3.35E-12 
IGP63 rs1972280 22 38161932 T 0.29 0.98 -0.238 0.034 3.42E-12 
IGP63 rs4821897 22 38165533 G 0.71 0.97 0.239 0.034 3.17E-12 
IGP63 rs5750830 22 38170774 C 0.29 0.98 -0.236 0.034 4.72E-12 
IGP63 rs8137426 22 38174296 G 0.71 0.98 0.236 0.034 4.93E-12 
IGP63 rs5757683 22 38180120 G 0.29 0.98 -0.236 0.034 4.95E-12 
IGP63 rs1557541 22 38181916 C 0.29 0.98 -0.236 0.034 4.91E-12 
IGP63 rs1557542 22 38182296 C 0.71 0.98 0.236 0.034 5.00E-12 
IGP63 rs5995735 22 38184367 C 0.29 0.98 -0.235 0.034 5.32E-12 
IGP63 rs738289 22 38185829 C 0.29 0.98 -0.235 0.034 5.47E-12 
IGP63 rs909674 22 38189115 C 0.30 0.99 -0.231 0.034 6.44E-12 
IGP64 rs17630758 22 22466542 G 0.83 0.99 -0.291 0.041 1.48E-12 
IGP64 rs12167679 22 22471690 C 0.80 1.00 -0.230 0.039 3.16E-09 
IGP64 rs17548631 22 22474125 C 0.17 0.99 0.291 0.041 1.39E-12 
IGP64 rs9620326 22 22476629 C 0.83 0.99 -0.291 0.041 1.39E-12 
IGP64 rs9624334 22 22496256 C 0.17 0.99 0.309 0.041 7.87E-14 
IGP64 rs2186369 22 22500996 G 0.19 0.88 0.318 0.042 2.08E-14 
IGP64 rs6519476 22 22512500 G 0.76 0.99 -0.198 0.036 5.06E-08 
IGP64 rs1972280 22 38161932 T 0.29 0.98 -0.183 0.034 9.45E-08 
IGP64 rs4821897 22 38165533 G 0.71 0.97 0.183 0.034 9.24E-08 
IGP64 rs5750830 22 38170774 C 0.29 0.98 -0.188 0.034 4.11E-08 
IGP64 rs8137426 22 38174296 G 0.71 0.98 0.188 0.034 4.09E-08 
IGP64 rs5757683 22 38180120 G 0.29 0.98 -0.188 0.034 4.09E-08 
IGP64 rs1557541 22 38181916 C 0.29 0.98 -0.188 0.034 4.09E-08 
IGP64 rs1557542 22 38182296 C 0.71 0.98 0.188 0.034 4.07E-08 
IGP64 rs5995735 22 38184367 C 0.29 0.98 -0.188 0.034 4.07E-08 
IGP64 rs738289 22 38185829 C 0.29 0.98 -0.188 0.034 4.05E-08 
IGP64 rs909674 22 38189115 C 0.30 0.99 -0.187 0.034 3.02E-08 
IGP65 rs7159888 14 64828395 G 0.55 0.99 0.186 0.031 1.91E-09 
IGP65 rs1760978 14 64840800 G 0.43 0.98 -0.172 0.031 3.26E-08 
IGP65 rs17102587 14 64844230 C 0.20 0.97 -0.206 0.038 6.43E-08 
IGP65 rs8017974 14 64844940 C 0.20 0.99 -0.212 0.038 2.34E-08 
IGP65 rs11847263 14 64845448 G 0.39 0.98 -0.202 0.032 1.47E-10 
IGP65 rs4902386 14 64848043 C 0.80 0.99 0.213 0.038 1.87E-08 
IGP65 rs8019473 14 64848881 G 0.80 0.99 0.213 0.038 1.83E-08 
IGP65 rs10138662 14 64849235 G 0.20 0.99 -0.213 0.038 1.72E-08 
IGP65 rs10134589 14 64850987 T 0.20 0.94 -0.219 0.039 2.17E-08 
IGP65 rs7151212 14 64851375 C 0.80 0.99 0.214 0.038 1.58E-08 
IGP65 rs11158587 14 64852465 G 0.80 0.99 0.214 0.038 1.56E-08 
IGP65 rs8019767 14 64852538 G 0.80 1.00 0.214 0.038 1.54E-08 
IGP65 rs6573598 14 64852772 C 0.20 1.00 -0.214 0.038 1.52E-08 
IGP65 rs6573599 14 64852880 C 0.80 1.00 0.214 0.038 1.42E-08 
IGP65 rs6573602 14 64854363 C 0.20 1.00 -0.215 0.038 1.34E-08 
IGP65 rs17102598 14 64854613 G 0.80 1.00 0.215 0.038 1.33E-08 
IGP65 rs6573604 14 64857694 C 0.20 1.00 -0.215 0.038 1.30E-08 
IGP65 rs11158592 14 64929721 G 0.50 0.99 -0.171 0.031 2.36E-08 
IGP65 rs11158593 14 64929737 G 0.50 0.99 -0.166 0.031 5.51E-08 
IGP65 rs10138570 14 64929791 G 0.50 0.99 0.166 0.031 5.54E-08 
IGP65 rs2411822 14 64948148 G 0.47 1.00 0.170 0.031 2.66E-08 
IGP65 rs1953416 14 64948560 C 0.53 1.00 -0.165 0.031 6.16E-08 
IGP65 rs883081 14 64950374 C 0.53 1.00 -0.165 0.031 6.29E-08 
IGP65 rs883082 14 64950693 G 0.47 1.00 0.170 0.031 2.74E-08 
IGP65 rs12879971 14 64971357 G 0.52 0.99 -0.171 0.031 2.32E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP65 rs12589698 14 64990188 G 0.52 0.98 -0.168 0.031 4.38E-08 
IGP65 rs4899179 14 64996501 G 0.49 0.99 0.173 0.031 1.75E-08 
IGP65 rs2184603 14 65000423 C 0.49 0.99 0.173 0.031 1.77E-08 
IGP65 rs3825640 14 65030957 C 0.51 0.99 -0.168 0.031 4.06E-08 
IGP65 rs11627084 14 65048589 G 0.49 1.00 0.172 0.031 1.82E-08 
IGP65 rs2149841 14 65080072 C 0.51 0.99 -0.168 0.031 4.07E-08 
IGP65 rs11158601 14 65095116 G 0.49 1.00 0.172 0.031 1.90E-08 
IGP65 rs1958561 14 65106514 G 0.49 1.00 0.172 0.031 1.96E-08 
IGP65 rs12887134 14 65115296 C 0.49 0.99 0.167 0.031 4.38E-08 
IGP65 rs7155541 14 65115995 C 0.49 0.99 0.167 0.031 4.40E-08 
IGP65 rs7161123 14 65122654 G 0.51 1.00 -0.170 0.030 2.25E-08 
IGP65 rs4581615 14 65125696 C 0.51 1.00 -0.170 0.030 2.25E-08 
IGP65 rs3783709 14 65128417 T 0.51 1.00 -0.170 0.030 2.25E-08 
IGP65 rs12889002 14 65133335 C 0.51 1.00 -0.170 0.030 2.25E-08 
IGP65 rs743085 14 65137886 G 0.49 1.00 0.170 0.030 2.25E-08 
IGP65 rs8012278 14 65152326 G 0.49 1.00 0.173 0.031 1.30E-08 
IGP65 rs12890902 14 65186375 T 0.51 1.00 -0.174 0.030 1.15E-08 
IGP65 rs2300865 14 65189768 C 0.49 1.00 0.174 0.030 1.14E-08 
IGP65 rs11627184 14 65191196 C 0.51 1.00 -0.174 0.030 1.11E-08 
IGP65 rs11627185 14 65191245 G 0.49 1.00 0.174 0.030 1.08E-08 
IGP65 rs7142651 14 65202474 C 0.51 1.00 -0.174 0.031 1.11E-08 
IGP65 rs1998036 14 65207952 C 0.49 0.99 0.175 0.031 1.09E-08 
IGP65 rs2268961 14 65216518 C 0.49 0.99 0.175 0.031 9.66E-09 
IGP65 rs2268962 14 65217026 G 0.49 1.00 0.175 0.031 9.53E-09 
IGP65 rs2064694 14 65217999 G 0.51 1.00 -0.174 0.031 1.23E-08 
IGP65 rs12588838 14 65232391 G 0.51 1.00 -0.174 0.030 1.21E-08 
IGP65 rs11628765 14 65238202 C 0.49 1.00 0.174 0.030 1.16E-08 
IGP65 rs2411351 14 65241294 C 0.49 1.00 0.174 0.030 1.14E-08 
IGP65 rs8018278 14 65249841 G 0.49 1.00 0.174 0.030 1.13E-08 
IGP65 rs11627067 14 65252706 G 0.49 1.00 0.174 0.031 1.12E-08 
IGP65 rs11622829 14 65261535 T 0.50 1.00 -0.174 0.031 1.31E-08 
IGP65 rs11624104 14 65265890 G 0.50 1.00 0.175 0.031 1.10E-08 
IGP65 rs1535173 14 65268892 C 0.50 1.00 -0.174 0.031 1.21E-08 
IGP65 rs927004 14 65270664 C 0.50 1.00 0.174 0.031 1.22E-08 
IGP65 rs8010876 14 65276729 G 0.50 1.00 0.174 0.031 1.19E-08 
IGP65 rs10483785 14 65289270 G 0.50 1.00 -0.175 0.030 8.77E-09 
IGP65 rs6573624 14 65296638 G 0.50 0.98 -0.180 0.031 4.98E-09 
IGP65 rs2411405 14 65301839 G 0.52 0.97 0.176 0.031 1.30E-08 
IGP65 rs743084 14 65302355 C 0.52 0.97 0.178 0.031 9.82E-09 
IGP65 rs11625362 14 65302622 G 0.48 0.97 -0.176 0.031 1.26E-08 
IGP65 rs11627605 14 65304066 G 0.48 0.97 -0.176 0.031 1.24E-08 
IGP65 rs11627578 14 65304201 C 0.48 0.97 -0.176 0.031 1.24E-08 
IGP65 rs11628840 14 65305395 G 0.52 0.97 0.176 0.031 1.23E-08 
IGP65 rs4902416 14 65307843 C 0.52 0.97 0.176 0.031 1.21E-08 
IGP65 rs730807 14 65309043 C 0.48 0.97 -0.176 0.031 1.21E-08 
IGP65 rs2411404 14 65309154 C 0.48 0.97 -0.176 0.031 1.20E-08 
IGP65 rs1075566 14 65309210 C 0.48 0.97 -0.176 0.031 1.20E-08 
IGP65 rs7157449 14 65309890 G 0.52 0.97 0.176 0.031 1.20E-08 
IGP65 rs6573626 14 65310448 C 0.52 0.97 0.176 0.031 1.24E-08 
IGP65 rs12894466 14 65310520 G 0.48 0.97 -0.176 0.031 1.24E-08 
IGP65 rs11625882 14 65314952 G 0.48 0.97 -0.176 0.031 1.28E-08 
IGP65 rs7142165 14 65319985 G 0.52 0.96 0.177 0.031 1.19E-08 
IGP65 rs6573627 14 65322079 C 0.51 0.98 0.170 0.031 3.95E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP65 rs4073415 14 65329283 G 0.51 0.99 0.168 0.031 5.65E-08 
IGP66 rs17630758 22 22466542 G 0.83 0.99 0.319 0.041 1.09E-14 
IGP66 rs12167679 22 22471690 C 0.80 1.00 0.246 0.039 2.49E-10 
IGP66 rs17548631 22 22474125 C 0.17 0.99 -0.319 0.041 9.55E-15 
IGP66 rs9620326 22 22476629 C 0.83 0.99 0.319 0.041 9.55E-15 
IGP66 rs9624334 22 22496256 C 0.17 0.99 -0.334 0.041 8.52E-16 
IGP66 rs2186369 22 22500996 G 0.19 0.88 -0.347 0.042 8.84E-17 
IGP66 rs6519476 22 22512500 G 0.76 0.99 0.208 0.036 1.05E-08 
IGP66 rs5757642 22 38094770 C 0.64 1.00 -0.219 0.033 2.14E-11 
IGP66 rs7286714 22 38095550 C 0.36 0.97 0.221 0.033 2.09E-11 
IGP66 rs5757644 22 38096386 C 0.36 0.97 0.221 0.033 2.06E-11 
IGP66 rs5750806 22 38096957 G 0.64 0.97 -0.221 0.033 2.06E-11 
IGP66 rs1569499 22 38099764 C 0.64 0.97 -0.222 0.033 1.75E-11 
IGP66 rs4821888 22 38100543 G 0.64 0.97 -0.222 0.033 1.78E-11 
IGP66 rs5757647 22 38104993 C 0.33 1.00 0.235 0.033 7.80E-13 
IGP66 rs4821890 22 38107469 G 0.34 0.99 0.235 0.033 8.10E-13 
IGP66 rs1010169 22 38108113 G 0.67 1.00 -0.235 0.033 7.86E-13 
IGP66 rs1010170 22 38108273 C 0.67 1.00 -0.235 0.033 8.12E-13 
IGP66 rs5757650 22 38108365 C 0.67 1.00 -0.235 0.033 8.17E-13 
IGP66 rs9611169 22 38112973 C 0.33 1.00 0.235 0.033 8.29E-13 
IGP66 rs9611170 22 38114791 C 0.66 0.99 -0.230 0.033 2.33E-12 
IGP66 rs2413590 22 38120137 C 0.67 1.00 -0.230 0.033 2.29E-12 
IGP66 rs5750808 22 38120933 G 0.33 1.00 0.230 0.033 2.32E-12 
IGP66 rs5750811 22 38123012 G 0.67 1.00 -0.229 0.033 2.36E-12 
IGP66 rs5750812 22 38123025 G 0.34 0.99 0.231 0.033 1.67E-12 
IGP66 rs5757655 22 38127124 C 0.66 0.99 -0.231 0.033 1.64E-12 
IGP66 rs4821893 22 38127725 G 0.33 1.00 0.233 0.033 1.11E-12 
IGP66 rs5750814 22 38127933 C 0.67 1.00 -0.233 0.033 1.07E-12 
IGP66 rs5757657 22 38128375 G 0.33 1.00 0.233 0.033 1.10E-12 
IGP66 rs5750815 22 38128395 C 0.67 1.00 -0.233 0.033 1.07E-12 
IGP66 rs4337572 22 38130650 C 0.33 1.00 0.233 0.033 1.07E-12 
IGP66 rs4821894 22 38139766 C 0.66 1.00 -0.233 0.033 1.06E-12 
IGP66 rs5750816 22 38140325 C 0.34 1.00 0.233 0.033 1.06E-12 
IGP66 rs5757659 22 38142355 G 0.66 1.00 -0.232 0.033 1.06E-12 
IGP66 rs6001585 22 38142932 C 0.22 1.00 0.213 0.037 8.13E-09 
IGP66 rs6001587 22 38148954 C 0.66 1.00 -0.232 0.033 1.07E-12 
IGP66 rs5750818 22 38150831 G 0.66 1.00 -0.232 0.033 1.07E-12 
IGP66 rs5757665 22 38151587 G 0.66 1.00 -0.232 0.033 1.07E-12 
IGP66 rs4821895 22 38152961 G 0.66 1.00 -0.232 0.033 1.07E-12 
IGP66 rs739141 22 38154396 C 0.36 1.00 0.236 0.032 2.96E-13 
IGP66 rs5750820 22 38155268 G 0.67 0.97 -0.254 0.033 2.17E-14 
IGP66 rs5750822 22 38156734 G 0.34 1.00 0.233 0.033 9.75E-13 
IGP66 rs7949 22 38157499 G 0.34 0.99 0.234 0.033 8.79E-13 
IGP66 rs5757670 22 38159682 G 0.34 0.99 0.234 0.033 8.06E-13 
IGP66 rs5750825 22 38161224 G 0.71 0.98 -0.281 0.034 2.85E-16 
IGP66 rs1972280 22 38161932 T 0.29 0.98 0.282 0.034 2.35E-16 
IGP66 rs4821897 22 38165533 G 0.71 0.97 -0.283 0.034 2.22E-16 
IGP66 rs5750830 22 38170774 C 0.29 0.98 0.285 0.034 1.15E-16 
IGP66 rs5757676 22 38171646 C 0.78 0.96 -0.227 0.037 1.40E-09 
IGP66 rs8137426 22 38174296 G 0.71 0.98 -0.284 0.034 1.15E-16 
IGP66 rs5757683 22 38180120 G 0.29 0.98 0.284 0.034 1.16E-16 
IGP66 rs1557541 22 38181916 C 0.29 0.98 0.284 0.034 1.16E-16 
IGP66 rs1557542 22 38182296 C 0.71 0.98 -0.284 0.034 1.16E-16 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP66 rs738289 22 38185829 C 0.29 0.98 0.284 0.034 1.17E-16 
IGP66 rs909674 22 38189115 C 0.30 0.99 0.281 0.034 1.08E-16 
IGP67 rs4917017 7 50305778 G 0.71 0.92 0.194 0.035 2.15E-08 
IGP67 rs17732497 7 50306619 C 0.70 0.97 0.186 0.033 2.18E-08 
IGP67 rs9886239 7 50307097 C 0.32 0.98 -0.189 0.033 8.75E-09 
IGP67 rs7805434 7 50311296 C 0.30 0.99 -0.185 0.033 2.10E-08 
IGP67 rs7781977 7 50316680 C 0.70 1.00 0.185 0.033 2.03E-08 
IGP67 rs7782210 7 50319291 G 0.38 0.98 -0.204 0.032 1.04E-10 
IGP67 rs6583437 7 50320813 G 0.64 0.98 0.200 0.032 3.00E-10 
IGP67 rs7789913 7 50323241 C 0.62 1.00 0.198 0.031 2.38E-10 
IGP67 rs6421315 7 50325753 C 0.37 0.95 -0.210 0.032 7.11E-11 
IGP67 rs7802443 7 50328511 C 0.39 0.99 -0.172 0.032 5.21E-08 
IGP67 rs17630758 22 22466542 G 0.83 0.99 0.267 0.041 7.14E-11 
IGP67 rs17548631 22 22474125 C 0.17 0.99 -0.267 0.041 6.73E-11 
IGP67 rs9620326 22 22476629 C 0.83 0.99 0.267 0.041 6.79E-11 
IGP67 rs9624334 22 22496256 C 0.17 0.99 -0.283 0.041 7.19E-12 
IGP67 rs2186369 22 22500996 G 0.19 0.88 -0.294 0.042 1.45E-12 
IGP67 rs5757642 22 38094770 C 0.64 1.00 -0.217 0.032 2.23E-11 
IGP67 rs7286714 22 38095550 C 0.36 0.97 0.219 0.033 2.46E-11 
IGP67 rs5757644 22 38096386 C 0.36 0.97 0.219 0.033 2.43E-11 
IGP67 rs5750806 22 38096957 G 0.64 0.97 -0.219 0.033 2.43E-11 
IGP67 rs1569499 22 38099764 C 0.64 0.97 -0.221 0.033 1.71E-11 
IGP67 rs4821888 22 38100543 G 0.64 0.97 -0.221 0.033 1.74E-11 
IGP67 rs5757647 22 38104993 C 0.33 1.00 0.251 0.033 1.67E-14 
IGP67 rs4821890 22 38107469 G 0.34 0.99 0.250 0.033 2.14E-14 
IGP67 rs1010169 22 38108113 G 0.67 1.00 -0.251 0.033 1.69E-14 
IGP67 rs1010170 22 38108273 C 0.67 1.00 -0.251 0.033 1.76E-14 
IGP67 rs5757650 22 38108365 C 0.67 1.00 -0.250 0.033 1.77E-14 
IGP67 rs9611169 22 38112973 C 0.33 1.00 0.250 0.033 1.81E-14 
IGP67 rs9611170 22 38114791 C 0.66 0.99 -0.246 0.033 4.38E-14 
IGP67 rs2413590 22 38120137 C 0.67 1.00 -0.247 0.033 3.45E-14 
IGP67 rs5750808 22 38120933 G 0.33 1.00 0.247 0.033 3.43E-14 
IGP67 rs5750811 22 38123012 G 0.67 1.00 -0.247 0.033 3.40E-14 
IGP67 rs5750812 22 38123025 G 0.34 0.99 0.248 0.033 2.81E-14 
IGP67 rs5757655 22 38127124 C 0.66 0.99 -0.248 0.033 2.77E-14 
IGP67 rs4821893 22 38127725 G 0.33 1.00 0.250 0.033 1.58E-14 
IGP67 rs5750814 22 38127933 C 0.67 1.00 -0.250 0.033 1.55E-14 
IGP67 rs5757657 22 38128375 G 0.33 1.00 0.250 0.033 1.56E-14 
IGP67 rs5750815 22 38128395 C 0.67 1.00 -0.250 0.033 1.52E-14 
IGP67 rs4337572 22 38130650 C 0.33 1.00 0.250 0.033 1.53E-14 
IGP67 rs4821894 22 38139766 C 0.66 1.00 -0.250 0.033 1.53E-14 
IGP67 rs5750816 22 38140325 C 0.34 1.00 0.250 0.032 1.54E-14 
IGP67 rs5757659 22 38142355 G 0.66 1.00 -0.250 0.032 1.54E-14 
IGP67 rs6001585 22 38142932 C 0.22 1.00 0.221 0.037 1.60E-09 
IGP67 rs6001587 22 38148954 C 0.66 1.00 -0.250 0.032 1.57E-14 
IGP67 rs5750818 22 38150831 G 0.66 1.00 -0.250 0.032 1.58E-14 
IGP67 rs5757665 22 38151587 G 0.66 1.00 -0.250 0.032 1.58E-14 
IGP67 rs4821895 22 38152961 G 0.66 1.00 -0.250 0.032 1.59E-14 
IGP67 rs739141 22 38154396 C 0.36 1.00 0.253 0.032 4.19E-15 
IGP67 rs5750820 22 38155268 G 0.67 0.97 -0.271 0.033 2.46E-16 
IGP67 rs5750822 22 38156734 G 0.34 1.00 0.250 0.033 1.52E-14 
IGP67 rs7949 22 38157499 G 0.34 0.99 0.251 0.033 1.42E-14 
IGP67 rs5757670 22 38159682 G 0.34 0.99 0.251 0.033 1.33E-14 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP67 rs1972280 22 38161932 T 0.29 0.98 0.297 0.034 4.28E-18 
IGP67 rs4821897 22 38165533 G 0.71 0.97 -0.298 0.034 3.98E-18 
IGP67 rs5750830 22 38170774 C 0.29 0.98 0.294 0.034 7.09E-18 
IGP67 rs5757676 22 38171646 C 0.78 0.96 -0.229 0.037 8.11E-10 
IGP67 rs8137426 22 38174296 G 0.71 0.98 -0.294 0.034 7.49E-18 
IGP67 rs5757683 22 38180120 G 0.29 0.98 0.294 0.034 7.60E-18 
IGP67 rs1557541 22 38181916 C 0.29 0.98 0.294 0.034 7.54E-18 
IGP67 rs1557542 22 38182296 C 0.71 0.98 -0.294 0.034 7.69E-18 
IGP67 rs5995735 22 38184367 C 0.29 0.98 0.293 0.034 8.21E-18 
IGP67 rs738289 22 38185829 C 0.29 0.98 0.293 0.034 8.47E-18 
IGP67 rs909674 22 38189115 C 0.30 0.99 0.289 0.034 1.12E-17 
IGP68 rs17630758 22 22466542 G 0.83 0.99 0.300 0.041 3.54E-13 
IGP68 rs12167679 22 22471690 C 0.80 1.00 0.236 0.039 1.13E-09 
IGP68 rs17548631 22 22474125 C 0.17 0.99 -0.300 0.041 3.22E-13 
IGP68 rs9620326 22 22476629 C 0.83 0.99 0.300 0.041 3.23E-13 
IGP68 rs9624334 22 22496256 C 0.17 0.99 -0.311 0.041 5.92E-14 
IGP68 rs2186369 22 22500996 G 0.19 0.88 -0.324 0.042 8.05E-15 
IGP68 rs5750820 22 38155268 G 0.67 0.97 -0.182 0.033 4.34E-08 
IGP68 rs5750825 22 38161224 G 0.71 0.98 -0.206 0.034 2.03E-09 
IGP68 rs1972280 22 38161932 T 0.29 0.98 0.207 0.034 1.78E-09 
IGP68 rs4821897 22 38165533 G 0.71 0.97 -0.207 0.034 1.72E-09 
IGP68 rs5750830 22 38170774 C 0.29 0.98 0.210 0.034 8.99E-10 
IGP68 rs8137426 22 38174296 G 0.71 0.98 -0.210 0.034 8.83E-10 
IGP68 rs5757683 22 38180120 G 0.29 0.98 0.210 0.034 8.82E-10 
IGP68 rs1557541 22 38181916 C 0.29 0.98 0.210 0.034 8.82E-10 
IGP68 rs1557542 22 38182296 C 0.71 0.98 -0.210 0.034 8.78E-10 
IGP68 rs5995735 22 38184367 C 0.29 0.98 0.210 0.034 8.74E-10 
IGP68 rs738289 22 38185829 C 0.29 0.98 0.210 0.034 8.67E-10 
IGP68 rs909674 22 38189115 C 0.30 0.99 0.209 0.034 6.24E-10 
IGP69 rs2072209 7 107379434 G 0.06 0.97 -0.374 0.066 1.16E-08 
IGP69 rs12342831 9 33114872 C 0.26 0.97 0.193 0.036 6.90E-08 
IGP69 rs10813951 9 33118021 G 0.26 0.97 0.193 0.036 6.83E-08 
IGP69 rs3780486 9 33129453 C 0.74 0.97 -0.192 0.036 7.69E-08 
IGP69 rs10813957 9 33143527 G 0.74 0.96 -0.193 0.036 8.48E-08 
IGP69 rs2186369 22 22500996 G 0.19 0.88 -0.234 0.042 2.37E-08 
IGP70 rs4917017 7 50305778 G 0.71 0.92 0.197 0.035 1.40E-08 
IGP70 rs17732497 7 50306619 C 0.70 0.97 0.185 0.033 3.47E-08 
IGP70 rs9886239 7 50307097 C 0.32 0.98 -0.180 0.033 5.10E-08 
IGP70 rs7805434 7 50311296 C 0.30 0.99 -0.183 0.033 3.24E-08 
IGP70 rs7781977 7 50316680 C 0.70 1.00 0.183 0.033 3.10E-08 
IGP70 rs7782210 7 50319291 G 0.38 0.98 -0.174 0.032 3.59E-08 
IGP70 rs6583437 7 50320813 G 0.64 0.98 0.177 0.032 2.72E-08 
IGP70 rs7789913 7 50323241 C 0.62 1.00 0.171 0.031 4.83E-08 
IGP70 rs6421315 7 50325753 C 0.37 0.95 -0.182 0.032 1.57E-08 
IGP70 rs17630758 22 22466542 G 0.83 0.99 0.314 0.041 2.52E-14 
IGP70 rs12167679 22 22471690 C 0.80 1.00 0.242 0.039 4.00E-10 
IGP70 rs17548631 22 22474125 C 0.17 0.99 -0.314 0.041 2.23E-14 
IGP70 rs9620326 22 22476629 C 0.83 0.99 0.314 0.041 2.22E-14 
IGP70 rs9624334 22 22496256 C 0.17 0.99 -0.330 0.041 1.50E-15 
IGP70 rs2186369 22 22500996 G 0.19 0.88 -0.345 0.042 1.18E-16 
IGP70 rs6519476 22 22512500 G 0.76 0.99 0.212 0.036 5.93E-09 
IGP70 rs5757642 22 38094770 C 0.64 1.00 -0.212 0.033 7.43E-11 
IGP70 rs7286714 22 38095550 C 0.36 0.97 0.214 0.033 6.84E-11 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP70 rs5750806 22 38096957 G 0.64 0.97 -0.215 0.033 6.71E-11 
IGP70 rs1569499 22 38099764 C 0.64 0.97 -0.216 0.033 5.75E-11 
IGP70 rs4821888 22 38100543 G 0.64 0.97 -0.216 0.033 5.85E-11 
IGP70 rs5757647 22 38104993 C 0.33 1.00 0.233 0.033 1.31E-12 
IGP70 rs4821890 22 38107469 G 0.34 0.99 0.233 0.033 1.32E-12 
IGP70 rs1010169 22 38108113 G 0.67 1.00 -0.232 0.033 1.32E-12 
IGP70 rs1010170 22 38108273 C 0.67 1.00 -0.232 0.033 1.36E-12 
IGP70 rs5757650 22 38108365 C 0.67 1.00 -0.232 0.033 1.36E-12 
IGP70 rs9611169 22 38112973 C 0.33 1.00 0.232 0.033 1.38E-12 
IGP70 rs9611170 22 38114791 C 0.66 0.99 -0.228 0.033 3.26E-12 
IGP70 rs2413590 22 38120137 C 0.67 1.00 -0.228 0.033 3.27E-12 
IGP70 rs5750808 22 38120933 G 0.33 1.00 0.228 0.033 3.30E-12 
IGP70 rs5750811 22 38123012 G 0.67 1.00 -0.227 0.033 3.33E-12 
IGP70 rs5750812 22 38123025 G 0.34 0.99 0.229 0.033 2.45E-12 
IGP70 rs5757655 22 38127124 C 0.66 0.99 -0.229 0.033 2.42E-12 
IGP70 rs4821893 22 38127725 G 0.33 1.00 0.230 0.033 1.84E-12 
IGP70 rs5750814 22 38127933 C 0.67 1.00 -0.230 0.033 1.81E-12 
IGP70 rs5757657 22 38128375 G 0.33 1.00 0.230 0.033 1.86E-12 
IGP70 rs5750815 22 38128395 C 0.67 1.00 -0.230 0.033 1.82E-12 
IGP70 rs4337572 22 38130650 C 0.33 1.00 0.230 0.033 1.83E-12 
IGP70 rs4821894 22 38139766 C 0.66 1.00 -0.230 0.033 1.84E-12 
IGP70 rs5750816 22 38140325 C 0.34 1.00 0.230 0.033 1.85E-12 
IGP70 rs5757659 22 38142355 G 0.66 1.00 -0.230 0.033 1.86E-12 
IGP70 rs6001585 22 38142932 C 0.22 1.00 0.208 0.037 1.52E-08 
IGP70 rs6001587 22 38148954 C 0.66 1.00 -0.230 0.033 1.87E-12 
IGP70 rs5750818 22 38150831 G 0.66 1.00 -0.230 0.033 1.87E-12 
IGP70 rs5757665 22 38151587 G 0.66 1.00 -0.230 0.033 1.87E-12 
IGP70 rs4821895 22 38152961 G 0.66 1.00 -0.230 0.033 1.87E-12 
IGP70 rs739141 22 38154396 C 0.36 1.00 0.231 0.032 7.70E-13 
IGP70 rs5750820 22 38155268 G 0.67 0.97 -0.250 0.033 4.20E-14 
IGP70 rs5750822 22 38156734 G 0.34 1.00 0.230 0.033 1.71E-12 
IGP70 rs7949 22 38157499 G 0.34 0.99 0.231 0.033 1.57E-12 
IGP70 rs5757670 22 38159682 G 0.34 0.99 0.231 0.033 1.45E-12 
IGP70 rs5750825 22 38161224 G 0.71 0.98 -0.276 0.034 8.04E-16 
IGP70 rs1972280 22 38161932 T 0.29 0.98 0.277 0.034 6.94E-16 
IGP70 rs4821897 22 38165533 G 0.71 0.97 -0.278 0.034 6.55E-16 
IGP70 rs5750830 22 38170774 C 0.29 0.98 0.279 0.034 4.15E-16 
IGP70 rs5757676 22 38171646 C 0.78 0.96 -0.221 0.037 3.24E-09 
IGP70 rs8137426 22 38174296 G 0.71 0.98 -0.279 0.034 4.19E-16 
IGP70 rs5757683 22 38180120 G 0.29 0.98 0.279 0.034 4.22E-16 
IGP70 rs1557541 22 38181916 C 0.29 0.98 0.278 0.034 4.22E-16 
IGP70 rs1557542 22 38182296 C 0.71 0.98 -0.278 0.034 4.24E-16 
IGP70 rs5995735 22 38184367 C 0.29 0.98 0.278 0.034 4.34E-16 
IGP70 rs738289 22 38185829 C 0.29 0.98 0.278 0.034 4.37E-16 
IGP70 rs909674 22 38189115 C 0.30 0.99 0.275 0.034 3.91E-16 
IGP71 rs4917017 7 50305778 G 0.71 0.92 0.196 0.035 1.90E-08 
IGP71 rs17732497 7 50306619 C 0.70 0.97 0.184 0.033 4.24E-08 
IGP71 rs9886239 7 50307097 C 0.32 0.98 -0.180 0.033 5.36E-08 
IGP71 rs7805434 7 50311296 C 0.30 0.99 -0.182 0.033 3.90E-08 
IGP71 rs7781977 7 50316680 C 0.70 1.00 0.182 0.033 3.75E-08 
IGP71 rs7782210 7 50319291 G 0.38 0.98 -0.175 0.032 3.47E-08 
IGP71 rs6583437 7 50320813 G 0.64 0.98 0.176 0.032 3.00E-08 
IGP71 rs7789913 7 50323241 C 0.62 1.00 0.172 0.031 4.69E-08 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP71 rs17630758 22 22466542 G 0.83 0.99 0.316 0.041 1.73E-14 
IGP71 rs12167679 22 22471690 C 0.80 1.00 0.244 0.039 3.38E-10 
IGP71 rs17548631 22 22474125 C 0.17 0.99 -0.317 0.041 1.51E-14 
IGP71 rs9620326 22 22476629 C 0.83 0.99 0.317 0.041 1.50E-14 
IGP71 rs9624334 22 22496256 C 0.17 0.99 -0.334 0.041 8.09E-16 
IGP71 rs2186369 22 22500996 G 0.19 0.88 -0.347 0.042 8.75E-17 
IGP71 rs6519476 22 22512500 G 0.76 0.99 0.211 0.036 6.82E-09 
IGP71 rs5757642 22 38094770 C 0.64 1.00 -0.212 0.033 7.77E-11 
IGP71 rs7286714 22 38095550 C 0.36 0.97 0.215 0.033 6.75E-11 
IGP71 rs5757644 22 38096386 C 0.36 0.97 0.215 0.033 6.66E-11 
IGP71 rs5750806 22 38096957 G 0.64 0.97 -0.215 0.033 6.63E-11 
IGP71 rs1569499 22 38099764 C 0.64 0.97 -0.216 0.033 6.04E-11 
IGP71 rs4821888 22 38100543 G 0.64 0.97 -0.216 0.033 6.14E-11 
IGP71 rs5757647 22 38104993 C 0.33 1.00 0.231 0.033 1.80E-12 
IGP71 rs4821890 22 38107469 G 0.34 0.99 0.232 0.033 1.70E-12 
IGP71 rs1010169 22 38108113 G 0.67 1.00 -0.231 0.033 1.81E-12 
IGP71 rs1010170 22 38108273 C 0.67 1.00 -0.231 0.033 1.87E-12 
IGP71 rs5757650 22 38108365 C 0.67 1.00 -0.231 0.033 1.88E-12 
IGP71 rs9611169 22 38112973 C 0.33 1.00 0.231 0.033 1.91E-12 
IGP71 rs9611170 22 38114791 C 0.66 0.99 -0.227 0.033 4.19E-12 
IGP71 rs2413590 22 38120137 C 0.67 1.00 -0.226 0.033 4.51E-12 
IGP71 rs5750808 22 38120933 G 0.33 1.00 0.226 0.033 4.57E-12 
IGP71 rs5750811 22 38123012 G 0.67 1.00 -0.226 0.033 4.64E-12 
IGP71 rs5750812 22 38123025 G 0.34 0.99 0.228 0.033 3.15E-12 
IGP71 rs5757655 22 38127124 C 0.66 0.99 -0.228 0.033 3.11E-12 
IGP71 rs4821893 22 38127725 G 0.33 1.00 0.229 0.033 2.46E-12 
IGP71 rs5750814 22 38127933 C 0.67 1.00 -0.229 0.033 2.41E-12 
IGP71 rs5757657 22 38128375 G 0.33 1.00 0.229 0.033 2.47E-12 
IGP71 rs5750815 22 38128395 C 0.67 1.00 -0.229 0.033 2.42E-12 
IGP71 rs4337572 22 38130650 C 0.33 1.00 0.229 0.033 2.43E-12 
IGP71 rs4821894 22 38139766 C 0.66 1.00 -0.229 0.033 2.43E-12 
IGP71 rs5750816 22 38140325 C 0.34 1.00 0.229 0.033 2.45E-12 
IGP71 rs5757659 22 38142355 G 0.66 1.00 -0.229 0.033 2.45E-12 
IGP71 rs6001585 22 38142932 C 0.22 1.00 0.208 0.037 1.57E-08 
IGP71 rs6001587 22 38148954 C 0.66 1.00 -0.228 0.033 2.47E-12 
IGP71 rs5750818 22 38150831 G 0.66 1.00 -0.229 0.033 2.46E-12 
IGP71 rs5757665 22 38151587 G 0.66 1.00 -0.229 0.033 2.46E-12 
IGP71 rs4821895 22 38152961 G 0.66 1.00 -0.229 0.033 2.46E-12 
IGP71 rs739141 22 38154396 C 0.36 1.00 0.233 0.032 5.80E-13 
IGP71 rs5750820 22 38155268 G 0.67 0.97 -0.249 0.033 5.66E-14 
IGP71 rs5750822 22 38156734 G 0.34 1.00 0.229 0.033 2.26E-12 
IGP71 rs7949 22 38157499 G 0.34 0.99 0.230 0.033 2.06E-12 
IGP71 rs5757670 22 38159682 G 0.34 0.99 0.230 0.033 1.90E-12 
IGP71 rs5750825 22 38161224 G 0.71 0.98 -0.274 0.034 1.49E-15 
IGP71 rs1972280 22 38161932 T 0.29 0.98 0.275 0.034 1.27E-15 
IGP71 rs4821897 22 38165533 G 0.71 0.97 -0.275 0.034 1.20E-15 
IGP71 rs5750830 22 38170774 C 0.29 0.98 0.277 0.034 6.63E-16 
IGP71 rs5757676 22 38171646 C 0.78 0.96 -0.222 0.037 2.97E-09 
IGP71 rs8137426 22 38174296 G 0.71 0.98 -0.277 0.034 6.69E-16 
IGP71 rs5757683 22 38180120 G 0.29 0.98 0.277 0.034 6.72E-16 
IGP71 rs1557541 22 38181916 C 0.29 0.98 0.277 0.034 6.72E-16 
IGP71 rs1557542 22 38182296 C 0.71 0.98 -0.277 0.034 6.74E-16 
IGP71 rs5995735 22 38184367 C 0.29 0.98 0.276 0.034 6.87E-16 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP71 rs909674 22 38189115 C 0.30 0.99 0.274 0.034 6.19E-16 
IGP72 rs4917017 7 50305778 G 0.71 0.92 -0.197 0.035 1.54E-08 
IGP72 rs17732497 7 50306619 C 0.70 0.97 -0.185 0.033 3.01E-08 
IGP72 rs9886239 7 50307097 C 0.32 0.98 0.182 0.033 3.81E-08 
IGP72 rs7805434 7 50311296 C 0.30 0.99 0.184 0.033 2.77E-08 
IGP72 rs7781977 7 50316680 C 0.70 1.00 -0.184 0.033 2.64E-08 
IGP72 rs7782210 7 50319291 G 0.38 0.98 0.178 0.032 2.00E-08 
IGP72 rs6583437 7 50320813 G 0.64 0.98 -0.179 0.032 1.73E-08 
IGP72 rs7789913 7 50323241 C 0.62 1.00 -0.175 0.031 2.72E-08 
IGP72 rs6421315 7 50325753 C 0.37 0.95 0.186 0.032 7.97E-09 
IGP72 rs17630758 22 22466542 G 0.83 0.99 -0.317 0.041 1.57E-14 
IGP72 rs12167679 22 22471690 C 0.80 1.00 -0.245 0.039 2.59E-10 
IGP72 rs17548631 22 22474125 C 0.17 0.99 0.317 0.041 1.38E-14 
IGP72 rs9620326 22 22476629 C 0.83 0.99 -0.317 0.041 1.37E-14 
IGP72 rs9624334 22 22496256 C 0.17 0.99 0.334 0.041 7.62E-16 
IGP72 rs2186369 22 22500996 G 0.19 0.88 0.347 0.042 8.63E-17 
IGP72 rs6519476 22 22512500 G 0.76 0.99 -0.209 0.036 1.04E-08 
IGP72 rs5757642 22 38094770 C 0.64 1.00 0.211 0.033 9.58E-11 
IGP72 rs7286714 22 38095550 C 0.36 0.97 -0.214 0.033 7.72E-11 
IGP72 rs5757644 22 38096386 C 0.36 0.97 -0.214 0.033 7.60E-11 
IGP72 rs5750806 22 38096957 G 0.64 0.97 0.214 0.033 7.57E-11 
IGP72 rs1569499 22 38099764 C 0.64 0.97 0.215 0.033 7.11E-11 
IGP72 rs4821888 22 38100543 G 0.64 0.97 0.215 0.033 7.20E-11 
IGP72 rs5757647 22 38104993 C 0.34 1.00 -0.229 0.033 2.80E-12 
IGP72 rs4821890 22 38107469 G 0.34 0.99 -0.230 0.033 2.52E-12 
IGP72 rs1010169 22 38108113 G 0.66 1.00 0.229 0.033 2.82E-12 
IGP72 rs1010170 22 38108273 C 0.66 1.00 0.229 0.033 2.90E-12 
IGP72 rs5757650 22 38108365 C 0.66 1.00 0.229 0.033 2.92E-12 
IGP72 rs9611169 22 38112973 C 0.34 1.00 -0.229 0.033 2.95E-12 
IGP72 rs9611170 22 38114791 C 0.66 0.99 0.225 0.033 6.10E-12 
IGP72 rs2413590 22 38120137 C 0.67 1.00 0.224 0.033 6.89E-12 
IGP72 rs5750808 22 38120933 G 0.33 1.00 -0.224 0.033 6.97E-12 
IGP72 rs5750811 22 38123012 G 0.67 1.00 0.224 0.033 7.07E-12 
IGP72 rs5750812 22 38123025 G 0.34 0.99 -0.226 0.033 4.58E-12 
IGP72 rs5757655 22 38127124 C 0.66 0.99 0.226 0.033 4.53E-12 
IGP72 rs4821893 22 38127725 G 0.33 1.00 -0.227 0.033 3.79E-12 
IGP72 rs5750814 22 38127933 C 0.67 1.00 0.227 0.033 3.72E-12 
IGP72 rs5757657 22 38128375 G 0.33 1.00 -0.227 0.033 3.82E-12 
IGP72 rs5750815 22 38128395 C 0.66 1.00 0.227 0.033 3.74E-12 
IGP72 rs4337572 22 38130650 C 0.34 1.00 -0.227 0.033 3.76E-12 
IGP72 rs4821894 22 38139766 C 0.66 1.00 0.227 0.033 3.77E-12 
IGP72 rs5750816 22 38140325 C 0.34 1.00 -0.227 0.033 3.80E-12 
IGP72 rs5757659 22 38142355 G 0.66 1.00 0.226 0.033 3.81E-12 
IGP72 rs6001585 22 38142932 C 0.22 1.00 -0.203 0.037 3.44E-08 
IGP72 rs6001587 22 38148954 C 0.66 1.00 0.226 0.033 3.84E-12 
IGP72 rs5750818 22 38150831 G 0.66 1.00 0.226 0.033 3.83E-12 
IGP72 rs5757665 22 38151587 G 0.66 1.00 0.226 0.033 3.83E-12 
IGP72 rs4821895 22 38152961 G 0.66 1.00 0.226 0.033 3.83E-12 
IGP72 rs739141 22 38154396 C 0.36 1.00 -0.231 0.032 8.98E-13 
IGP72 rs5750820 22 38155268 G 0.67 0.97 0.247 0.033 1.04E-13 
IGP72 rs5750822 22 38156734 G 0.34 1.00 -0.227 0.033 3.53E-12 
IGP72 rs7949 22 38157499 G 0.34 0.99 -0.228 0.033 3.23E-12 
IGP72 rs5757670 22 38159682 G 0.34 0.99 -0.228 0.033 3.00E-12 




Trait SNP Chr Position EA EAF RSq Beta* SE P 
IGP72 rs1972280 22 38161932 T 0.29 0.98 -0.271 0.034 3.20E-15 
IGP72 rs4821897 22 38165533 G 0.71 0.97 0.271 0.034 3.04E-15 
IGP72 rs5750830 22 38170774 C 0.29 0.98 -0.273 0.034 1.77E-15 
IGP72 rs5757676 22 38171646 C 0.78 0.96 0.217 0.037 6.80E-09 
IGP72 rs8137426 22 38174296 G 0.71 0.98 0.273 0.034 1.79E-15 
IGP72 rs5757683 22 38180120 G 0.29 0.98 -0.273 0.034 1.81E-15 
IGP72 rs1557541 22 38181916 C 0.29 0.98 -0.273 0.034 1.81E-15 
IGP72 rs1557542 22 38182296 C 0.71 0.98 0.272 0.034 1.82E-15 
IGP72 rs5995735 22 38184367 C 0.29 0.98 -0.272 0.034 1.86E-15 
IGP72 rs738289 22 38185829 C 0.29 0.98 -0.272 0.034 1.87E-15 
IGP72 rs909674 22 38189115 C 0.30 0.99 -0.270 0.034 1.69E-15 
IGP74 rs9624334 22 22496256 C 0.17 0.99 -0.226 0.042 5.33E-08 
IGP74 rs2186369 22 22500996 G 0.19 0.88 -0.236 0.042 1.66E-08 
IGP75 rs17630758 22 22466542 G 0.83 0.99 0.223 0.041 5.82E-08 
IGP75 rs17548631 22 22474125 C 0.17 0.99 -0.224 0.041 5.13E-08 
IGP75 rs9620326 22 22476629 C 0.83 0.99 0.224 0.041 5.06E-08 
IGP75 rs9624334 22 22496256 C 0.17 0.99 -0.234 0.041 1.73E-08 
IGP75 rs2186369 22 22500996 G 0.19 0.88 -0.245 0.042 3.96E-09 
IGP76 rs9624334 22 22496256 C 0.17 0.99 0.222 0.041 7.77E-08 
IGP76 rs2186369 22 22500996 G 0.19 0.88 0.233 0.042 2.09E-08 
Chr= chromosome; Position= position (build 36); EA= effect allele; EAF= effect allele 
frequency; RSq= average imputation quality (RSq) across meta-analysis populations; SE= 
standard error of beta 






Table 26: Pearson correlation coefficients and p-values for FA2 glycan as 
measured by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 




Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.895  0 0 0 0 
IgG2&3 0.853 0.804  0 0 0 
LC-ESI-MS 
IgG1 0.912 0.943 0.774  0 0 
IgG2&3 0.881 0.790 0.953 0.809  0 
xCGE-LIF Total 0.928 0.882 0.833 0.914 0.865  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 





Table 27: Pearson correlation coefficients and p-values for FA2B glycan as 
measured by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 




Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.738  0 0 0 0 
IgG2&3 0.747 0.716  0 0 0 
LC-ESI-MS 
IgG1 0.807 0.899 0.654  0 0 
IgG2&3 0.828 0.686 0.921 0.731  0 
xCGE-LIF Total 0.862 0.792 0.724 0.901 0.813  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 





Table 28: Pearson correlation coefficients and p-values for FA2G1* glycan as 












0 0 0 0 0 4.10E-03 
0.106  0 0 0 0 0.160 0 
MALDI-
TOF-MS 
IgG1 0.691 0.374  0 0 0 0 0 
IgG2&3 0.417 0.368 0.676  0 0 0 0 
LC-ESI-
MS 
IgG1 0.711 0.538 0.677 0.319  0 0 0 




0.872 0.042 0.620 0.336 0.675 0.448  0.536 
0.087 0.912 0.333 0.326 0.527 0.456 0.019  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 




*This structure is measured as two isomers with UPLCand xCGE-LIF but as only one mass 






Table 29: Pearson correlation coefficients and p-values for FA2BG1* glycan as 








Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total 




7.31E-05 0 4.44E-16 0 0 
MALDI-
TOF-MS 
IgG1 0.777 0.223  0 0 0 0 0 





IgG1 0.866 0.288 0.881 0.612  0 0 0 




0.858 0.286 0.718 0.563 0.771 0.768  0 
0.400 0.494 0.388 0.243 0.477 0.375 0.547  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 




*This structure is measured as two isomers with UPLCand xCGE-LIF but as only one mass 
by MS-based methods         
 
Table 30: Pearson correlation coefficients and p-values for FA2G2 glycan as 
measured by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 




Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.913  0 0 0 0 
IgG2&3 0.851 0.853  0 0 0 
LC-ESI-MS 
IgG1 0.940 0.931 0.808  0 0 
IgG2&3 0.890 0.839 0.924 0.877  0 
xCGE-LIF Total 0.947 0.909 0.842 0.937 0.886  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 





Table 31: Pearson correlation coefficients and p-values for FA2BG2 glycan as 
measured by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 




Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.644  0 0 0 0 
IgG2&3 0.672 0.687  0 0 0 
LC-ESI-MS 
IgG1 0.830 0.791 0.717  0 0 
IgG2&3 0.777 0.648 0.844 0.831  0 
xCGE-LIF Total 0.768 0.650 0.670 0.819 0.773  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 








Table 32: Pearson correlation coefficients and p-values for FA2G1S1 glycan 
as measured by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 






Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0.084 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.052  
1.12E-
05 
0.071 2.42E-03 0 
IgG2&3 0.302 0.132  0 0 0 
LC-ESI-MS 
IgG1 0.362 0.055 0.276  0 0 
IgG2&3 0.411 0.091 0.697 0.554  0 
xCGE-LIF Total 0.604 0.284 0.356 0.422 0.467  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 





Table 33: Pearson correlation coefficients and p-values for FGS/(FG+FGS) as 
measured by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 






Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.292  0 0 0 0 
IgG2&3 0.413 0.419  0 0 0 
LC-ESI-MS 
IgG1 0.581 0.332 0.555  0 0 
IgG2&3 0.443 0.341 0.703 0.727  0 
xCGE-LIF Total 0.775 0.379 0.516 0.703 0.551  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 





Table 34: Pearson correlation coefficients and p-values for FGS/(F+FG+FGS) 
as measured by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 






Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.495  0 0 0 0 
IgG2&3 0.666 0.561  0 0 0 
LC-ESI-MS 
IgG1 0.794 0.528 0.668  0 0 
IgG2&3 0.713 0.491 0.839 0.775  0 
xCGE-LIF Total 0.884 0.542 0.690 0.826 0.752  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 








Table 35: Pearson correlation coefficients and p-values for FG1S1/ (FG1 + 
FG1S1) as measured by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 






Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  5.55E-04 3.15E-12 0 0 0 
MALDI-TOF-
MS 
IgG1 0.104  1.83E-03 8.85E-03 1.92E-04 0 
IgG2&3 0.208 0.094  0 0 0 
LC-ESI-MS 
IgG1 0.254 0.079 0.512  0 0 
IgG2&3 0.278 0.112 0.659 0.732  0 
xCGE-LIF Total 0.581 0.303 0.263 0.309 0.347  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 





Table 36: Pearson correlation coefficients and p-values for FG2S1/ (FG2 + 
FG2S1) as measured by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 






Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.361  0 0 0 0 
IgG2&3 0.339 0.485  0 0 0 
LC-ESI-MS 
IgG1 0.399 0.366 0.471  0 0 
IgG2&3 0.399 0.377 0.611 0.777  0 
xCGE-LIF Total 0.750 0.414 0.390 0.457 0.443  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 





Table 37: Pearson correlation coefficients and p-values for G0n as measured 
by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 






Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.914  0 0 0 0 
IgG2&3 0.862 0.796  0 0 0 
LC-ESI-MS 
IgG1 0.929 0.967 0.782  0 0 
IgG2&3 0.877 0.782 0.972 0.795  0 
xCGE-LIF Total 0.942 0.914 0.849 0.934 0.866  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 








Table 38: Pearson correlation coefficients and p-values for G1n as measured 
by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 






Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.876  0 0 0 0 
IgG2&3 0.747 0.716  0 0 0 
LC-ESI-MS 
IgG1 0.908 0.915 0.612  0 0 
IgG2&3 0.784 0.702 0.959 0.640  0 
xCGE-LIF Total 0.917 0.860 0.710 0.916 0.748  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 





Table 39: Pearson correlation coefficients and p-values for G2n as measured 
by UPLC, MALDI-TOF-MS, LC-ESI-MS and xCGE-LIF. 






Total IgG1 IgG2&3 IgG1 IgG2&3 Total 
UPLC Total  0 0 0 0 0 
MALDI-TOF-
MS 
IgG1 0.922  0 0 0 0 
IgG2&3 0.863 0.856  0 0 0 
LC-ESI-MS 
IgG1 0.950 0.949 0.827  0 0 
IgG2&3 0.902 0.846 0.948 0.875  0 
xCGE-LIF Total 0.951 0.922 0.858 0.952 0.898  
The bottom triangle contains the correlation coefficient; the top triangle contains the p-value 
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